0001144204-14-050058.txt : 20140814 0001144204-14-050058.hdr.sgml : 20140814 20140814151303 ACCESSION NUMBER: 0001144204-14-050058 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140814 DATE AS OF CHANGE: 20140814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS INC CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS SHOPPING GOODS STORES [5940] IRS NUMBER: 870652870 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36333 FILM NUMBER: 141042116 BUSINESS ADDRESS: STREET 1: 2626 SOUTH LOOP, SUITE 180 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 8329716616 MAIL ADDRESS: STREET 1: 2626 SOUTH LOOP, SUITE 180 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 10-Q 1 v386337_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________________

Commission file number: 000-53404

Bio-Path Holdings, Inc.

(Exact name of registrant as specified in its charter)

Utah		87-0652870
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401

(Address of principal executive offices)

Registrant's telephone no., including area code: (832) 971 -6616

2626 South Loop, Suite 180, Houston, Texas 77054

(Former address of principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

At August 5, 2014, the Company had 89,237,872 outstanding shares of common stock, no par value.

Forward-Looking Statements

Statements in this Quarterly Report on Form 10-Q that are not strictly historical in nature are forward-looking statements. These statements may include, but are not limited to, statements about: the timing of the commencement, enrollment, and completion of our anticipated clinical trials for our product candidates; the progress or success of our product development programs; the status of regulatory approvals for our product candidates; the timing of product launches; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and our estimates for future performance, anticipated operating losses, future revenues, capital requirements, and our needs for additional financing. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “goal,” and similar expressions intended to identify forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. The underlying information and expectations are likely to change over time. Actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the caption “Risk Factors” in “ITEM 1. BUSINESS” of our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2013, and those set forth in our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

TABLE OF CONTENTS

		Page

PART I - FINANCIAL INFORMATION		1

Item 1.	Financial Statements	1
	Consolidated Balance Sheets	1
	Consolidated Statements of Operations	2
	Consolidated Statements of Cash Flows	3
	Notes to Unaudited Consolidated Financial Statements Ending June 30, 2014	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	26
Item 4.	Controls and Procedures	26

PART II - OTHER INFORMATION		27

Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.	Defaults Upon Senior Securities	27
Item 4.	Mine Safety Disclosures	27
Item 5.	Other Information	27
Item 6.	Exhibits	27

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

Unaudited

	June 30,			December 31,
	2014			2013

ASSETS

Current assets
Cash	$	15,721,128		$	3,551,832
Prepaid drug product for testing		141,345			51,364
Other current assets		171,563			64,117

Total current assets		16,034,036			3,667,313

Other assets
Technology licenses - related party		2,500,374			2,500,374
Less Accumulated Amortization		(1,169,168	)		(1,088,856	)
		1,331,206			1,411,518

TOTAL ASSETS	$	17,365,242		$	5,078,831

LIABILITIES & SHAREHOLDERS' EQUITY

Current liabilities
Accounts payable		78,915			76,109
Accounts payable - related party		3,213			-
Accrued expense		149,341			66,739
Accrued expense - related party		52,050			52,050
Accrued license payments - related party		50,000			100,000

Total current liabilities		333,519			294,898

Long term debt		-			-

TOTAL LIABILITIES		333,519			294,898

Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding					-
Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively		89,238			84,238
Additional paid in capital		34,113,436			20,096,991
Accumulated deficit during development stage		(17,170,951	)		(15,397,296	)

Total shareholders' equity		17,031,723			4,783,933

TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$	17,365,242		$	5,078,831

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

	Second Quarter						Year to Date						From inception
	April 1 to June 30						January 1 to June 30						05/10/07 to
	2014			2013			2014			2013			6/30/14

Revenue	$	-		$	-		$	-		$	-		$	-

Operating expense

Research and development a/		517,040			156,036			624,681			557,135			6,469,166
Research and development - related party b/		3,213			32,067			24,931			47,067			1,204,257
General & administrative c/		754,548			240,543			1,135,400			480,354			9,829,509

Total operating expense		1,274,801			428,646			1,785,012			1,084,556			17,502,932

Net operating loss	$	(1,274,801	)	$	(428,646	)	$	(1,785,012	)	$	(1,084,556	)	$	(17,502,932	)

Other income (expense)
Interest income		6,066			1,531			11,639			1,655			92,766
Other income		-			-			-			-			244,479
Other expense		(42	)		(129	)		(281	)		(345	)		(5,264	)
Total Other Income (Expense)		6,024			1,402			11,358			1,310			331,981

Net Loss	$	(1,268,777	)	$	(427,244	)	$	(1,773,654	)	$	(1,083,246	)	$	(17,170,951	)

Loss per share

Net loss per share, basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.33	)

Basic and diluted weighted average number of common shares outstanding		89,237,872			66,606,105			89,237,872			64,412,577			52,592,648

Includes $690,000 technology impairment charge for the period from inception through 6/30/2014

General & administrative expense includes stock for services, stock option and warrant expenses of $102,383 and $5,318 for the quarters ending 6/30/2014 and 6/30/2013, respectively; $182,039 and $9,923 for the six month periods ending 6/30/2014 and 6/30/2013, respectively; and $3,444,392 for the period from inception through 6/30/2014 for stock options and warrants and $318,500 in stock for services.

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

CONSOLIDATED STATEMENT OF CASH FLOWS

Unaudited

							From inception
	January 1, to June 30						05/10/2007 to
	2014			2013			6/30/2014

CASH FLOW FROM OPERATING ACTIVITIES

Net loss	$	(1,773,654	)	$	(1,083,246	)	$	(17,170,951	)

Adjustments to reconcile net loss to net cash used in operating activities
Amortization		80,312			80,312			1,217,670
Technology impairment		-			-			690,000
Common stock issued for services		-			-			318,500
Stock options and warrants		209,071			29,557			3,927,304
(Increase) decrease in assets
Prepaid drug product for testing		(89,981	)		(84,180	)		(141,345	)
Other current assets		(107,446	)		(3,836	)		(171,563	)
Increase (decrease) in liabilities
Accounts payable and accrued expenses		38,621			(61,388	)		333,519

Net cash used in operating activities		(1,643,077	)		(1,122,781	)		(10,996,866	)

CASH FLOW FROM INVESTING ACTIVITIES

Purchase of exclusive license - related party		-			-			(884,710	)

Net cash used in investing activities		-			-			(884,710	)

CASH FLOW FROM FINANCING ACTIVITIES

Proceeds from convertible notes		-			-			435,000
Cash repayment of convertible notes		-			-			(15,000	)
Net proceeds from sale of common stock		13,812,373			2,515,961			27,182,704

Net cash from financing activities		13,812,373			2,515,961			27,602,704

NET INCREASE (DECREASE) IN CASH		12,169,296			1,393,180			15,721,128

Cash, beginning of period		3,551,832			534,046			-

Cash, end of period	$	15,721,128		$	1,927,226		$	15,721,128

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid for
Interest	$	-		$	-		$	445
Income taxes	$	-		$	-		$	-

Non-cash financing activities
Common stock issued upon conversion of convertible notes	$	-		$	-		$	420,000
Common stock issued to Placement Agent	$	-		$	448,950		$	1,362,613
Common stock issued to M.D. Anderson for technology license	$	-		$	-		$	2,354,167
Due diligence and commitment shares issued to Lincoln	$	-		$	-		$	210,755

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

Notes to the Unaudited Consolidated Financial Statements Ended June 30, 2014

The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2013. The results of operations for the period ended June 30, 2014, are not necessarily indicative of the results for a full-year period.

Organization and Business

Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (“L-Grb-2” or “BP-100-1.01”), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement (the “License Agreement”). The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.

Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.

The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial are now being tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data needed to demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.

The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m². However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company requested the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors (the “Board”), advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose of 60 mg/m², which had been increased from 50 mg/m²in the revised protocol. The Company has enrolled patients in Cohort 6 for treatment at a dose of 90 mg/m², has two (2) evaluable patients and is currently treating another patient. Assuming the current patient successfully completes the treatment cycle the Company will be able to close Cohort 6.

Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (“AML”), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (“CML”) and Acute Lymphoblastic Leukemia (“ALL”), or Myelodysplastic Syndrome (“MDS”) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.

An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.

In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.

The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. Subsequently, in the fall of 2013 the Principal Investigator prepared an abstract of updated information on the results of the clinical trial through Cohort 5, which was accepted for presentation at the American Society of Hematology annual meeting in December of 2013. Highlights from the presentation prepared by Dr. Cortes for the meeting included:

Data from the Phase I clinical trial

Among 18 evaluable patients, nine experienced at least a 50 percent reduction in peripheral or bone marrow blasts from baseline.

Five patients demonstrated transient improvement and/or stable disease, three of whom received a total of five cycles each.

Two patients, in addition to achieving marked blast percentage declines, also experienced transient improvement in leukemia cutis lesions.

Disease Stabilization in MDS and AML

Two patients with MDS, a 53-year old male and a 72-year old female, both achieved disease stabilization and continued therapy for five cycles before disease progression.

A 54-year old HIV positive male with AML achieved stable disease and marked reduction in peripheral blasts, continuing therapy for five cycles before disease progression.

Experience in CML-Blast Phase

Patient with myeloid blast crisis of CML

Prior therapies consist of: imatinib, dastinib, nilotinib, DCC-2036, Cytarabine + Fludarabine + Dasatinib + Gemtuzumab, PHA-739358, Clofarabine + Dasatinib

Upon start of BP-100-1.01 patient showed a significant reduction in blasts from 81 percent to 5 percent but due to leptomeningeal disease progression discontinued therapy before full cycle.

Inhibition of Target Grb-2 Protein

Grb-2 levels were compared to baseline prior to treatment.

On day 15, BP-100-1.01 decreased Grb-2 in five of eight samples tested (average reduction 55 percent)

End of treatment day15, BP-100-1.01 decreased Grb-2 levels in eight out of nine patients (average reduction 45 percent).

Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology and has already identified one new candidate.

The Phase I clinical trial is typically ended when a maximum tolerated dose (“MTD”) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.

As noted previously, the Company has completed two of the three evaluable patients required to close Cohort 6. Once Cohort 6 is completed the Company and the Principal Investigator will determine whether the optimal biological dose has been reached, which would allow the Phase I trial to be ended. Since there has been no evidence of toxicity to date in the trial and none is expected even at a higher dose in a potential seventh cohort, the trade-off is ending the clinical trial sooner after Cohort 6 or waiting to complete a seventh cohort with a higher dose and potentially even better anti-leukemia benefits in the patient. Plans and evaluation of manufacturing scale-up of the drug substance batch size continued. Scale-up of manufacturing batch size previously produced divergence from desired drug substance product parameters, with some product in the fourth quarter of 2013 not being acceptable for use. The most recent manufacturing scale-up drug substance batch appears to have corrected this and a recent drug batch was released for use in the clinical trial by the manufacturer. Scale-up of manufacturing output of drug substance product and final drug product is critical to meeting the anticipated potential for high volume requirements of Bio-Path’s drug products for patients in multiple diseases. The larger size drug substance and final product batch sizes will also substantially drive down manufacturing cost per drug unit. The recent success on the part of the Company in raising capital should also improve drug supply by providing the financial resources that will enable the Company to commit to multiple drug batches beyond those required to satisfy near-term requirements.

Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.

At the end of January 2012, the Company’s Board held a strategic planning session. Among several topics was a discussion of the Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $345,000 at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (50%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $345,000, and cancel the license.

The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path became a publicly traded company as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.

On November 5, 2013, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on January 13, 2014. The shelf registration statement was filed to register the offering and sale of up to $100 million of our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

On January 15, 2014, we entered into a securities purchase agreement, as amended, with two dedicated healthcare funds (collectively, the “Sabby Investors”) that are managed by Sabby Management, pursuant to which the Company agreed to sell an aggregate of 5,000,000 shares of its common stock and warrants to purchase a total of 2,500,000 shares of its common stock to the Sabby Investors for gross proceeds of approximately $15,000,000. The net proceeds to the Company from the registered direct public offering, after deducting the placement agent’s fees and expenses, the Company’s estimated offering expenses, and excluding the proceeds from the exercise of the warrants issued in the offering, were approximately $13.8 million. We will use the net proceeds from this offering and sale of securities for working capital and general corporate purposes.

On March 5, 2014, the NASDAQ Stock Market LLC informed the Company that it had approved the listing of the Company’s common stock on the NASDAQ Capital Market. The Company’s common stock ceased trading on the OTCQX and commenced trading on the NASDAQ Capital Market on March 10, 2014 under the ticker symbol “BPTH.”

On March 11, 2014, the Board of the Company appointed Ulrich W. Mueller, Ph.D., as the Company’s Chief Operating Officer. This is the initial hiring step implanting a plan to put in place a core organization that can manage the Company’s expanding clinical trials and deliver on the Bio-Path business plan vision of rapidly converting validated protein disease targets into proprietary liposome-antisense drug candidates that enter Phase I clinical trials. In April 2014, the Company progressed further with its organization plan by hiring a director of clinical trials, controller and director of information technology. Subsequent to the close of the second quarter, 2014, the Company has hired additional personnel to add further to the core organization. The Company anticipates that by the end of the third quarter 2014 it will have added the remaining employees to complete the organization plan.

In April 2014 the Company entered in a lease for a larger office space. The new, expanded size office is required for the core organization the Company is adding.

As of June 30, 2014, Bio-Path had $15,721,128 in cash on hand.

As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.

Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending June 30, 2014 and 2013, MD Anderson related party research and development expense was $3,213 and $32,067, respectively. MD Anderson related party research and development expense for the quarter ending June 30, 2014 was comprised of $3,213 in current patent maintenance fees for the License Agreement. Accounts payable related party was $3,213 comprised of current patent expenses for the License Agreement, accrued expense related party for MD Anderson was $52,050 for clinical trial hospital costs for the clinical trial and accrued license payments related party of $50,000 for past patent expenses (See Notes 4., 5. and 6.). MD Anderson related party research and development expense for the quarter ending June 30, 2013 was comprised of $22,050 for MD Anderson clinical trial hospital expense and $10,017 for current patent expenses for the Technology License. As of December 31, 2013, accrued expense related party consisted of $52,050 for MD Anderson clinical trial hospital costs and $100,000 in accrued license payments payable due to the related party for past patent expenses and for the annual license maintenance fee for the License Agreement. See Notes 5 and 6.

Prepaid Drug Product for Testing

Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future R&D activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company incurred installments to its contract drug manufacturing and raw material suppliers totaling $51,364 in late 2013 pursuant to a Drug Supply Contract (See Note 9.) for the manufacture and delivery of the Company’s lead drug product for testing in a Phase I clinical trial. This amount was carried on the Balance Sheet as of December 31, 2013 at cost as Prepaid Drug Product for Testing. The Company incurred additional installment costs with the total costs incurred totaling $141,345 being carried on the Balance Sheet as of June 30, 2014 as Prepaid Drug Product for Testing (See Note 9.).

Accounts Payable

As of June 30, 2014, Current Liabilities included accounts payable of $78,915 comprised primarily of approximate amounts owed totaling $43,277 to the Company’s auditors for work on the annual audit, $15,250 owed to the Company’s drug substance manufacturer, $18,150 to suppliers of services used in the clinical trial and other miscellaneous items totaling $2,238. As of June 30, 2014 accounts payable related party consisted of $3,213 for current patent expenses for the License Agreement. By the first week of August 2014, the June 30, 2014 amounts included in accounts payable and accounts payable related party had been substantially paid. As of December 31, 2013, Current Liabilities included accounts payable $76,109, which amounts were subsequently paid in 2014.

Accrued Expense

As of June 30, 2014, Current Liabilities included accrued expense of $149,341 for clinical trial expense, advisory fees and management bonus accrual. Current Liabilities as of June 30, 2014 also included accrued expense related party of $52,050 for MD Anderson clinical trial hospital expense. (See Note 2.). As of December 31, 2013, Current Liabilities included accrued expense of $66,739 and accrued expense related party of $52,050.

Accrued License Payments – Related Party

Accrued license payments related party totaling $50,000 and $100,000 were included in Current Liabilities as of June 30, 2014 and December 31, 2013, respectively. The amount included for June 30, 2014 represents reimbursement of past patent expenses incurred by MD Anderson prior to the Bio-Path license and the amount included for December 31, 2013 included past patent expenses and the annual maintenance fee for the License Agreement.

Stockholders’ Equity

Issuance of Common Stock – In May and June of 2007, the Company issued 6,505,994 shares of common stock for $6,506 in cash to founders of the Company. In August of 2007, the Company issued 3,975,000 shares of common stock for $993,750 in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional 1,333,334 shares of common stock for $1,000,000 in cash to investors in the Company pursuant to a second round of financing. The Company issued 530,833 in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued 3,138,889 shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.

In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued 38,023,578 shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained 3,600,000 shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued 80,000 shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued 200,000 shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $180,000. In April of 2008, the Company recorded an additional 24 shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued 100,000 shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $40,000. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued 660,000 shares of common stock and warrants to purchase an additional 660,000 shares of common stock for $165,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 66,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.

In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $675,000 in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors 2,700,000 shares of common stock and warrants to purchase an additional 2,700,000 shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In January 2010, the Company also sold an additional 900,000 shares of common stock and warrants to purchase an additional 900,000 shares of common stock for $225,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $1.50 a share. In connection with these private placement sales of equity, the Company issued 360,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In May of 2010, the Company issued 780,000 shares of common stock and warrants to purchase an additional 780,000 shares of common stock for $273,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 78,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In June of 2010, the Company signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a 24-month period in amounts between $50,000 and $1,000,000 up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $200,000 from LPC as an initial purchase in exchange for 571,429 shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase 571,429 shares of the Company’s common stock at an exercise price of $1.50 per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC 12,000 shares of the Company’s common stock for its due diligence efforts and 566,801 shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.

In July of 2010, the Company received $150,000 from LPC in exchange for 375,000 shares of the Company’s common stock. LPC was also issued 6,251 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 375,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In September of 2010, the Company received $50,000 from LPC in exchange for 125,000 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In November of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

From November 2010 through April of 2011 the Company sold shares of common stock for $1,794,205 in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued 5,980,685 shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued 598,069 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.

In June of 2011, the Company received $50,000 from LPC in exchange for 164,853 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2011, the Company issued 1,920,000 shares of common stock for $576,000 to investors who exercised warrants from September to October 2011.

In November of 2011, the Company received $25,000 from LPC in exchange for 83,333 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In December of 2011, the Company received $50,000 from LPC in exchange for 172,414 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In March of 2012, the Company received $50,000 from LPC in exchange for 166,667 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $25,000 from LPC in exchange for 89,286 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $25,000 from LPC in exchange for 96,154 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $50,000 from LPC in exchange for 185,185 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In June of 2012, the Company sold $150,000 in shares of its common stock pursuant to a private placement, with shares to be issued, and $18,500 in shares of its common stock for services with shares to be issued.

In August of 2012, the Company issued 50,000 shares of its common stock for the $18,500 shares for services previously recognized in June 2012.

In July through September of 2012, the Company sold $795,001 in shares of its common stock pursuant to a private placement, with shares to be issued.

In October through December of 2012, the Company sold $708,600 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of December 31, 2012 the Company issued 3,300,337 shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.

In February and March of 2013, the Company sold $346,202 in shares of its common stock pursuant to a private placement, with shares to be issued.

In April and May of 2013, the Company sold $2,000,198 in shares of its common stock pursuant to a private placement, with shares to be issued, and $489,501 in shares of its common stock pursuant in a direct offering, with shares to be issued.

In June of 2013, the Company issued 11,664,665 shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued 1,496,499 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.

In August and September of 2013, the Company sold $3,220,966 in shares of its common stock pursuant to a private placement, with shares to be issued.

In November of 2013, the Company issued 8,052,416 shares of common stock to investors in connection with the private placement. In November of 2013 the Company issued 805,242 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.

In January of 2014, the Company issued a total of 5,000,000 shares of the Company’s common stock and warrants to purchase 2,500,000 shares of the Company’s common stock for aggregate gross proceeds of $15,000,000. The warrants are exercisable for a period of five years from the date of issuance. The exercise price of the warrants is $4.74 a share.

As of June 30, 2014, there were 89,237,872 shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2014.

Stock Options and Warrants

Stock Options

In April of 2014, the Company made a stock option grant to purchase 25,000 shares of the Company’s common stock for services rendered by a director of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is one year from the date of grant for the director service stock option. The exercise price of the option is $2.38 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $57,425, which is being expensed following the date of grant based on the stock option vesting schedule.

In April of 2014, the Company made two stock option grants each to purchase 25,000 shares of the Company’s common stock to two new Company employees. Terms of the stock option grants require, among other things, that the individuals continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $2.71 a share, which was the closing price of the common stock at the date of the grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value for both of the stock options granted taken together was determined using this methodology to be $133,200, which is being expensed following the date of grant based on the stock option vesting schedule.

In May of 2014, the Company made a stock option grant to purchase 25,000 shares of the Company’s common stock to a new Company employee. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $2.40 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $58,975, which is being expensed following the date of grant based on the stock option vesting schedule.

In May of 2014, the Company made a stock option grant to purchase 125,000 shares of the Company’s common stock to a newly hired officer of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $2.40 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $294,500, which is being expensed following the date of grant based on the stock option vesting schedule.

Stock option expense for the quarter ending June 30, 2014 was $122,793. Of this amount, $20,410 related to stock options for personnel involved in R&D activities and $102,383 related to stock options for outside directors, officers and management of the Company.

Warrants - There were no warrants for services granted during the quarter ending June 30, 2014. The warrants issued in connection with the sale of units of common stock were for cash value received and as such were not grants of compensation-based warrants.

Commitments and Contingencies

Technology License – Related Party - The Company has negotiated exclusive licenses from the MD Anderson Cancer Center to develop drug delivery technology for antisense and siRNA drug products. These licenses require, among other things, the Company to reimburse MD Anderson for ongoing patent expense. Related party accrued license payments attributable to the License Agreement totaling $50,000 are included in Current Liabilities as of June 30, 2014. Related party accrued expense totaling $52,050 as of June 30, 2014 represents hospital costs for the clinical trial and are not related to the License Agreement. As of June 30, 2014, the Company estimates reimbursable past patent expenses will total approximately $75,000 for the License Agreement. The Company will be required to pay when invoiced the past patent expenses at the rate of $25,000 per quarter. In addition, the Company decided to discontinue development of its siRNA technology and subsequently canceled its siRNA license in June of 2012 (See Note 1).

Drug Supplier Project Plan – Bio-Path entered into two project plan agreements with the Company’s drug substance manufacturer and its final drug product manufacturer for the manufacture and delivery of final drug product for expected manufacture in the third quarter of 2014. The project plans required the Company to pay approximately $370,000 in various stages as the drug substance and final product are manufactured and delivered to the Company. Of this amount, $141,345 has been paid for by the Company, which was carried on the Balance Sheet as Prepaid Drug Product for Testing as of June 30, 2014. The drug product is anticipated to be delivered to the Company in the fourth quarter of 2014 and the Balance Sheet item Prepaid Drug Product for Testing totaling $141,345 will be expensed when received.

10.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s consolidated financial statements upon adoption.

Recently, the FASB issued ASU 2014-10 to eliminate the concept of a development stage entity (DSE) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs. The amendments are effective for annual reporting periods beginning after December 15, 2014 and interim periods therein. Early adoption is permitted for financial statements that have not yet been issued or made available for issuance. The Company expects to early adopt ASU 2014-10 as of December 31, 2014. The Company is currently assessing the impact on the consolidated financial statements.

11.

Subsequent Events

At the end of July 2014, the Company’s lease on previous office space expired and the Company did not renew the lease. Previous to this, the Company entered into a lease for a larger office space, which it occupied as of August 2014.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

When you read this section of this Quarterly Report on Form 10-Q, it is important that you also read the unaudited financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto included in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2013. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the matters discussed under the caption “Risk Factors” in “Item 1, BUSINESS” in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2013, and other risks and uncertainties discussed in filings made with the Securities and Exchange Commission. See “Note Regarding Forward Looking Statements” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 for additional discussion regarding risks associated with forward-looking statements.

Overview

Bio-Path Holdings, Inc. (together with its subsidiary, "Bio-Path" or the "Company" or "we," "us" or "our") is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (“L-Grb-2” or “BP-100-1.01”), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.

Our business plan is to act efficiently as an intermediary in the process of translating newly discovered drug technologies into authentic therapeutic drug candidates. Our strategy is to selectively license potential drug candidates for certain cancers, and, primarily utilizing the comprehensive drug development capabilities of MD Anderson, to advance these candidates into initial human efficacy trials (Phase IIa), and then out-license each successful potential drug and/or the drug delivery technology to a pharmaceutical company or, if the final steps to commercialization are within the capabilities of the Company, finalize development and commercialization internally.

The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path became a publicly traded company as a result of this merger. On March 10, 2014, the Company’s common stock ceased trading on the OTCQX and commenced trading on the NASDAQ Capital Market under the ticker symbol “BPTH.”

Our principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401. Our telephone number is (832) 971-6616. Our Internet website address is www.biopathholdings.com, and all of our filings with the Securities and Exchange Commission are available free of charge on our website.

Research and Development

Our research and development is currently conducted through agreements we have with MD Anderson. We have added a new research and development relationship for pre-clinical testing and anticipate that new research and development relationships will be added in the future for clinical trials that require multiple sites for patient testing.

Basic Technical Information

Ribonucleic acid (“RNA”) is a biologically significant type of molecule consisting of a chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate. Although similar in some ways to DNA, RNA differs from DNA in a few important structural details. RNA is transcribed from DNA by enzymes called RNA polymerases and is generally further processed by other enzymes. RNA is central to protein synthesis. DNA carries the genetic information of a cell and consists of thousands of genes. Each gene serves as a recipe on how to build a protein molecule. Proteins perform important tasks for the cell functions or serve as building blocks. The flow of information from the genes determines the protein composition and thereby the functions of the cell.

The DNA is situated in the nucleus of the cell, organized into chromosomes. Every cell must contain the genetic information and the DNA is therefore duplicated before a cell divides (replication). When proteins are needed, the corresponding genes are transcribed into RNA (transcription). The RNA is first processed so that non-coding parts are removed (processing) and is then transported out of the nucleus (transport). Outside the nucleus, the proteins are built based upon the code in the RNA (translation).

Our basic drug development concept is to block the expression of proteins that cause disease. RNA is essential in the process of creating proteins. We intend to develop drugs and drug delivery systems that are intended to work by delivering short strands of DNA material that are inserted into a cell to block the production of proteins associated with disease.

The historical perspective of cancer treatments has been the use of drugs that affect the entire body. Advances in the past decade have shifted to treating the tumor tissue itself. One of the main strategies in these developments has been targeted therapy, involving drugs that are targeted to block the expression of specific disease causing proteins while having little or no effect on other healthy tissue. Nucleic acid drug products, specifically antisense, are a promising field of targeted therapy. Development of antisense, however, has been limited by the lack of a suitable method to deliver these drugs to the diseased cells with high uptake into the cell and without causing toxicity. Bio-Path’s currently licensed neutral-lipid based liposome technology is designed to accomplish this. Studies have shown a 10-fold to 30-fold increase in tumor cell uptake with this technology compared to other delivery methods.

BP-100-1.01

Indications for Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS) and Acute Lymphoblastic Leukemia (ALL)

BP-100-1.01 is our lead liposome delivered antisense drug candidate, which is being clinically tested in patients having Acute Myeloid Leukemia (“AML”), Chronic Myelogenous Leukemia (“CML”), Myelodysplastic Syndrome (“MDS”) and Acute Lymphoblastic Leukemia (“ALL”). If the results of the clinical tests are favorable, we expect there will be opportunities to negotiate non-exclusive license applications involving upfront cash payments with pharmaceutical companies developing antisense drugs that need systemic delivery technology.

The Investigational New Drug (“IND”) for BP-100-1.01 was submitted to the U.S. Food and Drug Administration (“FDA”) in February 2008 and included all in vitro testing, animal studies and manufacturing and chemistry control studies completed. The FDA requested some changes be made to the application submission. We resubmitted information to the FDA in response to such request. On March 12, 2010, we issued a press release announcing that the FDA had allowed an IND for Bio-Path's lead cancer drug candidate liposomal BP-100-1.01 to proceed into clinical trials. The IND review process was performed by the FDA's Division of Oncology Products and involved a comprehensive review of data submitted by us covering pre-clinical studies, safety, chemistry, manufacturing, and controls, and the protocol for the Phase I clinical trial. The primary objective of the Phase I clinical trial, as in any Phase I clinical trial, is the safety of the drug for treatment of human patients. Additional key objectives of the trial are to demonstrate the effectiveness of our drug delivery technology similar to that experienced in pre-clinical treatment of animals and to assess whether the drug candidate test article produces a favorable impact on the cancerous condition of the patient at the dose levels of the study.

The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m². However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company requested the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors (the “Board”), advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of L-Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose of 60 mg/m², which had been increased from 50 mg/m²in the revised protocol. The Company has enrolled patients in Cohort 6 for treatment at a dose of 90 mg/m², has two (2) evaluable patients and is currently treating another patient. Assuming the current patient successfully completes the treatment cycle the Company will be able to close Cohort 6. To date, there has been no evidence of significant toxicity from treatment of patients with L-Grb-2 in our Phase I clinical trial.

Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed AML, CML, ALL, or MDS and have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with L-Grb-2.

In this regard, in August of 2013 Bio-Path announced that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for L-Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.

The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D. (the “Principal Investigator”), is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology (“ASH”) annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. Subsequently, in fall of 2013 the Principal Investigator prepared an abstract of updated information on the results of the clinical trial through Cohort 5, which was accepted for presentation at the ASH annual meeting in December of 2013. Highlights from the presentation prepared by the Principal Investigator for the meeting included:

Data from the Phase I clinical trial

	•	Among 18 evaluable patients through five completed cohorts, nine experienced at least a 50 percent reduction in peripheral or bone marrow blasts from baseline.
	•	Five patients demonstrated transient improvement and/or stable disease, three of whom received a total of five cycles each.
	•	Two patients, in addition to achieving market blast percentage declines, also experienced transient improvements in leukemia cutis lesions.

Disease Stabilization in MDS and AML

	•	Two patients with MDS, a 53-year old male and a 72-year old female, both achieved disease stabilization and continued therapy for five cycles before disease progression.
	•	A 54-year old HIV positive male with AML achieved stable disease and marked reduction in peripheral blasts, continuing therapy for five cycles before disease progression.

Experience in CML-Blast Phase

	•	Patient with myeloid blast crisis of CML.
	•	Prior therapies consist of: imatinib, dastinib, nilotinib, DCC-2036, Cytarabine + Fludarabine + Dasatinib + Gemtuzumab, PHA-739358, Clofarabine + Dasatinib.
	•	Upon start of BP-100-1.01 patient showed a significant reduction in blasts from 81 percent to 5 percent but due to leptomeningeal disease progression discontinued therapy before full cycle.

Inhibition of Target Grb-2 Protein

	•	Grb-2 levels were compared to baseline prior to treatment.
	•	On day 15, BP-100-1.01 decreased Grb-2 in five of eight samples tested (average reduction 55 percent).
	•	End of treatment day15, BP-100-1.01 decreased Grb-2 levels in eight out of nine patients (average reduction 45 percent).

As noted previously, the Company has completed two of the three evaluable patients required to close Cohort 6. Once Cohort 6 is completed, the Company and the Principal Investigator will determine whether the optimal biological dose has been reached, which would allow the Phase I trial to be ended. Since there has been no evidence of toxicity to date in the trial and none is expected even at a higher dose in a potential seventh cohort, the trade-off is ending the clinical trial sooner after Cohort 6 or waiting to complete a seventh cohort with a higher dose and potentially even better anti-leukemia benefits in the patient. Plans and evaluation of manufacturing scale-up of the drug substance batch size continued. Scale-up of manufacturing batch size previously produced divergence from desired drug substance product parameters, with some product in the fourth quarter of 2013 not being acceptable for use. The most recent manufacturing scale-up drug substance batch appears to have corrected this and a recent drug batch was released for use in the clinical trial by the manufacturer. Scale-up of manufacturing output of drug substance product and final drug product is critical to meeting the anticipated potential for high volume requirements of Bio-Path’s drug products for patients in multiple diseases. The larger size drug substance and final product batch sizes will also substantially drive down manufacturing cost per drug unit. The recent success on the part of the Company in raising capital should also improve drug supply by providing the financial resources that will enable the Company to commit to multiple drug batches beyond those required to satisfy near-term requirements.

Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in L-Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate L-Grb-2 in salvage therapy for very advanced patients.

Indications for Triple Negative Breast Cancer (TNBC) and Inflammatory Breast Cancer (IBC)

On July 22, 2013, we announced that we were initiating preclinical testing of BP-100-1.01 into two additional indications: Triple Negative Breast Cancer (“TNBC”) and Inflammatory Breast Cancer (“IBC”). TNBC tumors do not express estrogen receptors, progesterone receptors, and low Human Epidermal growth factor Receptor 2 (“HER2”). These negative results mean that the growth of the cancer is not supported by the hormones estrogen and progesterone, or by the presence of too many HER2 receptors. Therefore, TNBC does not respond to hormonal therapy or therapies that target HER2 receptors. In addition, TNBC tumors are very aggressive. Approximately 15 to 20 percent of breast cancers are triple-negative. IBC is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.” IBC accounts for two to five percent of all breast cancers. IBC tumors are very aggressive and are frequently hormone receptor negative, which means hormone therapies may not be effective. Five year survival rate for IBC is approximately 40% versus approximately 87% for all breast cancers combined, making IBC a priority area for development of new treatments.

Our plan is to develop BP-100-1.01 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop BP-100-1.01 as a tumor reduction agent in combination with other approved drugs in pre-operative settings, and the second is to develop BP-100-1.01 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients. Following successful completion of the preclinical studies, we expect to start a Phase I clinical trial in TNBC and IBC in 2014. We believe that the observations that we learn from the on-going Phase I trial will allow us to progress relatively quickly in such Phase I trial in TNBC and IBC, as the toxicity profile of BP-100-1.01 is currently being established.

BP-100-1.02

BP-100-1.02 (“Bcl-2” or “BP-100-1.02”) is Bio-Path's co-lead liposome delivered antisense drug candidate. The scientific name for BP-100-1.02 is Liposomal Bcl-2, a liposome delivered antisense cancer drug. BP-100-1.2 is ready for clinic and is intended to target the lymphoma and certain solid tumor markets. Clinical targets for BP-100-1.02 include lymphoma, breast cancer, colon cancer, prostate cancer and leukemia. Liposomal Bcl-2 has the potential to treat 40%-60% of solid tumors.

Bcl-2 is a protein that is involved in regulating apoptosis or programmed cell death. Apoptosis is a physiologic mechanism of cell turnover by which cells actively commit suicide in response to aberrant external signals. Over-expression of Bcl-2 prevents the induction of apoptosis in response to cellular insults such as treatment with chemotherapeutic agents. Bcl-2 is over-expressed in more than 90% of follicular B-cell non-Hodgkins lymphoma due to a chromosomal rearrangement and is the key factor in the initiation of this malignancy. Bcl-2 is also overexpressed in a wide variety of solid tumors (it is estimated to be over-expressed in 40% of cancers). For example, Bcl-2 over-expression has been associated with the progression of prostate cancer from hormone dependence to hormone independence and may contribute to the relative drug resistant phenotype typically observed in hormone independent prostate cancer.

Other Liposomal Antisense Products

As noted previously, the Company intends to apply its drug delivery technology template to new disease-causing protein targets as a means to develop new, liposomal antisense drug candidates. A new product identification template was recently approved that defines a process of scientific, pre-clinical, commercial and intellectual property evaluation of potential new drug candidates for inclusion into the Company’s drug product development pipeline. The Company has one promising new candidate that is in the final stages of patentability review, which could potentially become our first new product candidate using our drug delivery technology template. A significant amount of capital will be allocated for in-licensing promising protein targets that can be developed as new liposomal antisense drug candidates.

Projected Financing Needs

The cost to complete our current business plan over the next 18 months was previously estimated to be approximately $12,800,000. We are currently adding a core organization that will provide increased capabilities to execute our business plan. We intend to conduct a review of our strategy in the third quarter once the new organization has been completed. However, we currently believe that the previously estimated funding needs of $12,800,000 and expected timelines are approximately correct.

In January 2014, we sold shares of common stock and warrants to an institutional investor in a registered direct offering that provided us with approximately $13,750,000 in net proceeds. As a result, in part, the Company had cash balances on hand in excess of $15,700,000 on June 30, 2014. Accordingly, we believe that our current level of resources should be sufficient to complete our current plan described below.

The remaining cost of the Phase I clinical trial of BP-100-1.01, assuming we are able to end the trial after completion of Cohort 6, is expected to be approximately $250,000, including amounts needed to have end-of-trial analysis performed on patient data and a formal report, provided that the trial is completed after the next dose level. If the Phase I clinical trial in BP-100-1.01 is successful, we expect to follow with multi-site Phase II trials in BP-100-1.01. Successful Phase I and II trials of BP-100-1.01 are expected to provide clinical evidence to support BP-100-1.01 as a potential therapeutic drug product for treatment of AML, MDS and CML. The Phase I clinical trial for Bp-100-1.01 has already provided important clinical proof of concept that the Company’s core liposomal delivery technology appears to in fact work. The Phase II clinical trials in BP-100-1.01 are expected to cost approximately $2,000,000 each, or approximately $6,000,000 for all three to complete the basic treatment for the estimated number of patients.

Development of BP-100-1.01 to treat TNBC and IBC over the 18 month plan horizon is expected to require approximately $1,500,000. This amount is expected to fund the preclinical program and the Phase I clinical trial. It is anticipated that the Phase I clinical trial will cost less than a typical Phase I trial because the safety profile will have already been established upon conclusion of BP-100-1.01’s current clinical trial. This is expected to result in fewer patients being tested and a more efficient progression to an optimal biological dose.

The Phase I clinical trial of BP-100-1.02 (L-Bcl-2) is expected to cost approximately $2,000,000. Commencement of the Phase I clinical trial depends on the FDA approving the IND for BP-100-1.02. Success in the Phase I clinical trial will be based on the demonstration that the drug is well tolerated and other key outcomes. The Phase I clinical trial will likely be a dose-escalating study to determine the safety and tolerance of escalating doses of BP-100-1.02. The study will also likely determine the optimal biologically active dose for further development. The pharmacokinetics of BP-100-1.02 in patients will be studied, as well as down-regulation of the target protein to corroborate any positive anti-cancer effects in addition to confirming effectiveness of the delivery technology.

Approximately $200,000 has been allocated to identifying other protein targets for development into liposomal antisense drug candidates. The balance of the $12,800,000 in funding needs from our revised plan over 18 months is approximately $3,030,000, which is planned to fund patent expenses, licensing fees, pre-clinical costs, consulting fees and management and administration. Of the total of $12,800,000 in projected expenses, approximately $9,750,000 in project costs is projected to be spent on clinical trials of our drug candidates and developing new drug candidates, and the balance is projected to be spent on period costs for professionals, organization and license costs. Actual spending of these funds is expected to be spread over the next 27 months.

The scientific evidence that our liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers could potentially be very significant in helping to meet future funding needs. The Company envisions that it might be able to enter into licensing/development agreements with potential pharmaceutical company partners seeking systemic antisense drug treatments, which could potentially provide funding from the partner to Bio-Path to develop their liposomal antisense drug candidate, with residual milestone payments and potential back-end royalty payments if the drug candidate became an FDA approved drug. There are many potential licensing/development structures, which would vary in terms of favorability to the Company.

We have generated approximately six full years of financial information and have demonstrated that we have been able to expand our business through an increased investment in our technology and trials. We cannot guarantee that plans as described in this quarterly report will be successful or that we can continue to receive additional capital investment. Our business is subject to risks inherent in growing an enterprise, including, but not limited to, limited capital resources and possible rejection of our new products and/or clinical development methods. If financing is not available on satisfactory terms or at all, we may be unable to continue expanding our operations. Equity financing will result in a dilution to existing shareholders.

There can be no assurance of the following:

(1)

That the actual costs of a particular trial will come within our budgeted amount.

(2)

That any trials will be successful or will result in drug commercialization opportunities.

(3)

That we will be able to raise the sufficient funds to allow us to complete our planned clinical trials.

Background Information about MD Anderson

We anticipate that our initial drug development efforts will be pursuant to our exclusive license agreement with MD Anderson. MD Anderson's stated vision is to “make cancer history” (www.mdanderson.org). Achieving that goal begins with integrated programs in cancer treatment, clinical trials, educational programs and cancer prevention. MD Anderson is one of the largest and most widely recognized cancer centers in the world: U.S. News & World Report's America's "Best Hospitals" survey has ranked MD Anderson as one of the top two best hospitals in the nation since the survey began in 1990. MD Anderson will treat more than 100,000 patients this year, of which approximately 11,000 will participate in therapeutic clinical research exploring novel treatments which is the largest such program in the nation. MD Anderson employs more than 15,000 people including more than 1,000 medical doctors and Ph.D. clinicians and researchers, and is routinely conducting more than 700 clinical trials at any one time.

Each year, researchers at MD Anderson and around the globe publish numerous discoveries that have the potential to become or enable new cancer drugs. The pharmaceutical and biotechnology industries have more than four hundred cancer drugs in various stages of clinical trials. Yet the number of actual new drugs that are approved to treat this dreaded disease is quite small and its growth rate is flat or decreasing. A successful new drug in this market is significant and substantially impacts those companies who have attained it: Genentech's Avastin, Novartis' Gleevec, OSI's Tarceva and Millennium's Velcade are examples of such drugs.

Over the past several years MD Anderson has augmented its clinical and research prominence through the establishment of the Pharmaceutical Development Center ("PDC"). The PDC was formed for the sole purpose of helping researchers at MD Anderson prepare their newly discovered compounds for clinical trials. It has a full-time staff of professionals and the capability to complete all of the studies required to characterize a compound for the filing of an IND with the FDA, which is required to initiate clinical trials. These studies include pharmacokinetics, tissue distribution, metabolism studies and toxicology studies.

We anticipate being able to use the PDC as a possible source for some of the pre-clinical work needed in the future, potentially at a lower cost than what it would cost to use a for-profit contract research organization. There is no formal arrangement between the Company and PDC and there can be no certainty that we will have access to PDC or that even if we do have access, that our costs will be reduced over alternative service providers.

Relationship with MD Anderson

Bio-Path was founded to focus on bringing the capital and expertise needed to translate drug candidates developed at MD Anderson (and potentially other research institutions) into real treatment therapies for cancer patients. To carry out this mission, Bio-Path negotiated or plans to negotiate several agreements with MD Anderson that will:

	·	allow Bio-Path to develop MD Anderson's neutral lipid delivery technology;
	·	give Bio-Path access if needed to MD Anderson's Pharmaceutical Development Center for drug development;
	·	provide rapid communication to Bio-Path of new drug candidate disclosures in the Technology Transfer Office;
	·	standardize clinical trial programs sponsored by Bio-Path; and
	·	standardize sponsored research under a master agreement addressing intellectual property sharing.

Bio-Path's Chief Executive Officer is experienced in working with MD Anderson and its personnel. Bio-Path believes that if we obtain adequate financing, Bio-Path will be positioned to translate current and future MD Anderson technology into treatments for cancer patients. This in turn is expected to provide a steady flow of cancer drug candidates to commercialize or for out-licensing to pharmaceutical partners.

License Agreement

We currently maintain an exclusive license agreement with MD Anderson (the “License Agreement”). The License Agreement relates to the delivery technology platform for antisense nucleic acids including two single nucleic acid (antisense) drug products. The License Agreement requires, among other things, that we reimburse MD Anderson for ongoing patent expense. Accrued license payments totaling $50,000 for past patent expenses are included in Current Liabilities as of June 30, 2014. Past patent expenses represent patent expenses incurred by MD Anderson prior to executing the License Agreement with Bio-Path that are being amortized in quarterly payments. As of June 30, 2014, the Company estimates remaining reimbursable past patent expenses total approximately $75,000 for the antisense license. The Company will be required to pay these patent expenses at the rate of $25,000 per quarter when invoiced by MD Anderson. In addition, accrued expense-related party of $52,050 was included in current liabilities as of June 30, 2014 representing accrued hospital expense for MD Anderson services treating patients in Bio-Path’s clinical trial of BP-100-1.01. This expense is unrelated to the License Agreement.

We intend to use our relationship with MD Anderson to develop drug compounds covered by such License Agreement through Phase IIa clinical trials, the point at which we will have demonstrated proof-of-concept of the efficacy and safety for our product candidates in cancer patients. At such time, we may seek a development and marketing partner in the pharmaceutical or biotechnology industry. In certain cases, we may choose to complete development and market the products ourselves. Our basic guide to a decision of whether or not to obtain a license for a potential drug candidate is as follows:

Likelihood of efficacy: Are the in vitro pre-clinical studies on mechanism of action and the in vivo animal models robust enough to provide a compelling case that the “molecule/compound/technology” has a high probability of working in humans?

Does it fit with the Company’s expertise: Does Bio-Path possess the technical and clinical assets to significantly reduce the scientific and clinical risk to a point where a pharmaceutical company partner would likely want to license this candidate within 36-48 months from the date of Bio-Path acquiring a license?

Affordability and potential for partnering: Can the clinical trial endpoints be designed in a manner that is unambiguous, persuasive, and can be professionally conducted in a manner consistent with that expected by the pharmaceutical industry at a cost of less than $5-7 million dollars?

Intellectual property and competitive sustainability: Is the intellectual property and competitive analysis sufficient to meet criteria established by major pharmaceutical companies assuming successful early clinical human results?

Out-Licenses and Other Sources of Revenue

Subject to demonstrating proof of concept for our delivery technology and obtaining adequate capital, we intend to develop a steady series of drug candidates through Phase II clinical trials and then to engage in a series of out-licensing transactions to pharmaceutical and biotechnology companies. Such companies would then conduct later-stage clinical development, regulatory approval, and eventual marketing of the drug. We expect that such out-license transactions would include upfront license fees, milestone/success payments, and royalties. We intend to maximize the quality and frequency of these transactions, while minimizing the time and cost to achieve meaningful candidates for out-licensing. Our near-term strategy for these licensing transactions is to develop sufficient revenue to cover our burn rate and provide development capital for clinical testing of drug candidates through Phase II for out-licensing, and for some candidates, potentially through full development and commercialization. Longer term, out-licensing transactions will be viewed in terms of creating maximum shareholder value to add to the economic value of drug candidates fully developed and marketed by the Company, as noted below.

In addition to out-licensing revenue and value creation, we may fully develop one or more of our own drug candidates. For example, there are certain cancers that are primarily treated only in a comprehensive cancer center; of which there are approximately 40 in the US and perhaps 200 throughout the world. As a result, “marketing and distribution” can become a realistic possibility for select products. These candidates may be eligible for orphan drug designation by the FDA which provides additional incentives in terms of market exclusivities and non-dilutive grant funding for clinical trials.

Finally, there are technologies for which we anticipate acquiring licenses whose application goes well beyond cancer treatment. The ability to provide the delivery of antisense and small molecules, and their efficient uptake into cells is a very important technological asset that is expected to be commercialized in other areas of medicine.

Business Strategy

The results seen to date in the Phase I clinical trial of L-Grb-2 have created the opportunity to conduct multi-site Phase II clinical trials of L-Grb-2 in three separate blood cancers (specifically, AML, MDS and CML), a significant opportunity for the Company. Additionally, we have the opportunity to develop, in conjunction with MD Anderson, our lead cancer drug L-Grb-2 to treat TNBC and IBC, two cancers characterized by formation of aggressive tumors and relatively high mortality rates. As a result of these opportunities, our business plan over the next 18 months includes: (i) milestones for the additional two Phase II clinical trials for L-Grb-2 and (ii) development of L-Grb-2 treatments for TNBC and IBC, including a pre-clinical program and a Phase I clinical trial. The Company believes that the potential to enhance the value of the Company from these two project additions is significant; however, these projects were expected to cause the capital requirements to be raised by the Company over the next 18 months to increase to $12,800,000. Since then, in January 2014, we sold shares of common stock and warrants to an institutional investor in a registered direct offering that provided us with approximately $13,750,000 in net proceeds. Actual spending of these funds is expected to be spread over the next 27 months. We are currently adding a core organization that will provide increased capabilities to execute our business plan. We intend to conduct a review of our strategy in the third quarter once the new organization has been completed. However, we currently believe that the previously estimated funding needs of $12,800,000 and expected timelines are approximately correct.

In order to capitalize on the growing need for new drug candidates by the pharmaceutical industry, and recognizing the value of clinical data, we have developed our commercialization strategy based on the following concepts:

	·	Develop in-licensed compounds to proof-of-concept in patients through Phase II.

	·	Manage trials as if they were being conducted by a major pharmaceutical company: seamless transition; quality systems; documentation; and disciplined program management recognized by diligence teams of major pharmaceutical companies; trials conducted, monitored and data collected consistent with applicable FDA regulations to maximize Bio-Path’s credibility and value to minimize time to gain registration by partner.

	·	Leverage outside testing firms for pre-clinical capabilities and MD Anderson for clinical development capabilities. Outside testing firms perform pre-clinical studies as well as clinical pharmacokinetics and pharmacodynamics while MD Anderson’s world-renowned clinics will be used for clinical trials, particularly for early clinical trials. This should allow us to develop our drug candidates with experienced professional staff at a reduced cost compared to using external contract research organizations to run clinical trials. This should also allow us to operate in an essentially virtual fashion, thereby avoiding the expense of setting up and operating laboratory facilities, and without losing control over timing or quality or IP contamination.

	·	Use our scientific advisors and the Board to supplement our management team to critically monitor existing programs and evaluate new technologies and/or compounds discovered or developed at MD Anderson, or elsewhere, for in-licensing.

	·	Hire a small team of employees or consultants: business development, regulatory management, and project management.

	·	Outsource manufacturing and regulatory capabilities. Bio-Path will not need to invest its resources in building functions where it does not add substantial value or differentiation. Instead, it will leverage an executive team with expertise in the selection and management of high quality contract manufacturing and regulatory firms. Future manufacturing capabilities may be developed at a later date as a means to control the technology and ensure adequate supplies of our future internally developed drug products and for out-licensed drug products.

Manufacturing

We have no manufacturing capabilities and intend to outsource our manufacturing function in the near future. The most likely outcome of the out-license of a Bio-Path drug to a pharmaceutical partner will be that the pharmaceutical partner will be responsible for manufacturing drug product requirements. However, in the event Bio-Path is required to supply a drug product to a distributor or pharmaceutical partner for commercial sale, Bio-Path will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. There are a limited number of manufacturers that operate under the FDA’s current good manufacturing practices (cGMP) regulations capable of manufacturing our future products. As noted previously, future manufacturing capabilities may be developed at a later date as a means to control the technology and ensure adequate supplies of our future internally developed drug products and for out-licensed drug products.

Intellectual Property

Patents, trademarks, trade secrets, technology, know-how, and other proprietary rights are important to our business. Our success will depend in part on our ability to develop and maintain proprietary aspects of our technology. To this end, we intend to have an intellectual property program directed at developing proprietary rights in technology that we believe will be important to our success.

We will actively seek patent protection in the U.S. and, as appropriate, abroad and closely monitor patent activities related to our business. In addition to patents, we will rely on trade secrets and proprietary know-how, which we seek to protect, in part, through confidentiality and proprietary information agreements.

Agreement with ACORN CRO

We entered into an agreement with ACORN CRO, a full service, oncology-focused clinical research organization, to provide us with a contract medical officer and potentially other clinical trial support services. Under such agreement, Bradley G. Somer, M. D., commenced serving as our medical advisor and medical liaison for the conduct of our Phase I clinical study of liposomal BP-100-1.01 in refractory or relapsed AML, CML, ALL and MDS.

Competition

We are engaged in fields characterized by extensive research efforts, rapid technological progress, and intense competition. There are many public and private companies, including pharmaceutical companies, chemical companies, and biotechnology companies, engaged in developing products for the same human therapeutic applications that we are targeting. Currently, all or most of our competitors have substantially greater financial, technical and human resources than Bio-Path and are more experienced in the development of new drugs than Bio-Path. In order for us to compete successfully, we may need to demonstrate improved safety, efficacy, ease of manufacturing, and market acceptance of our products over the products of our competitors.

We will face competition based on the safety and efficacy of our drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position and other factors. Our competitors may develop or commercialize more effective, safer or more affordable products than we are able to develop or commercialize or obtain more effective patent protection. As a result, our competitors may commercialize products more rapidly or effectively than we may be able to, which would adversely affect our competitive position, the likelihood that our drug candidates, if approved, will achieve initial market acceptance and our ability to generate meaningful revenues from those drugs. Even if our drug candidates are approved and achieve initial market acceptance, competitive products may render such drugs obsolete or noncompetitive.

If any such drug is rendered obsolete, we may not be able to recover the expenses of developing and commercializing that drug. With respect to all of our drug candidates, we are aware of existing treatments and numerous drug candidates in development by our competitors.

Government Regulation

Regulation by governmental authorities in the United States and foreign countries is a significant factor in the development, manufacturing, and expected marketing of our future drug product candidates and in its ongoing research and development activities. The nature and extent to which such regulations will apply to Bio-Path will vary depending on the nature of any drug product candidates developed. We anticipate that all of our drug product candidates will require regulatory approval by governmental agencies prior to commercialization.

In particular, human therapeutic products are subject to rigorous pre-clinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in other countries. Various federal statutes and regulations also govern or influence testing, manufacturing, safety, labeling, storage, and record-keeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with the appropriate federal statutes and regulations requires substantial time and financial resources. Any failure by us or our collaborators to obtain, or any delay in obtaining, regulatory approval could adversely affect the marketing of any drug product candidates developed by us, our ability to receive product revenues, and our liquidity and capital resources.

The steps ordinarily required before a new drug may be marketed in the United States, which are similar to steps required in most other countries, include:

	·	pre-clinical laboratory tests, pre-clinical studies in animals, formulation studies and the submission to the FDA of an investigational new drug application;
	·	adequate and well-controlled clinical trials to establish the safety and efficacy of the drug;
	·	the submission of a new drug application or biologic license application to the FDA; and
	·	FDA review and approval of the new drug application or biologics license application.

Bio-Path's business model relies on developing drug product candidates through Phase II and either entering into out-license agreements with pharmaceutical licensee partners who will be responsible for post-Phase II clinical testing and working with the FDA on necessary regulatory submissions resulting in approval of new drug applications for commercialization, or internally developing a drug product candidate through commercialization. For more detailed discussions on the clinical trial processes involvement with the FDA, please refer to “Part I, Item 1. Description of Business - Government Regulation” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Results of Operations for the three and six months ended June 30, 2014 and 2013.

Revenues. We have no operating revenues since our inception.

Research and Development Expenses. Our research and development expense was $517,040 for the three months ended June 30, 2014, an increase of $361,004 from the three months ended June 30, 2013. The increase in research and development expense for the three months ended June 30, 2014, compared to the three months ended June 30, 2013, was primarily due to an increase of $233,985 in drug material expense for increased drug material released by the manufacturer for use in the clinical trial, and increases of $35,860 for clinical trial expense and development of a patient data system, $89,360 for drug manufacturing development expense and $12,190 for stock option expense for employees involved in research and development activities, offset to some extent by decreases totaling $10,391 in advisory and other services. Research and development expense-related party was $3,213 for the three months ended June 30, 2014, a decrease of $28,854 compared to the three months ended June 30, 2013. The decrease in research and development expense-related party was primarily due to lower patent expense from the License Agreement. Our research and development expense was $624,681 for the six months ended June 30, 2014, an increase of $67,546 from the six months ended June 30, 2013. The increase in research and development expense for the six months ended June 30, 2014, compared to the six months ended June 30, 2013, was primarily due to an increase of $89,436 in drug manufacturing development expense and increases in clinical trial and patient data system development expense of $14,117 and non-cash stock option expense for employees involved in research and development activities of $7,400, offset to some extent by a decrease in expense of $39,262 for drug material released for use in the clinical trial and $4,145 for reduced advisory and other services. Research and development expense-related party was $24,931 for the six months ended June 30, 2014, a decrease of $22,136 compared to the six months ended June 30, 2013. The decrease in research and development expense-related party was primarily due to lower clinical trial hospital expense of $37,050, offset to some extent by higher patent expense of $14,914 from the License Agreement.

General and Administrative Expenses. Our general and administrative expenses were $754,548 for the three months ended June 30, 2014, an increase of $514,005 compared to the three months ended June 30, 2013. The increase in general and administrative expense for the three months ended June 30, 2014, compared to the three months ended June 30, 2013, was due to significant corporate development activities, including filing a shelf registration statement with the SEC, completion of a $15 million registered direct offering of shares of our common stock and the listing of Bio-Path shares on the NASDAQ Capital Market, all resulting in the step-up in operations as Bio-Path builds an increased core-capabilities organization and office that will enable the Company to better and more effectively execute its business plan. These actions resulted in an increase in general and administrative expense for the three months ended June 30, 2014, compared to the three months ended June 30, 2013, of $85,417 for legal and auditor services, $50,383 in expenses for listing and filing fees and directors and officers insurance, $44,883 for expenses of starting up an expanded Houston office operation, $218,528 for organization costs including healthcare, wages and bonus accrual, $97,065 in non-cash stock option expense for employees involved in administrative activities and $17,729 for various other items.

Our general and administrative expenses were $1,135,400 for the six months ended June 30, 2014, an increase of $655,046 compared to the six months ended June 30, 2013. The increase in general and administrative expense for the six months ended June 30, 2014, compared to the six months ended June 30, 2013, was primarily due to $76,114 in higher auditor and legal fees, $127,534 for stock exchange listing fees and increased directors and officers insurance, $46,210 for a new, larger Houston office, $211,843 for increased healthcare, salaries and bonus accrual for a larger organization, $172,166 in non-cash stock option expense for employees involved in administrative activities and $21,229 for higher Board meeting, travel and other expense.

Net Loss. Our net loss was $1,268,777 for the three months ended June 30, 2014 compared to a net loss of $427,244 for the three months ended June 30, 2013. The increase in the net loss for the three months ended June 30, 2014, compared to the three months ended June 30, 2013, was primarily due to higher research and development expense and higher general and administrative expenses as the Company raised a significant amount of capital, achieved a listing of its common stock on the NASDAQ Capital Market exchange and significantly increased operations. Net loss per share, both basic and diluted, was $0.01 per share for the three months ended June 30, 2014 and $0.01 per share for the three months ended June 30, 2013.

Our net loss was $1,773,654 for the six months ended June 30, 2014 compared to a loss of $1,083,246 for the six months ended June 30, 2013. The increase in the net loss for the six months ended June 30, 2014, compared to the six months ended June 30, 2013, was primarily due to higher research and development expense and higher general and administrative expense. Net loss per share, both basic and diluted, was $0.02 for the six months ended June 30, 2014 and $0.02 for the six months ended June 30, 2013.

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily through private placements and direct public and private sales of our capital stock. We expect to finance our foreseeable cash requirements through cash on hand, cash from operations, public or private equity offerings and debt financings. Additionally, we will be seeking collaborations and license arrangements for our product candidates. We may seek to access the public or private equity markets whenever conditions are favorable.

At June 30, 2014, we had cash of $15,721,128 compared to $3,551,832 at December 31, 2013. The increase in cash balances during the six months ended June 30, 2014 primarily resulted from the sale of an aggregate of 5,000,000 shares of our common stock and warrants to purchase a total of 2,500,000 shares of our common stock to the Sabby Investors for gross proceeds of approximately $15,000,000. We currently have no lines of credit or other arranged access to debt financing.

Net cash used in operations during the six months ended June 30, 2014 was $1,643,077 compared to $1,122,781 for the six months ended June 30, 2013. Inasmuch as we have not yet generated revenues, our entire expenses of operations are funded by proceeds from the sale of the Company’s securities and other capital raising efforts.

Net cash provided by financing activities during the six months ended June 30, 2014 was $13,812,373 compared to $2,515,961 for the six months ended June 30, 2013. Since inception through June 30, 2014, we have net cash provided from financing activities of $27,602,704. We believe that our available cash and our ongoing capital raising efforts will be sufficient to fund our liquidity and capital expenditure requirements through the first quarter of 2016.

On November 5, 2013, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on January 13, 2014. The shelf registration statement was filed to register the offering and sale of up to $100 million of our common stock, preferred stock or warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

On January 15, 2014, we entered into a securities purchase agreement, as amended, with two dedicated healthcare funds (collectively, the “Sabby Investors”) that are managed by Sabby Management, pursuant to which the Company agreed to sell an aggregate of 5,000,000 shares of its common stock and warrants to purchase a total of 2,500,000 shares of its common stock to the Sabby Investors for gross proceeds of approximately $15,000,000. The net proceeds to the Company from the registered direct public offering, after deducting the placement agent’s fees and expenses, the Company’s estimated offering expenses, and excluding the potential proceeds from the exercise of the warrants issued in the offering, were approximately $13,750,000. The offering closed on January 21, 2014. We will use the net proceeds from this offering and sale of securities for working capital and general corporate purposes.

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles in the United States has required the management of the Company to make assumptions, estimates and judgments that affect the amounts reported in the financial statements, including the notes thereto, and related disclosures of commitments and contingencies, if any. The Company considers its critical accounting policies to be those that require the more significant judgments and estimates in the preparation of financial statements. Our significant accounting policies are discussed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Information not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. We maintain a system of disclosure controls and procedures that is designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934, as amended (the “Exchange Act”) reports is recorded, processed, summarized and reported within the time periods specified in rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. As of June 30, 2014, our management, including our principal executive officer and principal financial officer, had evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) pursuant to Rule 13a-15(b) under the Exchange Act. Based upon and as of the date of the evaluation, our principal executive officer and principal financial officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods and is accumulated and communicated to management, including our principal executive officer and principal financial officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic SEC reports. Based on the foregoing, our management determined that our disclosure controls and procedures were effective as of June 30, 2014.

(b) Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting that occurred during the period of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

Information not required for smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.		Description of Exhibit
2.1		Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among the Company, Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the Company, and Bio-Path, Inc., a Utah corporation (incorporated by reference to exhibit 2.1 to the Company’s current report on Form 8-K filed on September 27, 2007).
3.1		Restated Articles of Incorporation (incorporated by reference to exhibit 3.1 to the Company’s registration statement on Form 8-A filed on September 10, 2008).
3.2		Restated Bylaws (incorporated by reference to exhibit 3.1 to the Company’s current report on Form 8-K filed on February 13, 2014).
3.3		Articles of Merger relating to the merger of Biopath Acquisition Corp. with and into Bio-Path, Inc. (incorporated by reference to exhibit 3.2 to the Company’s current report on Form 8-K filed on February 19, 2008).
4.1		Specimen Stock certificate (incorporated by reference to exhibit 3.2 to the Company’s current report on Form 8-A filed on September 10, 2008).
4.2		Warrant Agreement, dated April 25, 2008, by and between the Company and Randeep Suneja, M.D. (incorporated by reference to exhibit 4.2 to the Company’s annual report on Form 10-K filed on March 31, 2014).
4.3		Form of Warrant issued to Maxim Group LLC, Sabby Healthcare Volatility master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (incorporated by reference to exhibit 10.2 to the registrant’s current report on Form 8-K filed on January 21, 2014).
10.1		Lease Agreement dated April 16, 2014 by and between the Company and Pin Oak North Parcel TT, LLC (incorporated by reference to exhibit 10.1 to the Company’s current report on Form 8-K filed on April 18, 2014.
31*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
*		Filed herewith.

SIGNATURE

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 14, 2014	BIO-PATH HOLDINGS, INC.

	By	/s/ Peter H. Nielsen
		Chief Executive Officer, President/Principal Executive
		Officer, Chief Financial Officer, Principal Financial Officer

EX-31 2 v386337_ex31.htm EXHIBIT 31

Exhibit 31

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

I, Peter H. Nielsen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; and

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2014	By:	/s/ Peter H. Nielsen
		Peter H. Nielsen
		Chief Executive Officer
		(Principal Executive Officer)
		Chief Financial Officer
		(Principal Financial Officer)

EX-32 3 v386337_ex32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc. (the “Company”) for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Peter H. Nielsen, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2014	By:	/s/ Peter H. Nielsen
		Peter H. Nielsen
		Chief Executive Officer
		Chief Financial Officer

EX-101.INS 4 bpth-20140630.xml XBRL INSTANCE DOCUMENT 0001133818 2011-01-01 2011-12-31 0001133818 2013-01-01 2013-06-30 0001133818 2014-01-01 2014-01-15 0001133818 2014-01-01 2014-01-31 0001133818 2014-01-01 2014-06-30 0001133818 2014-01-31 0001133818 2008-04-01 2008-04-30 0001133818 2013-04-01 2013-06-30 0001133818 2014-04-01 2014-06-30 0001133818 2008-04-30 0001133818 2007-05-10 2014-06-30 0001133818 2013-05-31 0001133818 2012-06-01 2012-06-30 0001133818 2014-06-30 0001133818 2012-07-01 2012-09-30 0001133818 2012-08-01 2012-08-31 0001133818 2014-08-05 0001133818 2011-10-01 2011-10-31 0001133818 2013-11-05 0001133818 2008-12-01 2008-12-31 0001133818 2013-12-31 0001133818 2012-12-31 0001133818 2007-05-09 0001133818 2013-06-30 0001133818 bpth:SirnaLicenseMember 2011-01-01 2011-12-31 0001133818 bpth:SabbyInvestorsMember 2014-01-01 2014-01-15 0001133818 us-gaap:WarrantMember bpth:SabbyInvestorsMember 2014-01-01 2014-01-15 0001133818 bpth:MdAndersonCancerCenterMember 2014-06-30 0001133818 bpth:MdAndersonCancerCenterMember bpth:ClinicalTrialsMember 2013-12-31 0001133818 bpth:MdAndersonCancerCenterMember us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001133818 bpth:MdAndersonCancerCenterMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001133818 bpth:MdAndersonCancerCenterMember bpth:ClinicalTrialsMember 2013-04-01 2013-06-30 0001133818 bpth:MdAndersonCancerCenterMember bpth:ClinicalTrialsMember 2014-04-01 2014-06-30 0001133818 bpth:ClinicalTrialsMember 2014-06-30 0001133818 bpth:PlacementAgentMember us-gaap:PrivatePlacementMember 2010-01-01 2010-01-31 0001133818 bpth:BioPathHoldingsIncMember 2008-02-01 2008-02-29 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2012-03-01 2012-03-31 0001133818 bpth:BioPathHoldingsIncMember 2008-04-01 2008-04-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioOneMember 2012-04-01 2012-04-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioTwoMember 2012-04-01 2012-04-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioThreeMember 2012-04-01 2012-04-30 0001133818 bpth:FoundersMember 2007-05-01 2007-05-31 0001133818 bpth:PlacementAgentMember us-gaap:PrivatePlacementMember 2010-05-01 2010-05-31 0001133818 bpth:FoundersMember 2007-06-01 2007-06-30 0001133818 bpth:PlacementAgentMember us-gaap:PrivatePlacementMember 2009-06-01 2009-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-01 2010-06-30 0001133818 us-gaap:WarrantMember 2010-06-01 2010-06-30 0001133818 bpth:FinancingAgreementMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-01 2010-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2011-06-01 2011-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-07-01 2010-07-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2007-08-01 2007-08-31 0001133818 us-gaap:InvestorMember bpth:AdditionalSharesMember 2007-08-01 2007-08-31 0001133818 bpth:PlacementAgentMember 2007-08-01 2007-08-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-09-01 2010-09-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-10-01 2010-10-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-11-01 2010-11-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2011-11-01 2011-11-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2011-12-01 2011-12-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-11-01 2011-04-30 0001133818 us-gaap:InvestorMember 2011-06-01 2011-06-30 0001133818 bpth:PlacementAgentMember 2011-06-01 2011-06-30 0001133818 us-gaap:PrivatePlacementMember 2012-06-01 2012-06-30 0001133818 bpth:MdAndersonCancerCenterMember 2007-11-01 2007-11-30 0001133818 bpth:OgdenGolfCorporationMember 2008-02-01 2008-02-29 0001133818 bpth:InvestorRelationsServicesMember 2008-12-01 2008-12-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-01-01 2010-01-31 0001133818 us-gaap:InvestorMember bpth:AdditionalSharesMember us-gaap:PrivatePlacementMember 2010-01-01 2010-01-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-05-01 2010-05-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-06-01 2009-06-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-11-01 2009-11-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-12-01 2009-12-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember us-gaap:MinimumMember 2010-06-01 2010-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember us-gaap:MaximumMember 2010-06-01 2010-06-30 0001133818 us-gaap:PrivatePlacementMember 2013-02-01 2013-03-31 0001133818 us-gaap:PrivatePlacementMember 2013-04-01 2013-05-31 0001133818 us-gaap:PrivatePlacementMember 2013-08-01 2013-09-30 0001133818 us-gaap:PrivatePlacementMember 2012-10-01 2012-12-31 0001133818 us-gaap:InvestorMember 2013-11-01 2013-11-30 0001133818 bpth:PlacementAgentMember 2013-11-01 2013-11-30 0001133818 us-gaap:InvestorMember 2012-12-01 2012-12-31 0001133818 us-gaap:InvestorMember 2013-06-30 0001133818 bpth:PlacementAgentMember 2013-06-30 0001133818 us-gaap:DirectorMember 2014-04-01 2014-04-30 0001133818 us-gaap:EmployeeStockMember 2014-04-01 2014-04-30 0001133818 us-gaap:EmployeeStockMember 2014-05-01 2014-05-31 0001133818 us-gaap:OfficerMember 2014-05-01 2014-05-31 0001133818 bpth:ResearchAndDevelopmentActivitiesMember 2014-01-01 2014-06-30 0001133818 us-gaap:ManagementMember 2014-01-01 2014-06-30 0001133818 bpth:TechnologyLicensesMember 2014-06-30 0001133818 us-gaap:SubsequentEventMember 2014-06-30 0001133818 bpth:RelatedPartyMember 2013-01-01 2013-06-30 0001133818 bpth:RelatedPartyMember 2014-01-01 2014-06-30 0001133818 bpth:RelatedPartyMember 2013-04-01 2013-06-30 0001133818 bpth:RelatedPartyMember 2014-04-01 2014-06-30 0001133818 bpth:RelatedPartyMember 2007-05-10 2014-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2007-05-10 2014-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2007-05-10 2014-06-30 0001133818 bpth:PlacementAgentMember 2013-01-01 2013-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2013-01-01 2013-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2013-01-01 2013-06-30 0001133818 bpth:PlacementAgentMember 2014-01-01 2014-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2014-01-01 2014-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2014-01-01 2014-06-30 0001133818 bpth:PlacementAgentMember 2007-05-10 2014-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2007-05-10 2014-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2007-05-10 2014-06-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-01-31 0001133818 us-gaap:InvestorMember bpth:AdditionalSharesMember us-gaap:PrivatePlacementMember 2010-01-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-05-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-30 0001133818 bpth:MdAndersonCancerCenterMember 2013-04-01 2013-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>4.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Accounts Payable</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As of June 30, 2014, Current Liabilities included accounts payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">78,915</font> comprised primarily of approximate amounts owed totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">43,277</font> to the Company’s auditors for work on the annual audit, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,250</font> owed to the Company’s drug substance manufacturer, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,150</font> to suppliers of services used in the clinical trial and other miscellaneous items totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,238</font>. As of June 30, 2014 accounts payable related party consisted of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,213</font> for current patent expenses for the License Agreement. By the first week of August 2014, the June 30, 2014 amounts included in accounts payable and accounts payable related party had been substantially paid. As of December 31, 2013, Current Liabilities included accounts payable $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">76,109</font>, which amounts were subsequently paid in 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>7.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Stockholders’ Equity</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Issuance of Common Stock</i></b>  In May and June of 2007, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,505,994</font></font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,506</font></font> in cash to founders of the Company. In August of 2007, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,975,000</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">993,750</font> in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,333,334</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> in cash to investors in the Company pursuant to a second round of financing. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 530,833</font> in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,138,889</font> shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 38,023,578</font> shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,600,000</font> shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000</font> shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000</font> shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">180,000</font>. In April of 2008, the Company recorded an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24</font> shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font>. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 660,000</font> shares of common stock and warrants to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 660,000</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">165,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.50</font> a share. In connection with this private placement, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">675,000</font></font> in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,700,000</font> shares of common stock and warrants to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,700,000</font> shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.50</font> a share. In January 2010, the Company also sold an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 900,000</font> shares of common stock and warrants to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 900,000</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">225,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.50</font> a share. In connection with these private placement sales of equity, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 360,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May of 2010, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 780,000</font> shares of common stock and warrants to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 780,000</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">273,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.50</font> a share. In connection with this private placement, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 78,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June of 2010, the Company signed an equity purchase agreement for up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a 24-month period in amounts between $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> from LPC as an initial purchase in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 571,429</font> shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 571,429</font> shares of the Company’s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.50</font> per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000</font> shares of the Company’s common stock for its due diligence efforts and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 566,801</font> shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In July of 2010, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 375,000</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,251</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 375,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In September of 2010, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 125,000</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In October of 2010, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 135,135</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In November of 2010, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 135,135</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">From November 2010 through April of 2011 the Company sold shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,794,205</font> in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,980,685</font> shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 598,069</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June of 2011, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 164,853</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In October of 2011, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,920,000</font> shares of common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">576,000</font> to investors who exercised warrants from September to October 2011.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In November of 2011, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 83,333</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In December of 2011, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 172,414</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In March of 2012, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 166,667</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 89,286</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 96,154</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 185,185</font> shares of the Company’s common stock. LPC was also issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June of 2012, the Company sold $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> in shares of its common stock pursuant to a private placement, with shares to be issued, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,500</font> in shares of its common stock for services with shares to be issued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August of 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares of its common stock for the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,500</font> shares for services previously recognized in June 2012.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In July through September of 2012, the Company sold $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">795,001</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In October through December of 2012, the Company sold $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">708,600</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As of December 31, 2012 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,300,337</font> shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February and March of 2013, the Company sold $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">346,202</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April and May of 2013, the Company sold $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,198</font> in shares of its common stock pursuant to a private placement, with shares to be issued, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">489,501</font> in shares of its common stock pursuant in a direct offering, with shares to be issued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June of 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,664,665</font> shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,496,499</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August and September of 2013, the Company sold $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,220,966</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In November of 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,052,416</font> shares of common stock to investors in connection with the private placement. In November of 2013 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 805,242</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January of 2014, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares of the Company’s common stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares of the Company’s common stock for aggregate gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000,000</font>. The warrants are exercisable for a period of five years from the date of issuance. The exercise price of the warrants is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.74</font> a share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As of June 30, 2014, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">89,237,872</font></font> shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><b>8.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><b>Stock Options and Warrants</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Stock Options</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April of 2014, the Company made a stock option grant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000</font> shares of the Company’s common stock for services rendered by a director of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is one year from the date of grant for the director service stock option. The exercise price of the option is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.38</font> a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">178</font>%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term.<font style="FONT-FAMILY:Times New Roman, Times, Serif"> The Company used the simplified method to determine the expected term of the options due to the lack of historical data.</font> The total fair value of the stock option granted was determined using this methodology to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">57,425</font>, which is being expensed following the date of grant based on the stock option vesting schedule.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April of 2014, the Company made two stock option grants each to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000</font> shares of the Company’s common stock to two new Company employees. Terms of the stock option grants require, among other things, that the individuals continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.71</font> a share, which was the closing price of the common stock at the date of the grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">178</font>%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term.<font style="FONT-FAMILY:Times New Roman, Times, Serif"> The Company used the simplified method to determine the expected term of the options due to the lack of historical data.</font> The total fair value for both of the stock options granted taken together was determined using this methodology to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">133,200</font>, which is being expensed following the date of grant based on the stock option vesting schedule.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May of 2014, the Company made a stock option grant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000</font> shares of the Company’s common stock to a new Company employee. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.40</font> a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">178</font>%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term.<font style="FONT-FAMILY:Times New Roman, Times, Serif"> The Company used the simplified method to determine the expected term of the options due to the lack of historical data.</font> The total fair value of the stock option granted was determined using this methodology to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">58,975</font>, which is being expensed following the date of grant based on the stock option vesting schedule.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May of 2014, the Company made a stock option grant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 125,000</font> shares of the Company’s common stock to a newly hired officer of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.40</font> a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">178</font>%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term.<font style="FONT-FAMILY:Times New Roman, Times, Serif"> The Company used the simplified method to determine the expected term of the options due to the lack of historical data.</font> The total fair value of the stock option granted was determined using this methodology to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">294,500</font>, which is being expensed following the date of grant based on the stock option vesting schedule.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Stock option expense for the quarter ending June 30, 2014 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">122,793</font>. Of this amount, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,410</font> related to stock options for personnel involved in R&D activities and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">102,383</font> related to stock options for outside directors, officers and management of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Warrants</i></b> <i>-</i>There were no warrants for services granted during the quarter ending June 30<font style="FONT-FAMILY:Times New Roman, Times, Serif">, 2014. The warrants issued in connection with the sale of units of common stock were for cash value received and as such were not grants of compensation-based warrants.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.5

345000

15721128

100000000

5000000

2500000

15000000

13800000

52050 52050

50000

100000

32067

3213

22050

3213

141345

51364

3551832

171563

64117

16034036

3667313

2500374

1169168

1088856

1331206

1411518

17365242

5078831

78915

76109

149341

66739

52050 52050

100000

333519

294898

333519

294898

89238

84238

34113436

20096991

17170951

15397296

17031723

4783933

17365242

5078831

78915

76109

43277

18150

15250

2238

3213

149341

360000

80000

166667

200000

89286

96154

185185

6505994

78000

6505994

66000

571429

12000

164853

375000

3975000

1333334

530833

125000

135135

83333

172414

6506

993750

1000000

1794205

5980685 598069 150000 50000 3138889 38023578 3600000 180000 40000 24 18500 18500 100000 2700000 900000 5000000 780000 660000 2700000 900000 2500000 780000 660000 225000 15000000 273000 165000 675000 675000 7000000 50000 1000000

50000

25000

50000

200000

50000

150000

50000

25000

50000

2084 1042 1042 2084 566801 2084 6251 2084 2084 2084 1042 2084 0 0 0 0 0 0 0 0 0 1920000 576000

346202

2000198

795001

3220966

708600

8052416

805242

3300337

489501

11664665

1496499

89237872

25000

125000

2.38

2.71

2.40

57425 133200 58975 294500

1.78

122793

20410

102383

75000

25000

50000

52050

141345

370000

0.001

10000000

0.001

200000000

84237872

557135

47067

624681

24931

156036

32067

517040

3213

6469166

1204257

480354

1135400

240543

754548

9829509

1084556

1785012

428646

1274801

17502932

-1084556

-1785012

-428646

-1274801

-17502932

1655

11639

1531

6066

92766

244479

345

281

129

5264

1310

11358

1402

6024

331981

-1083246

-1773654

-427244

-1268777

-17170951

-0.02

-0.01

-0.33

64412577

89237872

66606105

89237872

52592648

19633

27032

8220

20410

482912

9923 182039 5318 102383 3444392 318500

690000

80312

1217670

690000

318500

29557

209071

3927304

84180

89981

141345

3836

107446

171563

-61388

38621

333519

-1122781

-1643077

-10996866

884710

-884710

435000

15000

2515961

13812373

27182704

2515961

13812373

27602704

1393180

12169296

15721128

534046

1927226

445

420000

448950

1362613

2354167

210755

1.50

4.74

1.50

10-Q false 2014-06-30 2014 Q2 BIO-PATH HOLDINGS INC 0001133818 --12-31 Smaller Reporting Company BPTH 89237872 10017

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><b>1.</b></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><b>Organization and Business</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (“L-Grb-2” or “BP-100-1.01”), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement (the “License Agreement”). The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial are now being tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data needed to demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m<sup style="font-style:normal">2</sup>. However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company requested the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors (the “Board”), advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose of 60 mg/m<sup style="font-style:normal">2</sup>, which had been increased from 50 mg/m<sup style="font-style:normal">2</sup> in the revised protocol. The Company has enrolled patients in Cohort 6 for treatment at a dose of 90 mg/m<sup style="font-style:normal">2</sup>, has two (2) evaluable patients and is currently treating another patient. Assuming the current patient successfully completes the treatment cycle the Company will be able to close Cohort 6.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (“AML”), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (“CML”) and Acute Lymphoblastic Leukemia (“ALL”), or Myelodysplastic Syndrome (“MDS”) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. Subsequently, in the fall of 2013 the Principal Investigator prepared an abstract of updated information on the results of the clinical trial through Cohort 5, which was accepted for presentation at the American Society of Hematology annual meeting in December of 2013. Highlights from the presentation prepared by Dr. Cortes for the meeting included:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Data from the Phase I clinical trial</i></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Among 18 evaluable patients, nine experienced at least a 50 percent reduction in peripheral or bone marrow blasts from baseline.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Five patients demonstrated transient improvement and/or stable disease, three of whom received a total of five cycles each.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Two patients, in addition to achieving marked blast percentage declines, also experienced transient improvement in leukemia cutis lesions.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Disease Stabilization in MDS and AML</i></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Two patients with MDS, a 53-year old male and a 72-year old female, both achieved disease stabilization and continued therapy for five cycles before disease progression.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">A 54-year old HIV positive male with AML achieved stable disease and marked reduction in peripheral blasts, continuing therapy for five cycles before disease progression.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Experience in CML-Blast Phase</i></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Patient with myeloid blast crisis of CML</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Prior therapies consist of: imatinib, dastinib, nilotinib, DCC-2036, Cytarabine + Fludarabine + Dasatinib + Gemtuzumab, PHA-739358, Clofarabine + Dasatinib</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Upon start of BP-100-1.01 patient showed a significant reduction in blasts from 81 percent to 5 percent but due to leptomeningeal disease progression discontinued therapy before full cycle.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Inhibition of Target Grb-2 Protein</i></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">Grb-2 levels were compared to baseline prior to treatment.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">On day 15, BP-100-1.01 decreased Grb-2 in five of eight samples tested (average reduction 55 percent)</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td> <div style="CLEAR:both;CLEAR: both">End of treatment day15, BP-100-1.01 decreased Grb-2 levels in eight out of nine patients (average reduction 45 percent).</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology and has already identified one new candidate.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Phase I clinical trial is typically ended when a maximum tolerated dose (“MTD”) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As noted previously, the Company has completed two of the three evaluable patients required to close Cohort 6. Once Cohort 6 is completed the Company and the Principal Investigator will determine whether the optimal biological dose has been reached, which would allow the Phase I trial to be ended. Since there has been no evidence of toxicity to date in the trial and none is expected even at a higher dose in a potential seventh cohort, the trade-off is ending the clinical trial sooner after Cohort 6 or waiting to complete a seventh cohort with a higher dose and potentially even better anti-leukemia benefits in the patient. Plans and evaluation of manufacturing scale-up of the drug substance batch size continued. Scale-up of manufacturing batch size previously produced divergence from desired drug substance product parameters, with some product in the fourth quarter of 2013 not being acceptable for use. The most recent manufacturing scale-up drug substance batch appears to have corrected this and a recent drug batch was released for use in the clinical trial by the manufacturer. Scale-up of manufacturing output of drug substance product and final drug product is critical to meeting the anticipated potential for high volume requirements of Bio-Path’s drug products for patients in multiple diseases. The larger size drug substance and final product batch sizes will also substantially drive down manufacturing cost per drug unit. The recent success on the part of the Company in raising capital should also improve drug supply by providing the financial resources that will enable the Company to commit to multiple drug batches beyond those required to satisfy near-term requirements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At the end of January 2012, the Company’s Board held a strategic planning session. Among several topics was a discussion of the Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">345,000</font> at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50</font>%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">345,000</font>, and cancel the license.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path became a publicly traded company as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On November 5, 2013, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on January 13, 2014. The shelf registration statement was filed to register the offering and sale of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font> million of our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On January 15, 2014, we entered into a securities purchase agreement, as amended, with two dedicated healthcare funds (collectively, the “Sabby Investors”) that are managed by Sabby Management, pursuant to which the Company agreed to sell an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares of its common stock and warrants to purchase a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares of its common stock to the Sabby Investors for gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000,000</font>. The net proceeds to the Company from the registered direct public offering, after deducting the placement agent’s fees and expenses, the Company’s estimated offering expenses, and excluding the proceeds from the exercise of the warrants issued in the offering, were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.8</font> million. We will use the net proceeds from this offering and sale of securities for working capital and general corporate purposes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On March 5, 2014, the NASDAQ Stock Market LLC informed the Company that it had approved the listing of the Company’s common stock on the NASDAQ Capital Market. The Company’s common stock ceased trading on the OTCQX and commenced trading on the NASDAQ Capital Market on March 10, 2014 under the ticker symbol “BPTH.”</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On March 11, 2014, the Board of the Company appointed Ulrich W. Mueller, Ph.D., as the Company’s Chief Operating Officer. This is the initial hiring step implanting a plan to put in place a core organization that can manage the Company’s expanding clinical trials and deliver on the Bio-Path business plan vision of rapidly converting validated protein disease targets into proprietary liposome-antisense drug candidates that enter Phase I clinical trials. In April 2014, the Company progressed further with its organization plan by hiring a director of clinical trials, controller and director of information technology. Subsequent to the close of the second quarter, 2014, the Company has hired additional personnel to add further to the core organization. The Company anticipates that by the end of the third quarter 2014 it will have added the remaining employees to complete the organization plan.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April 2014 the Company entered in a lease for a larger office space. The new, expanded size office is required for the core organization the Company is adding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As of June 30, 2014, Bio-Path had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,721,128</font> in cash on hand.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Research and development expense includes stock option expenses of $20,410 and $8,220 for the quarters ending 6/30/2014 and 6/30/2013, respectively; $27,032 and $19,633 for the six month periods ending 6/30/2014 and 6/30/2013, respectively; and $482,912 for the period from inception through 6/30/2014 Includes $690,000 technology impairment charge for the period from inception through 6/30/2014 General & administrative expense includes stock for services, stock option and warrant expenses of $102,383 and $5,318 for the quarters ending 6/30/2014 and 6/30/2013, respectively; $182,039 and $9,923 for the six month periods ending 6/30/2014 and 6/30/2013, respectively; and $3,444,392 for the period from inception through 6/30/2014 for stock options and warrants and $318,500 in stock for services. EX-101.SCH 5 bpth-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Business link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Related Party link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Prepaid Drug Product for Testing link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Accounts Payable link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Accrued Expense link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Accrued License Payments - Related Party link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Stock Options and Warrants link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - New Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Organization and Business - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Related Party - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Prepaid Drug Product for Testing - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Accounts Payable - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Accrued Expense - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Accrued License Payments - Related Party - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Stock Options and Warrants - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 bpth-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 bpth-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 bpth-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable Disclosure [Abstract] Accounts Payable Disclosure [Text Block] Accounts Payable Accounts Payable Disclosure [Text Block] Accrued Liabilities [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expense Accrued License Payments Related Party Abstract Collaborative and License Arrangement Disclosure [Text Block] Accrued License Payments - Related Party Collaborative and License Arrangement Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Stock Options And Warrants [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Options and Warrants Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Disclosure Organization and Business Additional Information [Abstract] Disclosure - Organization and Business - Additional Information [Abstract] Organization and Nature Of Operations [Table] Organization and Nature of Operations [Table] Legal Entity [Axis] Entity [Domain] Product Or Service [Axis] Products and Services [Domain] Phase One [Member] Phase I clinical trial Phase 1 [Member] Subsidiary, Sale Of Stock [Axis] Sale Of Stock, Name Of Transaction [Domain] Private Placement [Member] Private Placement memorandum Statement Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Warrant [Member] Warrant Warrant Range [Axis] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Related Party Transaction [Axis] Related Party Transaction [Domain] Sabby Investors [Member] Sabby Investors Sabby investors member Organization and Nature Of Operations [Line Items] Organization and Nature of Operations [Line Items] Organization and Nature of Operations [Line Items] Percentage Of Change In Depreciation Amortization Of Intangible Assets and Asset Impairment and Other Charges Operating Percentage of Charge Percentage of Change in Depreciation Amortization of Intangible Assets and Asset Impairment and Other Charges Operating Other Asset Impairment Charges Impairment of License Technology impairment charge Technology impairment Cash Cash Cash, beginning of period Cash, end of period Authorised Capital To Be Raised Authorized capital to be raised Represents capital value registered through shelf registration statement Stock Issued During Period Shares New Issues Stock issued during period, shares, new issues Common stock and warrants issued, shares Stock Issued During Period, Value, New Issues Stock issued during period, value, new issues Common stock issued , value Proceeds from Issuance Initial Public Offering Proceeds from issuance initial public offering Related Party Transactions [Abstract] Schedule Of Related Party Transactions By Related Party [Table] Related Party [Axis] Related Party [Domain] Md Anderson Cancer Center [Member] MD Anderson Cancer Center Md Anderson Cancer Center [Member] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and Development Expense Nature Of Expense [Axis] Interim Period Costs Not Allocable [Domain] Clinical Trials [Member] Clinical Trials Clinical Trials [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Accrued Liabilities Related Parties Current Accrued expense - related party Accrued expense - related party Accrued Liabilities, Related Parties, Current Accrued License Payments - Related Party Accrued license payments - related party Accrued license payments - related party Related Party Transaction, Expenses from Transactions with Related Party Cash paid to MD Anderson Cancer Center for expenses Accounts Payable - Related Party Accounts payable - related party Accounts payable - related party Research and Development Expense Research and Development Research and development Disclosure Prepaid Drug Product For Testing Additional Information [Abstract] Disclosure - Prepaid Drug Product for Testing - Additional Information [Abstract] Inventory Disclosure [Table] Inventory Disclosure [Table] Inventory Disclosure [Line Items] Inventory Disclosure [Line Items] Inventory Disclosure [Line Items] Other Inventory, Gross Prepaid drug product for testing Prepaid drug product for testing Other inventory, gross Statement Of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets Current [Abstract] Current assets Other Assets Current Other current assets Assets Current Total current assets Other Assets Noncurrent [Abstract] Other assets Finite Lived License Agreements Gross Technology licenses - related party Finite Lived Intangible Assets Accumulated Amortization Less Accumulated Amortization Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill), Total Assets TOTAL ASSETS Liabilities and Stockholders Equity [Abstract] LIABILITIES & SHAREHOLDERS' EQUITY Liabilities Current [Abstract] Current liabilities Accounts Payable Current Accounts payable Accrued Liabilities Current Accrued expense Liabilities Current Total current liabilities Long Term Debt Noncurrent Long term debt Liabilities TOTAL LIABILITIES Stockholders Equity [Abstract] Shareholders' Equity Preferred Stock Value Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding Common Stock Value Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively Additional Paid In Capital Additional paid in capital Development Stage Enterprise Deficit Accumulated During Development Stage Accumulated deficit during development stage Stockholders Equity Total shareholders' equity Liabilities and Stockholders Equity TOTAL LIABILITIES & SHAREHOLDERS' EQUITY Accounts Payable [Table] Accounts Payable Accounts payable Accounts Payable, Trade Accounts payable, trade Accounts Payable, Other, Current Accounts payable, other, current Firm Owes Facility Expenses The firm owe facility expenses. Disclosure Accrued Expense Additional Information [Abstract] Disclosure - Accrued Expense - Additional Information [Abstract] Accounts Payable and Accrued Liabilities [Table] Accounts Payable and Accrued Liabilities [Table] Board Committee Meeting fee [Member] Board commottee meeeting fee Legal Fee [Member] Legal Fee Legal Fee [Member] Stock Transfer Agent [Member] Stock Transfer fees Stock Transfer Agent [Member] Expenses [Member] Expenses Expenses [Member] Management Incentive Award [Member] Management Bonus Accrual Management Incentive Award [Member] Accounts Payable and Accrued Liabilities [Line Items] Accounts Payable and Accrued Liabilities [Line Items] Accounts Payable and Accrued Liabilities [Line Items] Disclosure Accrued License Payments Related Party Additional Information [Abstract] Disclosure - Accrued License Payments - Related Party - Additional Information [Abstract] Reference Period Disclosure [Axis] Reference Period Disclosure Reference Period Disclosure [Domain] Reference Period Disclosure Previous [Member] Past Patent Expenses Previous [Member] Disclosure Stockholders Equity Additional Information [Abstract] Disclosure - Stockholders' Equity - Additional Information [Abstract] Shareholders Equity [Table] Shareholders Equity [Table] Investor [Member] Investors Placement Agent [Member] Placement Agent Placement Agent [Member] Bio Path Holdings Inc [Member] BioPathHoldingsInc Bio Path Holdings Inc [Member] Ogden Golf Corporation [Member] Ogden Golf Co. Ogden Golf Corporation [Member] Statement Scenario [Axis] Scenario Unspecified [Domain] Equity Unit Purchase Agreements [Member] Equity Unit Purchase Agreements Financing Agreement [Member] LPC financing agreement Financing Agreement [Member] Statement Class Of Stock [Axis] Class Of Stock [Domain] Founders [Member] Founders Founders [Member] Additional Shares [Member] Additional Shares Additional Shares [Member] Due Diligence Efforts [Member] DueDiligenceEfforts Due Diligence Efforts [Member] Lincoln Park Capital Fund Limited Liability Company [Member] LPC Lincoln Park Capital Fund, LLC [Member] Other Ownership Interests By Name [Axis] Other Ownership Interests Name [Domain] Investor Relations Services [Member] Investor Relations Services Investor Relations Services [Member] Presented Scenarios By Scenario [Axis] Presented Scenarios By Scenario [Axis] Presented Scenarios By Scenario [Domain] Presented Scenarios By Scenario [Domain] Scenario One [Member] Scenario 1 Scenario 1 [Member] Scenario Two [Member] Scenario 2 Scenario 2 [Member] Scenario Three [Member] Scenario 3 Scenario 3 [Member] Shareholders Equity [Line Items] Shareholders Equity [Line Items] Shareholders Equity [Line Items] Stock Issued During Period Shares Contingent Considerations Common stock issued , shares Stock Issued During Period Shares Contingent Considerations Stock Issued During Period Shares Merger Common stock issued merger transactions, shares Number of shares of stock issued during the period pursuant to a merger. Stock Retained By Shareholders Shares Merger Transaction Common stock retained shareholders, shares Stock Retained by Shareholders, Shares, Merger Transaction Fair Value Of Common Stock Issued Common stock issued for services, value Fair value of common stock issued. Common Stock Additional Shares Issued Common stock issued, additional shares Common Stock Additional Shares Issued Issuance Of Common Stock Shares For Service Common stock issued for service, shares Issuance Of Common Stock Shares For Service Issuance Of Common Stock and Warrants Shares Common stock and warrant issued, shares Issuance Of Common Stock And Warrants, Shares Common Stock Repurchased Shares Common stock repurchased, shares Common Stock Repurchased Shares Issuance Of Common Stock and Warrants Value Common stock and warrants issued, Value Value of issuance of common stock and warrants. Stock Committed To Be Issued During Period Value Acquisitions Equity purchase agreement value Stock Committed to be Issued During Period, Value, Acquisitions Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock and warrant from LPC Net proceeds from sale of common stock Stock Committed To Be Issued During Period Shares Acquisitions Committed shares issued Stock Committed to be Issued During Period, Shares, Acquisitions Issuance Of Warrants Shares Warrants issued, shares Issuance Of Warrants, Shares Stock Issued During Period Shares Stock Warrants Exercised Common stock issued for exercise of warrant (in shares) Number of shares issued during the period as a result of the exercise of warrants. Stock Issued During Period Value Warrant Exercises Common stock issued for exercise of warrant Stock Issued During Period Value Warrant Exercises Issuance Of Stock and Warrants For Services Or Claims Common stock issued for services Common Stock Shares Issued Common Stock, shares issued Common Stock Shares Outstanding Common Stock, shares outstanding Disclosure Stock Options and Warrants Additional Information [Table] Management [Member] Management Research And Development Activities [Member] R&D Activities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBased Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Stock or Unit Option Plan Expense Stock option expense Disclosure Commitments and Contingencies Additional Information [Abstract] Disclosure - Commitments and Contingencies - Additional Information [Abstract] Product Liability Contingency [Table] Technology Licenses [Member] Licenses Agreement Technology Licenses [Member] Finite Lived Intangible Assets By Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Supply Agreement [Member] Supply Agreement Supply Agreement [Member] Patented Technology [Member] Patented Technology Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Product Liability Contingency [Line Items] Product Liability Contingency [Line Items] Cost Of Reimbursable Expense Estimates reimbursable past patent expenses Accrued Patent Expense Current Patent expense per quarter Accrued Patent Expense, Current Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Accrued Liabilities Related Party Current Accrued expense - related party Accrued Liabilities Related Party Current Drug Product Testing Agreement Consideration To Be Paid In Stages Drug Product Testing Agreement Consideration To Be Paid In Stages Represents consideration to be paid in various stages with respect to agreement with its drug product manufacturer for testing. Preferred Stock Par Or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, shares issued Preferred Stock Shares Outstanding Preferred Stock, shares outstanding Common Stock Par Or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Income Statement [Abstract] All Other [Member] All Other All Other [Member] Related Party Transactions [Member] MD Anderson for License Related Party Transactions [Member] Related Party [Member] Related Party RelatedpartyMember Revenues Revenue Operating Expenses [Abstract] Operating expense General and Administrative Expense General & administrative Operating Expenses Total operating expense Operating Income Loss Net operating loss Nonoperating Income Expense [Abstract] Other income (expense) EX-101.PRE 9 bpth-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`IT0$VL+5-6Q#^O=WXB"$((9)X;M9L;<_[K,G>[+R]P:*N MHCE85VJ5$9:D)`*5:UFJ248^1B]QET3."R5%I15D9`F.#/J7%[W1TH"+PF[E M,E)X;QXH=7D!M7")-J#"S%C;6OAP:R?4B'PJ)D!YFG9HKI4'Y6/?U"#]WA., MQ:SRT?,B/%Z16*@$^H-\N=K0=V)E!FO=K"Y_(P9%P7"/AN$'"<8N$ MHX.$XPX)1Q<)QST2#I9B`<'BJ`R+I3(LGLJPF"K#XJH,BZTR++[*L!@KP^*L M'(NS_?R]MF2.=G//+"MR9_[Y6 M18\I%\*"?/]=J>*V?5@^@8B)G:13'&HX< M85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]H MJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`1DRD=:GU8B\4&90C76Z$R[[>/#YDTW*L27?%5W M/HE1C,]$%4+W+*7/*]TJ/[&=-G'E:%VK0ARZ4G8J/ZE22TS3A71_8XCM3Z'W"K M`5(.RRRR<)1^^$0?PWH:PGW0]D_ATM)WOQ;V/X"``#_ M_P,`4$L#!!0`!@`(````(0!H>4_,&0,``-0(```/````>&PO=V]R:V)O;VLN M>&ULE);;;N(P$(;O5]IWB'*_S0%Z5*&BD*I(74`+VUY:;FS`:F*GME-@GW[' M8:$3TJ+N57"<^?U[_,V8ZYMUGGEO7!NA9,>/3D+?XS)53,A%Q_\]N_MQX7O& M4LEHIB3O^!MN_)ON]V_7*Z5?GI5Z\4!`FHZ_M+:X"@*3+GE.S8DJN(29N=(Y MM3#4B\`4FE-FEIS;/`OB,#P+!1\9=Z#W-!;/PG)U,I]"JG= M[$B\72[EZ"?(#TJPS".M73D]7V=ADA/)(@E392:1_UTE"! M3.RS$I\CG=.OZ3@S_=[T'LF<(96*"KRGL5Y0*?Y4J!(H*');&B&Y,4@@AFK; M'\_YH8]?#G3.((_:;G#4)8JZ.(R::%Y0P*7AS*]-%6EM`96W]#GC./`&E3A!Y&Z!-O)&GJ"J05BE*(&CK!D%?@`)0^! M;F57]894B<`&,$Q1@\FI5>G+4F4,F@))7DLH#AR,&8H:*%;!9%Q4':8ZMR>J M-04;6`,J=Y^ZJ`FBRG-AM][=R?<55*A<0*,5T$[?,6QA@*(&AR.^(O^.`:+= M64HXDA0:TH$;3'/4`'%:/AO^6D(02=X.0S&`48/`3QDF/<9J+&$DHP:3-9*K M6)=>FFU[%LI(5--I0'F<[5J%8[BA%1]TOD.ZZYZ0H1BS#H.F#F:]+C/'.AC] MN('LTEM M[]B@:J=P\Z4T2^%*=@]WIU6G&>S^D'3_`@``__\#`%!+`P04``8`"````"$` M%(0D/[X(``"$)P``&````'AL+W=OOYK3]_:]KL\3B'!LGZ;OY_/':CYO-^_U8=W. MFH_Z"$]>F]-A?88_3V_S]N-4K[>=Z+"?VY;ESP_KW7$J(JQ.]\1H7E]WFSIN M-I^'^G@604[U?GV&_K?ONX\6HQTV]X0[K$_?/S\>-LWA`T*\[/:[\Z\NZ'1R MV*R*MV-S6K_LX;U_,G>]P=C='T;XPVYS:MKF]3R#<'/14?.=E_/E'"(]/VYW M\`;<]LFI?GV:?F.KRG:G\^?'SJ#_[.JO5OE]TKXW7]EIM_W;[EB#VS!.?`1> MFN8[IQ9;#H%X;JC3;@3^<9ILZ]?UY_[\S^8KKW=O[V<8;@_>B+_8:OLKKML- M.`IA9K;'(VV:/70`?DX..YX:X,CZ9_?YM=N>WY^FCC_S`LMA0)^\U.TYW?&0 MT\GFLSTWA_\*$NM#B2!V'P0^KP2Y(71Z(7SV0F;-`F8MG0!:OR%T>R%\CFL1 MPG;O"Y_C6O1[(7R.:S'HA?`YKD68HEU7X7-")_C6F20?B(;>!Z:Z7!C M0)A,)/@%6[5GKNT%BRZ53.U:+#UOQN)C3 M(H3,\J$DA^SF4;[Q,$]3L!WRMX69^>/9=Q[G/V`R;7I*>(7BZI0(*7SJ\+`Q M!1(*I`A<&F9ZT`P9G0$&!$H%+4-_3HU9(X>L%6"G]A&GY__"3A^%^8J=# M!"Y=LO4>1+[NB9!"FI2!"X:TDR&#)3D"%PDM)D"*:@I$;AH2#,5 M,D"B^0NKE^;O];47TY*SGZ80ZY*6@6Y!*"B++FH]PCC.ANU)-6ZAFQ,*"OR4WI(Y$B$#ASU&8%"2 M(`,E*0*#D@P9*,D1&)04R$!)B<"@I$(&2#1;86_3;.W6SX#O_P/'`DQ-+B2I MN20."XK?I:;'`LNE^2D(?">18Q`03JP&89YO.70-N"-(J@;Q;==?T$7VCB"Y M&L3S`N:0?"GN"%*J07S77S*ZV%2WHVB#!^>+/S=X7*@/7D`<"05%#%[@N9Y+ MYD\D"/K@D54P5H/8KN6Y9%--[@B2JD$8N.Y:)$>R.Z+D:A1W84$8/5N+.X*4 M:I#EPEYZ%LGYZG84;?3@M*&-WNVM@+/)D!$S0T$10\;L`-Z2#&HD&,J&H$I< M>P$9J;N24$6J*EBP\"Q&!CVCDER36`O7\T@K!964FB3P+'OID&8J1:/9RJM5 M]41XVU;.)K:2Q`@%1=CZ<-U705%\U317C:625)-<=Y9J8M5`DCO.5L?1,.R)(9"@IL3G(#((P(&;C7Q0@,2A)DH"1%8%"2(0,E.0*# MD@(9*"D1&)14R`")9BM?1$?XVM%)TI(9%?89J'^NI*RF8)Y#UH[$ M4*2Z@OD.60PS0Y+K$M\CHUT8BE)3+.V`ODFE2G17>8US_TK`JT>Z%-##=L]Q MKYZVY4/,B%@BO*`DFU8B'R(]E<@5>B8?(CV7R!5Z(1\BO>P1D1&VZ[H!&:Y* MU>A.\FIFA).B^%'+EH"<'D(F.,+)!Y:$SPE-1%VF>$@M" M)C@XYVW2EZA_KLYY5<%&SJ&H@W>1& M3\H.;Q;R2)(4F-5D@W,D.2 M_TY2&)*22AQ2#E6J1#>6EPZJL?Q+#P?.8+=+!28J#LU@TF;8<\1:L5C:3K`( MR-M'/4?U6"UW?!^.:\PBJ9\8JO2.MC)#E6LJWW7A"W>ZFA6&JM14GNTM8:3FA^OT;GT7UH?E,ELZ0884R.*\B2<')&$MD4)1("HI2B0R*,DE! M42Z105$A*2@J)3(HJB0%1+K%O+088;&H1-3EV"?#&3*L5@:[$TD*OD,LD4%1 M(BDH2B4R*,HD!46Y1`9%A:2@J)3(H*B2%!!I%MNT2+O[J]).J==K/CV[]1SQ M/;YC,[*P1/US7NS(W7%!UHB8!+%\R>*+D6Q0V,OA3W M1"FU*,RV^/\(]9--]9LX^AB.*PEM41)"7809%)I09$*Q"24FE)I09D*Y"14F M5)I0I4&Z#;"V:JL%;H`C_VMJ\SAZ8M/O[\.>P^N@2^*2TVET(:'1L0DE)I2: M4&9"N0D5)E2:4*5!NH6\WD$R#Z$*Z6"AU""4F M*S6AS(1R$RI,J#2A2H-T"WF%1"WDI^&Q62@J+=5"NC*&<*V&9ZIN(=GQH@L) M_8I-*#&AU(0R$\I-J#"ATH3XG:"^\]`O8:&XXR-N0ASJTUL=U?M].]DTG_S^ M#E3'SX\2[B\7V?QV4;>2D2&)S=P?_U3;SD9G!\ M+E\,[D!]K-_JOZ]/;[MC.]G7K^`QW#V"5#V)6U3BCW/ST5U(>6G._X?````__\#`%!+`P04``8`"````"$`?T_^ MB9`<``!)[```&0```'AL+W=OTHB:OC*&6[.]W__FR*`$5L0OBVTP]M M!UKZ.&&16R`%?_CO/\_?K_X^O+P^'7]\O`YN2M=7AQ^/Q\]//[Y^O%XMV_^I M75^]OCW\^/SP_?CC\/'ZW\/K]7\__?__??AU?/GS]=OA\'9%"3]>/UY_>WO[ M>7][^_KX[?#\\'IS_'GX0:]\.;X\/[S1/U^^WK[^?#D\?#Z]Z?G[;5@J56^? M'YY^7*<)]R^2C..7+T^/A^;Q\:_GPX^W-.3E\/WAC=;_]=O3SU>3]OPHB7M^ M>/GSKY__>3P^_Z2(/YZ^/[W]>PJ]OGI^O.]]_7%\>?CC.VWW/T'YX=%DG_Y1 MB']^>GPYOAZ_O-U0W&VZHL5MKM_6;RGITX?/3[0%R6Z_>CE\^7BM@ONX%]Y= MWW[Z<-I#ZZ?#K]?<[U>OWXZ_.B]/GX=//PZTN^E`)8?@C^/QSP3M?4Z:Z,VW MA7>W3X=@^G+U^?#EX:_O;_/CK^[AZ>NW-SK>%=JD9,ON/__;/+P^TBZEF)NP MDB0]'K_3"M#_KYZ?DKY!N^3AG]//7T^?W[Y]O(ZJ-Y6[4A00?O7'X?6M_91$ M7E\]_O7Z=GS>I%"@H]*04(?03QT25&[*8>6N]IZ42*?03Y,2W-0JE7*U=B=? ME[).H9\F)7S_NM#R3KN%?F8IXMU1U6^FG]F;;\):):A4W[%3[W0*_3RG!.72 M>S)(\]-FT$^3\1L'IJY3@J1WZN-/AUK8.8*LB]$OYNW5]Q^2P/2RY!>3$[Y_ MOP:FGR6_F!RRX[W')S`]+?G%Y+QCMY@N%M#NU6^/2N_O[R$=E-,Q3G[1.6'E MYIT=)30'*?GE_1L3FF.3_&+>_AO[-#3')CJ[$P7O/S:1D2?YQ>R4Z#=RC$!1 MSJ#PW>?'R!B4_&)VSV]TW;(YUN7?.DIE[8HRLG#O-;ZV/Z325\VX.WW]1K9B] M7#WOGJ#V_O-FU>R>Y!=SM,K2/GR;U@NG\J/Y\/;PZ:9F0E2*7*A$J09(4E<1\O*8=3D7&*]5/?W\*[ZH?;O^FDN=1,W'* MT/_/3%2QF88C)V(Y3<,D55"R\!9O:/.&#F_HI@WT_VQ=JF5[57KF/6ZC"OU'%3J0TCTHMZRLPV3+*G00I7M([EVZ0^1:=(_(M61=(DO6'2`M MWT\"NGH`[S:JT`54H0\HW0ERB\^.>;;XPA%6^A#30)"5XBSDXU9YSCK"I[%QX7>$1=Z1USH'7&A=\2%WA'G>\,:;J8NIW3C[#,+C@3!Q.Q0S!U,#6VK)E>F>C2RLQ=(6RW+!Q,F>V8I8.IL6.]]Q[6H>"GG/5BY?Z[P7.(3E9Q>EA=5]NUR*0F:TTKKFURZQ22'N\5=X)"W M>'`E]L8.>POK%#OLY0/KBQP]S"EL4.T.`-3=[0X@UMWM#A#5W>T.,- M?=XPX`U#WC!*&_2`?%*&C].6_&X+R^P,-'$P-78DIP)F)F#F`F8A8)8NAIVD M5BZ&G7[6`F;C8.KLY+,5,#L!LQ;^CSA@%O&/*&4=J0O^JG+>?1N`EO MF/*&&6^8\X8%;UCRAA5O6/.&C6DXCPX%X?EXGDZ16P&S$S![`:.4!(HED.XO M^1-[8=.4[D-^2/93UI+)D[4X3"D$-#=[0Y`TMWM#F#1W>T.4-/=[0YPT#WC#D M#:.T(7^925O.3DYXPY0WS'C#G#,.2-ZQXPYHW;'C#EC?L>,.>-RA5:(D+ M+?KHG?>`TH@HJM!35*&KJ$)?487.H@J] M116ZBRKT%Y5U&-^IM=")5*$7Q85>%!=Z45SH17&A%\6%7A1GO2@[9V5=)FO) M^D?6DG4&?EZC!Z/><5Y+:'JD,W=W-0I8#XY3AJ[2V1U8]AF@`8DF)%J0:$.B M`XDN)'J0Z$-B`(DA)$:0&$-B`HDI)&:0F$-B`8DE)%:06$-B`XDM)':0V$-" M*8Q@ZQ363F'O%!9/8?,45D]A]Q263V'[%-9/8?\4%E!A`Q564&$'%99080L5 MUE!A#Q4646$3%59181<5EE%A&V-L8XQMC+&-,;8QQC;&V,88VQAC&V.OC=9G M*7H\TZHYDF<](WHJU?_(4?*NC]=T/S"K*Z*`%<9QROAJ#T@T(=&"1!L2'4AT M(=!\2`T@,(3&"Q#@EJJ<':RIW]%P2.W`3&#&%Q`P2IW=+%A#8I,G@BK]QT=++>`NI&>][">]=GF@%M%_]NO[_.M!M5RK,$`I MBX@J`7](6FG=TBVEEXM$P\H(*Z7"HSE:MS2#'O44=DYAZ12V3F'ME.5=5'=U)2V>;[_8YB7>1/PP;]-.[4O1]OD0+:`' MB2T#*_2@%9\V%+PKE;H[ZP"@[XH8Q48_L(BH5EA$?(M3)G:Z0(6)""8T4\1S/)B1: MD&A#H@.)+B1ZD.A#8@")(21&D!A#8@*)*21FD)A#8@&))216*9%V0RHMV!5J M[7]Y`_.WD-A!8@\)I3`28P0+I[!Q"BNGL',*2Z>P=0IKI[!W"HNGL'D*JZ>P M>PK+I[!]"NNGL'\*"ZBP@%9[^UB?IRXKJ:**RB MPBXJ+&.,98RQC#&6,<8RQEC&&,L88QEC+&/LE=&J-NB+M>^H-A*:5QOLUEV< M,IY2H@&)9DJD]=:I8+'+E19,:$.B`XDN)'J0Z$-B`(DA)$:0&$-BDA+ZTYUC MIT]AQ`P2T@HA1&LG,+.*2V=1UR%O5-8/(7- M4U@]A=U36#Z%[5-8/X7]4UI`?4JKUTK5POB*-M!W`+"#"DNHL(4*:ZBPAPJ+ MJ+")"JNHL(L*RZBTC;ECQ$9Z8RQCC&6,L8PQEC'&,L9:QG2#Z.&X6JW&MPC+ M&&,98Z^,5KV1S)MD%1RR^R>GM_'*@ST/%&O((U`#(TV,M##2QD@'(UV,]##2 MQ\@`(T.,C#`RQL@$(U.,S#`RQ\@"(TN,K#"RQL@&(UN,[#"RQPC-&Y)X_/': MXQK-)((9@9!*8"3-/X*7)7"2YBC!.0(KE4!+)?"2YCK!ZR,P4PG45`(WE4!. M);"3)E'!VR7PDR9:P3D"0Y5`49J>!2]+("E-SX)S!)K2%"XPAR9UP8S`4YKX M!><(/*698'".P%.:+0;G&$]U^5,KA1'-PFF/)-"4,KX@NW2A!XU_IW1)WL9+ M%W:_.@Y2R',Z;6"DB9$61MH8Z6"DBY$>1OH8&6!DB)$11L88F6!DBI$91N88 M66!DB9$51M88V6!DBY$=1O88H=(%ND:E"V8$0E+I@G,$2M)D:CA'("5-N(9S M!%I2Z8)S!&(J@9E4NN!E"=RDT@7G".RDT@7G"/RDT@7G"`RET@7G"!REJ>5P MCL!2FFL.YP@\I=(%YM`,=9@1>$I3UN$<@:Z18^=OLC=Q4OI8:2/D0%&AA@9862,D0E&IAB9862.D05&EAA9862- MD0U&MAC9862/$2I;H$54MF"F(6`$.M*("UZ6$=)C/HVXX!R!E33B@G,$7M*( M"\X1F$EE"\X1N$EE"\X1V$EE"\X1^$EE"\X1&$IE"\X1.$IE"\X16$IE"\X1 M>$IE"\RAL@4S`D^I;,$Y`D^I;,$Y`D^I;,$Y?D_MLB69#NPWRI9T%C%:E?.7 M;?AZN]FKYRUF7UON8:2/D0%&AA@9 M862,D0E&IAB9862.D05&EAA9862-D0U&MAC9862/$2I:H&94M&!&X"*-M>`< M@8TTUH)SSCY>-([&6G".0$L::\$Y`C%IK`7G"-2DVT0X1R`GW2;".0(]:?9] MG",05`D,I:(%+TO@*!4M.$=@*14M.$?@*14M,(>*%LP(/*6B!><(/*6B!><( M/*6B!>?X/;6+%BHI?J=H2=[&[Q*QKTC$00IYBQ:(-'5*.DI"7_/C8R`MO)@V M1CH8Z6*DAY$^1@88&6)DA)$Q1B8:N;C[ISACAI$Y1A8866I$K^SI87_[!NH* MAZPQLL'(%B,[C.PQ0D4+=(B*%LPT!(R1T:,TC;3@90F$I)$6G"-0DD9:<(Y` M2AIIP3D"+6FD!><(Q*21%IPCD)-&6G".0$\::<$Y1E`BLP^[[*,?%2TX1^`H M%2TX1V`I%2TX1^`I%2TPAXH6S`@\I:(%YP@\I:(%YP@\I:(%Y_@]M8N69+J[ MWQAI26?)LT=:V&0/<9!"M+Z7>FA#(^E5QOD%Y29.:6&DC9$.1KH8Z6&DCY$! M1H88&6%DC)$)1J88F6%DCI$%1I8866%DC9$-1K88V6%DCQ&J7*!K5+E@Q@CI M<9:&6W".0$D:;L$Y`BEIN`7G"+2DX1:<(Q"3AEMPCD!-&F[!.0(Y:;@ES4E/ MLJ>Y--B];RI<\DAXYRCW:;0%KX[`3QIMR2_K-"\'7QV!H/1,+EX=@:+T3&Y^ M=>JN+17894LR MMV2^;/DG*#\\WG_^MWEX?3S\H'J#_NYV\O<$T[]C$J134=KE"G\@6$.>4U]# M(ZE)IWFA^!!*$Z>T,-+&2`5*?ED7RA6\*(&A M-,R"<()*51%ISCE]0N M5Y*Y]_+EBO"[S^F4?7;9PK_''QZX)HYI8:2-D0Y&NACI8:2/ MD0%&AA@9862,D0E&IAB9862.D05&EAA9862-D0U&MAC9862/$:I;H&PTS((9 M8Z2_;L$Y`B6I;L$Y`BFI;L$Y`BVI;L$Y`C&I;L$Y`C6I;L$Y`CFI;DES](?# M._I[WGQ<0V`G#;/D8ZJN^6"-GNF2G(C14Y_R:=+%PLH(]*1!%KQO!(+2($M^ MHT+7C,H"0VF0!:X.52V8$2A*@RPX1W#1I$$6G"-0E`99<(Y`41ID\>7854LR MFV6^:@&#+.GDEU:U$C$%X@#.D-G`2!,C+8RT,=+!2!J!B)@7F MT"@+9@26TB@+SC&6>CZ:T"@+SC&>^G($GE*]XEN67:\D$V;FZQ7A*$LZSZ9= MM_"Y;0,X&6<#(TV,M##2QD@'(UV,]#2B/T1$M2",^)]/[UM,6`DJ]"=&[`=% M!S9R%]1HQ)9]D6F(UV:$D3%&)AB98F2&D3E&%AA98F2%D35&-AJY>.'=(F!G M`8Z/>'L+<%W;%21B2!@-+VX(U2JIR[I;NU;$6)@BKK_[094*/"-0K8(9XZ%> ME..#NJVA8\?2D$I^BUP;9!STG(UI0`6OK4!"&E#!.0(-:4`%YPA$I!$5G"-0 MD>X$X1R!C#2H@G.,CK[C98ST,49*'V.\]#!4I9V.H;UG&43=C52EA,NU M$LBGC'WIRA1WF#+N702,>1>WUWB7`I5JM5;B6RSP3@G$4P+SE$`])7!/">13 M`ON40#\E\$\)!%0"`Y51T'.%449#'V-4]#%&1P\3&R-]C)'2QQ@O?8Q1T\<( M[(P%=L8".V-CIV]]C*!NQJY'D@GGWE&/I//3V:,E?%+;$$YBU\!($R,MC+0Q MTL%(%R,]C/0Q,L#($",CC(PQ,L'(%",SC,PQLL#($B,KC*PQLLF09$X>=O-A MZWMQYWMQ[WN1:A#CE&.A*O:^>I;-]=ZS9ZY7!8I1W6'6[>(W_:CNP(S`,BH] M<,[9,]<6"113`L>H]L!K(K",:@^<(_",:@^<(S"-:@^<(W"-:@^<(["-:@^< M<[;N<@\\RW>9.3MXD:':`ZY/?/;QJGT6+[PUL; MIW0PTL5(#R-]C`PP,L3(""-CC$PP,L7(#"-SC"PPLL3("B-KC&PPLL7(#B-[ MC%!M`D6B"@4S#0$C,)+&2O"R!$Y2S8)S!%92S8)S!%XJ@9A4N>!E"=2D41.< M(Y"31DUPCD!/&C7!.0)!:=0$YP@4I5$3G".0E$9-<(Y`4R7PE"H7N"RJ7#`C M\#06>!H+/*7*!:^/P%.J7'".WU.[Z9Q&L;.K[7AQ8+T:.:7B'FO#LSQ%&QAB98&2JD71/1&%8JE?9Y,0S M"TF&OX(ZFUMG;B%1N1KR/K2PB+M2C8I1NQ9=:L*S5U8866-D@Y$M1G88V6.$ M*A3H%E4HF!$(2!4*SA$H2!4*SA%(2!4*SC$>$IE]HF*?IZA"P3G&2E^.\3)U MH5:JA.6`N4`52KHL[0M]"3B*V+R8-+2"UT>@)@VMX!PCIV^[C)T^QOCI8P2& M4H6"UUG@*%4H.$=@*54H:4[NF+*K&Q4H<%%4H&!&H"D5*#A'H"F-K.`<@:;T M/`K.$6@:^S6U"Y1D$KC\R`HH4-(YX_(C*OP+*#'-!)<4,;0IE\X1#8PT,=+" M2!LC'8QT,=+32#JX4ZO35W=J=ZQK]W',0!`SM)FR:U$CBRG7J*1B%=48K\P$ M(U.,S#`RQ\@"(TN,K#"RQL@&(UN,[#"RQPA5+-`VJE@P(U"2*A:<(Y"2*A:< M(]"2*A:<8\3TG(VH8L$YQDQ?CC'3QQ@S?8S`31I32==9WP M-*B"-UX@*`VJX!R!HE2RX!R!I%2RX!R!IE2RX!R!J%2SP!RZ&Y0R^J"6Z]5R MG4]`)A"5!E7PL@2BTJ`*SA&(2H,J.,7LVH6=FF.0S@! M70,C38RT,-+&2`".&0ABAC9SH6:!BQKCC9I@9(J1&4;F&%E@ M9(F1%4;6&-E@9(N1'4;V&*&B!1YJ*EHP(W"2BA:<(["2BA:<(_"2BA:<8\ST M%0E]08Y1TY=CU/0Q(\&R!&Y2T8*W76`GU2PX1^`GU2PX1V`HU2PX1^`HU2PX M1V`IU2PX1^`IU2PPAVH6S`@\I9H%YP@\I9H%YP@\I9H%Y_@]M6N69!ZX?,TB M?((EG3XN7[M$$1L%C4/?''/ZV=L4J9_NL)1O[MCCNTTN@6YPBG9M7@" MX+I0B8(9@9-T*PCG")RD6T$X1^`EW0K".0(OZ5:0+R_DC_M0]]!RC5?O1R^?+P>A?>CRO5MH9UF$;JGN0-= MKVR">YK7QO$*S?U[3_/.N5X)[V/74AKA?J']WU7^R"\'[C:A^']\-1^>^X6GS[\?/AZ&#V\?'WZ\7KU_?"%NDCIYHX& M^%Z>OB9%;?J/M^//C]?T[;4_CF]OQ^?3K]\.#Y\/+PE`\)?C\&PO=V]R:W-H965T[CH%"81T\)#8^]_C<<^Q,'W:R01NNC5!M MAJ,@Q(BW3!6BK3+\Z^?B;H*1L;0M:*-:GN%7;O!#_OG3=*OTRM2<6P0,KIX"RNETI):F.J*F$YS6O1%LB&#,!P1246+/4.J;^%092D8 MGRNVEKRUGD3SAEK0;VK1F0.;9+?02:I7Z^Z.*=D!Q5(TPK[VI!A)ECY7K=)T MV4#?NVA(V8&[GUS02\&T,JJT`=`1+_2RYWMR3X`IGQ8".G"V(\W+##]&Z2S& M))_V_OP6?&M.QLC4:OM%B^*;:#F8#3&Y`)9*K1STN7!_03&YJ%[T`7S7J.`E M73?VA]I^Y:*J+:2=0$.NK[1XG7/#P%"@"0:)8V*J`0'P1%*XDP&&T%W_WHK" MUAF.1T$R#N,(X&C)C5T(1XD16QNKY!\/BO94GF2P)X'WGB2"X8W%\;X8WL?B M8#!)HF3T?PG$M].[,Z>6YE.MM@A.'`@V'77G-TJ!V=DR_*K>71%?2F@ M#42YR0?C9$HVX#_;8YZN8,X1LRN(\1%"0-]1))AT*O)Z9@=Q#@SI8/0F+GDO MSF.&)YAWB-E'B#-ML-&I-F=@#*?S8XVN*,.PQU'C,#ZVWGO\Y"&3WMTDA-_Y M.MP51^'7([?^!O#Z_%7P87>TXB]45Z(UJ.$E[!H&8XA9^XO@)U9U?:A+9>$` M]\,:OE<<$@\#`)=*V2D+ZYEP05D5(\]VD46JA*6T.L3H]Z^'JVMD"8FK%!>L(C%Z)0+= M;#]_VIP8?Q(Y(=("ATK$*)>R7CN.2')28F&SFE3P2\9XB24\\H,C:DYPV@25 MA>.[[M(I,:V0=ECS.1XLRVA"[EER+$DEM0DG!9;`+W):BS>W,IEC5V+^=*RO M$E;68+&G!96OC2FRRF3]>*@8Q_L"UOWB+7#RYMT\G-F7-.%,L$S:8.=HT/,U MKYR5`T[;34IA!2KM%B=9C&Z]]DKH8=<0KE#6)%:V#I]O2V'RBEA!0#`7ZNDJC4@(_BEN9YH*O,8!4L[C-S``[FU)T(^4&6)K.0H M)"O_:I'76FD3OS6!:VOBP>W,X*`-AFL7;/O7H1CE-=NZQQ-L-9R<+ M6@Z`18U5`WMK<%9I"2"YXVF!?*B86Q74A():0"V?MW[D;IQGR'_2:NY&-*9B M-Z*(.HD#?!TD).GCD"H(%H.L'J37^3<+N=.:14\3FHK=E,)@A!?U&:<3J,0Q M`N^.;3%$TY+K)KO>8A4,!;N^8+F,@E5';G#!XN9S*?&`R^]L=_]W`PLVS7PL)3:Q_&C(I37P]BZEPU).*0RVI5)B%\RJMOL872]V*)CFUS[C$Y/S0 M9P,&I.%V.2^VUHR_NTUC_]-AGN$:3D]1>DZH\8%\Q_Q`*V$5)(/3U;4C.$JY MGJ'T@V1U,P_LF839I[G-8=8E,"RX-H@SQN3;@YK2NNEY^P\``/__`P!02P,$ M%``&``@````A`-!R!PP[`P``2PH``!D```!X;"]W;W)K&ULE)9=;YLP%(;O)^T_(-\7L`GD0R%5FZI;I4V:IGU<.V""5<#(=IKV MW^\8$Q)(EM*;$/#KE^><8W.\O'TM"^>%2<5%%2/L^LAA52)27FUC]/O7X\T, M.4K3*J6%J%B,WIA"MZO/GY9[(9]5SIAVP*%2,>IY*27F%K,-"CO$06<83]B"27K#%&WFK9).@/9WMU\M]1 MN=A_D3S]QBL&V88ZF0ILA'@VTJ?4/(+)WMGLQZ8"/Z23LHSN"OU3[+\ROLTU ME#N$B$Q@B_3M@:D$,@HV+@F-4R(*`(!?I^1F:4!&Z&MSW?-4YS$*(C><^@$& MN;-A2C]R8XF<9*>T*/]:41-19T):$[BV)CAT)R2Q_"8-,&9,[XQ*C*7(@ M%PJJ_+(BT63IO4!EDE9S;S7PVVEP7[$^*$Q!`:]CA+R=,EZNW0'%B`V*J:5A MN[CD)F$1AYVOAK&9RHADHUM<4/38P&<]F MQ#&"P+MB!/,!FI7,FFI.9W,\!.N-1]@_SN]AP389CV7$?2P210,NJXD:KDE` MIL=2-2E=VW&@ZT([DO?(HH^0&?&0;/#F>ZNQ9#@DH=\G7]OQ$62PD<;GS(B' M9+/^F^^MQI(%!`?]X;4='@%FVN+)U^+Z3C3B(=AQD=CU;S67WVS+>4W1*^?\ M(VQ&_-[>M)IK;-<4/38,C6M\XAKU,'/#;="*VM4VPV>KK15:%$WK7`C-#3QYF\.AS8& M_<-W09P)H0\WICMUQ\#5/P```/__`P!02P,$%``&``@````A`'B4>N%$`@`` M/@4``!D```!X;"]W;W)K&ULC)1=CZ(P%(;O-]G_ MT/1^*(BH8X3)J'%WDIUDL]F/ZUH*-%)*VOKU[_>4*M'5S'HC%-_S\)[WM,Q> M#K)&.ZZ-4$V*HR#$B#=,Y:(I4_SKY^II@I&QM,EIK1J>XB,W^"7[_&FV5WIC M*LXM`D)C4EQ9VTX),:SBDII`M;R!?PJE);6PU"4QK>8T[XID309A."*2B@9[ MPE0_PE!%(1A?*K:5O+$>HGE-+?@WE6C-F2;9(SA)]6;;/C$E6T"L12WLL8-B M)-GTK6R4INL:^CY$0\K.[&YQ@Y>":65480/`$6_TMN=G\DR`E,UR`1VXV)'F M18I?H^DBQB2;=?G\%GQO+NZ1J=3^BQ;Y-]%P"!O&Y`:P5FKCI&^Y>P3%Y*9Z MU0W@NT8Y+^BVMC_4_BL7965AV@DTY/J:YLNNM>Y+9*<3P*DG$81R!':V[L2C@D1FQKK))_O"@ZH3QD<(+`]02)X/;! MXOA4#->^.!A,DB@9_=\"\>UTZ2RII=E,JSV"'0>&34O=_HVF0':QQ!#N_5@@ M#U?SZHJZ4E`;&.4N&XP&,[*#_-E),[^CN58L[BC&O82`O]XDA'1I\F-S3@Q- M8'1A+NZY70-SKQE>:))KQ>(CQ94W>-'CWIPXQ<#NO<7A]8OG7C+I4HV&43S\ MU]FE((GBT;`'>%_^"/@AM[3D[U27HC&HY@6\-0S&L%^U/P!^857;#7.M+&S< M[K:"[Q2'28(UUI;Z@E)6[6NFU8NH::`N_+YKC6__D[^;;0-=+ES3ZO<(/6^@$.@T4&K+63UUW7IHF*4ZHSHF!SZB!D@-NZ[R#S_9HDG.+ M\CVK5%>F8UESL\[+1N<*R_89#7PXE`6*<'&I4=-QD195>0?])Z?R3'JUNGA& MKL[;U\OY6X'K,TCLRJKL/IBHKM7%\L>QP6V^JV#<[[:7%[TV^[B3K\NBQ00? M.@/D3-[1^S$'9F""TF:U+V$$U':M18>U_F(OLT`W-ROFS[\ENI+1?XV<\#5M MR_W/LD%@-DP3G8`=QJ\4_;&G65#9O*N=L`GXL]7VZ)!?JNXO?,U0>3QU,-LS M&!`=UW+_$2%2@*$@8S@SJE3@"CH`OUI=TL@`0_)WEE[+?7=:Z^[!]I@;D/8JL$Z>',C\5MD?*G_!0FB&M0QIW_+\Z?Z;?%)9C$1Y MEV]6+;YJL.Y@VL@YIZO87H)R'QQ\*H=P^56T0)A0D1>JLM9A6!`(!"+\;>.Z M_LI\@[`L;DQXS]@BL>T)&H-4-I(SXC[CLQW'G8LJ2<_T*JFJ;V+,M)Z#UP25')"(E$=\3KF>)*@EG')=-A&?[ M@02D3XAD$R*":;`HGS>-PH)IW'GR<:`$W@0B`,@^`CWCZ_[ M2"O)/DH'1LB9*1^51*0DXEM//&:D;?A2+Q)%>:HHSWY=+K@8B"Y.1R&%9?>D MHS3D#(\/VW'\X/-L8V?/5@`LQUU(0#0&',NS/^>?"<2\?&)^$B61*@EX8]&Q M/FZ%.\C?4/Q^7*/VB+:HJHA6X`M]']&)'7*'I]N+2Z^`4GYH+^'R>I\?PU/O M47[H+$.F8PY"\`0[YT?T1]X>RX9H%3I`%RR#;LPM?\3QCPZ?V2U^ASMX?+&_ M)WAK([@_6P;`!XR[_@,Z9`ZO]\W_````__\#`%!+`P04``8`"````"$`QY!^ M)I4#``!>#```&0```'AL+W=O'7`2JX"1[33MOY]K+J'@9BE]@8"/ M#^>>:U_?K+^]E(7WS)46LDH)]4/B\2J3N:B.*?GG[\>O2^)IPZJ<%;+B*7GE MFGS;_/9E?9'J29\X-QXP5#HE)V/J51#H[,1+IGU9\PI&#E*5S,"C.@:Z5ISE MS:2R"*(PG`NOF2QKH-B+0IC7AI1X9;;Z<:RD8OL"XGZA,Y9=N9N'=_2ER)34\F!\H`M0 MZ/N8[X*[`)@VZUQ`!-9V3_%#2N[I:D=G)-BL&X/^%?RB>[\]?9*7WY7(?XJ* M@]N0)YN!O91/%OHCMZ]@Z[-H["4 MQ,O.VLCR/P31E@I)HI8$[BT)3?Q9E"R6GV&)6Q:X7UDB/UHF-)E_K"7`N!J; M'IAAF[62%P_6'BC7-;,KF:Z`^>H/1M,Y]G^&@5.6Y-ZRI&1!//!"0Y:?-W$2 MKH-GR$S68K:(@6N'H4/$[HJP"05YG4;PK:_Q=NZN4BS82K&YM-JV^*+_W-XBV&@$'9.7^&X>Q;L*HN'WFP1 M,V^413>4X?@$9?.ALFGYM9-H?C$Q3"'IONG06[RMYR@ML# M,:B,SF@\(6""=W=# MB>/KSH)=:6]5`;U#S.TOXZX=0PSLHU!&/N]?,^NCVM*"QF2.0H8Z;9'NY7G< M1(HE?5A7G`6V;4$C2[!%W(Y@*,_6\NGRL/(/Y2V=]4<1=/OCF.51R%"?+>,] M?=,J#,7B#]>NM+X_0EK0J,[)APCT9`.='Z39HH>;9>:>'@UC2O#X2*+0[0]L M&VA);NM'$['-P_ZEY.K(=[PHM)?)LVWA*-3_[FW77MY'38/8#4!W5[,C_X.I MHZBT5_`#3`W]!9P1"OM#?#"R;KJCO330US4_3]#' M:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2 M!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(* MQV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B( ML()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^) M@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM M+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69] M>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H M(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,0 M4V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG M'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK M')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN M=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$ M45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B> MF8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%> MA?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX M3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9 M(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"8 M6Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+ MT5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8 ME+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7 MO#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FR ME)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED M^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I; M02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^` MVHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6 M["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP M]`Y\-I@Q)4TPP:_$P4``!84```8````>&PO=V]R:W-H965T&ULG)A= M;ZLX$(;O5]K_@+AOP#:?49*C`U5WC[0KK5;[<4T)25`#CH`V[;_?,>-@[*24 M[+EHPLGCX?5KSPQX]>V].EIO1=.6O%[;9.':5E'G?%O6^[7]]U]/#Y%MM5U6 M;[,CKXNU_5&T]K?-SS^MSKQY:0]%T5D0H6[7]J'K3DO':?-#467M@I^*&G[9 M\:;*.KAL]DY[:HILVP^JC@YUW<"ILK*V,<*RF1.#[W9E7CSR_+4JZ@Z#-,4Q MZT!_>RA/[25:E<\)5V7-R^OI(>?5"4(\E\>R^^B#VE:5+W_L:]YDST>8]SOQ MLOP2N[^X"E^5><-;ONL6$,Y!H==SCIW8@4B;U;:$&0C;K:;8K>WO9)G2T'8V MJ]Z@?\KBW(Z^6^V!GW]IRNUO95V`V[!.8@6>.7\1Z(^M^"\8[%R-?NI7X(_& MVA:[[/78_,E!>RP*>>D3NIC(.,[X91Q%3:Z_I$K9Z]_T2_-7-#35SJ0V8J.628VX@N M[ZX.0:Y;!#-;A&30FC"*B;%+4QT(B*LBZ-)$O9[OG*#UC>>9'8(@@](8'16S MWME4_N[U+40-UE7=U1[$(YRI2FT4N9[C^D^\F'D&D M8>[S1#)RGU/75ZY(R\8MPM<`W3:C0\RL)ECEQ^GJF:V"(",ENO!O*!12XA@@ M`E"$KO&N5D&N>X5G=()$,G+#,>83M7)2G-8L8B^*5;KKXNYJ%N2Z6YB/0XED MS-TN=6$`\T=-$C4ZQ'3I[6DC08VRGTAFPB^-H!-^T;OZ0D_KSR2>V1>%LV>H:O;B`7&1D4^D!"$KJQ":4RT`7R61S2 M6*6<+O6NUD&O6X=O/"(EDL&[@SY&0FK4[E1CO#!B\>A-0-?WO_H'G-A<66EH M2"0CWVEO/^YIS.W'/3S9P;.+4[8O?L^:?5FWUK'80>:X"Y$[#9[KX$7'3_T9 MQ3/OX#RF_WJ`\[<"#C#&PO=V]R:W-H965T&UL ME)9;;]HP&(;O)^T_1+YO#D`"082JP+I5ZJ1IVN':.`ZQB./(-J7]]_L<4UJ' ME`$7.>#W>_/XM6-G=OO,*^^)2L5$G:'(#Y%':R)R5F\R]/O7_4KC.L>5 MJ&F&7JA"M_//GV9[(;>JI%1[X%"K#)5:-],@4*2D'"M?-+2&ED)(CC7<]R769HF/CQ.!Q&(/?65.E[9BR1 M1W9*"_[7BJ*#E349'$S@?#")X/+"XN&A&,['8G\PB:,X^3]"8+O3IK/"&L]G M4NP]F'$`K!ILYF\T!6<3RQ#"[8\%\C`U=Z:H+06U@J%\FL>C6?`$\9.#9'$J M&;B*98]B?)0$@'=DA(S>,YYG,^(,P?&-+3[:MO@+*TE;\.C+S=!M7G[8[$!! M6)=#&7$'*G&?NK"2Q$*%]N=*EFIO(.3MK!L9(/Y].'S0[4^!HH(W:ADLZP M+*S$SB?8:GHGU'F-@V>VP7?KQ/EWT(@[>%$G,RNQ>)-T,!Q/QMT%PI&,.A(' M+KT&SH@[<)TG+ZSD+)PCZ8>S>Y%=;1N\H=^QW+!:>14M8&T*_3%,56EW(GNC M1=.NJFNA80=I+TOX8*"PY(8^B`LA].N-V>N.GR#S?P```/__`P!02P,$%``& M``@````A`,CXM?"V10``DO4``!0```!X;"]S:&%R9613=')I;F=S+GAM;.R= MZW(C1Y;?OSO"[U#1P;5:89!-$+S.:N2@R&Z)X[YPFM2.-R;\`02*)+9Q6Q2@ M%N?3O(,_.<)^N7D2__[G9&;=`+);(VEGO!LQVFT6LC)/GOLML[[Z;S].QMD/ M^:(8S::_?=;=V7V6Y=/!;#B:WOWVV??7K[:/GV7%LC\=]L>S:?[;9P]Y\>R_ M??V?_]-71;',>'=:_/;9_7(Y_\V+%\7@/I_TBYW9/)_RR^UL,>DO^7-Q]Z*8 M+_+^L+C/\^5D_&)O=_?PQ:0_FC[+!K/5=/G;9WM[O<-GV6HZ^M=5?N:/>@;/YZN[G:RW8/U/R8P*FMG?WP]FN;9 MQ3*?%/^S.=L7S0=IANN'>=[\\8ON[O;OFP]/V??0]OYJW+]K_OK%;7]\OLE?@NFBMLPY7:9GP>EAM_02_WVO. M&>CX/K\;%/S3'?;&[N]OM]GK'W>/F3V>KQ4(L5L7%)L1]L;W=W=ON=9MS MA"V]&HWS178&QN]FBS8,5Y/^6`/>Y_/98HF@96>SR;P_;8V\7O0EA]G5P^1F M-FXN]L4WE]??-1\&")AP,IMF5\O9X$,GN[KO+_(B>[=:FB0S9?.ULW=OK]Z] MOC@_O7YYGGUS^OKT[=G+[.J[ER^OK[+GWU^=9UM?-E\YSP>(4=! M:.O7N9XM88;'Q_@\&][/!_?3V7AV]Y"-1X-\6H#$[6R1CZ'L,)OW%\L6R5[G M19&=#E!7*Q]U.A&-_]1?KM%3%U,4Z]WH9IQGIX:H3O8V7V;/7_XX&*^,\M_. M9L./H_'XRTYFFVEBX?K=]>GK[/3J"D(U?XLT&(_Z-Z/Q:#G*6X0`4"G;@KT\ M]`&C.47S]Z=VS_C%"M3D/V("VGJI\?.GSA9P+R"E")^D09WLCVS_]0SA6N:+ M23;,;Y;-S3MN7U^8I>8DL/5MCF(9 M1EGR'_KC59YU=SOH)/V7%2ZF_=7R?K88_2D?=K+I+#X=%84PBR'. M9H_(<4WN&VM)5!]9+3L^Z>SUCCK'1WNVS/%^^C-`MAZ&K%]DL]OL\$5O]T5W MWU[M[KWH=5]T>QV$I9CG@^7HAWS/9?^I/Y/Z(' M3]^_E/5Y^?X*.O_^^XOK?VY"^*@"O43]XH_DRQ%6]LM-"K7%*HE)FHNU1K8X MYU/?<(I^ZNA/9KR-D-?MTI-@KQV^'N:U0Q\#N&KQKJXQ?&]>OL7:O7N5O;M\ M^?[T^H(!FTC5>]3!//YT_[/71/U[V'FZ:C'QNWF^P(3`[QM4Z_N\P'D;W)OX M562B.?\?NRTG]=M\RN3CP.S]X60T-8=,0MMZ?:_UNLL7/O_C`,JPE8/&LZ)E MC-P2CP@^)GGV/.SSRR8$V,P^:0[(/N:CNWOY'WVB M-O1=-EU-;E@3%0SFY/4%L7J$^=\'%P;%U#99?^RU:+R)NR(WBAAX++A'A3Q. M""V]'G\U\["UM]O9[^[:7K>..WM[N^[=W>?9OZX``QM*X&E.CUD2!1PV./[5 M,";_F&WM'75V>VZKMKHGG<->+TU9C'[,0,7R7L@F!/KSU=V]V[]U8=)C\A51U$2@'-\B7_R`UUETZD@5:!_[ M"PN8`B\[@KN[>YW><<\Q?-#I=8\3Y#\5PUTPL-L[\2E/.B=[/S.&>YW]_?U. M[^2S<6P[J_):83`&O/@?6V"@.+^V+)T_T?$ M9Z.%.1D#O#2DSD(3F/7EV3A'J$$2Y7N&%L708Y5R!?X$?%_,%3(6\+R-'T M!\]_L+]-C-``\M7%6](W3P"YF`WR'+-HQ@R6Q)=86B)B.B/ATJ2G$C:P;@C` MW=5XXA7MA#1.996B#]=7O!1Y"LV%TOX-KMO1M(^PX/5NWOS;E]=*"+Y_>7KU M,GM^_M+_]27/3,Z;"V@GN%WD'*=330P\KL'7#\0C>7R(1ZY(3?/]Z*>VGYM_ MN^S_V$;SV]ETVUCT4S:^3GI7<[PNIZ;R^9]$J,MQ?Y";93N](TIMPKMFF>:0 M-^?*R^/`L:+TQVO/E36'O;X\:SYZM[CK3T-RS`SX-TC+E!3:8P,[I$NGQ6P\ M&IK5L?>(B`N`]P?0])5S#E'-%0]M>T7VQ],;)9H'RY8=_&8TV[[LXRV.T&OM ME()9.?*SV<>1QI"!&E/-0)O@!"X\8\F_AP(H[[#]^:R8D>/-OEW<;.]ES__R MY__S>MO^_9<__]\,!/'@F\OM[N[N-O66+@])[X4LY?A!NF\P)@931GZY&)'@ MW\FN\32@Q-R`(-]R2]J.TH8#M"RMHHF-!G\_1>M0U*%0`CJN\Q_[^)%50ITY M\,J8LP?!6/E5(!E>P0?+`(H"#@Q5B"PE.=,9B9^:PWCF? M/2<5(AP$/LE.[Q:Y_:)EZWM%D3I^A_E8&WK(YJ158;()>;N4G#6R#$#/C`T' MOJ?TI(V-V![)]L%R!3;11P@[*#$K]U#`&$1?:6H0115B!",5^4Z6>`("S+3L MM!`&@D*^`R-5;(R=Z'FV7&&6LZ5\1(O72S`[VY'<^?:#_E#-C&WU(#2A!4.5,WQ]O91E&FGHV%>$LK8(&X% MM%HI(0EF(<'2*K>KY6K1(K!"J;")F\6L/\RGAJ<*`HSX%B/4N7[&I,(T?)^P MVF$Q#=76FV`$%`YC(`FFERNQ+7@HIZK@HA6J)-:\02IP]\5/?3(BT&`P6\"# M232`XS8K5@/"R.)V-0:?%!.(LY7L9WS@/-X58JAP2&3@$*1Q@86\R[`(REJR ML2'Q-')$52-R]S;)"S$KN^_/K M#XA\O^-/A@\%8@WZ!X`Z'1+6H[T'A//H7A_!]FJ5D]*?L`V,E:AFCD$&0/*`MF5(\ M6@D:@X9HF;BF74,>',D8*98GB$$IRM>]D>LO9]O,X_/KM]^#?N_?834*\ZU-Y7I`XFI&Q8;L MGC09/+N@G"`K2'8R+S9+$H:NM,`)_W.60RB*3S'\+;MO6O#20H&+AD7?H4*= MO;%\K=.*;H0DU(2(.6C$N"]&V+`IEG8YHN;A6S<++VG]?N=*Y*>\+_8Z5]FT M&L+CBT4[^^K\U`QZ4A+]^1PF#?/!0!<>9(A\5HUYFW_T">467+P]M[=1R$MD MP1P\]V:P9-`E!$[9:/RH4081+IZ,3]:#&,>4;R_VZ+T-<,V+`K(.'U8J^U< M;1`LA$0X&,`SS&%!B/JT2IO(8;T8J-T.;,1QL00]^@>RHT!Z->D58?>XYDC+I#V986FGKZN+" M4$2=*W_TC&`9J;PXZ9MQQA#@.A46_['CJHOSD:I5="22HU3:%P5/@#8!@_(: M9$(EJV88X,#Y(M].OJRO:F88IY_=%B8&T6!W(IS9S5A<79A2"Q&J$5E6(I.> MG\X^PG>BDIH#6%!1`T$B*NBCD@S]AZC07''H[>@]L[$Z@D/`,1^G&XO\CM5 MZH-6L77,=Y.SN&0-=!)O#Q!%424K!E(($L<,;U\KYD,6,3XAX:SX`H-CDJ;W MUJ%L.(,](,LM]*W89@@>1MN*#4M7K(A=C-E8RB#"K34V[`\6*BJD9_*I8$O$ M;!J&R@=>C&`@^#0-@["@`)*9%O5843^ZYQIWKX`(<@P^N'"#B%ID8C\;(0@Z MU;$!*K`OU\RS)@"I^7=G;AT\_FA(ZT(]7YJ$,CAN"&A'"44E(TL@0-%JPF)- MBV;(S>RCZ,&`"L6AI1(1KL;[F_3`??\'L=&M;-CS@R]16-3AY5.MQLB_JP56 M[",V/XXF*[H&))D@]6`WF]R]F'C0"O#ZWR7_1TF5T_'H;JI:_V^?%2NDI8"5 MYLMG+^A5^Y,_[N[JKP&";_[ZA":[KIXL7E'`\"'7HPD\([7\GL!RJE]O^Y,1 M+&,3V_`7MN3RZ]!G50'C%UIH)_L.7+-'$G;$.A0*>,_E)M*@X8`@KJA- MB`0+)B-"KT,NASYHU`*\F=D#"76%Y<_ MZGHB\@V"89QB3@(N+X04Y2NZTA7K)2T&@]%<#)A,I!2Q4ZHA#(8&Y*!8C3&5 M4B@6D$2[;B[M-[,^A@JPSW&0!_A!1;+2]I,L+?[B\`>B4'$QPF23"/#^#9&I M6QNYA3A9XQ(Q-P38([BKOO/BWMQ,@,*FT6S"OG.UG4A'R3_RK0=K54];.`(J M:ZZE1XC!9$"KO\_FZFRCG5,D"\B*K""E!#7JZUH3DDZ71ITNWDI'LT;+M#>&5B%7A]%"?B%BEX=H>J M#X*="CPD53D;2]D)3N7+G'W$,R4:^;\JWQX,F_4QZT9!Y!Z_.]+X-J568E8<\B_[6A99^H3OHW#-U1!^@*-P.? M%DJ%6#3^6E<*46NXTU=:P\'#@+7U>M1`%F[@:O"T^ATCM_ M&54,J25O394"=[XPLB>WA[2* M99]/W[QVXW=Y/QJ3?AO/[T?][(QLS$39=((W2^XRMYXI0V/3A`Q-;:HSG\H, M@:_XNI:PJ0T^?1W6!4Z;L9(5N@I9H9`>O[(X6"3]>#_#;P&6VSZE7`RZD3+9 MCT02(ISK>Z30HI;$%&;1+9F-H9<;3+"CSL64!QUB_0FA/'$DCT(.S'0Y?E!# M*)H?SS]-EB16@5&B<[`KQ@S4"A;;'_/\0\5QL-@:8?NGJ34D"<&&N[\\NM3(G6R\^1B<.;H2X*#/:357!OX MB&7U:]]ZE[&$N&ST2!/I1(?B=K3`C2!N=IX/D6@,R/5N$`/SO-9%8JF6@)*K M9QG:FC$$W4(!XIX"38"TY'W$?/!/JG$BCT`P_X.2:AK2/P7=&HA\6=\84?AL MK-PN0::56I0Q,'>%`)8.8%F)H)=$_(P(7LRBO&O)6*%W(E",;Y"T()2SF MX,S2"DF`K>I9WPEJ%&Q/^O\"HT1GU#`8_$\RV\GI7X>>2(DT"2$GKCOGP*)' M44E%:?TR:0'FRJI`R@<1)93Y$T_4P%CP>S!\<$#R>).&,W6IG&&]D))52JB` MJ%/"#)"I/BI#\#[&*3(*HIOB$:0'C0G#>6BXCA9?04 MB(RQ$):FC!Z:61\68^D!&@1;[*7,&2;<]):0E>:79C`:5IBB0L\XJ1)]D#&= M"*R8`@F,Y`*]-#'C2ZI"#:I$*M&@E170])!\OQ,HX!.KIQ5B'897+1H,B*/+ M1[9M5-R[,T(W;:6&4H]"58?X$-LSI2PKVZFPIP())7(JO$P43>*7*#D"0ZDG M6N>2K45X2W\7RH*HYC`>34:*YDA1]=%M!UE!2\? M@QE+$6)V^!$X*](+M7B%_\U3CD0HQM>(6A6;G>J0*"&PHZ8)$.L%4+FZVL1- M:/FHXI_^-RE7)1`XM=2)F6^]H@72*Y,9:JNE(J_9QQ.9F_4^1R?['8=5Y3?0 MC\RR;W;.=]"P8D?!KN65XY;6#W6')!4@`K>SD^'&JL_BRK:&;TD?07"RA%TB M,I)#D9/(;I@'8WEM\(D=@'?($\0\NM`3$ZXF_N1QT;^"(\X$((6]FV8Y,$P@4C,;":F0ZI+F9H.< M5EV0)^?DX0Q%3_:'Z;[C4#"U$IVBPPBI#V/",6!M`N#/*795TH;=G>Q]P)$Q MW#!/2?5*M91YJBF=D/BQ[(R9#P",^/#,CA?C>1SH5@5])[LBMUYZV&'(K;QL MH`_YFHT MD-#O'C9-M<8JOD1WYR*TW/EB)TA+\D9+XEJOQ/`WGA8O3V>?JVZ2IEXOB7JD6"U.F1(0O"\H#D/ M1W-9!:B.AI&/,R&GJDJ3ZOP!&?)D9&1;.N>5B@:)Z6IL:S91:3O%0$HPFN5" MME^P$(94L"<#Z7D^^`Z;-`'"4`KNHS=UEI4?K#QA\1OI&CRT%BC7Q"<1$O,/ M8X5-NM==.@D?NZ.JX[N+*)&U'N9B2*D_\Q:J:%R_$Y"7LJO$]ZA+G$1E55N0 MG;L;D%VQ:4ZD^J%8R612F&]>-PE=W8T'FPP&MNR@M_V@\^J"IJ3X-/#%QS:S$7)6!U7K#]!")MXE1G39I6''"1]6>`_*5L MG$F.:(-9V_Y&(N"!>I,^EYXOV^T=T@CZ@%EQS[;5NCY@N/>1L;M]_'*M#*!1*Y(*; M'P'X42,"FTK,/$FYH=;:[Z80]"'K4N6H8A&-@Q^E_*`O!=.9S(%L.^N66@%" MM?]Y//E68O@@8;%U6.\E:H&9$E0"X2D(PF8!Q`&0Y\T<9E>B:LW6@+%?@M': M_#=6)T\II](WEC(KBS[HW^CR5&//V/Y:ON:^#/)5ZRQ11`DSQ-27Z$&GC#;R MXQP5)PU1*TC68VKBF0<*>018^&HT"3T$C;+6I:=[5KLQ?N6V@V5H`OOH,8O[ MLWB%QF&%M7I8XH*@D/.FE7XGN8LT#`X^L.C-:H0ZYP%9'WFGTI8&8IQN/IJ; M`0[Z)BY;&\.$WHL=#D4J8V3JY1 M(`.'71R0>!G-?N@7-`9@@)!"/\=.G`"OD7@B9[T*/S*1A:\@X,SOJE`6MTHA M*"A'6LU@`C*%LQ%SYEB%3*Q'BD89ZZ(JTS>-$'!M-@?@%++VQ^R:"%*E=G6R M('?R=I323)AK<>^U8BK>YJ:;%)($AY4-+!_FH6YK"RCX)[Y22-VP= M$]9L?NU=9;R,BZ9+*`AM2/FEEH*@"(6I&$BG+@"),\^-Z#"X!^HDXIAL2GY< M+HNUHE@(T<_>7)][PH6<2FVQ4T5V'O@X3=IM6`YQK*.DIBWQJ+0N*]J6X@#+ MKB)M`D^MH+./HFE`7!-S2FF4DHHL>8=YJM`G31."*Z_>L/E8P)%TI]'53JT- ME`KM`(:&(=2P>?5_R*$CH(;`.O(,S=5L%I;0\W9QQ[CR5NAQ=02"O;\@Z*X( M%'F$4!?"`17#A7ZWD+=C=%P?`JHS30;56DN,A@*CQ07@/B4W54=1"25%(76] M5C,WWGRBO*WH4\0*?M#YH#?R%7B*I^'%G&;;`"201:ZUV:VH(RN26V:7T+[6 ME=`2*'C/MJIPZH<17<9-O2!1M5R7]0>HZ!#8WD.$=MP#)UO?M0':J/1E[U!] M)=^`NLK4%29TKMX8[!K1DQ`0HY3-@9&B-ZF#T24C)2/+AB#8$J"F3(C/0;1EP_"\TW2-;J&D&X(^B.SHTYE>MK1UI4L1_I*=@8G* M'@Y+;%.@B#E%#F$SBNC!,R&N);!,PWQ[=LM)"FDO,ZK:0B.0+V:LB+FY1;65 MJ,='^M@G#$`M`&JD`D#45W+[5@=-NTB082QM`]@DS?](1J1DV9WLTI2,)JK+ M*49Y)3E>D.,X$H"R,W_27'6`K:LH'?.XO0W%>5E^K35<:7 MS"Y?UA->0XP\63?1V+("0Z)'B5MCU>0!X+%3?;)>)XNA"LM_>1DEDETU3Z@6 MSKUK'Y;'D77PQE'RR+C8%GLKEX7>=FU,L5F)`1D-*`RW>'3<:$6U;= M%!WG,)A%)L^,A#`N4V/SV@3^FI(Z9([=^PV`Q#TTV`G/3$Q6`I63>]F,=%S6 MN7NM#7@C'@62SAF&6="FEKQ+7F1TOYPF.%EWL+@Q7&,SY28B_"6SI2H+Q[<" M\^JT%8(S7)A?*;M6HE.,/Q#UB"9Y0Q?'-Y'LUB-C=LKD)\Q*^*)EM*2>\]:Y M2]]C?R)W7V]5*FZ@10QNDH+?%=KJ)=X"6M5+Y>,E/KYK>YUJ&S4T"YN"/I<1 M8>+F=F+/^-P['>RP&JBBN93".030.N)Z"A:6<<,3MGY?^G,=$]ZW*VOM>0\Y M_O"RBE%H>AWO)[EG9W[+0*P,U://(^?%2$GN&B6S%D=H5C_$JK1`Z+)@1XJ% M43O6/"`]@9M>PX0U#*5:-_I$S0-!;0!K\!)6=DQ[J>,5(4BI5/38W<1;=H4. M%E\A*E@FVHKE\[K8-$BF:QKBSIM(CXZ;9U^Q'52+$%5-[D-!I;I'/.KQMHA/ MVY;S4:2)W]LB1H&#)).<.@71.(@89=:P3'^_D-).!YA%!NMI(=*P/NAMGL.&I^9$>%.Y%L`P+^NB5&TT$I,R@,!L<>4P9LBQ M9_!I)U&CAUY)=_)0Y?#.Q)#%W=0.7!2L=?E6#);LRH5N,)BC4 M?(ZI=^_=_2!96R[ADIP9IM@1B6B@KNEFP)I]@'_"/4",W.KM']@%CLY_4;MK M*[=0`D5CA8JPUGFL>(:[4[O:IV4R?3=DEQ:6=U,@[X#+>C6[15 MS",_/]C]!SLZ#\Q!OU*E8T-P/X06IN[[8ZO7"ZS:U"(M6Z:OAWZ%.SPC$Y0J M]1*KI_,X=7`D;M&L$PEZ6C)L M4/P7:8#61+]8I@]3R%21_%\U[HB^YK?(W`9_N%$!O?B&'#5DY;+,(^]%^7[9 M5P2XH"&5F!=9(\QASOAF M>.&&-H?0B?GT.Z3Y:JO%N;!3-DM$`MYQV'[$!M#'E)V`\(RRH=9W'$AJ[DV) M#5.*2E5;;&8>:VS50?CH^=`M)&(C,TZZ>-)<9W*6?LD2GJ]X<7Y=_;9XHS26A;:B\R2^.37YH-1-MZ=NX MNHR),M"J9&L#T>UM9B/@:\%G/3CFXK:6:+JZ+>?UW31+I[PHX2BBM@ZA6^N! MQJ+BJ]XBEGZ?M^E1JF:4";13-,PK]85=;?>2`[GE6H2`Y3N]36]R2[LAA,PS.OS>`447%NJ5LQ3XRUU&BAH9-A-;.I# M9RWR&3=?Y-PU8TXB^9'1D+89A('QT%%.6A!PHB?N&-PW$ZTV62HNJXFQ45(.-H;[TRB3S>!,XWF39!ZI@TKVD+5&85HG4LGGC,67S?6%QF5(QIAQ_,=V1?0E!) MZWZ\Q09=(2.,N;=LIZX,4O:6OZB1R!K?4])=WF/C\`^`ER.`G"[3'378WI@% MYN#]5?\&.^\'#PE$[/"!*7V]2-Z"$-0Z#7W<&WL@48,Y5XMBA>`+BVUT*=J,-2#)7IGH?-<^D.6J\+*Y8R_&51I4]7;[XU$1`*-@: M>S6]>&?GFE%3?H>8^'3.7QR]!8L(PQ95W'!U=K!VM$.FX6'BN.G4;^3L8\1T M.Q7M;50'D,\\;>@5=*H`),$0;LD"[=.EV9?;'/H+$ZJ9X%!C.RMXMB'JUA.X M9CI=VY2#_=587[15XF83N/F/=`H0.3G[*K*QFS\Q!WX?."*E%TO@RY.,%43U M=HZC.MO)_B`/''DFYVGOV.78"11TU[>GEZ=G_Z>)B'YH_S^`?A>OSY#]M!V$U!9 M03+_1J1)?,D1,O;0^4T-H$78#")`5\8;46J\S4&!)V6%],[SLVN!+>K)M[#P8>B=#2FBZM>_2)/YE!M27MNGA9_9T[A4(6;,/_]`*)&;O:BHLYA!N+MM17H'A8 M)M?26&XKE6QQ^>*Q95."0^;VR2B,'Q147@LEHQ9&;,K&SPV`H+I$Z9P$J!P32C"5L=5&UF7R=IE7$-9M^I&:[(*\+%4$3`- M!@0-1CEJ4D*'^ITQ^](CIADM2F#1H$H6M!'"SW"8.EYF#U+[@(%X6Y1G$U=! M,=YN*;N+:582L\K%`!6="P3`:D$Q+O#"!YJ8J"NS8[W1TGW$033&!T8KC(1! MB%_*[BNU;O1HXJJV.F\([QQ>;^J24W.:[.!Z_%Q2).#YRFA8%XY)[2!7R]MQA:'L)D*0!" M-RO7^ZA62*X9^(36:LZ/GTB"&Q%Y8YV=>\_Y5ZG92UVWGEWKC(SGT%60^=K.C"GBNDE76PP61A\;>V0*!F?*\\6@G>``Z M$)V49(S2=<^4LU+S(O$:O]7M`LTXQ5R?94$$K1,^,$-CE`Q&7#9DW;1/ MA216Y#812$RV=>"Q@9:;J[LXH#-M[OD5-;RWU#&*;'^GDQUX3NIPAS1G%?2? MG_CD)Z!#C0!;>R5NJHLW,)#P%#;A#*PO_'2/'*]UUDE[C2QSG>PJR1A+:EO: M&IEL9HU)@$1S"*I,B,5PKA_MZTXMXD9NKO3L MU8'92&0M$3JR9^&P.WD= ML.J0M`6-PI,#5DQ-W4/#QDL8E%+!@(['KB8P39YKT'?\E"L5O>H]&MK-HD\% M#7UB!Z:X5FO.-:C6?,-,TN5;!]U.[Q"'COHDPRQ567Z7KU,S;7(9<4*6VS9SJ^*4"@Q"R4D1!OI[ M^GP!]5J-52^"3I;U\XLMVX75+V6-?2>Q-6<'K`JYA(B6]7LREOJW#QMQ4J"MV M<4VY1+)DH#V^/7<*H[L>-/I96+M!A5V& MVQ94?O!PHP&="3`;BAS@AK/.!,)"BS/JVTC76M5;UV3%(EK6^`2?QXM;1X>= M[NY)+,$DBX"!L8ZY>"@66X;M9"-6Q<-&0U@DL.#_3+0L3[51TWY[\85=+/X$=6H@[/.QP.,Z.^G;VO!L*;&<7;.=)[M;>R^!&'3W[]+W_^7Y^VG#V>ZI0ZN05I#2JW.?JDC0O'6 M:')#&2@47W5/YIH8B[G<"2,]5HT+L$=,'LQ+2@=$_&C?4NWK`&KMI!2'M1"D MN<+-`"3:B*IC,)UM`_.+7L6ZX^4_,?Z&:@#`J[20-^?;@D@;Z`AYS.8= MHP&Z`Q*TQ[V>K5/%6Q#AR[3O4U4O%3T(O;RLLH=(*MQMP#WE?:L6)UP;QE(G MR&/\>=X^.3.+=(UX"OJG>`2TZ<6M_-C2/4]2*00%1@J$+ZLDR2!(U$ MSDWW`E=F"D:I?K7AQ;JFK2K3`-I/[-LRBQEHP8YW]WJ=@Z/CN.LF-_.WEFTT M>B4]&].NV7.V3,%SZ;7.6R5^#>MF7J^C'V:W7,)M%C8/FZV#M3F M5>A!AL`[XL4JNG/9$JO8O-CZ0.U<]TWB:L<,K/(:;KNXN#%^@5NQ=O"L:-B: MPTJEA-044(QO7&.@4^P^#E0IO7]5-@I\$#ZVO8D)V`)G)[GZS(66T@?I&];S M,AX)"=4V%.TUB,9[DH1`88F+3IEMII8[#Y7]&O>1:G!]+F"]Y/&Y:/`N4K"[ M5$1HY'H*,\HQ<;4S[Y25IXW#V#BAM9(,W[9[?YHM5M1D;*WD M;K"IC82(*6C0@BUM$(<0502_AJQ_851N1\PR5*$8>96 MTN$9R62F,6PD?`%=K.:PY2[)ZVX[V):MH>*:QJRV>`^\RHV M2.1&GMLPWKCK,'B0:[GK,]F)SJBP5)"_931+H8\@[ M'A'P+)2]@VW@$6N4W+_7.7KF,6X:&_O;UQ')0^FH:8^42V)[5IZR3IVS;+X(;BU+-M[W$Y@&GX! M1=6,X-$QZ71&DWF":!T][CE^HB`],8OSRE$OED;_PYYQ]-D[4BENT)4;]2?6 M\U>P9VO8I/1[FGRB#Y6X"QJ.?)8N38P3S.L+1P&.8N>L>^:OR9G-QE/U\GS( M8@?G*X)T/OQ*DZI][/7RC,Y,56OM(Z]_:3N]PEK)KB"[ M?)PWW,EH]ZDCS/K_=NBHCW^^32J&/G9JN2,_.QIK!1PLI3`R)97M7J3$:ZO, M>S@.I6Q(;;`!,H6@X3<.DQ"%PP69`XJ&8%0D"'2"7/85W MY@I:=4C>\$":-G)UG4N(Q?PS@ULQ4+4DBA@!*"!9;.%-B`;QM43#P5&WL[^7 MBW5SI7XQZ3J&V<'0>PI@*0_""J"<^8435PB7YT<.J`(=[W8K M&N/1"<4MIN1'_ET8ZFFF/_52XUQG1>*;NFP@P;$)U@46E<^:-ES&DHTI21L> M$ALW^;77RC$_MJ\=TXF22+^YPZW;86?OX*_"C&NU1K!8T6:!!]JP"D$Q';5# MI)782AH^\F_*YV%.2H5??;4AAN%^9-^<[$`P;QO`C.=`A+CJK.MH=J6KHBMW M.V\DW%-TZP:?O-S0Y],-$3E.6:8G-<@:CMZ`D(3X,&<;UAJ:_A[H]FZPG-V@ MT]A1.T(KQ>U)JO4.R/X?5-CP;YAJ+5C_[JA6K\5]#>7:?E1$1=!;H@H#;I.VPXK0E5E5#.[>-]')_N=O=T#>1$6160X(%0+2;B/CRN2GH-*##/:]5TUP9':'W*E$U48KDZ+B(( M)\2_WGOZU:QP"]8:AO[^K/!ZT>MV3O8>+=Y8FNJ`+C_%!\AA MS#!P/1A?L(LA4J7`8[YSZ;CQ2O0&T$[==:R5U%?059O8*_AP&YWS8[53_'7< M1=IA?^\3^=-BW&;4\HD^7@O4OSOF2N6+)XCVI(]WM-?9[WZJ7_UOK!-:L/[= MD9)F1/>'AT>?*"?_QC1KP?IW1[.J(P?-E*^Q[_+Y M'96%3I]:9UI(F#V9@/(*WEDH)Y9D?U*_GG3VC@__*JK_:OJU"6J=Z-<59SCM MOS_U4P5;3^'AA);W@[].8_U:>&B!6L?#*U*$7`KTD_7`,?%YS6NOZ)._-7^N M!6L=%;^4*_XS9L,J+GA#=5M`QTEZ]^3P0=HXX3I?L/8ATL8N8ZC6]%=;6]3JXD2=,A*L M`=`:4/-T9[X,7SRV&"-%7-6]=>!9$CD&V*63N]:>.E&.3M0-T'T"7S^9*.N` MC/YVA+/AJC6P&L"D`Y%&S%\-S%.S4@FR<)'E7LTA"?3&JZ=WH]>K^ALMDK7:$ZAGO[)/YW]WXU#%], M0P;(H;-S@;#U6MBL^M/IGM@5'(^(]4]FTZ`[]H]/$,A/%@:D,5XV0RK9K]K; MK)_6D:BB,AL;#\S5[>+)[O/?8[FG,N8%HG:?WKIV&"$]7`X6(?>V+K[-&=+B MO77,3CD4F[U_\O]K)DJ:>7V;SP;4?DZ.*A@/X;XIP`WJ!Y'L[)'\.#FTW(TP+5_>+\6N8V?_INA':7J(U1P(!IC('^*YVJ:V!)EQ)AB-!"P,W)8K(S$"'4B%O MBQ,DFH[/,82K;F6GN3!CQ4E`28E]'86*1[P9)=V%K2,;:G,JN5?S."+BJ7:J M2KK^W*Y@M^RSAL3.?T=6##G2=7=AI1IB/?$2<^9JHAVDPP$!]>K!W=OI'4>. MCR"HB42KZH()`[?Z;HVA`R;JX(4O%LV%A^8U*NEC7*UC38%&;6K0^ZC+#]4D MQ\60G`S\P&>$./@%LNU[ZL;AX4"4X&97?E^\]0#2:Z9/?NJD%,RF*2(1"GW> MBY,YD3MJ*_?1/UQ<\`KF@2_M.E"-B^`+G/)<3=T#7VDUM1!R(:-N6@LW6?"Y M(<[IC/7-#B:R&^[IQ=*-,OXE+;Z/9?V/\`;GR9?9\^[1\3_0@UE^37O0'^L+ MCO^/O6O;;>-(HK\R"/Q@`S0E2EHH`;P":%T"/<@B1-EY"/(P)AU9&XD2.*1W MM=B/V6_)E^6MVEEM+[R ME9$UYU"X[C-2!,.\'?[^_TO\9E/7(?,A05E0Y$A#M<`N=4NI165K_;COZC;1 MT#,[Q(7],"QP&9*O""+)O5DJ^;3(3.`+UT]M_+*%,6"2SX\AL#BX5\>H"/3X M['O8%OZQC\A%5)TU7$W&?'+]?!I@P&[D?)/MZ`KS"2EBT9ONA.PDZ2'-F::4 MSP\9B@0NHC!TD95FZ.PIU4EN]$R03[>I,_='`;";Z1X'#[;"2XW%L$$*KA M**ITM_#PD6-P=7>E^**?)=I'*,S`B/:_0+:'U*3DZOAGZ.F0Z&6C/']4G,-F M+@A_O:7Y-RO,]WR6KF.'C2I>;%1QR_K>J.)_"U4L\U)\*7WQ/ MG$4I&]3=15[C`JW5[K5B^S=G3/EZJOA&>JN9K78=W$COC?0V"^??07KO(-6` M,$]?6WQ/8[N+F6U\UJ&K@V,IQ37KOMB)GHU0T'W_A]UA<!4UEN.$!0(7(G<'N][O=7=)] M`?A6C[@"N[B=#^IQB&J3VLW)#IK$QB2E".ONB;^J]*"Z,J*O7V\=O*K^2V/R M/[\;;7^'_V8PRHD-]?8#?N(ORQ-6WY)'+I&!7A5O8+&Z`++R@JV_E@#E>[`> M^,/6A\I\K M")H5=RV^%BNT%-P$@S@=4(H)+(#/B(*&-*DC>?X&GA>X".IU"ZDV1K4+454" M6"++XA!>"WH8`FBU5.7VU>=7@1I<\@`U10^E`O3*"W`;$26G$CZ#+]U__!$S M0)@'AN#KR=9&RN_"H2<`E/>8([:NR>)A<6&U?EFA#LY#*Q)M'_?H"*@>MUI> MOU^KKP,?(C'\>-Q9!1Q1L.!8V1IFZJKYEP[M.H.,3H]B7X0JOR*H^B^J<*O MX$>H'R6J*P\9^LR2X;F$C317L82->T\<3X=#X<&E,'[42<:Q#W\53T%X0]4% MV3@,\VLZ[Y6+TL9!2OS.)?A`%@D20<=YCG*&^!)+"!*LT4%["3CJ@`,1K2$*R M."T<=R2&29L(M`.$<4P6X0C(NUZ6@>8-??`U[DQQ2,;O8JG((-#<(@@W7;<] MY=MXBMY]I0SJV,HX.-D6N_L^#OL3(!F(32``7SCDU(F?T(/"5H?N9D[1%`V6 MG@^$$WYP6"FV\6T4#1JHP\[PI6BD^CYI8<7G[%6G<].D^1C"QN01_)LF.:>$ MK"TJ%66/K`=J&I!8\]2H$W.5:#!`4+I3@6R9A"ILKN.:$`?B4>22Z#APQ'+R MR00YW,$43$[W:=B^JP-JEF/%DJ#O=X*ZKRBVK/6A,P4F>O!02NVJTG.\7&)= M#N^`9"/56[L`W4XD9CDJKS00\SU+G*[I*Y6]$PU!XI=,&\3*GXRGKT%/2%(R M6#F',QUBK,X2MHPD*ZO'JXL^@&G3CPV??G'ZJ]2GF0.!8UTANF)`?O70!^!4 M`)R3V5U<#HX`2#4L'.DI8M2&)1%7".S`;44]Z1S:`JA^#PA5\-]%(_%F^;LB M*^)SD/BL\@Q(4.E:.<48VZ+=%HCS-.!-;K`,Q$\"4(0.T%AMA8-Z>F%#U:-3 MB&>#'D_?4L#OO62Z/;)@B;Z^P("$6:%SSU"WA)-%O),"O4M(A0@!BE(&G#P_ MFAX#'X@+*M6@?AR/)R3L):^2,RW%#!4!Y7OG^-^*685)8#.BV`Y7W(Y3Q4<0 M@@N%0C0$CBP(**R([#9\MM+O@`/PTEQ?)-4]M4786HQ,^)!&2#'.X>IZ(:6A M%.78!_$#R5&H(OM2HE2N;RVN2N0>%,`%/WU;KQ+8>".@32Q?&4L2KJDJ; MGYKE)^RE/7&M%+N',\)&0#ETK`EW3YTOP13=O)AQ7U1:ZO@3F":3)]D#'0&" MXY6,"!2YV$`,;JW6RVOB='ZSI% M@#H9'<^75R4PR;0(/,_1UPZW]V4Q!FHI+ZL0(Z<"#:U//3]B=?*;%\7SM].C MXMF+5UNK@_C>NEVMHZZ6WTG;::$:D]&=5L>V&EC9F MR_6F7*TAG,"VAA?-"-J?D5;WH3@EXM,O:0\3C=9CG!]>PE&[O/J0/G.*0P.E MN<%_?*9E*./UZB,"R@AG9]AWIJXL2T)ZIGVJ/=$$DAEN5&9:97PP/W>'/)'O M9K%&-K\M5IBNEZ%X*,*]G"=.[&%;*8*VH02X1)1TX.Z:/9%K]I-W1;V;"**V M<[4N<`WV8*Y'X;1,!WDV+\:LDU=!-M6M&S^?28FPC`^FIQ=OQKAABDUA%2P= M=EG[_`\4_RL.;T!31AA>4O<`'[9\^_'1HK.VJ:,4),UH0)%KZ?VPK%!(DX!: M$)OM9A]W]T%7&;M!+DL'1RUHEL63V>`45?`ASI28I\L4R/($"NKIO?4X\IV"F4UU?>5/]>QL1J*O;\R._.A4W_X^Z_8>UC+5 M)/)&Y,ZYQE'VS8DA$H3DKX"#E'XE[BC3.I`PZP>?-5*(P&FVA(R\$9VL0D:? M@MJF'XDTD.W]M/&$V$N\IFS6>X0"[7=_F!/E/T\_CP"*=\D/'][:SQFAU\T9< M2MPRY(P9$S8C7W0MF4J^6=>@,IZ'T792KCXZ"*C3Q2Q]'8GKPV(':!K$NTD; MZS!`::N,QT$\V4;I.F5Q0?0E9\4NX!R"OJA$U3C#VGNF%0\TB2@=4O.C_;LU M&*2HA#<4]1ZO>P@K>=9HTNM-FP_U,^?Q[3\WA-R&6VN/8>8?ZS5&J@:V5I^S M5%`K36+")-AC=-%GF#Y1K6E*?%?>K#-%S)C-=1^<#LUZUUDP[T\`:6*K;;B)D0?<%$MP%N'O8VCOF9].%GY1[*9*O>>\\;6-R.G@7(C.&L5R1ZM,G8M&ZES8>P7PUHV+1=K`X-']=?BB.:,T_(<)?HS#Z`@L0.@?X,U[*DPVX+3I"L;)?(?Y((-" M#/ZM(LK,E57X6ICY5E6M#OX```#__P,`4$L#!!0`!@`(````(0#:TDL^%0H` M`.E0```-````>&PO"U10+4ED11EN18 M#DZRV1QP=8.7;K/6VJFAM&B%GD>+.///, M[.SN<,FK;Y_#P/CL):D?1R.S<]XV#2^:Q7,_>AB9?[UWS@:FD69N-'>#./)& MYHN7FM]>__8W5VGV$GB?'CTO,R`B2D?F8Y8M+UNM=/;HA6YZ'B^]"+\LXB1T M,QPF#ZUTF7CN/*5&8="RVNV+5NCZD9E+N`QG*D)"-WE:+<]F<;AT,W_J!W[V M(F291CB[_/`0Q8D[#0#UN6.[LU*V.%@3'_JS)$[C178.<:UXL?!GWCK*86O8 M@J3KJV@5.F&6&K-X%64CTZI.&?DO'^8C\\(TMW>*Q<^YY%9AP?75(HZ8 M(39H(K8NGZ+X2^30;P@&F$>775^EOQB?W0!G.@1O%@=Q8F3P,NP39R(W]/(K M)F[@3Q.?+ENXH1^\Y*]DUG6=;I.OU'+I%A<]QLI[#I-4KE'H?.^?W,R M.IM7MLVZ(@V?J@=0AVN611]==T?_[COT.46D0#J#'WOAUYJW'E?C!_BT(T()!]:Q=72S$`* M_^;%*_+7O&(I^IL73[2]F0KAH!2>\X.@FA-WNS1KQ)GK*TS/,R^)'!P8Q??[ MER7FC!%6$N3R5G[=GJL?$O>E8XF9DUJ#-`[\.:%XF(B9:C%3F%S<.I-;H9'M$33-:<_4[56&0)-7&0)-7A6+FU8# MF;_H*:CS:.ZK#($FKS($FKS:;S@#][5[E2'0Y%6&0)-714FNP;Z*^JGFOLH0 M:/(J0Z#)JXU-/HL,/-3N589`DU<9@J.]*E976,]-XV2.\D%YEZ/3QEHJ/W=] M%7B+#"NWQ']XI+]9O,2_TSC+YNO'>PX@W8[+YJIZMDMD`'?$#&;0;`VZWSN M;;*!T;UM#K45^66M;XPM^HA9Y`9+][18MW-/@PU6[FFA:J,<-Z5W)>'5$I_2 M\P8DK_B6+M\%HTCU&#EF7A!\HES^]T4U?*!R<7WUO&!WL['%@&[WTLUR^HKR M8/$U'RKR`V#AYZH MO9BYF.^3./-FF=@7(2JSV_!TM^#I%()4\!RC'S?O-Y((GI3Y.$8_UO8;]8,7 MK?H17,KZFXP'V@%2!#55E.`@QT4.!AUFQGR.MMROC9"6-(%AIH1I(%= MC#07E2SG0F<-8#LI7CO"%6$NQI30] M(^32QF.JG1J/<>+_@D4F/2LTPPDO,>G9LLR?\3-?$G=Y[SUC*9K?LGA>;*_U M`DE9WW@=C#+"K9AJ_2AYF\8ARAOGYP@LQQ.QUW*QJ-];F'\5&7)Q>V^$[`5! MQ1W=&(CK`D/C(=!0%Z&>JYLF#)+:,7!7$9ZBYHS3TAQ"SA4.F*/DLR>;[8U5 MIIR^*NG>FJ=.J^V(3-3!Q$3-5D6>C\!"B[A?"Y;&>3DD(F@9UR@1ARAOW'*> M).FNO#QL&[3]G7IPOE%[U_2A<5J:0]9TY![BL,:[S3HMOZ9.S=']M$HS?_'" MYZ4'SPLM=@<*;CS!2,.G9NI3DLUS,\6LS$D[8BXO;HKJGJG\7]$GEH-8`++M M-/)FFFJY:-`#E7@-1?OWQIGQ?D9>PJ0FG^M03IZN_`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`Q,NOO'^EI+O1B[+E'NOF8X@DA_#56B3\R_WT[[@]O;AWK;-`> M#\[LKM<[&_;&-V<]>S*^N7&&;:L]^0\HHW<`7N(E\8T^\"Q#W@CKV91K@ M37Q)86P!_E-];F2R@QR^>(0#L/%L0VE$*ZW>47C]7P```/__`P!02P,$%``& M``@````A`":?;$*.`P``4PP``!@```!X;"]W;W)K(?#\$AS,BC)JT>G>D76DUQVN3&+`ZB;.V:;K??JIB M"+$#,^D;YC\NWKTX,P/^]4%4 M^J)6I'WD"J:>C]6'5!852&Q%+LQ;+4J"(EU^VI=2L6T.XWZE8Y9>M.N+CGPA M4B6UW)D!R(76:'?,BW`1@M)ZE0D8`:8]4'P7DP>Z3.B8A.M5G:#O@I]TZSS0 M!WGZ2XGL'U%RR#;,DV';+SSGJ>$9S!P)<$:V4C[CJY_@UA""Z!K`(/K_2YB' M"*.$39CV^27D4SUM_ZD@XSMVS,UG>?J;B_W!0*0)I`&SL'KE.81H@UB": MH&HJS5NA.9.<1D-!U,9L,1!3S8!$J2(#UJ(XL?%J)G M*2L2G47@>++/H_>+C,XB<#R+T&@PCB:S>0\KH1U6G;%'9MAZI>0I@/4*QG7% M5D/5^$+9#\]$QM+P&]#4)=(+@1.('AH MC$!N^AM!&(W@?*&SC;W1CAMY<;O$J"$<(Y"%_D80AB71&N^X4;7.+#%N$1.7 M2'Y%.,Y`I+\SA&,"HVYF8NK&W5BB[6SF$DF7N'IWG$$I]'>&L.ML[L;=6*+M M;.$229>XXVSZ'F<(N\ZHO\`M,JD7_YC.(^]Y8I^WK=\Q!E74/V4(>\:\NMI8 MI!V8^B701>YXPR]F[TT!8<_;M;)L#5C$\>:52=)%[GA;O,<;PIZWJZSU9A'' MFUYBCAE0.&;UC]Q->VY\RIPUZU)#>8>_YP\^T]L=1NU>TMA'IU MN#DS;7^=DKC!W/.'FW1_?W9+;_N+_*J@EG'\^65Q@[GG#[?J_O[LQN[X\RN# M=C?_R"^-&\P]?S#.MC]L=D:P)G_S5<>WW'4870/8*H&^#IEV'CT$6S]$IO76 M.%]$H]E\=DVUK1/;LMD&I.!JSQ.>YSI(Y1%;,`JO-G>;GO+<[#4/H#NKV)[_ MR]1>E#K(^0Y>'0YF\$E0MK^S%T96=7NSE0;ZLOKT`,T[AW9A.`!X)Z6Y7&`S MTOP=6/\$``#__P,`4$L#!!0`!@`(````(0`E7]T*-0@``+LE```9````>&PO M=V]R:W-H965T5L/__-O]XW$XR/+=Y;`[I9=D-?R=9,,_7_[^ MM^?/]/8C>T^2?$`6+MEJ^)[GU^5XG.W?D_,N&Z77Y$)W7M/;>9?3U]O;.+O> MDMVA$)U/8WLR68S/N^-E*"TL;_?82%]?C_O$2?+NDM]WW$_7[ES7;[6&[ M^**9/Q_WMS1+7_,1F1O+ANI]?AH_CONXY3_*_WTD^/;>T[IGE./1,>6A]].DNTIHF1F9,^%I7UZH@;0_\'Y*(8& M163WJ[A^'@_Y^VHX78SF#Y.I1?3!]R3+W:,P.1SL/[(\/?]/DHH>L1&[-$)7 M&)EV"NANX96NI<":5%X[/,U*(5WO\T2=*#S1]6N>%J60KO=Y>B@%=/V:)YJ* M11/I"D_V:&;/'QZ+''1$XZE4TA4NK9$UFRQ$[CIT%@TSF74QWO2T=TEYP-`' M.)V.[,>Y->]UBW%BU09*;;3I;L=RM!:#W]GENY?G6_HYH!6%G&?7G5B?K*6P MAF$O3?!$,,T#F@#"RC=A9C6DC-$0SVCR_GRQY[/G\4^:^#>-%)`JV,C!>UK.L:R8-/J7;<[5[*_EAQ:/-FW MPMB`@>8Z`(R2+1B0N`",$@\,2'P`1DD`!B0A`*,D`@.2&$";I!%YBM`7(B_8 MJR'EE:,Z4T;!6E(>BR5F;D_F$\YXL6!LY/T93Q,'0&53R=06#/3.[?'AJ0(? M@-%'``9\A#T^(E40FP6-@-/SJA%PL9Y/Z>'4/>2%2@G\M!G8M:0L9.`G]->\ MOY'W:X$'8`S*%@P$Q>WQX:D"'X#11P`&?(0]/B)5$-<%ENAXU?-&Y&E_TXA\ M=\0%6XEX9;<8RFM)D1&?VI:2D(V\70LX`&,PMF`@&&ZW"T_E^P",+@(PX"+L M=A&I_!B`V$-4$6E$FK89C4@7>Y8'L2WO&>9"V`RZ/5<>@&O)*<>Y]3"958V0 M*XPDB)T?KU(/"L>I&Z'MW&2J>-G>8<2M&UG8L\6CNK&YPXA?-S*?/UA39?4+ M[C`2UHTL9HLG2WV>1W=8B26'UC&.6]661GY%25W?DW;/),%6DUKM`^14DIQV MUS*K8&#<.@#:6EM(MF!`X@(P2CPP(/$!&"4!&)"$`(R2"`Q(8@!MDD;DJ?[Y M0N0%NV^C)#E=D0<#K74`M+561AX,2%P`1HD'!B0^`*,D``.2$(!1$H$!20R@ M3=*(O%A/OA#Z@MX<]=I6J>242UG+7JDDU!XAC+2U5\:>*>BCV^?'TR0^(T8_ M`5/@)^SS$VF2F)$V/\WXB_+M_D7'DM5>?:MJSQ^;6Z)U2>H:_$Q!+YT2D5FC M_8:EK&5;3>(RTM;+(FL>4^#'9\0H"I@"4DCHANF((F.XQ4EJNM0[DLH22% MR.T7>4R!R&?$Z"E@"D0A(T91Q!2(8D;:1,TT4+"^D@9![WLT2$YG%D!!BQT+ M2%N+RRR``I';+_*8`I'/B-%3P!2(0D:,HH@I$,4ETO:,;.9`5('UJ7#GRB2+ M1YKM/"5F2AVW%B\9*%^=N0`%[7;Z15NF0.0R4K5&F48>4R#R&3&*`J9`%#)B M%$5,@2@N$7[R&2MM2]2(]63TK$NRI*PG02_["INKH73>4FV7]^M[)6E6*FQ] M>[75)"XCQK!X3$%8?$:,HH`I$(6,&$414R"*&6D3-:>#J.7J&1#384:CM"<3 ML@1L9&*AU,YKJZM.+):9#5/0=(>1MJ:7:Q/L0N3VBSRF0.0S8O04,`6BD!&C M*&(*1#$C;:)F.D2!5T]'3QID/=CSH.XJ&LLT@((F.Q:0MB:7:0`%(K=?Y#$% M(I\1HZ>`*1"%C!A%$5,@BAEI$S73(*J]>AKN?$C((K$Y*Y3?>M:6),D?OMO6 M)U2::+>C*"8+K9!0)6XIZ7@4>4R!'Y^1MO@4.0^8`E'(B%$4,06BF)$V42,3 M]M>JZ8).;T#ERWCQXG&M0QL=@9F34.A=C M](LO?&V]`%9_!5V7'%%P\/;G4?DE=%.1D&='A[8ZY.J0IT.^#@4Z%.I0I$/B M^(G8J5%_J*DRJO(XB7RC?DYN;\DF.9VRP3[]$$=%:$"]/#-.&(BW*'SKY\*YPJ^-I:T@MQ:HR"N]:2WFGK>&@MZ;VUCJ_M);TLUG'' M7M(+81UW[26]]=5QWU[2FUT=#^TEO;XE?,P-I:,SU]U;\H_=[>UXR0:GY)7B M-1D]T![B)@_?R"]Y>J4XT@&:-*=#,\7'=SHDE=`&ULK%;;;IPP$'VOU'^P_!ZN>PM:-MHE2ENIE:JJ MEVGPAM;P).>B(@INQ#"E&51I].=53_Z"Y)VW.9F1E^Q5'#)<^4`G6N%SG.^=J]=8-IM,P89:-N1H'F,]WZ4;+"[ MVQI_?C-ZD8/_2!;\\DFP["NK*9@-9=(%.')^KZ%?,AV"Q>YL]9TIP'>!,IJ3 MJ/!?DME24)6A*XMB0;9^U[U^$:.%Y9 M%[;KX-JN"U?/+Y\O=*UXX\4M462W%?R"H+]`GFR([E8_`K+.!,O0V_(O5\`. M3;+7+#%>8P0)2ZCDPRX(_:W[`/:G+>8PQTP028?050-YO48PYQTT:A:M45=2 MBSYT@8'HL>2D0TP%@5'O($BSQ!A^!Z8%8P4'B_'!F1ZT'$.2'C)5N7@7E9H% MF@.LZ!7,:]N"7I/90Z8RH=&'9KZ\_;I&TV"CIJ^BC02>Z3I_VE+MTZ&PH?I1 MFZW^1X@&CX6T$3LJ=(,EP\CH3;!1ABGK3;<*G>J9",EY%MN]XMD6KA*>L.D;VSQ\/-VO;DHI4*2EX12/[E4K[;OOQP^;, MQ9/,*546,%0RLG.EZM!U99+3DDB'U[2"-QD7)5'P*(ZNK`4EJ4XJ"S?PO*5; M$E;9AB$4;^'@6<82>L^34TDK94@$+8@"_3)GM6S9RN0M="413Z?Z)N%E#10' M5C#UJDEMJTS"QV/%!3D4L.X7?TZ2EEL_3.A+E@@N>:8]6,R7ZQ607$F<-8EPO?#U::)KU&LS[HDBVXW@9PL:#/3)FF"[ M^B&0M2X8ALZ7?]D"?B#)#EDB>V5;L&()I7S>^BMOXSZ#_TF#V5_`#!%QB\"R M@;Q.([CS'S0B"VK$4J+H?1OX*SH8"6H18T%@U%C0#!KP:=@6LH&=$UF!QG+!$E][ZY[ MAF"MIBN:B02>;K+9R)OF95]77_R@J9;OT8'@H8XF8B8#ME/`Z`,\Y5^X#UZ?Y&;/\```#__P,`4$L#!!0` M!@`(````(0#A%<)O`0,``)@(```8````>&PO=V]R:W-H965T&ULK%9=;YLP%'V?M/]@^;T0$D(("JD2JFZ55FF:]O'L@`E6`2/;:=I_OVL# M7H"N:J6^A/AR?'SNN=JIHK5H204NB0+\L6"-[ MMBI]"UU%Q,.IN4IYU0#%@95,/1M2C*HTNCO67)!#"7D_>3Y)>VXSF-!7+!5< M\EPY0.>V0JC9WGQ'\F"G[\( MEGUC-06SH4RZ``?.'S3T+M,AF.Q.9M^:`GP7**,Y.97J!S]_I>Q8**CV$A+2 M>479\PV5*1@*-,Y\J9E27H(`^$45TYT!AI`G\SRS3!4Q7OC./%QZRP#PZ$"E MNF6:$Z/T)!6O_K0HK^-J6>8="SP[EM#Q_)FA>&7:HIL&SW[QP%FN9@M/KSV= MZ+;BC1">L18 M$/CT`8(T"_3,A6=>$`X5[%N,!\Y88Y=#2&(A8Y7^AZC4+-`;8(55,"EMAWE- MI86,54*W7GKY\N;KVTR#C1A;Q"[BFYX;U\^^?%'[H,>"]\C0X*&,+K*VW95< M1@8KP2:Y3%AON(47.BL0^\Y-IYF&,KH(4-EB><%ZU#`6-"Z%OM[OI5 MM[V;9A?SZ:3=+KNGU?;E;OJ__W[YY6HZZ?>+[=-BW6W;N^G/MI_^>O_WO]U^ M=+MO_6O;[B?H8=O?35_W^[>;V:Q?OK:;17_1O;5;1)Z[W6:QQ\?=RZQ_V[6+ M)]UHLY[E\WD]VRQ6V^G0P\WNE#ZZY^?5LE7=\GW3;O=#)[MVO=B#?_^Z>NMM M;YOE*=UM%KMO[V^_++O-&[KXNEJO]C]UI]/)9GGSV\NVVRV^KG'?/[)RL;1] MZP]1]YO5CJ[ MO]4"_;%J/WKV_TG_VGW\8[=Z^M=JVT)MC!.-P->N^T:IOST1A,:SJ/47/0+_ MWDV>VN?%^WK_G^[CG^WJY76/X:YP1W1C-T\_5=LOH2BZN<@KZFG9K4$`_TXV M*YH:4&3Q0__]6#WM7^^F17U173Y7N_[S9_#DF9Z6KH M)#>=X*_I)*LNLG)>4Q\'VA6F'?[:BQ_,+TT^_MK\D\G.AAO7.JK%?G%_N^L^ M)IB!QR,F@C).ZDBF-2W$L.2)H8L1#FK1\1HX^]8+Y M`RT>((`Z2G'AZO5M=*5GSL_T^&J1P8]\8I!PFKU14N6#Z M!@6S>@PS2I;,##*8%2V")D(41\2UL0"Y*K28\_SZ`O1'CBAU)'D9!%WY,2[F M4J?&)5FA%4<$5:K`S'<.#R`E2SH&83)%B.*(N/:UO+;VO+JZN!RO$_4DB1E$ MZI0%.KDDIQ-'!-<,-?%TH72V)&0A)E4,*0%)`F3";*1(K:MK*J=C)Q695J"6 MA:1OZ+*>7@"1?LF3&]_#,(M,*.1F("Q9!RC;469(`N2TCH*?7Y=49JS`S MOIT[FWJTD!2L".:7S_*"F;X2?,ED&=\C@AE+YIP,Q`6+()5Q2`J&F^$$M&U= M7I^S'JEXA<-I(*E8&2KFLKQB')*$R8!/5\S8-5>,.[C>ZC19!"D!20)DJXR` MGF)9>99BQJ$Y.V?:W.O#74;FLKQB')*$R8L9X2-SS#@WY\3-W"@602KCD"1` M!LL(:,7.\_S,>#5GY^R;*U:'<\QE><4X)`CGHWQ?9TO?MQ!;E3&D!"0))'P_ M+_-SC#^/C=]"!HKY+*>8@"3A4<:?Q\9O(:Y8;/PB2Q+XRXP_CXW?0E*P MX!FK\5E>L$^-/R='9FOB\*+4V<$4XY8^+$J;Y354`I*"D<.>3L#X,5MWM`DA MNX=WLEUI\,C4^"POBFL(2'(B'V:I$<8&Z_FC`W$&3OH(.-DEM_%2<;DT0'C$P0VSL[I&HC3 M==!!NLDLOX>2=,FA&=TCJAH_YS0-Y-\S-'D$*0$)`L6H0J"SY2JU$.[:+Y(R MW`#Y++=(!"0Y)6K#\3$LXC)@(3:&'N)TPT62SO)[%$DWJ`RTINM"[Y8.#V<1 M%PD+<<8F"T;+!(X8)[/\'D$R#DK)$9IQN2@,=.4>'9H84@*2!$;5AL(4`C;M M+21G75C@?9:?=:8OS5QR&E4NBKA<6(B/G>B&P:,367AC!UTD'$JJ_ID M*U`FRLAIC.,RHOO"37#&R0+AUX">%,HW9/=5^6HN)\6H,E+&9<1"?CO?Q)`2 MD"00E!&:E?AF[)R'R#*N,1;")&?+R&\"AF7DL]PR$I`D3$Y_LK?05SK!ZR8+ M<<5,EH>4R)($$M4CJS`R(]_@EW$]L9"4R^]`C%RF(6?+(2OUL20$I`D0+[-"-`$*[*K<]Z$E:8$<'8&DHJ%FQC;T-^#$I`D/*IVE''M ML)"_6A-#2D""0)4H%&8S/'**Z9ZD$5M("N8W2L,4\UEN10I(\@WJQ.%R1D\A MP8JT$!,LAI2`)(&4[==GO9ZNXD)@(:F8WZL9Q4Q#?P_*-X2(DO`HUR=O"14S MD+]:8[,\I`0D":1<_PP/JV++MY"0JPZ*9..S_`0S?>D;D&S1%[>0(Q.,LH-) M;R"O35-%D!*0))"R_/.*9!6[OH7`R!?).MQK^BROV*>N7XUR?9T=*!:[OLWR M(BH!2<42KI^=]S:_BEW?0E(QOXTU2]+5!J\8AR3A4:Y?Q:YO(2]/$T-*0()` MG7#]2YP>&KVOT!W)T;20U,MOH@>]?);32T"2[BC3KV/3MQ#3*X:4@"2!A.EG M9WV)6\>>;R$IF-_#&\%BS_<-H:'D.\KSZ]CS+<0%B\J`$EF20,+SS!L.M MO,_R:KF&T9H;9>HX!AMN'`Q4TCO:08;AH.MP0'/3[E[:IEVO^\FR>Z=#K"A, M][<.'D[8/M8%CMCJUPA1I$1$=QY%*D3T@$21&I&:"$612T3T&[,HB8L3Z4&T5R1/0371BIT`93 M*\4`;;"[3D6@-?:QJ0BTQJXS%8'6V/NE(M`:^ZY$I$0;O")(1=`&S_&I"+3& MP)F[,'Z9 M\+9X:7]?[%Y6VWZR;I]A^G/]+FLW_+9A^+#OWE!V\?N$;H_?).C_ON(W*"U. M"\]I2__<=7O[`5K/W*]:[O\/``#__P,`4$L#!!0`!@`(````(0`O\$#$+`<` M`)0A```8````>&PO=V]R:W-H965T&ULE%K;;N,V$'TOT'\P M])Y8)'4-XBQ6(K8MT`)%T(MVJ[8;XIMO2]7 MWH^R]3X]_?S3XT?=?&W?RK);0(1]N_+>NN[PL%RVZ[=R5[3W]:'R* M#EXVK\OVT)3%II^TVRZE[T?+75'M/8SPT%P3HWYYJ=:EKM?ONW+?89"FW!8= M\&_?JD-[C+9;7Q-N5S1?WP]WZWIW@!#/U;;J?O1!O<5N_?#;Z[YNBNAB;2NMX"`?BY MV%6F-2`CQ??^_X]JT[VM/!7=A[&O!,`7SV7;?:E,2&^Q?F^[>O)^>TJCQ^4WJ,?:0K)3B*"(_(@P MR3=1-;X!/X>H43C,68*`005D<:KB?%&/9`W8D#T^)\,WIL^1PV-Z)ODI(F+Z M]"ED#$*X0O&G7$W&%;2SF[.9!+A)*M*8.5!@@9F:<+((R3I6^=.Q+&*PH!"<@KQ$R4#7@,*B47LI^'8940`+-JI M@.NJ8":Q*J249880(#)HY56816@7@HB(J`AW%0R85D'X/F./F*@O0V+V-CJ> MSXSKZ;B0(H[B\0F$.6P5T_2[F1LP9SZ6M>_M##%!SWQ\)O:]8TSC&"J.4A_^ M#9()87,.F.R3;L(&S`FS5&:(.4_8,:9Q#`DKD827"*>W$#9@3E@-B<`,(P8? M+/W4CUD)<@)(PY!M4'HZKE(9*W]-?5_2+0Z:8[I!K[T"I`#.;_+DG3A.??1CDB`I&P&)HB1"!4,.Y.E+^Q ML^OYH_D1_HQ=)A!CV0D_#OCVG5.(2A3?WRE`Q"*,QBZE_(V37<\??0]^#KNV M\,?,V`*XS+&'Y&(6HIT0*L&XV43"=18ET`.GI1`^RV-F05@+E422%2LG@+M( MJ(09MB8(I50H1B>D,HR;362X=TYS)#_9B=A&DEG0L96B0/DQP^0,(Z2$NM`W\B9+[M&<]6@VV#<6=($U&O;906UG'KWC32S./OQ MM&79(P@YP!8OI(J9PMP&0HP,19A&K/LTA<0BD?'D^$4;Q_CC1(Q[Z4IT4[IT MN2M;D%L$!G**()`X\ATBF"_/B#CCQX+[L420%2%%E$K^_4E.,2J%L__8Z'U! M-86$L11"CF9#*W&3*YNON$[:B3EN9D$H0H6A@$_HU'!S`@E5X/,CH+8(OF@H M=V;%,P5`ZZ1=-&;%+@4$V0+PS/687!(,?'Z1DM514P@/0T4P$YX1@=8)33H> M4"<'+BOBZ*\CB*V67,Y"M!-")=QDQ/*,$4O6P9D%\?+;`KB,F,P,+GVLDY)<\_<*;.@\[EW#6H[B`L^@+N82Z<&!0QN*(!!,]^5 MW'?[D*9C+J_3>8AV0F@!C+==[;H*G9!L-:<]A""GA%F(MH\Z'X5*`,P-$@R: M5X%MA9E"T(7>P4';'D&2AGSQVNG6,50DX4/RX':4^TU6J\Y8+?>9S(*`Y&`' M3%X^#]%.")5PD^,J-,J9#D*04\(L1-M'G8]")=SDMPI]DNX^+,69!5WHH*/3 MGMOY[4QL'JG"0$3C:8K2OLECU3F/'2/C,<&"SN<,G78>HIT0*N$FSU7HF#/- M<[151__/0K1]U/E$$`EP,7W#]M.CY[8?"\(;+[:YY*Y!<*>&+U'!L M3&2-E^!XS;LKF]S]3#SD_0WV/!R^'N*I_\!``#__P,`4$L#!!0`!@`(````(0#E$.D>W0,` M`.D.```8````>&PO=V]R:W-H965T&ULE)==CZ(\%,?OG^3Y M#H3[E3=EA*B;4031W62S>5ZN*U0E`Y30.LY\^SVE"T*9M;MSP5[J__X3?IKK&F6H3%%.2KS4WS'5/Z_^ M_FMQ(_4+O6#,-%`HZ5*_,%;YAD&3"RX0G9`*E]!R(G6!&-S69X-6-49ITZG( M#=LT7:-`6:D+!;_^'0UR.F4)#DAR+7#)A$B-<\0@?WK)*MJJ%BNE8D?GPN28V..8S[S9JBI-5N;D;R19;4A)(3FX"<(1(= MC]DS/`.45HLT@Q'PLFLU/BWU9\L_/.G&:M'4Y[\,WVCOMT8OY!;56?HE*S$4 M&VSB!AP)>>%HG/(0=#9&OS(="WCMB"D+,ZZI M:\F5,E+\+R"KR4J(-;D%B*'5HB8W#?P&FE:(SQ[+Y\IM5D*BR_-7:4)^7.69 MRRSU)UV#!"B4]G4U]Q;&*Y0C^8FLQX@['2*;%N&#Y[)!&[C+6L,NVY9HNX0B M`-],L"43/IX2 M;:TYS6O=/F@M`OT'V<,1;\:$ZPZ18(Q((MLQ(8N$8T02B93$;DS(CXG'B/28 M_9B010YCY"XR<,>1W.&OB`.O_V.7>*^!2R+0=\DSAQYLU$B@1K9J)%0CT0>( M-.-W:B16(WLU&>O6;%F_ M?6[;4G/0;[9AJ9;DM_UVRW,=9S@CPG[[=&Y[EB00"0"NW1"DU6ZG)&(EL5<2 MAT?$P"'X5`T^.(\=XK3DD%2BM4#@^;^JP$9)!$IBJR1")1$)PFWFDF7:SEP: MRJX/S!QK/IP,<;_9FMNF(WUB]WW`\VQ)_M!O=J;3J=.;[0./W#_RB-.21]+G M="V01QXIB4!);)5$J"0B);%3$K&2V"N)@R#$7(&9,#/O*\O`*MAR_<'KQ&G) M*FFY6`ODD55*(E`26R41"D(LO*YGPM_P;8B4$CLE$2N)O9*`(P.OZ<<%$U:) M(X'8=A>X/N,-SG.J)>3*M_LS6`^Z:'<2>7;X_DZ*KRT?]LCC>&#YL!$>QR/+ MAYWL.!Y;/FQ7(6YT#X"31H7.^"NJSUE)M1R?(#5S\@1K1BW.*N*&D:HY-!P) M@R-&\_,"1TH,NW5S`O")$-;>\`=TA]35#P```/__`P!02P,$%``&``@````A M`$>(O\`C!@``@Q\``!D```!X;"]W;W)K&ULG)G; MDJ)($(;O-V+?@>!^5$KP0*@3HXCB<6-C#] MW$MT]D[3F]EN)][9#]VD%=W\*WQS MC.+03>%C?&HGM]AW#]E%X:7-.IU>.W2#JRH4S/@9C>AX##S?BKSWT+^F0B3V M+VX*_4_.P2TIU$+O&;G0C;^_W[YX47@#B;?@$J0_,U%5"3W3.5VCV'V[P'U_ M:KKK%=K9AXI\&'AQE$3'M`5R;='1ZCT/V\,V*$U&AP#N@`^[$OO'L?I-,_<: M4]N3439`_P3^1U)ZKR3GZ&,1!X=-?.3U`ZXI*IX[TD:A?\*2,NEA`C+1;K0 M^_Q[HZ4SHS]X147/5:#=0@6$G^Q"+[^X_[BX]WH78%9DHP&O]RZTV,#0C-X+ MPS',5>#UH?+JF&I@!9$9[HE\5-GKG='N&88WN<[P%V2*'&N0IJ([OY!D[DUQ M6Z4T/Y^IMK!O-ALL-W4GHSCZ4&")@9M+;BY?L#23MU',`^':^\SXOXD!,X*K M?.,R8Q5,!)Y/8#;_F+"N/FK_@!GHYC)C5=O29&)>$'S: M\N[9=;)]^:)%E>FAWBT+I-!U<&"%`VL MD646-8Q,+&N(Q]AEMG)J$!UY<57',+FIM6!@I>03ISMD&A+9"`#269HZ:'BW M-8R.IN"NANDBG7T-4QH]R33PW'K!-)R63(,#,QRP<&".`S8.+'!@B0,.#JQP M8"T"^7.?+R`;$9$2H'?E+&[K�C=T\P^SKF87$I`?!,>2$!G)82@`,S'+!P M8(X#-@XL<&")`PX.K'!@+0+E!(B(V#[QC&QQ8%<$2G,$IVA?,+!N2>,(#SYI M'/E3L`O[A^95D%\%7'E6ZFB)F`H&VKW/7&2)&4E8)#$G"9LD%B2Q)`F')%8D ML2:)#4EL26)'$OLF0C(/;*$E\S2;AM-C%1;9NR&8CI;@J6":3$,2%DG,2<(6 M!-.SYU*GA9R[(`66).&0Q(HDUB2Q(8DM2>Q(8M]$2(Z!??(+CN$T=@S:-TT% MT^0800S$%D,W.AVT([+*`/INWO"=33:]*%_=&T++2'Y)2C@DL2*)-4EL2&)+ M$CN2V`NB-A.22WBIJ?S3K'E=X31R"3:)0)I,0A*6('J9C32C#UM5AE:ON80, M69^QQ^Y%_!PCFUE(&K7-+,M(US"T01=MJQVRF559P^CJ'1WU=%U(\(TY90 MDX-HQ**1.8W8-+*@D26-.#2RHI$UC6QR1#B6/]`K?MW*2%_3&7HF["2""179 M]/O&KLA>X@6G\B/K22^).I6T)S;08C[E]5A8L8HG3]WMSG*FP6\6CN?'>R`P&=W#XNS19B:4M:!&A.(+9D)UJQI?,A.* M7-6XPTRH=57C*V9"R:L:7S,3*E_5.)R%?JN+6YH)1QU5?LK,:1T_8R94^*J\ MQ4PH]%7CHA0./[.W9SCL]J%R!W4$53E&45I\X`W&ULK%9=;YLP%'V?M/]@^;T0R%>+0JJ$JMND39JF?3P[QH!5P,AVFO;?[]H& M!J2+\M"7$B[G'A^?>WW=S?U+5:)G)A47=8P#;X81JZE(>9W'^-?/QYM;C)0F M=4I*4;,8OS*%[[:%@-7S(A*Z+A M5>:^:B0CJ4VJ2C^Q#T6+%:.Q+)2J)!ORIXHSJV MBEY#5Q'Y=&QNJ*@:H#CPDNM72XI11:,O>2TD.92P[Y=@06C';5_.Z"M.I5`B MTQ[0^4[H^9[O_#L?F+:;E,,.C.U(LBS&NR!*;K&_W5A_?G-V4H/?2!7B]$GR M]"NO&9@-93(%.`CQ9*!?4A."9/\L^]$6X+M$*@I7#)89L,SS9YY2W7LWD`2UW*F[=Y\.P7O93H.]'6@P>BR78CQ0E! M7X$\U1#3I4$$9-WFG>3>CO^Y`388DIUAB?$:(]BP@@H^;X/U?.,_@^VTQ>S? MP(P128^;N`C-=VB-_];DS3&,9;02H!N6:MDP/FM;"7&F#:7"Y%@8\7MQ%%G;$T'`KV)\%7/X,6F;F`3@30G&ULK%;;;J,P$'U?:?_!\GNYY4912)50=;?25EJM]O+L@`E6`2/; M:=J_W[$--$`W:J5]*3`Y/CYS9CSN^N:Y*M$3%9+Q.L:^XV%$ZY1GK#[$^-?/ MNZL0(ZE(G9&2US3&+U3BF\WG3^L3%X^RH%0A8*AEC`NEFLAU95K0BDB'-[2& M7W(N*J+@4QQE[Z"HB'H_-59SH$B]W)ZCM3@.\"930GQU+]X*>OE!T* M!=5>0$(ZKRA[N:4R!4.!Q@D6FBGE)0B`OZABNC/`$/)LGB>6J2+&LZ6S6'DS M'^!H3Z6Z8YH2H_0H%:_^6)#?4EF2H"6!9TL";Q?PLQ8/SV[3A3,/%JO0[#I= MZ5K5QH1;HLAF+?@)06.!+MD0W:9^!&Q=]I:A]^-?=H`/FF2K66*\P@@RE5#" MIXV_NEZ[3^![VF)V;V"&B*1#Z'*!O%XC>/$?-&H6K5&74(O>=8%7T<%(4(<8 M"P*CQH)FT'AOMTSGD5X$S7'N4>@--]Q9C`]&]$8NAI"DAXQ%S:>B=!]_L)*: M!7H!,N\53$O9@B[)["%CF2#IW+O+GFFP4=,7S48"SS39]"@ MJ98?T:'!0QUMQ$X$W4[)>62P$QR+\XS-$0M6#HC]8&TTT5!%&P&JUVJ%XR[N M0>-2Z!OL[.Q?+H4&#S>WD;F9KN:XVAEKQTM%Q8$FM"PE2OE1S\\02M9'^]&^ M#?3Z47P'(]\,R'$\B)(W\;,(SL649SN/MN;J&//,H\3H'L>7$91QRK-;18D9 M'&Z_`*Z`AASH`Q$'5DM4TAQ2])P5E$+82\1^*-Z`:W`1<`7#W[P6<-=3Z!A/ MMT#.N>H^='WZ_QXV?P$``/__`P!02P,$%``&``@````A`%1HX2DQ`P``N@D` M`!D```!X;"]W;W)K&ULK%;);MLP$+T7Z#\0O,=: MO`NV`UM!V@(M4!1=SHQ$640D42#I./G[SE`+M+A&#/1B6:/'-X]O1AQM[E_S MC+QPI84LMM2;N)3P(I*Q*(Y;^NOGX]V*$FU8$;-,%GQ+W[BF][N/'S9GJ9YU MRKDAP%#H+4V-*0/'T5'*S[U9NQJ.&V-R/Z7$1*:IF8"=`YE=#QGM?.V@&FW286 ML`.TG2B>;.G>"T+/IDXD5.)MAX\,,-V&R7/!!H+9.F289MZ`9`UFZ\86CO^ MY0;8@"1[9-G2)26P40TE?-GY_G+CO(#M48TYC#%>'Q$V"*P6R&LU@BG_02.R MH$:L((H^-(&.Z(&@!C$4!$8-!4VA[RYW3.,1+H+>Z'FTZB<\5!@/C&B-G/:Y`W/JIUUA7?6]KEK<(@3!?2%UI#H1L)_";J27"=Z+[I;M.^:"PS>6!FGZ M&NH([+I3K/7`DQ8TK`0.L,ZK?[T2".XGKR,=`[J1G@'K?B9KP&(^68+P&SU` MIKZ,.M+S8#KLBQ8T]``&RPTF6'0_?1V:V1%C#ZUJT%2';,[5D8<\RS2)Y`F' M".!WFS;<3KB]CP2#^`$GWZ6X'X07\=,`CH-'<"Q4ZD-,T-)FB_NG9_`0``__\#`%!+`P04``8` M"````"$`<:*/<3<#``#%"0``&0```'AL+W=O7;`!&L!(]O9[/Y]9VQ` M7-)H(_4EA.'XS/&9P>6'D36QWN]8&_6;T+#O_+9GQ M\Q?!DF^LI.`VU`DK<.#\!:%/"89@L3M:_:@K\%U8"4W)*5<_^/DK9<=,0;EG ML"/<6)B\/U`9@Z-`X_@S9(IY#@+@URH8M@8X0M[T]365(_)H$KC6)[RQGLV"^7`#)E873>B%<+V0?+W2- M>FW&`U%DNQ;\;$&'@3Y9$>Q7+P2RQ@7#T/KR+UO`#R39(#.?]"(+*@12XFB]TV@(WH@J$$,!8%1 M0T%3:,#+K=-XA(N@27H>!?V$>X/QP(C6R%D?$K60H:A@+`K[^<9*(@OT`NR\ M53`N90VZ)K.%#&6"I*YWUSU#L%;3%JV.!+K)5@-OS$._JZLKOM=4\UMT(+BO MHXZ8DP';*>I&>IG@M>CN&%\Q?^GAJ7)K<9"I+\-$_'ZYABW3@H:UP%G6>?FO MUP+!_>1UI.-!-]+S8-7/I#V8ZI/U5@^0J2_#1`8>S`>MT8*&'L",N<$$C>ZG MKT.!GC;ZV#(SQQRS!15'&M$\EU;,3SA/`+]=M^%VV.U\)!C$]S@$+\7],+J( MGX9P0(QY=D&X@[SC!_L@C+3R8>)Y"`U]`;\((WV$#O'+,%I>PJ_":(5QMUT` M0[0B1_I,Q)&5TLII"J9,'!QXPHQA(`..5< M-3>8H/T`V_X%``#__P,`4$L#!!0`!@`(````(0#TE-G:_@(``)H(```9```` M>&PO=V]R:W-H965T5:%%(E M5-VMM)56J[T\.V#`*F!D.TW[]SNV@062K5JI+R$,QXJ)", MUQ'V'0\C6B<\974>X5\_[Z[6&$E%ZI24O*81?J$2WVP_?]JK;XS M!?@N4$HS**CV`A+2>87IRRV5"1@*-$ZPT$P)+T$`_***Z@PT"<;HOO5#X&LL\&^ MNC?F?[Z`(9IDIUDBO,((,I90RZ>MOUINW"7D#=HVFP49-7T4;"3S3=5-O MVH=#74/QHRY;OD>'!H]UM!$[*W1_QOG385%3F-:5E*E/"CGJMK M*%@?[4?^+M#K)_$]'`5F;D[C01A?Q,]"V!7G/+MYN#-'RI1G'L9&]S2^#*&( MYSS[51B;.>+V"^!H:$A.'XC(62U123-(T7/T42#LX6)O%&_`-3@?N((SP?PM MX!N`0K]X#H`SSE5WH^O3?U5L_P(``/__`P!02P,$%``&``@````A`&[%XC(M M!```\@\``!D```!X;"]W;W)K&ULK%==;Z,X%'U? M:?\#XGT")M]1DE&;JKLC[4BKU>[,,P4G006,,&G:?[_GFH]BXT;)J"]-N1_' MQ^=>7_#ZZVN6.B^\E(G(-RX;^:[#\TC$27[8N/_]^_AEX3JR"O,X3$7.-^X; ME^[7[>^_K<^B?)9'SBL'"+GJ*E:>)Z,CST(Y$@7/X=F+,@LK/)8'3Q8E M#V.5E*5>X/LS+PN3W*T15N4U&&*_3R+^(*)3QO.J!BEY&E;@+X])(5NT++H& M+@O+YU/Q)1)9`8BG)$VJ-P7J.EFT^G;(11D^I=CW*YN$48NM'@;P61*50HI] M-0*<5Q,=[GGI+3T@;==Q@AV0[$[)]QOWCJUV@>]ZV[42Z$?"S[+WOR./XOQ' MF<1_)3F'VJ@35>!)B&<*_1:3"(/M15>#OTHGY/CREU3_B_"=/#L<*Y9YB M1[2Q5?SVP&4$10$S"J:$%(D4!/#7R1)J#2@2OJK?N,G#;YLWNY3HU>25 M%@]A%6[7I3@[:##0DT5([?PI)0T!R0HF,PK&T3=(EF%V+21*/W MQ;0?O[;1*%BQZ:I86S`HJ.L6NGR[QMGGU2>O==GL%AX4K/-H+/6DH/[:]2W: M2C@GU^^8@O65:DN@5V1F[+P+,N6FUU?OP%^6FX+UQ1M+;YM]B[;-I;X2C9;Q M(ABA)C=.%P+263060/6:FG@J:29.!#F]_-:7# MYWEKTJ58&EWQ'C5H"V-@7CX:K!N,W2AJ37TIFBB+%*#Y25(0DM$5 MC4F3(O!-*;JH@10W#4,VG(:MJ2_%A_.0&0.1NF*.SYG;S\=P6"IL\WP$@R^/ M)M%2IIOF)1L.S-;45^+#D,=J M'7OY?*AHO2L;T^0=N?XXKS](,UX>^(ZGJ70B<:(/;_52[\SUK>">S58[=!?( M#3QS>-3WW<"S@&=AS5G"L[1Z?'C4#6*`AHL)!JJ-00"/$FZ0,X9G;,V9P*,D M&>1,X5%M8WAP,[JSKX($VQJ@98T'*1NGNPGPK5L'5RM5U,1:$E3$6A#4PUH. M5$,5P^MVC!M7$1[X][`\)+ET4KY'8_@CNF*5]9VM?JA$@6;#O4M4N&NI?X^X M6W-\B/DT2?9"5.T#-79W6]_^#P``__\#`%!+`P04``8`"````"$`Q<^6Y#,( M```_*@``&0```'AL+W=O5ONBO/3;?#W7Y\_+(-)W63G778L MS_EM\".O@X]W/_]T\U)67^M#GC<31#C7M\&A:2[KV:S>'O)35D_+2WZ&9E]6 MIZS!S^II5E^J/-LII]-Q%L[GZ>R4%>>@C;"NWA*CW.^+;?ZIW#Z?\G/3!JGR M8]8@__I07&H=[;1]2[A35GU]OGS8EJ<+0CP6QZ+YH8(&D]-V_>7I7%;9XQ'W M_5W$V5;'5C^<\*=B6Y5UN6^F"#=K$W7O>35;S1#I[F97X`XD[),JW]\&]V*] M2<-@=G>C`/JGR%]JX_^3^E"^_%(5N]^*R_"I-O^RD",XSQ_NS MJL`?U627[[/G8_-G^?)K7CP=&I0[P1W)&UOO?GS*ZRT019AIF,A(V_*(!/#O MY%3(U@`BV7?U]Z78-8?;((JFRR2)T^4"81[SNOEN&]/H<@T\6DFH*$OUU\:46%?".C'O M6*ZY4"RF2-9SV+T4TMB^>"=IZ5(NL8TI ML2!8V5>2$,3SU120>4(@`]E9=!*@:30L;8S>B$(@L).\'0-E;5]>BPP4+)$% M@US8YM54*ZPBN>7X`J%"D51D=(AL*):D&[2C2MC.3O+?F_M!4@0IA1:96'16 MS-4DD1E74UM1K+9?;RPZ3AP6XX/H1#86*XI%;^7T!6'3U]>&Z%FSYRDM,K'H MK!@LD";%(DI74SE:>"X067U:EDZ$/\,26G&GLK8)2XL,+"R1U1=R5S>[4/'%N+Y0H4@J''>NR$R[ MT8[N"I9;L)G=ZVM$69,$3*)L!PIMQ5R-X\Z16+C<&?:L:/(%&54W@Y73%U[< M&;K*0FO24:`(QS)-=F7HK!P@OX@Q=XM0B M$XBKQ!F^'W&J4`2+GA)-+.BHJ1V9EO4BSM`E3BTRL;A*G"%#G-%RS)RE(A$H M^FG2A(*.G-K1A2+RXDUE;2>@1084ELCBS>C]>%.%(JFPO$EG3NW(8.'%FU%' MDL9LH44F%B:5VEB\'V]&+F]JD3U;T)ESL*)T$7GQIK(FQ3!)LB4G;<4@S_'F MN#TDZAC0+$M/BL,:P2M/,F=I1R8[+^J,7.K4(K,OKE)GQ%!GF"[&S)PJ%"D+ M0YWAG,Z MO*FL[02TR,#!$EE<$3.\.6X+49%()@QMAG,Z;FI'!@HOVHQ=VM0B$XJKM!DS MM#D2"I01EMJD=D5)HW:7?%NG)FXG*E%%A2"#IJ#E0.%%VT54D MLE2Y45/045,[NJLW]:)-96TGH$4&%);(6B`I0YOC=A`5B63"T::@HZ9V9*#P MHDVWVE$9[+N&45T_Y)C\>Z\FV?)8G,&!_=].+V^,A#\ER MO4%[(82C64&SXC3I'&=*U+$0ZI/*TR;J:`;5)"&BJ37E:")H(NXZ20R-NCW' M)X%&0>IH4FA2-MH"&G5L@?K$\,&$QF`0PP?C$* MTP`W;+",)H8/GJ4X#7SP(,-I@#6>0S@-L,;$SVF`-:9S3@.L,1HSF@@^>`_" M:>"#=Q"TP!KO&/G-,`: M;[HY#;#&*V5&(^`C6!\!'WSEXWR`-3Z_<1I@C>]K:A,C+%_ MD"W`R673,/+[>'W?'N.CMR'7+>/P@#JR9405V2*BAFP)44%5P%E_81S?NV1/ M^>]9]524AG M7Y:-_@%$9_W1S[O_````__\#`%!+`P04``8`"````"$`^^N.\,@"``#"!P`` M$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"<54U/XS`0O:^T_R'*'5)8A%8H#0IM4)&Z3;4)<+2, M,VTM4CO83K?EU^\XV98$#"NX^>/-S//,FW%XN5V7W@:4YE(,_9/C@>^!8++@ M8CGT;_/KHY^^IPT5!2VE@*&_`^U?1M^_A7,E*U"&@_;0A=!#?V5,=1$$FJU@ M3?4Q7@N\64BUI@:W:AG(Q8(S&$M6KT&8X'0P.`]@:T`44!Q5!X=^Z_%B8[[J MM)#,\M-W^:Y"PE$85U7)&37XRN@79TIJN3!>LF50AD'W,D1V&;!:<;.+!F'0 MW889HR6,T'&TH*6&,'@Y""=`;=+FE"L=A1MSL0%FI/(T?\:TG?K>`]5@Z0S] M#56<"H.T+*S=-.NRTD9%]U(]ZA6`T6&`@/:P67:QW34_BT[/&P2N^DCKH66" M%WV..3,TEF6 M3F_&<9Z,R54\C6>CA&23),FSS^+)G/[?),LQTJ]DEFMW1AQ+U>XAGE=C6%4&JQLC)%OO7:OQP\Q8S MQ6Y&C/5G&UJ3AK;3)#.2/:YD6>"H(8$)H5!X\-ID=4/&IYJ?"!)-O:9 M3M2[]25Q4;CKT2MR`[.OIF7;1\XH'U?=+=;79>]')#$[YMF&S)+FX'*GAP(3A3?8G+7!9LTY$:[_7NSKJL3 M?1+R$LZY7\X]*1<[TR2?X%&WMB(LRTD"5K9*V[HB3^ME.B<)!F&5:%H+%=D# MD@6_O"BE*V3KX<&W#GS0@$DD62RDJ\@V!%=0BG(+1F`6'3:*F]8;$>+5U]0) M^2YJH),\OZ(&@E`B"'H`IFXDD@&IY(AT'[[I`4I2:,"`#4A9QNBW-X`W^.=` MKYPYC0Y[%W<:XIZSE3R*HWN'>C1V79=UTSY&S,_HR^K^L5\UU?;0E03"#_TT M`L,J5KG1H&[V?/?FFP1Q6]+?6JEDGZZ0'D0`E<3WBF.ZD_(\O;U;+PF?Y&R6 MYO.4S=;LNF"S>%Y+>G(-\WP$FB'`OXDG`.]S__QS_@4``/__`P!02P$"+0`4 M``8`"````"$`*=$!',(!``#I$0``$P``````````````````````6T-O;G1E M;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+```` M`````````````/L#``!?4_,&0,``-0(```/```````````` M``````@*``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`%(0D/[X( M``"$)P``&`````````````````!.#0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`']/_HF0'```2>P``!D````````````````` M0A8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`-!R!PP[`P``2PH``!D`````````````````\#@``'AL+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0`P7N>_ M$P4``!84```8`````````````````---``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`,CXM?"V10``DO4``!0`````````````````&U8``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`-K22SX5"@``Z5````T````````````` M`````YP``'AL+W-T>6QE&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`"5?W0HU"```NR4``!D`````````````````!ZH` M`'AL+W=O&PO=V]R:W-H965T2M/Q!`,``(L(```8```````````` M`````*RU``!X;"]W;W)K&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`,H"/.\-"@``&C,``!@````` M````````````';P``'AL+W=O&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`$>(O\`C!@``@Q\``!D`````````````````U=$``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`%1HX2DQ`P``N@D``!D`````````````````GMX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&[%XC(M!```\@\` M`!D`````````````````J>@``'AL+W=O&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`-KKZ;0R`0``0`(``!$`````````````````=?D``&1O E8U!R;W!S+V-O&UL4$L%!@`````C`",`9PD``-[[```````` ` end XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options and Warrants - Additional Information (Detail) (USD $)
6 Months Ended 1 Months Ended

Jun. 30, 2014

Jun. 30, 2014

Management

Jun. 30, 2014

R&D Activities

Apr. 30, 2014

Director [Member]

May 31, 2014

Employee Stock [Member]

Apr. 30, 2014

Employee Stock [Member]

May 31, 2014

Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 25,000 25,000 25,000 125,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 2.38 $ 2.40 $ 2.71 $ 2.40

Share based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value $ 57,425 $ 58,975 $ 133,200 $ 294,500

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 178.00% 178.00% 178.00% 178.00%

Stock option expense $ 122,793 $ 102,383 $ 20,410

X

- Definition

ShareBased Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value

+ References

No definition available.

+ Details

Name: bpth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Weighted average expected volatility rate of share-based compensation awards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

ZIP 13 0001144204-14-050058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-050058-xbrl.zip M4$L#!!0````(`*AY#D5..J\Y'V@``(LJ!``1`!P`8G!T:"TR,#$T,#8S,"YX M;6Q55`D``TP*[5-,"NU3=7@+``$$)0X```0Y`0``[%UM;^.X=OY>H/^!-VWW M!;`=R>].=O8BD\G,YC:9#";9WFV+PJ`EVF9'EK24E,0M^M][2$JR),N.[;%B MR2&PL[$MD2(/GW/.P\-#ZI>_/L\L]$B81QW[W8G>T$X0L0W'I/;DWZ"+^H5V_"";U MIJ:WT7]J^EF[=]89_!?ZWXO;_T-7]P^HCIZ>GAHFU."+&AJ&,T/U>O2<]]B# M9T`]?[S_>H.:#3V\]CQB%CWC_T?0;-L[&[G^]-W)U/?=L]-37N6(.B[VIU/' MXCT0]9[R5FC=%O1,%K*H_2U5B%?8<-@$[M1:I_SR"!H0WRHO MQK_9^ MZCGMIMY;5T+>$14PB,QL1Y/`TO\I%IU36]WM+C8@%C@+]5Y<*K8DC3!4U"\\O`A9S; MR;,QS;^?7\DI0.U'XOGY1>2UG-[8F!I>?AEQB1?1TT4\:N07@`MYM_LN6W$_ M7,DI$'CU"<9N7&:,O9$8V?!"3M>?K37X^>,F`>K`9VM@`U=/0(L1^H4KPIDG M(/Z5C)%0C#-_[I)W)QZ=N1;'K_AMRLCXW0G7\GJDQ8UGSSQ!IU"1-!:7CNV3 M9Q_=$\,'&R0,!3Q"F@HCO$@!SE\T?0C_<9$\.'ISV)*?99/B$L3VJ3\/?XM_ MI2;_?4P)0Z+9)-7-2.27U_]Z\JL&&JRW6GV]_\MIMG#TJ-/,LU(M<`FCCIEM M`>@U\\'DDE^C,=7TJ)[%M:BJ1'?,12&]":.Z>+@9%DDV*?'PZ*=0AF'=:P7; M>G"T[K"EB<]5%&QK%\%"H6Z]I14IV#8(5A_J'?&YBH)M[R)844CO%"]8:0K> MF&"+-07MA"EX4X(MR!1<>'=VY9`JZ:B?`[GHRCX@UY:0T_H`N;:$G-:OB(22 MD-/Z=:V]+>1DH6*\3_N(W/K6@BW2K;>/R$AN+]B"C6353,#"2&9U>9]&LC/4 MA51Z%8> M;:U_"X%< M/24\[OYO]\Y?<#G1%;Y)WLNO8[O*?,QC?4@'K( M+9F-"#,)O2$3;%V)OET\4^^5!9PUZV0"O?3CYX473&C(LVM1@_JRWPM2/L[6=DOC)$7O0M#P[YC! M+W[R]GL?[N;RN_HS`(%=.C/7L>&K5VW(O="MZ+:40%8#3H'^=4&?CD0.;\T+ MVR3,<^Q+GH3(+J&?A&T`>N_]/'FEVI#>IH\"7^O$]GHX>Y4`;7HB.+RTJ$T- M;#TPBJV4=?R,_8"1N_'5L\NYBK"*"EZO"*]=FI8S:&$;\@;Z(-`N;B:?GRVQ M5]`.OQ*/8&9,HE@'Y:^6]:/^+ MHW<@6E&)_!BE2DJ5RJ]*)UQ M2Z0)P>>FR%#H#]]3YPOVI[^%1P_`/$;Q@!<@OTIDA\$9SV3<)6L*"C4'1>"L ME4BZ;44Y0D.Y4O:[3?TO`4R!,?BJ"2-"2U/>.9Y"WQO$QO!\88UO*,RO+1M& MXMLE=JF/K8^!;=[0&87QN:%X1*UP'0[;\^-)B5A:;TP*96'V7I;M?BSRZ@R- M'<;G0%895*6U2R9UJR"KG+L-5%GE8[#*I=P5VUS@K!Q6>1A5>6>',5`^G%^` MX_'IM1E=A8%/&[^J`OMMV?)MFB3G$R\.O,QNR8+F<.YD^R!(\RVK^<.3H]1< MJ?EV:AZ#1JEY5=1\"D]6BJX4?4M%7\!&J7IX!(:<(/(C,,(3&[3>\*,3B+6H M7+6^M+#GW8WO?DEG$@O MCAPJ;5':4@9MT78Y7584*B9TV$^$#OOQRDQTY(H*`145`EKLN4U*6L5_PKCG MU@<%RT*OJ2,7IDGY\&+K?HI!L!N%V;]3LY1N[$LW7EHUR!]=I1!K%&(?JP=O M`^`[Q/_?%+X&"0H_4`%W1>'+1N$'NU#X@EX0$9_6KR5.ZU?:HK2E+-JRPRL8 MM,)>P:`GMMO#9^5;E+:43%MVV6\/A8KQ+"7%E^I]T^_5=]<55]8LG=O1WR1KSI&L0BMI\X! MKO*;;S*KD-MS+UFH&".6?];DW02&\)-CC2\=YCI,G)"OT/8"VE8+[4!8*]EY MD_FO/XYYOI`J%_`]88_42.<:O6W/*>#U@IP.AK%2O0EZQ4'3*MY2MIGH6^*8 M93M?.E]'#I'JJ32K')JU[T11I=V'T^[\0X64GAZ#GE981TIYEE#Z9!BE(TI' M#C>3*MF!,'$DR1^_U:[U56EE1&L??3+Y](GNK\-??"5!U%*@J"ZKM M7YG1*BX.VT^`*CH#08&J>J#:^F`-7JCHHP*:B0UJ*B^W8J!J[K*COEG\/JY6 M8H]P2^U1J=H>E=8N6Y]:Q6\]3\-*[5&IZAZ5LN&KF>L+E=FJF-EJ[K*KN3AO M>.'=V7%(4'G!*L")V@`:J$%2[V3D*;JR?UPH-U8A-_8J`(FC2.W$<0CMX0?* MB*$,R$8&)"VK`_FC]BYQI';Q;UE.P^IJYEK.G!"1S:RP]3*V<@2F`)9*JFXG MHM\*8-4&V/89R>WB7P6$P-M=%[$VBE1*5`E=KHU4YD<+2'7XE',#.F M%_`D\D@LQQ6D$T3\2'V:WOBET)9#U#<3X.$PN'T$JEU<,D(^!F^QC2=+ZS`* M;?FV+2LM!:VE:$-[^$",J>U8SF1^`X[`]I0A>]&0K1+90:(.[=<)2[6']\'( M(W\&T,RKQXP!REQZF+L57_Y=V:$5-QSE^&N)5;9$>#*I%,I4O,AYLL(Z7+;) M+BMLK\QO%+:JB*V2$9Q4SJ6R6]7&UJZIET5C2]FMZF-KUVAY4=CJ#'4M>G6> MPE:EL<7?@->IZUIIL+6*R^>%Y*Z>73ZK7;6/K'IPRMV;M<#8BS)0G'WKN+C" M4#DP5!5NKC!47@Q5A8,K#)470U7AV@I#I<5013CU)V(3ABT0WX4YHS;U?'ZF M^2-Y6RC:2`J*5Z_AU0I'9<=1-;BUPE'9<50-?JUP5'8<58-C*QR5'$<5X=FK MM\FM.!&L:OAYX8"S$FQ^JP2K7IT%D%Q1>J/X62\.A:0U2-KA6+\W!Z_JO`"] MK)A+ MSII4/J^4/J\B2%(^[XA\7MDP)_98JAE%'XN<7IB_-2]L$TR"8U]BVR#LDG##H+9.O[!U>IW8#K>TV[JO3.X8_>Z MA]#AH9A299YBTD=`8'84>-'/P8PP#)X["[^-FY84>+;&G`=^(+8SH_;Z1[XD MZNPSERN-KB9ZOH$,W6!)=.DF\1LV&I]?_E*O7UG"4Z![(I2R7I>WRBFP83@! M>)$O>(Y'%OE`/<-R>'4/@,[W%LR740C5KV2\\^([XQY;^Q&;9.D$$LRW.Q0>W)NQ--?G>Q:8;?%RUF47,? MKOYXJ%_<7'\"&?#ZZ7A^CO[MZNO#]>7%373!=]Q$63.OK$7&?H.6 M-YH=:B^*@+SY9_YQQ#^T&_SCZ2CZ\32\0=Q\ZILO/"MLY^KZ(^2@$#H;/NW4 M9XG/HF#B"5%++F^N+KZ>C1Q_*L>V_O'B]OKFW\\R@WLNKMU?_\>5'/SSG9&V M+0BP12?@_Y)2^@'/W/-_TKO:L@`JWK,+#SEC]+?`)JBEU1#7^!JZ#!CC5B4B M?Q2:`"31"DQB(AR!PY7@X.7_F4N"/S,21;+[Z,=,)WZL_>CQYO\8BFDA"M&D M7K\VT#M"T+Q*(6D#V">C'CP>_LR`15MS_ESLNLQYAA]\@O!,-LMY@KM\!V@L M:.U^6]9NU9J]7KIEOH-@\HA">BR!T@=?=NXA')@4W(4'H\'0D\.^(<<6-V/; M#K`EK]?VVT2]4VMVM'030XFL;*?)@@GR@A'GTP9!\)!@#/8>/`7;=^OZ-3W; M.FB8%[C`!H$R\C&%\H_4@$H#/MQ42LR`P:0&R,QGE$O.-I'#Y^QH!EX-C#2V MB1,`2&&FY14T^,U:L]5/-;V!]?CW?>L-@%-OI67+ M@6>$RNQ"(^`/D?M")"BY:,.C9U$\[6R@]W-Q94R9YZ,G0K[QMEX$$[`;H87@ MES/=#M4OMA,P1LI:6+A[>V MM5C[-5?=FJX-4G*OH:M%#15 M=.#Z\XL[G+:V>Y;`)UF3 M5603WTD/(I8A2,FE`[,!Z*#8!'W!US$$O;U@#-M2L?9!,%J*8)2!8'1?B6!$ M"A+O:68QM0%V^EB4;S%/=P&>51#QD*>T^=^A?L3^,1Y2WV M5S1HJ2>+R[DMB.N2H;X9IN!@;!%?`ZZW)OA20?>]N]_-Q@=$%N?4L?APR<0( MS@/WX;#;K^VP_>]RV/Z>'382"'EWPB&2Y[TW=-0;NN5>P6XY"9-$)!M)R"@? M',F)?Z`Y7IG&PLD7T]'U_]KS`F%[P6%<.K,9N`*!H3QI)+G=M8UN\5P8<^&1 MH#C?^E-++J4@"I6#&]BG)]YG7:A;ZVB=VF#03CGVM)>7>1"\?X84C\?%(]S4 M7BG&7J?@T*_NFCX!5S&P-^7N?@P.W0S7EQ)#U^`#'*YKO-;0HE9MT.LL\ZS7 M&H'!H%7K96,T"5'1,,W6BY;>(EFXP+I`B7Q^$^9,BJ?!(C?*@T4S,@/O;YO! M+$>L>5+%-L+Q+HW]REBOM5HM^-<^C(QU/KS+0[R]E#T"/,=$C,.7-WM,.84$ MGRZ9P\2K[]BGJIM_JU?G^0BYFT!0+O";/3XLZ3V'>XC^!J.+7 M?493#@^-F3-+UK3,_[_?&9\DW=H1SLP!+A_)B`68S4.X]--PX=DC%N%S=`P3 MR$<0-`%SQ28`KR<*$\"[B4EL],FQ.#MHP#_F.N'X<==?"-KZ-:W9JG5Z_8U, M5.BWW&`$R!']X?V*9["_@0Z!5?#03X`WZ)DU7].GGSF8R;,QY1,S`5"87==# M>62?&CVB!DII",V,;'9-MC6DX?S>-6*$0809\/Y5MIMG9U?+<$E@HD=9\"QN M*V+D^YNWF*?&\.,\R40,NNT%%L^(\%)>@CP3(Q#8CO<-Q-&',:8,/6(K(.@) M3%08G3!1X(+=61CJE">,\F^D%P<_;^4K51&R:6XQG,)!CBF;2=MLVS(%5FHT MM7WFF`%WE5D(ZVH0DA2Y2+VP&C:866PM85@?CYN\[ MR6I9B"\-)@.BP7*SZO'3CSG&`6LF3^,)/7"3*(D":K MBDKRIQHD(DOQ`T"I]BNB1G;^C.7P""QG79%0ZB5QO`;*M[%:14SCMC,.3L!` M6EGK<&QSE:.>A<63]M3:7ZY=%W#9UN96,DJ9$^S;P+AN:4T7P@G5S8]LRDCF MQ=W\YLME_$T_1]#6Y$593^*&GVN@ MSY=3:N")4Q]AN9$;A.4'H;&/(-Y`O_.%;R$MG[!9G*&S4E!IR<(U\9W1R528 M38]85D*_^$I/5D^A+Z$U!$D*Q>5_G4<>MT#-=AUN!N'(@WW$BD2XBW=$_">^ M,;F"B=WY^2@2;MP+3T"ZD\4A"F*?4B\&BTE<(M=G`I=OX"*,+^9R*RV=MP=2 M%P`6"V_A0O42P&6^M`SW85^LQ$_"MQ6*T0E/28O3Z4.+ZB^.G!*C+?:&F\2P M,,_O)N.Q3":/XAR_-^X;_#2<@(69Z3;?'AJN=5\N3'$2W/=727#++6>\>7RY MM;:ZH7QE9DPMH=@FXHUF:QH&#^''/_PML.9(;XH<<@W0SP7*S4,4!EV!YRZU"-;B.8$^N95&1UA*/:#9Y8+]91SV]UF[FI^`DA^PZ;%5T9AZ2 MI_PFAS&3ZY(3?_"2IB.#%[*S17QN*R:J<>Z$[9!V/8H26Z5,H54D=^[WX7BYCJZN)&( MHG0Q,P"B3H%F$!XG`6,"QE4:L_V"LMNM]37]^T#)C:4@N;XD,HGM+2-L16G7 M_&O"IV3]^Z("E0&W(_NT5LS_B_$=>AYSB7U'H4ZBM3Y_>A/4-D0KN0>7V^6+ M6'^M-3O[UZR<7*<4WPKK#D6TT[LJ5A=?(]"_*"&:SCI4Q/%9CN-8D M'!WMZK9K_4Y+T:XUM$N*2-$N96F*CBB]`O_0:X/F`1-2.__/WKY(JV>'[,7.2*H\],_'NC.T=.^?LWB\N6H)D;BA2AZ3L\?GUMQL@ M*9`B04BB9-FC5%*1)1+H;O0;C8;3E?#6;+F8V=F-BFG9/=F%@7VS_MNX75!JJIOY2%910Z&-B#KNE?UU3/_KYY M=][1!Z:VD:O\YMUY1J(?6=O\`#5H7WU8MESF]36 M^8.'L2U5P^^0@*I!29KZ(X([*,"A*9GY"4W+KUJD7FVL^N:B(F^@N_:>*ZV7 MC8HHA82-/9:8PX_87:1OA$D\>Z!9^^[-OBB3,`JU,LFG(,([2]^X`^1:`ZU] M0W5/V.1E'2!&HH,#='"`MKI;JC>T5MO^61_@+L$YZXYRD`%CQWP`>.:^8.#! M%HX_NP-K->@K_53;(#W(RZO!K'8?15UBME*5(]SO:^0X>D1RVXS/M5TN.7R6 MD,<@GJEUX/57@UEQ%K2H):R?UMJZM7`\#%VTG5B+`U^^ M&LRXNHN"-6O;1-OG3-7%&R,.G'G@S.6+Y.LW?.I;=Q&,@:&J`\-HW45HZEY4 MK=DI8L;VFO`D;_N6]S.B%KW5-!R8]M5@QM];@Q$3O_=F;%N1&J8]T%7]H$@/ M/-FX+\,8\GE7[$C[[@PTS]T)0VXA0V&Z'D1JZ[G,V*%.&040N&%T.R9XH\)! MFMX`9M4DG[&#*F5M8-LF_"=]3*KS9,[R.3"4G1JWU@^$&3NHQS8]&_[[(0Y- M+6Z\KV-PV"!XP[HC3WBBO-7]_.W[AP-=5P>>;1\\Q`-?BL\A[,"NN0/5PO+3 MUL*7S(4-^GB(2$C.DC/N_N-]*U=,0'P%R<$ M_?N0%13Y158QQJOI'\E>7C5AGCBU"J#BJHFW)J9O5P&Q##T-$0UUL-!`Q?62 M??)+GV-A-:GA#%RG:J.E#':A5$%MQ?,LS7S:@K^X5=-GEVK.$@(Q=,+E_Q>/ MHFVO4VV9YXL_\'-&)?L>;X).?CU2CPH2/`6C[.&=IJK_]EZASQR'_C/,]&X< M?">C]T?*D(1A.O.QZ39]#_^>H0O`_B['3\I/HY(._,=D\1&GP;_^^LL\/9[X M_NS=#9(EOV[^(VT??1EGY#Q(AV&.WVXNSTR_% M#UD\X]X=-;T;DC'\_O>+\]O?`?(3W0JBHPX=QSXJ^+GDPWLJFTP6[DN6JT@% MXTH!*+QZ6F=ZRLW*U8Q=H(%2_O?<`DJ"E4N+4A67MZ#MWZX=*U@N$#!A>PJ.SN MXZ4PA8%7Y$!*_/*9*JB((ID\3D.SICN+#82X^-2*_?"I\5=FT8O7&*7]UT^$!&\[!Y9A^B M2`#]$ZP:B-0LS@_^%>#C^PO8J_(Y3]D-;3ZPDS_!RRDCY+W'&'S$(,2[2F`@ MY)V'>32B#C=Y!#?Q62'TZC%@NB%FHW[J-3)WJBO^;S_S:SWTP^&/*<[ZCTW'=J M8.K5S61.$3.%DZN`$:QP&,9/A<:HZ2:>ORLXUM7"(:GS:C"3\)?P^MIEEDX5 MX@\?]MIO0H$&V".8LD"(@)J(GPE).SVD=&47*>W91QK'\Z0MF;OPDN@J%&BM MZ![UG^?53QQM._X1?C[X2``CO6X?">F#)K*)-FDID6Q=LGA"J-9],>=) M,XR!7C-#!^_IX#WQ[;9:]N-?9ZZ)EGTU>4Q[GU)ZG>Z26;]V_)!..KA*!U?I MX"KM;3K)'7C.&T@GU?>$WW;EX#YY*3UV#'9R6 M@]-R<%H.3LO!:=FJTZ)[YE(3IE?IM1S2.-O`[(9?QYP-2D'_Q]Q/@&45PNIY M*Y6\E*/[33CJ^L#QJG>FG"A78R8FX*3,\1!>O\*A#DRM9M$35I6+LEA-T")5 MP,2D>-@GQ*-!&:ZP`+Y9CHY=6%!,! MY^3N(@,/Y@1#2Q5]S7U\:XS^=D5XN:BS4LE;J^=4RJ>.%S_?+HXR1-R!NDKU M76')1O.DL`_-^F$S2Y^?$Z@>_LG/(G0*:W?HZ!8H68T#MCF:7F6F>/ M\)A".D=_CJ&?%9O@;*"R6O^8V;\"IJI#$J/-6QX.J%^V.&L;%6NS#=E&9QNRGL\V*)1G?CU"IFDZZ"!YIJ']!$-%H7C] M'U&HC,_Q"I7$"K<D4FO3CG#,Z*)3DE@S2BQ_.$S0=.:3 MP[?/N;QE61+)`C! ME\"_Q]P/=:@;#A2VX%N$,EM"0!^H5AV!9>!@]68)+#W2^R%.9T%&LZAIMLBE M#`$XFF2`U?!90L[/W1#.L6] MAGE.@R8@O],WP^>>6Z`V72N2TZ(!0UZJ*8#WI!`?2AA@9^7I@40T'(/763JH M$;\\X5IDO;9^60J$BH6#3+MS%!TIJBLT(L-@Q'`9@7N49]@+S5,$9NC7,LW" M*1^J;N;W*9`#'H.%&J+^"E%\RL<+L0^J#?N5GVX(4?#XJJ+]?`CU7@]F2X;S M'"W-S7PV"P/@M^LD_E_L;'8=^E%S\+_02[XL,4_H19/YJ4K1(:Z<-H4I`#[0='A1%/PH4Y*;<)MYI@TTQM8)BU M?G[HGMT34-HS/QBQJLAG'J;J!DN2!(NT\P<_I%C?/!!"FP==@XG%4:@<7',, M<9OGI!M]AMN"C@7-$']0O<-@5IC<>])*LX*O<`<3)*+&6.7^1Q76("/3;FBW MXZXTKD)A3LO/C9GT8G$,?AA?JP[!D*WNK MX*C(D*9M.4&RX$6%,>,A*?)F?;M3%I^0:,0,%G@92P%=Q>,*";WK+2JOS\FW M=A242:K7@\+Z5R(.L#\LO,1:9[KEC0.=H'%BPU!K%]1R$14OT<\G9TVX0C^9 M4/NWF+W<88;P93B@W$[`0U\LOP"\]3&Q4\,AB](ABG\^PA3@)P.\]\FA:[C3^0;SY^L0P%+*=J M(11&%0J]'8IC&\!0\W]R5A;,N>0#XL[A!=UT/*?;G=>TEI%N@Z5@`NA/;8R( M#J%VIU&(S;L;__[^^:+H(\I8<9[B+'GBDB:U;Q.(/WVZK[G$F8AVB2A41<#JD"O)5:Z"48?].F_D^2F)IQ=Y9\P+F#7PP^OY?1@,K_*^^*O# M;PLDT@($#+>&@#0L5>W!DOSX,'\ M>Y`]\*_45):9JRR#\ZB,7JER]XVD!*^^@B'/%YLV.;S\F!?1,)Z2TII]B8=^ MH[G7QIIAFW*@M`<@+=-+/:<#,O2 M7$-OCK^7DP.KJQ:Q3Z0YFF4;36F(-E4B`TL+*0RQ)V*;FN:L`LIZ%#$Z,B*V M:IBJ87,*=P,8VBC18;ELVS$J.E\$PB?0.AGY@EN!>1:MK,I)/]/[(*1)([9# M&)`;#BA0[JKKNI;=)S+UURX)V"NL1@RBR>6V!3HGNEZ[DJPQ-$$>[*I@M!%# MK'A=9UAQ<4[&P3#(N%B,;5?7WY`FK=VQ_^1HCNI9'`J;P[8+ M;%L6S.ZJMS$\1_?L;6*[?/F=_%J)+06LE*$Y.I>86IYK'6C::"FV&:;C&IZQ M$C"<8C^-1IL0JB-&6`IYNV;>'-(V(HJ-SE*8O"J@S0$DO+J&WV2+39-4-%V9 MN1=@VP@K-F!2OTVP![M:VT*I(=R2A7L]HS M#.LBR>ID5UP.I\,P6KH`4G[&GH#;@.B.V.KI%5].`A,:;W\*DNG5$TEA#MI1 ML-BJ7_UPCTR=@'#*7I),F]!7;`G73DEM5$2JTN)"IAK5N^O0']+ME-,)J5:% MKE`B\_T=["UVF+B(ACV4`SA6-R7<%R.$P172&SDSZ7?,U?@# MH+[.F_LN=NL:"XYOAB3"([B4B[X$T3`.(R#'GWGX\VD>@31,@VPA%,_Y:1FI M$P>.W4U#S89_G!FFA/YR!>XFQTYF<2YC']CIKACR*LIK MW=#@7+.6(V14_`KDY^>NDMZ5$&1/=^T#Y1LI?_L4KTMYKYORGJU9YH'RS91_ M@)G7I+VK2JA>UX)_7X3X5JYZ'2"^Q>R7ZMQ]`@<70^9&0I^%?II>C>ETR^AJ MW>C:EFIYWLLPF\4Y?]:^.G^NWDU$QWTI&V5S+),'!YNQC,2ALY=DF0)?C\/7 MVSN6D8@7;/N%689*71%/JON@XJLTE(@T+$A%DD`@E-?VF!TSC*:?LGOI%OL4O.WI9RNC8D>I5L$FZ^9N`_ M+^.S-9.M#Y^M2@8)1]TR5'=IEW;MK=OE2?C_FOY2$@@$*XD(G_?5 M"G@2_K]F6/#OBQ"1VW.!SWO+B1(!P!X04>.(N'].G2<14[AH&5Z$AGIC"Z>] MHZ%,<.'HIK8MZRKL+M-WSM`3UW78EMJ])2#N0[,.EGVGN3QQ8<<+8;GG[KFF MBHM,/`]#F[VAVXO[Y9K:4;_92UNG-0C&>P#E+H^V3XS653KJF;K:;?>;"4>+ MJMEOT;5P+KQU1IO>(3U,E'&U* M'V\OR5-I^-BK_,CXSA;7(W$_Z.)R='&+^IT:9C))\GU#K-"W:*"*8`$,U/8: MK*D2+JNA&:[K[D@POA+:*OC%ZM8T52*[;;BJ;EB.*T,2AM`R`;Z1S,>;?C\\ MT^?R:G?^'0YJ*7I<348D^AR'X[,XF<6,\KU01"95;:MU65H)P6H)KA\DU"+3 M^P:+$UB,P#(U:+56M!T%SRX'N&CF-4'4N,4J8M+]4]J(;RE]--%D[&F^$554\$`.M(F#OE=X27I?WDN0V.7+7.[M+^$=E&^J=`M]<)+A'JR[A M1SGN"Q"NN51N?PBG2^SVV_9FA.,>_$9F^7;"Z%5J^UKX137=&^TD3J4M,- MK5W>JEH1MR#0\SH:>:KU1F>1CNEH8KF:%]@/V'NO<<2;YKIC[)IB>Z]^.CHK MV+L6C3)'[W$Y^GVB6%?#:V?G%-,YBA49H+VBF#C_NB'%Z!/LREE``.\4:]F` M/AW^8QZD@6@C<+^/XFBB#N-XXYI3,0EK$>;'(>W=UR`*IO-I13[P@L4&NHL[ M=2SMC6F>KUY QYE7K>/>"FW79'L=)^VTCKLU=DRU5W*T3NNX\&/75'L= M9^FTCFM(7HIJ^WUX3NNX(F7'GMXK.2ZG=5W:LB:O2)(M_:-=U])-L&2 M*'K;/]Y]+5D'2Z):;@^I^TJR$Y;,097]I>Z>9S$LF?XU>^=YX^&5+A%_;(.LK\?1MB4AJ&^1Y):ZZ M+1$(;8,\K\37MB4BF2V0Y[4XR[9$*+(-\KP2;]>6B"6V29X]=U=MB6!@&^1Y M)?ZF+>'-KT0>KM/(LA-*?RQ>_OB=),,@76J%HG*4*]225H-:9M_$TV4;-S6# M)8,6+<;-WRQ>;%.S(GS$]5668W=BT@A)?8MXL8+U`PF+1A;I57(6^L&TY5I` MS>`"`*//\Q4==XX:IJVKW*W%*^'2)R%,CA#65@C1<6,I\(+FN7M`"8<+>@K_ MJM9LIN-^4\>S5%7;`U1<;E$+5/I=5'&AD:'KJF?;+T^)4EWIG.'JM7&2(RX> MU?>")9E+TWX#3$=?Z4(+L@0DH MG;NJC/3*&N)3`8:AJH;A]$2*I;96K;W?2GM7@U;"'S-=T/66`SU037$0L5/B4C9= M:8Z_DV#R`$0X?22)/R%%@@:BJJ4.KCO0Q#7?\FY&DCN*#$]Y'1CZQ'!7H'I_ M)-GWU>A?O;C22^)H/_B2[$KC>])+8JZBFWZ<)>G12GCJ:UD,EJ/OV4#!7^=` MG;*M^\Y-AB=.25N.J9=7QFP9]_TC=.^JQ^NXK\@P],5VT!LF]XXTO2=.S5NN MY_P(S+U])2Y._.N>:>VR`LARS*!< MAW[T\3O.+NJ!W+)!T'$]K*;KCE>_,GEIVOZ`N_M&4N(GPX?3:'1.'DD8SRC- M`-C'(`NJC;'77&.]XW)7736U^E6EVT3YJQ_YDZ7*A;61Z[J)53?G.O\#PI0?F[6S)\B.(PGCQ_`S8?9+4DS_FA_Y8Y+/*%U[0>CB^@F`WTDNK.CC1,["D,:OT*C0-HB#-,/OW MV+'+(-)E8MMONJIAF0M@.^;O!UR1B(N-MP:.BLF'05N%5\94=%RZ8JJ6:>P8 M7`%Y.RX[<2S3,MT=@2NA63IN&?%T M+$[W+4VY+DRB11:;2X1)0DXZ+J,P=1?,Q!9`$I%);+8TW3%=/H^U M,4PR#-]A6QQ+U3UCK;6[B(;QE'Q9/CTDP^5B(W+VJ&VW9%(6RI3:IAU0^A$Z]I1 MU<=GFGN&3D(>[`X#H8L6MA_H1+03VP>^W5'/P,F(1;74`T@_ZQ2[AE!$6V!0;" MK>T8;@&]7=EN$;N$6T+^7$T>;L-8&^[:&;C+.6Y<7HWIJUR5VL;B*M,7SS9- M#:)\3L&M!]U6<12QFD25]7+OOSW"44(-R+26LVU;M375VFL<1>LH4>2]U^LH MHUXD6JU9NN5!5.?VC>-I&,9#K'QH/LV[6E&?H.A!ZM8#O=X!K1[T>#:O7N5@ M[Q5CF?.ZJV$L#D0ARN+W/W:(<5LAVN88BP-;5]?5%T6X]R6N]\@2G[C>(<9M MM5.;8RR.O$T7GEB;JP5M:+CSW(M&VZNHL(YB$DGLQ0&^!]9*V$Q'A,5VB%!E M^7Z(T+$[Z>HJ;D_N!1F:55T_9.@XGVYH[IX181N\T%%UDW=EV`LR-.O$?L@@ MSN(8IFD:GMX3'?#!-DW*W3RP0^P[SL=KKE6]2DD"^L8-EM,T)=G%=.8'"3U0 M#X1^<[?$#!4ZG<9(%_Z1T63T!T-'WQE6- MBGENFWA3"-O#/J.C2\VV(>P.VHRN5C.ZYMB.N@:,\DS=:-8!-Q1<KH#6F55Z"ZB M84+@H7/"_G\1%3V/@G5,@R8V8*ZIN3Q#BB;O`U+!6FMB(^9ZE7W\K4$JL_`= M46^M<=6&H%)+4_0K0X.S#A=TG#AT#5L$[S((/8(M8HFND-(QS=T#+L,A7:<] M-,LV^@9UOX MYNV,T]OX=/B/>9#@B0L_F@0H#6M:8OFV/9V3]P6MB-^D&_UL'5H9=NFXT-XRG#GQUG6NL,VB^V,,R0D%'Z M*8FG\/PC23)D]7-RO_JI2:.CP5&E(6/KM)M#*&"JCJ9$VX90@ATZFA&9AE5K ML"H-YC[H(E1IR],Z[>80BI9ZA59X6X!09JF[3LE65GH%*'FF M6&03N>Z':ZRWV(KJEF9YMM;,EXT@]`6SB`,ZXFW#U73#,78(M`Q3B,V>[FBN M[O`)Q)6!;C$@GX((7MV"P]+1XV>)=3:#;R?8BIBNX^S6$M/M,;H2[-K184AW M;+7*KOVB2X>BUXG5,Q6K\VE']R'-\(Q*6KQ][HVA%/!75P90*M0FE=UY7F*N-93LL MG*<[NMZ!7=$O`B^;6$-HI*,T?IXU8!")A'3;AS5AD.%WL=HWJUL_(BCPY-ZM M_YVDZRU(1\>?ZK8>/]5ZD`B6I:/%3U^02"Q.1S4B8WYV")2HVYZ>8#,_= M<3+2UE@OZ3"E<_*^H!6MJ73J;^O0RJQ[5Q^'>H_]%4&F#[$V]U(K?W<=^D-Z MU<_II'XW$MZ2@+_<#$GD@QE<*B\T.MH"F:;K6?7KVW+@-@:\K7GJJBA(6XM> MH?\2@%B'$4#_YYD_"S(__#2/1E^":9`M]JV>L?["CYY714G:^&R(4K4X>S-. MDL[3]0IS3TPDW[&H5^BWR40=K8XV1ZFYYGDC)NIH?Z3!`[96OW"Q+\C[8J6. M)DE@[S2^&WJO.&R5H3JN]=94A^]@*,*KC=3G03H,XW2>D%O`]$.X5HK.MHY^ M^_
S\*'I4T>P[)KT=?3[]]OKA\IZBS#/[[_E[Y='5Y^T[1\._;8$I2Y9(\ M*=_BJ1\-V!<#Y08"Q[%R].^3[+V"PV58FE`=\/CVZIH.*C_@>R5_]W5 MU_SM,>!XG`;_),<^+>M^IT1Q1(KOLX1DPP?\+@%J'RE#$H;IS,?,!E*>_CWS M1Z/B[Z=@E#W\>J2IZK]QX"<%['_[^.WVXNSTR_'IEXO/0)0LGG&/C8K'_GYQ M?OL[P'>B6T&T>`"HBI_QXSU^T$_PXR_WQ9>_Y`_0AW_)1MS(K6/D[*!0?I`< M[I++_[RKK=%[^MO-Q?_[R-;P M_=H,L^):EC`SA/WI[/W_T6SUO8`(KP@[Q0^#2?3K$3X8C)\IMK0L58DC).2-D#Y^YW M#GV@VDYED@&B.B.8427A\\DF)!E7J=],?*0;Q,^S)*!\,]XZ$8$'BVN#9_1. M8F7J!\!SF$L&F`F,7@">7[>KE+>MGBA%*1N\2VO9:C39!1=4J%5#A11MQ5M1 M&"@^J[TKEZF*`;[(KWGO&%G`CI]N"%$NXPP^FB<#Q3JAD-LG M/V];P(PM"YC>LIH\5FTK6Z#1NUK38&DTIX'%.H1E<=%V(3<@\"G2[)P,J3.M M&-H@MQ5B,1KBO7 M^PG1[%V':"LYN4LAVO>>0[2&J.SVXW_?%A%9[B^_5R1#-?[=D(SA=\G@S9`/ MW@1PMH]_G9`9[J[@!?5*?D,]E;O\FOH?*M9KBH9J$=\;BO-.1X]4TQ8Z?0`* M?QC.J0,"0R5D/(]&5%Y]NB,"#R!C3.)X!!85Q*+H*)$]^)GR%(0A1G=SZJ,D M8`W0E!&FZ\?S#-21\HT2$_\[5_RRXD/!"ZI'^57=5)D/66(,KSD&33]'_XE! M4,Z2D&$\B>@=S#Z:E(4GDE9L$0.631!"/)0PX/A'2C3PJ1E)`-XISGN["'.1 M,',*71"E`%C(;"#8O2"O34\`'66$,@0K-1_#7_,$Z8C8)/X3?$LCX%!)Y[-9 M&&`@F\6((CS3KV^A#0S;7++CB"IS)F?S!*O%,H3>9V)_@S`]*V<%'J6KJW@G M/Y=&>($8R=U92E#JEG,I`28OKJXY[U-0=?Z(D67&J9:,J1;J7RC7#UAI)#\09HO.W.`_20)6%X"9_O@AY1Y;QX(R7#5FUP\Q<^HPX2_=RFZE@5'BX"V M&`#CUCYWPYZ"[(%"0]%[0N_1[B91+6W2398J,[Q& M)VLU3VEI?SKTT_1JG)_%OTJ^80O&C]]),H1@[#H)L.JR.*B?_YIJ#:4\6EZG MI-ZQDOTX6>^6RCN8\Q&^*3=Q^&'H2=&K(E=7%)S`*)?^E#1L%\@V<=9.^"WF MM4BR?;J>EI+*;GEOW#O)IV7[_$C./5H-V=;4KV`UZL&$;/=J\\0Q]Q0U:P\% MN'XAPVMDF3S^5+U]HJML]^_]IROPZ\=_S(/L^0_`YWH.)A#?SL+&.9IYK-K'AEK%K#)TT]R? MP'ORP_\!O^H3?+/&H0G'9K-7YZT-VSXS`W#=N9VCW_Y+;YJ9&Y:?FS'S-S*A MS1"C##7'&M.Z1[]]N+@ZOCZ]_5WY_>K+^<7EYQOEXO*,0=(TR3(0N,&:^.$% M!-C?_Y,\KP&%=_2;JJJ:9A@NMB-M'9J?.^]`LEB>M;G.Q0.NQYI^C/=!BH9> M1OU3$)+D#'Z:Q,D:B+O:T6\WH%Y@$.4;F6%+/@AQ MI_=QN`8`H-4^7-_^SN:J#-:PSHO37,REY9J\-VA\]PZ/)%[PCE)EL+U(R%-T+B[//R)SJ"=`KF+]=U60]6:S\GB@5\E@3+JM M"O\?*!%,YB_X85;A!YJV#F@1IW+_K'PZO?G`$O+XO3^*9QG[@4O1YKE`_`;K MA((Q)@W)>,Q*AI01*,&3!8&5BS'`FRDCL,[S-"6C`::"_0F=7KDG84`>BTT` M'#*`.8893I`0T)Y9^%R`1ZV'GXR`6D\/`6;U`40<^IEDB_D'+,F/WS_X`(Z_ M2)X70T>M"6?1".?1:.;SE' M#2@#4%[/>>OTY@^:TS[65!0]"ME.,`7$Z(0ZN\H M/YW??/Q9&:/\_7%R`S+;1L2U9&$'C@9Z+4V18+P&BPKF$:N4U[@ITJS+YWL0?[J.#GHTZO7>9LA^0<+%19[^C'*E/PTD[-RH4@0\PCH4D=*%^"69P"F*'R M.;D_UI6?"H=>5]]_.:;?E=]H[]%_X![X<`VF7SW63E2->^CG`6?;@WHQ;5HM M]<#BDC%8MQ&8=U;0L:@AILX@/OQ'%-!#XJP*'4R3GXK.OO`X<$_Q(#(7+`7J MC0)Z%1KZ-CDI6046?.1I!J$+#L.*G88A2!EX6$7E+-WVR$.RG]!KX8E8KY[E MP:C2X@%H0=>G+.Z9A7Z&%5$\52B5<(WCE.ZX(TD@1D/$T:<,0W#5T#&%0!7< MQ;P6.'U.P<0'PTK=D`\^1@@6*<=J(%5BQ!H<3=.4YZH2,:<"]GT^Q MH@@OVZ`N\`+,(LA\R$O"9C'F]M!U*XXAT=$8X?WYA-*N-:[,Z\Y+X#ER()13 MP!6]\GF"7C0=IO3541DBL@$MW"X1OHC*XJ*BDHQ\#](:%OFB%^N<-?O$M'#: MI_54Z#T1Y2E._F0A2,A:*.'9+;IN?Y)G94I=Y#()P/,Q"/!X+"3=C/5P6BP8 M'9:KDZH*>%H<&6,U@/6%YI"X3V((#-BQLQIY:5TBJ4I#G%/:CQ94Y4L8ZV#D M)!PQH<9BKB";L_Y7W%`<+;:2'#@8I*T:I&HZBE5G0MS,:P5PZ=/Y<`A".9Z' M>;*)1-1_#;)<-^2IK"'3YB`FH#>3"7+5!,0Y`RV&VGL:@Z:;AWZA?X[OZ2*@60>>7Y[2T;Y=GAZ'P9^D3'=55'-%&V5/,3.I86D[2Q%8 MXGO,&S#XF*H#4_YB$E M-ZT+7>B@B$6\HX)AJ#L`W@+,32?BG9M-S5K#UU`0\-Z)*S;V@."NMT@4G^R7*[:*#] MPA+[$[#S*?4.J'%D)VZ8(<`#H+G>\ESA569(/#\I4>9F12I`X68H29?F`N<*`33`Y&F/D+QKE8 M,H.+^I2F53_%,:ORIR7'_/V2\&C==_UT?EIQFDNU3O.FQ?@@ZA>EG\B<$*0_ MG8!WQ2\NSRNC80YOS@X/YI$&N#PCEJZ<8/T%.P<0I+F!&%7\+Q!S<()!,PP) M!:F9;OA8FLU'S^440.2'.7!&N52%NW4/>B(JW*7L(4A&Y;E0I/=!1E\-9FBX M6]B!AY?0/.ZJ#L`1LUY"&)&!C0>FDV,6Z'N`]/9`R?&J*M/+3.2GF M^EG@@/:O:%[<4D:GY2/X&U6WR'D22P)<'`GSW*=I7BI$"0/O:$ M6TNX9-0S:<,>9>,>,_[%\:MET%&2X$"_P!Y.:*'P+CA/'3LG&>L1;I>7ZB31\_^(_(4F-4?C]9 M/P-O/8!KC*Y52'>0RX-J4_][,)U/F8:$J2U5F4Y^F2+1T_FL('J.*7Q^QZV8 M3M<)'L,_3I3?`5S@5QJ77,:/;,.28:,/JI4:U?@$-,^0L(W:A:<2Q0K!C$QN M'%(@*O6]Z!F_[\$0I8+I-?01BTBFZB?F"KPZ.8:M3.7]__:NK;EM(UF_;]7^ M!QR?;%52"TJB*-F2X^,J18YC;\F1-W+.GKGKZ^K4A/3QE(#;;$+@^X4WHA M0)@,B+*VA00&94I&N0PLWQ_*I&)`AA=D3T\:6#==E9$?"9W!27J1UX:&MF@O M&=>&9K):5M:48&.NI:OJD"+UC*W3B6"4LWC,+I*BA1AV)-$+.=2MA3#>.WOW M29UKT!'\OY=+A/B1R7AEB>AQ.BZF\/W^14P_<_093TYS"''A8::&?:%A;^?K M&V>+;$JW-1=[MI4S,.G/`VO;BYN35P<_M.1E1I?@4-+1X145;1]P3[(+D/;E MI&1YCGFB8$/8"KP4<%;HG7:'@>WY16;M>6.\PRE=L*/CF(]QM!^'EYXUDYI9 ME66.1O"(V)/]^'-/MO.;ZM',%=1 MU@MK:L%&FIVN55LS:YI<38K036[TT$053G&0&Y+<:V7@ZS*JWAJ&(L65.[,Q M.PO#\]Y;'73]58\C-(7S#(XV1BDHDB5.U!'[+]^H/_3$2#??>W#TYB2\5M[. M\B(A-7HYHR>/9W3")2;UEN-B]*YC=9F^\5RFO4,?AT/SD9$9G00>U?YYG73F M!2BACAOW3-VXGET&F:Y!`C`&\R*,LYD-:=7S[V$E,JV&EQFV?L5 M`3#.)DDK@HUF;AVB]O4BIW/$5`T.A/*.&TD4(W.+JWG]T`[5PQ471PN$9>'F MA@+5-H#XM\K3>N>,:(9.G;]+CPWW694!M9@;&B\G^"0`;-(/B4]R($X!67Q*"9N/"781MC=FY6] MAGV0`S#SG*Q?MJB/VG-Z8#7D*=G7]-^_)(7<9ORZX(H+*_84+F4?T3DQW0#.2R9T1^QA/0TA%1DBIC:/? MUBB3.NSA8.&8U&I:*:15F_*@6E?3F&GBV)+LLN,"G*/W768G%EQVG37#U$$S/4!N;\1CZ M8=2A9RQO,$D(]!3[-`Q.U(3UPKR>B2%0!P0*?2D(K[\G\[]LSV=:1M''GI@5 M#$6/EV/VO'/2HDP&@`3*!XZML0PV_FOX^!!P+P0L`3Y,(F,"/&T0=#4;9)ZA MO"2OY\+T-%T.`<%9CQ!I/FY5\66>US60:L.?C4G?9_J"GS_JU/\\)_Y6]%)" M0D293,,OZI7LT3>6U@,($I.>WBM*YG34.3Q-[Y7\+`.:-M8LXE"66#=8#N&I M(2I\!2^P7YF7]*[-Y75O5G8-CW&_OAY'?RM)?).N7#68T)NM%UNQ1%C!56`, M\"DTI47'N",6):,[CH[P#QG"8G*?G&Q%/ZCI*/XV.*6M4JK:/YL*HCLA'+BP MH4@V:G6&+)@%9T82,64DF@AKA"[VWZQ?_1+@;`**",^QH//I7'JG)L$+7YV% MTJ_%6DNO]L9DN!W-,U2B+:*SD@ZQA,]>94A$DJM>*LP`Y:]^?EM?)7K%<"OZ M12?"+_7BDMXEU7$9JV.YMAE=OKN2/<>:\)F:??.G#D3(L>HIRO MM(1K^'GE5;==PC6XV7*M(Q++Y]'PH"<^$T<+V`=\4>89^VQ).!6<@YH@9$6? M(Q&:Q*!Q%L!*HH>74'L+N)O'4/GG254A5P8N9Y5%,/%@??24R%ZO!&S#E`^8 M*5_")6\O_D!U8(N1_71:6B-&YB+=1BF1<(4U'R662QP,7&ZC$T]:,M;I5V3']2$*_%$5L_*_:#GW5V?[HQ9E53-U:ITU M'%K2:FDDLAG+\\W)1C7;2!UQWA)3Q%"]1H.K+"%+KX#/M,@TC>K)KOMXFN$/ M,0_F_/+&A5H'W*81=TY<,T5J5XKBXF['<39%P9P9P@;/^\HA-W?FAGN/HOT] MQX^O7O]OM#39+\RSS-`DW1QWAMJ;1@3X1EUG8(A%$1ONU=C)7;'O`[A^.I=K M_R7S`-;YHU6Y..OQSRN5^_3@FE:8,BB4S!LRCODRJO\UIC`9OK M;<,\J\PCF3-\VZ"<3)M"$LL\)5,.E/KCB^/CP>[.Z'$< M'5\U246JV"*+_AJ]+-K4_?8BJ640^OFG;-ZT_]_.$_KRVU='@R>CP]'^`7V] M**<]W]CPZX9?5X;[=2D8+A7'M/Q<&)M%/^-:J3`G(M"\?`?NP="Z?YLRVK>_ MC-O&M/XLLF53SC/`3:*"ID?UDE23KN6AJAK2^45[^QHUM`?M]0B3I=Y)II6D M,KV5K)Z-3O9UBBEA@@*I/1KQ9\@XZ9IGHT9((I*\59NWL7%";-AI=;A3NF*2 M*T8W]J^\-#/5=Q:=@'T%0%!`PH1+4I['!5\2-PH5(X*0Q.`IO'<$]O+CG>/$+4I4V.9`W@^K$ MP!8]:)N(!+C*5R]*[N>@]Z36YEH1$$#!(+.\4SO.6/$(5FI?H=ZR^RZFW/B* MS(?Y4O'KKVPV>Q\Z9C9?,%IXVT7B!5&-;MH`D MN7^W^>0]$.':O)`$OH;S][BTSQ]NF2]%@Q"GCWEM\(RW'%L6+5UT&2LD@6(" MHM7N3PHX9ZO*U-:I?=3)/!EGG(PZ2:HT+R^26D#O4,242W$\7-Z+K"7[JM4_ MFG1V(L"Q*9,.D0>XMD-ZV#*C.$1.H1RO0:L:)7.<=Z93SM%)">^M[J#)<29^ M0:LFS@&P1",M0I#D@YVSE-OD6-^;E7TL,"37&UL,"J4D'U-R]V) MM1#&%B'$1YN01&+%7K#X#/[3/AC6FIU3.!(F0RIY>U(M1;Q#HI0)&!*/R>S7 M(2$PS!57%B:!H:+0DD-6K?/1V\9,ZC(SU?3)9`;1H(3.K$# M.XT5+N"\?2U+0_4X)]4$=:;]55X"BI,WI1$86]%9`"A5]P)*V0.JHMD5TTAI1\K[$\@:.GH+@9?Q4(FT M_MJ>*M3'+1A)'J2+=5$QRJ:WTD"*2 MSIL,()@_-:S"+QGD!9`BUV35QXI7G/38BMZRO,=`H<@D#F\A4ELN5`-R8S9H ME\&=YTKSQ@DQ=P3F=[DZM$O>E\+AO.<=L[O:I!3JW3EO)+OSTZQF+NZ\U:K- M297,P8*H?@21I%1)_VJO093=66124W*#BUK0^:3HQ;9V:J6\-8OF9=UH3[AU M1.FE!BFRI/?R50#Y&NIOJJQ0^"69B%E#AYT47,Y- M"H6EZXE.!OM2;/8U=&2\Z]QBX5L"U@XQ@,$+,EL'#!Z#4`C+IC!K1FN^*(MV MGH4-Q1#?66NKZ2O%+/"AH)PMI+:+03H@-JF$D;K5HG8Q9AV.Z6S)I)2L67D-:CEE!KJ!:NJ:TJNE1K("4X@$7I+78JMQ1W*C"/$\ M3"\&709;06.#K&;H[;=KJXFA)P%4A<+!=RQE@/T*0GQH4#(Y./?HJF09#X'B M7Q@(V-;3*[*=DFH``1]LY+W6)+XN(\HZ(\1`KDNY+TVS#8LLN.:*%_P]&A?2 MFF\+G,XUQ@2?UA4,P3,7M%6EIC9CF289HL/8466PF(UWJ`G\3E/ZRH>;TTW] MZ^BC^.!U4EQ`,?9>1U)XQ&@)??$N@)%P:L`?TE/5U/9U,\Z?8`3(!U4)" M%8PSI.7W`25ZL5),MY;::-S<\XB655K?BP3KM;),U!F%&3Z0C1)I-<@-B[M*"^F>G M#9O6[YT]>49-,PT94N_E!A5)=#]NN3;):PN5X^.$!PC\YCJ?.V.\!+8("4U_ M?GZ#*H4S5>4[QB%IEJ7"[IOG4<&HP9,QS5^IHW\5)^;"-N>MFVQ)ZK)8PJ*& M0V,M6A?_X6@)SDWHY*#C\YX1A[02:!->( MZ-FP[2(N$-!%=#OT#D%`CG)JL^:DJCBB!"O:PNK)SAL2HN=-/FVN;#[:MS>Y MMOUP67_YSJ`,R8U090JOH"&165),S32#.8,9.1T/(N,"P5)_?[.&TF.?A M.KDWH:J,*0?'&/9X%2?<.U5HP2(N%$8%2@H?G?`:Q(W=`O'@K7.-8H%BED5P M$FY#R?KBP!L>K$KIAT+\%IN,WJ^=N':>")#6KTT"YURU+"N%>"%.?YF-*U9# MY=$#/Q9L':R,*DYG"?<6>S!8:)^>HX_@3V6!T`H#GIB1H:TLVW$A>H3(2;@< M4];=]-1R/"G2-N;P;EHX->@^/([J6XMDSH?(>R'6*DWB^33:.;\J"X@_HO#K MQ63+7ERIQ;%/6&J2AJ.=&&:;O7G&ZQ8]??YZ#_P4-*IUZ!CG]65$3]V'M% M:RCDT,DS)I)$+ZGL>4)])B-?X;D;O>>'7%*JQBC#K-*$;D@J95<6TH M?W#)[8P%C7+95A,^:8$V)7!:_K8!RGVX32SL0:$>.W21&*2!:=+%$1VSX1[_N7%[I5)+ M``O%=(*'8,W@<6>X2C:)FUA=1?^B@>HTMX4:PD5URZUPUG_;>BO:19%<(HG, MYE4'#$0?_9M(X_KV2>OA1C"8=1$1#:%(:'0]^C.ZUV+LZ]+-3CVQ(E)M3T`] M)9%&<$`3?]?M*4Q,$W'!0)US'%FCA0BDNW;FLRPIFMDDX1J?15I'WTY*=B-Q M%U(Q7[Q$HK-D3(+OM?%GK79]9#<,0\A7F6T%'L@SP?CND7H>B-&-3G$WWO_$ M*6JV3&>?6+,Z9SQ9[;?%W^:&$1]0(0GTVIN]6_JIJPJY8#G+/'3&A@,L-)ZY M$ME+!%7:F`3F>HPULR#-C+K'7EDT*A()! MZWHG]H*IT!5`WV1U?$%=@]>HDG?CBY5:-L)N8K4,<+#BH8VS'#P5FB`];F M-KHW*SLU_?SL501.^?GH[,71WZ,SECUO)-IQL-X&"(B623QU+(FG[Q'UL;5?%P600^\M^]>;7E7Z$-CF:_@,`R'_FFP?0\# ME6;)H/W$2;\6%?2=?VQ%;UK$ZBHTIV(P;.U"T,>UQ[,\FT:GXKPA-CP51Y(Z MN[453@ZP=?3.RB53"^$(!"^2A;I!\*-H+(W7S4_"C>KP,<:80MHK_O_:^]&6 MHG03(K@1H7:M-3$EZ]@RX.\\GXOU M%*S_(M)9Y5D#+=DT'VE@NB&)]09REY_PC0*9Q%VT*J&>]ZP/=!U$0RVZMNU"8_+4U11$ MEI.F_\4]2T'X>,:Y3P8_$7%C#G@L,LY\H\_M*LT[NOS2;?UH\N.4TNHD\4)- M*PW3]W`CL/;!WDAZJ5X*539/07=K=M:;(7F]UJA>.!>NN!N+WZ9'<8#W<[-A+:]B3U##?9C)AMPR)?QE+6 M%)1T+SA)=S]O)=K#26^L4)C$3R\FQMWW2.>OD&^LX:_5J)`FG4TT$&?2/21) MV?KV:R^R9OLZ0+C1]ZJ4(_VL-NA$&.^:`1?S>J9BRP^+<7-.$9+TC5ZSV?SB MH`S&7*K*B`&ZIPP<\!2X`=]'_,R@2*[*MGDZS3]DZ?>_B3Q@QZ_L3ZD%!/!_ MK-R/IJS]V79;#\Z39/GTU!/#QT3XDM4\^N5HD;[U&F*<3E\:PIY9NK[(:Z@Y M;96]RSXT/R"AZOF?__3G/SW[K\'@95DV/Y.F2/PDOO=?LNE@P'^.HF>D7LXNU4?/,;@9GJ:C3\VJ;/H_C_[[)1+MTG_N[CX)OTX/(M78?%@D MXZS@3_\Y?!1MZY2[D_Z$"9NOT`OF!0V/_(1O#F(R>>V-K`J@K1YZO#W: MV6:]``^;WT;(P6Y\.-RU@\I0X@/+N3>G:`_23,:._&P[V*HU.WA430+Z$WD?17I,AW9K M2MT!_1VOMKPA']'W?H,+](EM%'0,'#=T66L]PQYEE2[/WR'1ZL[/+K#'3Z\[@[OK]_AW\G0^W>WW-'.=9?[ M^&:6V[.[C^]PNWNDSM<[NYUEWMP:[M[<(?+'5UWN8>WMKN'=[C< MO6MK3SNWMKW#G3M<\/ZU%_P1??'W:AMWJ&Z,'E][P;NWM\.[=[C@ZQL$7XB" M1?-X_I/&<=F%8$$Z8$!?9.O,`JA9=59=Y!.8^H&IX&53A&;#<&_: M&OGPIG34OA7?H9:Z=VVE?'A#:FKOBF]&4:5IA6+GA'ZASY]M8XC\*?[E%?P' M4$L#!!0````(`*AY#D4@0O4=Y08``"57```5`!P`8G!T:"TR,#$T,#8S,%]C M86PN>&UL550)``-,"NU33`KM4W5X"P`!!"4.```$.0$``.5<;6_;-A#^/F#_ M07,_RR])^I(@6:$Z26'`38(XW08,0T%+9YNK1+HD93L;]M]'2G9JZX6B$0>F MW$]-E3OJN7N.QR-YROG[110Z,V`<4W+1Z#3;#0>(3P-,QA>-SP_7[KN&\_[7 MGW\Z_\5UG8]`@"$!@3-\="Z10`\,^5_Y2M_I-#O--X[ZX<3UXK%[U.Z<.'^V M.VG_[E_.M]^L^Y&CPXKC.?SYN!'$$D(S1]&CFNJ]X38O)UB#@X$ACA M%XV)$-.S5DO)+X8L;%(V;AVUV\>ME6`CE3Q;<+PA/3]>R79:?WSJ#_P)1,C% MA`M$_.]::I@BO<[IZ6DK^:T4Y?B,)_I]ZB.1N*H2EU,JH?[GKL1<]:"!PWI`\Q@Y"8`S\3B%BP;'T314P)-G$P:CB\9P*B:)F]MOCMM* M_Y7G^S0F@M^A1S14XFJHS_>]#<1#3*=(3"8T5$0G[F\IN59.NR7Q/!/10%#_ MJWJ5C)*K;S$6CUN"*AI@![BZE'`:XD`%]`<4JJ@83``$WQ*>9IP=HQS(^0(1 M2'YN1[=3-15E*#X';MF`+X7[=M1%?'(=TOE.4&\,]X391Z$?AXDI?8EP`SLL M!)``@A5Z-?9S64YFK'QO2/V-=X4J5U"VZ:CEJY*$,$)\F&2%F+MCA*8MY<`6 MA(*OGB0N==N=97)XM7S\Q>,\B:]TY!`-(4S>]R4KL'+*/N!U8\8D294HG^36 MP*YQZ+%-W(CYJR'ECSD"-U/M4J+%XRA*1G.Q#)V5_HC1J-AORQ=2+=Z8RU?3 MJ1H6A0V',IF@Y!HJE]`YX/%$R)_WQ8":%QK'I[^VQM^92,FZ/45KL;=OQ018 MC\RD#90]:OR>%:P+`UGX+XTBQ`8$742;P/XDKS<@V'NQP MV#"8I.!$HCL5IU/]-M#9<9>BLF MB"D1VE(`PW1B M;:=>"VZV,ZF8IA,;)M9E#`]TVPRI4ZH%?2:&%)/VV@;2^I2,'X!%ES`4-Y3X MU35BB8)=9)76B27H+5ZOMMH<5FP'+6!FJUU6D:3%5-W)L4!&5&KA;RB,0<-5 MH;0%9)G34VB!Q=5\ET81)4;DY$5KQ4P>OL73Q@L"G.*Z0SCHD2Z:8H%TUR>E M&K4BJ=0*B^^]+F$&(9VJ*X"!0&.X(@+8E&$.ES#"/A9K1\.7,<-DG-70%8,[ M&+Q6$;`+@ZMW!%8ZP`H`F]Q-7$/'*0C)K*B79N55XNINBC5D%2A9P%=FJ#+DE9A3#5][M[X M2]N_0XG<"R),,!?*Z!E4,UBI62\.*\TQO]7=8X)+^ MN+FAA&X:5SVW-#H6<&6TD&E,L'@7IOHAN5#9.\7<4[6H?*+M8BM3L8&JJN#+ M-[.566-Q$9*T3>9-K6H2+=*H(V>EQE@\T7*8JY-BN?@<,TT#ZG0%2QP;IO[J338W2GLH$$`DH1F=8[YY_<[+%NW$&(%U!= MD[,2+_@[3FNK:\H,6ZXU.@?+J,9FVRN:I#.\%TT19@I_=X+86+\;UVD=+,-: MJRV^^.EQ'JN>^=M1!WQ!@B@LM('0";81_X+>N&"$R^N\[*O0.EN(* MNXN9?F/%*6T>>K)&+;L7*_\V@YGZ#T1\D?G%_+^UE/],C[^Z&,KU)V\5$68# M_D`Q8N:0XJAY9\/Z4.*H]`S]!V((AV=F9C;+3%>T,9X4G7SP/U_&\Q M9I#]EEC7(5NM:P'=NYD*N=[::MMM;JXH<W( MG&.MUL%RK+7:YD:L]>#\?KBU]B&"X70NT3U8P@UL-T[?Q;?BYT]_Q#7QX?]0 M2P,$%`````@`J'D.1;JA(8=N)P``IWD"`!4`'`!B<'1H+3(P,30P-C,P7V1E M9BYX;6Q55`D``TP*[5-,"NU3=7@+``$$)0X```0Y`0``[5UM<^,XJOP' M9^ZSQY8E^67K-E<:>[QQQ3-RV=[;I%(I%DW"$F\I4D=2GO&E\M_3H-XH"0V` M)""T=O+E;G8&H/KI!R2`!]V-/__E^R0^>F-9'J7)SQ\Z'T\_'+$D2,,H&?W\ MX=?GV^/+#T=_^==__J<__\OQ\=$O+&&97[#PZ.7]Z,8O_.?,#W[/E_V/.A\[ M'\^/^!]ZQX/9Z/CLM-,[^J_3SD^]BY_Z5_]]]#^#+_][]/GI^>CXZ-NW;Q]# M>$)1/N%CD$Z.CH_Y[\11\ON+G[,C,"S)?_XP+HKI3RYNKHZ M*?\5FN;13WG9_SX-_*)TE=*N([0%_Z_C9;-C_E?'G;/C;N?C]SQSTJ;?VI>)^RGS_DT60:\'8G37[@!%"UQ/7(8CY('_RL>#<' M1ONI!A`\9&SJ1^%--AL]9&DX"XK;-'MF>0$FF4/4^%<,(+Q.DSR-HY"[]),? M\U?R:!0PY!J_H"1[]AD$A7EX(!?A:\1_WC""BIB!K$U_1&;WVEX!\"> M,2NBP*^/1^^AANU_@N4F*[TX?!U.^4J6#Y86MF,/W(O=I@C0>KHM1,/7:S\? MW\;I-R,\;#S.@,TW:3#CSX6W[C.\=,5[Y26K::_\42M;_2Q8FKOX8_475MN` M*"E.PFARLFASXL?Q!R4^9$.RW$_PG4B_A%T^K:U)\&>8.@'=<_5E< M\&R#YJ83/TKL6+MX=&MCR^<<3]CDA64F+=U\;ELSQV!1%LQ>V/'*!0:-%3Z] MK6]O=ZFO6O>!]FFY3#VEC^U&(:U/OBO63II[M&%(6DS?+,<;$VG M\S'VX2C-8$?Q\P?^V/(U^"F`M2J,ZL]Q.3W#J\1&_`_K?X_3G(4_?RA@LU6? MW:J3GG86V]B?X*^^>C?QX/@,/OD>B<2EHY?7. M+'(I^4S6Y7;-S":O&"8Q?V?[H6)NR\W&=+O%0[6)U^M:)`&;_]<,8#[<]?2. MU6(W=ZFZV=M95=ET]^;JT("_U^:+_=XS-H\\15GB+S2B+QN+L>TY8[=NS-,!7,!9K?8L_UV(_K5SU]*,+/\>.3[T_FP9G&1+_]F>WPO_MI; MZ-?#[(EE;V`M\FF7-?=ZO2SVOQ-'O)HS#RL_[^*/,1O)$2+[QU-G'*YM_.I/ MX(_/F9_D?E#J)JIOG;JSU[LD,4O)24&(U$.',-I`NSD41FE-8]:H54UJG9:J M09MU2?3F%^PA]H-29D(G0WD'KW?E?E[4?,NP-0F*"^&LI031XK5<'MG-PP^N MT\DT3OG]4__().F$B7"9P-IPPR?6X8JOZS"]E[?JB*B/STJW2^F M#0>%T.5,+S%%%[&YSS!ORBG/F7;"(X+2I)PFE+/=3ENO;_,T0W.BP]\5,4=B M%`@OSB221=B9DI.-=E[?ZL&&'3YV$2!<-!`[S'#QZ"7][ODC>70(U?$'0G:>N*#/WR] M@Y;)*.*9G7G.RE/N\@]WDZD?98LTD&$Q9AD\*QNQ?#$Q)"/T"']/O^^=.]2& M#,4O[]57R,ASIGJ4EFX!6!@N^8)+>GGG#M6I]B-"%R'"HS.EA">RR41=^&?O MW*9FM3=F5E"0*.D&>@GR$1_,BG&:13D+K_UI5/CQ<_J)/?K\+[#OKJ2+=^YP M+V[H4ZF"AU#B+IJ#Z_]W>3YCXLC1@+,QO MP2O<3%X)X(XSX,G@1QA<+!_#"R68^ MJM4L5=WR*;524ZU*'_>2_%7=KMZENZ]H,&;AC$>4(4;FG]XW_@5)>VWU/._" MYI92F`A;BQKDH]H8*IV<6..OPQ;F9CJ]X"'>AUUR=A!J/4&J-M?FO"7$%9[+,O3Y)JO MUK)K^-RS3"[+FJ^*V4[2 MR[NPJ10YG=Y4J(GE'"/F*C^4TG[>A56U2'N64W%1B\$*-&)IR+8XI#7OV2'3 M0F:RJ65+SL!+8Y@I;M@;B]-I&<<_+RRKCEE4]_8N'&I]^N\:MG[1PT`7`:#&1U?= MW;NT&H^B/7]BE&"?6DUDU#*B]\,HK=G4"K4V,J*1'>0U-.&5>)^SR(\5(5^B MMMZEPUI3M=\8P1X2!64NL1D+&EA6@O=?HAA2`-9#+:V.DEKA\,V//J2ZCZD[>I<.8'`/''@IDU/*8$:2+SWQY1EI=HOT6 M%>-JE_J'%[I/]BZ)270UQX$)^-22IK+T.`1VG MZ4))C4R>L+WG>)VF%X29*"W/LSP2:/Q^$^4\(@*V;_>J8O*R/MZ5N2V!X'>D M!>.Q]MZ53>$#+Q&O])-@Z$HQT`EYL5L&_LKF+EH_NU3*Q29W&(J#*OQ^934G MJ5'A]RMAB?T=JP^J\/O5&0W1KK&_+41T&$S*6KVUDN7H9D/ORG6"3\V90@)# M&N.QYW4-?FFH@\CC]6F@1JSQ;F.O<^JN6N[2&F7<\$9#[\KFMDH:$(SY3SR, M!6;_,"L=YW4T)"1H+''P$AE$YUZWE2XP'ZJF7#S#A*J;"2]Q=/Q-=HFS2)Y_ MR8O,#Z0RZD9#^/P2.)FL-RV($!`+89V;N!!LM4G9:@_("!0*%7E;QHL0!+$P M5)WD_LXI@1-AB4O%'*Q-)Q8UVG0+UCDE<*!;FP81"&(1G^N"'!IG;[N-`1.! M$]9FQ`B`$(O>'!4>Y:('C">@7-3='<^MIA;&68D< MYA="\GI&_-2&9?G\6@J-I8[N(\`!!$2->H)3/6S4PBXKUNL+4G@G`$E`&*E' MB9)6(49J,99;P:&U(V976ZP.`4E%Y7SD(RI!1.W^FWV$.WO- M7C,5*FKW^M3Z,`H_'@0DEF9486BH7?QSGR:C9Y9-;MA+L=859#0).WB=,P(: MB9&]@`0?M;M^*GCU7BR`04`J,;QEFX.B=H5/(^U$YHLS`FJ)">94&,W=VF.J M-#9[9?`1F,,M:WE+&!2T!E@$=!*5V\5DH7#,W?-C*)!G?2NQBJ+MI@"(@`S2 MC!\Q%FI7X:Q3%!_\*+Q+%E=60<'[5P78/V>:L][UC)*6`1"U]3I=FUMCO`:`W#MB-1>Q_D?)B>MT;>Z%]=/_<28V:4,Q M'%1F7*=K=1O;*#6N].*NLW?M/JCD.+"8;G:UKX746K4L@Z%%]K[Y5J(Z.6^;U_65L9F.JR]U^DYG.V:B4ER+/*Y]SN;#^!-,5-3'QM>Q5Y MI^>V*&93&M1D5@$2JY-F@#0:D]D^V+-PG>Z^KI#O]`EDSF#OA&#N4X,A)J2: MOT6^TZ=Q_821N4T)E)IP:N?:\4[?:GZ-D;OC2SIJL5@%1ZTFFS4>:4U[M@BU M<>GM'JZ`,W*%?*=/(*-*XY7#EC":"*D56S,0.M4G&3K5;.9$`5(KI+:/X)M. MWVIP0+N`JGZ[F)L2&[52;7LBE=9D:HE=Y5S:0+I!]H^EK*M423=;@8D$TMWT M7Q7!KE$$R%Q9->S.4YZ\4TH-KRP;C&"2E7L=:P_F$LA-:^5_.33KM\\NPPKD M_M]L!:812"EKY741('-%S#"%RD_\4;DDA14J_&_TQ@;?_"Q4:%327F`Z@5(\ MK;C0`6B]4%GK@-K..0&UL!4/."QJE<<,E_<[=UC`Q4S`C"9(H M,I@-<=+'*R]0YB;D;W$M`7BAO)1@X[C(5!B@U5/V>XT;1957V76]V#-0L^/!=>/;MK]V$%'YY?TM#:6KA\?\&'C[PN'8.-W'P3LKX5 M'?GJJ#N!_3:WN&X^0KJPC04KUJ4+?3]TNL&LZS:+6]>]=4BI0C,61[AW6FA\ MRNSRL[\\[(>,O47I3"$8;;8""UUGHVF-<8'O14"(95L;KTI_02"BH[P$6$]O#*URO@D(LCV^5:?$4 ML,3/HE2Q?Q&V!V0T,A`:;%4D@*CEZ"TM_#7)IRR(7B,6*A>Z:!^`2".W0$(` MPI@<$K6,/..LT=JEF*6/;O[=_'/R*_CX898%8S]G@U'&2N3X"8)^9P!/(!M! M\6J)"=4%9R[Q#BTYF,!"$Q8\J]^7KSJP]F`N@E!**8AS9:>9TK`A(;-M!%TX[`?.NY;^NSY?*+J_"P MN#682D!1J^%I&0SK&7`W,W83Q=&(AYY\?GU-,\FZ5]X!#"8@I]7PNP*)N02W M/0:'7]F4U:RLEU`8=E+9%_>O_J3U15B)1]`;)-.U=NR8YM9C=AHDPZVPS;YU9&I/D_BA6 MSJG.ZA,_9-&;7[!5U(KR9$'<`4`2J/*B^;J)B90!0U@SIRXL0[/*<_?$ MLKD,"701&\H-7/.SNUJ;M9 M6;+4`(9$ZYJKPB,S0Y[YINX)$*PJ=7HYB7J.KLE0%2#"D;D+K&QS1&,AL0^R M5$N(KL%&<.A,1]BR5*D="-L#-+%#$]`@P('<[R'1[]9*0Z MW5BU`0@'&U6X!0))\W26RU":I[ZV9-T*8-"(&]QRK,3[5<,1_SO+2FCD?UJS M2!,BE'G/SO(+OH`3)[.)DI*-=MY9AT"LX,Y@%U,AL!PAP5D-@2_^=ST2JNT` M"H$P0ET2=BU'2'"8&)`&O]_E^8R%-[,L2D;S0E?SD,>O[%OY3_(]I\X#`+QK ML:9FF9TF^!!R'>H(0MO_ZL!D`=AH0UKX35'"M"JN';>S#;OK!LI+C(1]X50#C, M8K1#6!490H^YP(/2DD=>(B]AX:?W*IBJ-95R0%*V:CT)(#H4'=J1UP`HPJ6Y M0(5;/\K*#_?P]3J=3-*D,LPPUF1]P&R'03V-^5%#0HH>&;P@:/V[VRDTQIQHXD*(,1>/P'^,UP;:&!IS.V[3;!%>A$9;Z73VSLX<[I`;$U0# M&T*2N?@#H2V#)%RHO8NO;"V6=GH#%-=UE8W1A(!#>#(7MU`QX9%-%Z480CD[ MLCY@MNOHD9;?-@02PH2YB`;5L"BGPZ8O3-D9@!R8>%$7&T*2N5*(Y6]S,Z*B M8.%S^HDA^^Y!`.CR2+V]K?LP`'JPNZ5F6!%2G45$/&1IP%B8WX)7A&-3HD0I M^P+D`UNOUX2&L&E8K%",M/F'W=0[NOLT@'J(*_PV8!%>#:97K,94W37D]L*J M>]B+>Q$8@K_<9(D3+#YL0-V9'! MPJ:E2775>>$S`-8A;@OJ0T28B4D`(7\["1W:,'9[76[\X"BV; M+"YY'WSSL_!>X]KT]@_WS@Q&HJSO.*S#C?3&M1:/A(^7345`>F6Z*6($"^36 M'J%SQYO=TGEG/1IU`EH3MCD(4*@'=;7Z6<]MH0#4B[O.WK7[H*Y6!XMIY`.T M<#G9:]#V?=?D6<_FHM/9-ZVI)XQ=PT;C:L.SGE4-Q\9]E"4-:C*K`(U=Z$:& M-!K?UWVP9^'6=U,908D_TBO%MMT4<#D4W51OBY@=,0;;%\8]LIP!K#%\YV_8 M&XO3:;EO@>'U%O$[S^5%0?1Z`Q*'0EH]-FK#(G:IW$V4L4#G$M?-AE[/9&LMKBXW*+^4>Y2Z9GRW_DJ6Y%945_S7P/X'"(7942NMN,W=! MW9Y&8UX+Z6^,'[FPDV[T]R]?U@`DN'W M$?[K!J:55=X8&K1D^7>]LSZ!XAH63WSVXT!J]Q[>V;DS,4MB'Q9AHML5AIU-35(:2:+O=O&+I(?MAXD)Z3N_[JH>,1JQ'WW\ MDBNB$0E]MW=4H5Y4!2+T\4*I9#U-XVRRA""*Y#,+QDD:IR-8R@9\?Z>((,#: MP_J7@`*(O0L"14\.Q'88QS4TB0(_?LXB/U:X7-06K"0@5=5P-PZ"6$#&+76'B7%'XRBF`R'>0YXZ<-7_R_I5F9O*-84]1X"GC!>4"IB45%;U*:P]$G#XU&)-G(X&6BL==\-"M0YJ$OZ"'0:O,6O#(A0OL&JN<'-$^ M`-&M1*U%@39K55#DSL1-\T9K^6*:0.6BQ%D&SI;9REE0V!X@.JS%J/D*:=%6 MQ8-0Y>RNP^LT+X:OCRR:O,RRG$\#ZE`4M(]W=D%`?&M[3*Z`AS!HKMC?(`BR M&5>S^(II\=/7LRR;'[(+]P&2+F`T`86N*2=ZZ)`C;V<*#AB+74IL\#N`1TF%;O73OH"-,] M1P&V29[&4IU3;3F/O[,K9 M0>/*&E5H[&9#,-FFLB4OJ88X$-F-">S^88)K$-M]6"&M5Y$I",ZDTH=9`1"UG=-'UQF\BL&*=9]`]IE7)Y1\!*0&1J MPZ(8$;'859')ROKR>"?`2$`;:L]:%0VQ6F0B<_4JS"MZ`EH"@E![[G8@&8MX M-7X_0(,Y4*,WH"8@$M4C4AL6L9C:G?L-M*8^22]`24`>:DR>&`ZU>%AS5ZIT M3QU>WFB(K2H4:K&J-BY3Z9Y2J([5CK,=//(H4H>JZ@IH/GP=3A?*<'Z(BFK7 MW?%O4T6UV[&Y%:ZKJ)8.U%)42[M_%$6UV[&YTVVCJ)8TJ!75$L!!*:K=CM5M M:B-%M?2B0MXK[3XH114LIJNH:KJEV?`I;X692J0LI%[0&AS7V_X>^/ M!A1B`NG2P%^3?,J"Z#5BH3H&&>L#"*WN[?5CQW'_(X3)(1'318V31N,C:(>] M_>7T#^*X#!Z2Y[!MM@(+*2@J\N&_Z744A?T[&,25'U1W+\AZ@>44-)+:_M=! M14R-W'?1H&Z':BR(9.50%Q\U\;)MN9ENQVTT25,>U&Q6`5(3,@VP1FL)89.^ M/2;'5PW0G^56+LE;*!]`"+-@!`)/0HPU'+3Q5>$J7,NI?T`*H%@ M$`43V-NEQ$4M3?T7E@#0F">AA1-P,P=91&\:B;.*G@"70"A((QJUD%%+4]]! M6N>;"9`("!6-R$*P4$M-7YEYEP3IA-W+;^82M`98%+2,9M/9-@QS:>=FV/F: M)NFFK8O1I+$`4?8%R#2C/B3,:8*BEJO.,SOS\M**N=%W2<$R^!L)?5@7`$B@ M8HQ2O[2HI[`#P">^-6S$F1D4PHKQJK7CMB7;QNET`" MC5GJ-J"9RS6W//$UF?``(@%!I!5["FSR!'(']+%":SVYT0Z@')PP(@"`<.%, M#/GL9PF/15TF#6@L';$N`)"`!%*/(3D6A"QGLL>VM9_\/`JX;!/%LT(:CJ_H M"7`)R!YR,O0(%`)#>'2F>FQ=EOAUQOTR?"T!5`+5]>EM]D!P#@']I-X+VP8I M,@PNB8;\'WQ%E6[/70QAT_C_KLWM<^WX_QY>#5A@]P\3_]^UN5-N%473W3E' M1@$<5OQ_S^H.MUG\?W^53#$L@,4QYQ*$K7Z`W*'8D,=&FO`H98Q8"87ITIQ/^ M52_E`?6)A]X#P`=$S_GQS6\=9.:R$;#;PH0VE*4GAN7/PMS\FY]EOBS&L.&3 M`"*!XWX]\EI!-)>=@+'(3/2Q`FD5.KP],P6>.<0"J`25I0 MXK=!4U/`!^'?9O-TROPY?61!F@11S#8,?TXUW:3Q$;#Q<^!8`MD)]D>3/=]1 MJU>T1GJ;9H-)FA71/TH_:8VLK3X`D4`:@SWR5(-%Z`YR19+,'\2=$Z@LL6_6 ME0ZA5FR)WY7"+PD>OI8'R>OC_;QR=CS,KF,_DAZJU7H.N()`3,N^QT8#%U&K MZR0.#Y$)9\(.`(Z`5K-O_F6^H%;W"5R0,3#UALW_OPJ:?]UTEIK:SP`7$!"- M]OXYJ.<>:J6G=LWGA6$2^+5(NF20]O.Z%P1$J)K,Z-*[@Y-:O2H!;KZ^[[3'8`3*.9AB6`,+KUZ5BC\I6"J)R;4>Q`X@X!R2.@SC_J(6A&M M70R#($AGX,('_YT?Y_/TIB#(9FO%O>XDH/-`<`X!U;()H;I#0]\+U,IUM5/? MK)U:@+-^"&G2A)?(51$38YK7'[1X(%;S!\!Y!.1-(P=BC9!3JUX&W\[%[#X( M_CZ+,EZ@TD]&$?^>JI:PRKX`F8"J:9(^\0#1=`2U:FGM'&/M4P'.(J!WVA\U M)KQ$K:8;@NDV2GS8.=B;A6K^`#B/@*1J9!9JA)Q:"3D`%3`6YK?@([#^C64% M_WC>L!?96)#T`I@$1%*3E"$SC\H%\BIQ+FK63!>3Y?!5GVE)+Z][24`$M<^T MT@4(T\[TT>K07!_F7:>3R2)%6O/-%O8%R`24T?V^WQ)'()E0U*(S-1UC;?H' M9Q'05.V/&A->0H:4,U6U!,2R*`VWA4#)<,$[`4@"ZFB]%:`*#4*9,Y63VZL@ M!PPGH#C6IV%N-^)P9QK@TVPZG2>!^_&RPL`B*UQG;Z73'8`3D'1JYM1KXT(( M;:#.(5DKY2OL1^'-+(-O[OQEYA&/.#DZW6*UG9:`EP'"H&[8D1@$&X M<:;R+#\*7],D@#^NA*@(K0]`MJU@O(L'$F M&*00:'G`H1U9_)1:2J7/.0$ M5YL!$`+;>YM<[J)%"K&<.BEV=I,&LS(Y/PGGI6/NDM+!TWT\I(8$56'DS67,PV&9HA;#(F9X3-P>S&L./4O"L9_7& M9ZV"0VHR=LD3PCBHLF<]N_HSS60STEXXQ>J,;_1%C`X5'/:#GX!%"LW:=2EXQ8V*W[\G\S/;N%O M5(OJK=9>K^-08FE+B1",E9LRFI&R5`MU::FT!RR.;WEJ3\P.'"O77]1;)#VR M47F!45)\]2?8UTO4%!`XOJ^I"2$X$CNUP^J1<0UH,C^^2T+V_=_9NY2-K;8` MPF&H0#LZA%#L%.72Y6.1\KG^H,JG=ZPY0'$8.="4%3D:.]6VZKTHMU',LFLP M:91F\M=DHR4`<)C7T^XE$0"Q4V)*EXGGS.?*ZM/[Y"6-$0XVVH#1#J,RFGI? M`,%.H:>:4\4ZNK(L0I)7;N*6SQN2C@#O`'?CNKCD=9J$IQ!_/N&_]N+GK/3) M_P%02P,$%`````@`J'D.19A<$BK3.```-40#`!4`'`!B<'1H+3(P,30P-C,P M7VQA8BYX;6Q55`D``TP*[5-,"NU3=7@+``$$)0X```0Y`0``Y7UM;^0VMN;W M!?8_\&86@P2PN]OI[,QT9N9>E-\RA76[O'8EV8O@8B!+K+)N5%)%+W8[B_WO M2U)4E22^ZX6D=S],QFWS4.>0ST,>DH>'?_NW+[L$/,.\B+/T[U^=O?OP%8!I MF$5QNOW[5S^NKT__\A7XMW_]K__E;_]R>@I^@"G,@Q)&X/$57`9EL,Z#\->B MD0=G[\[>_0G@'[X[753;TV\_G'T'?OEP]OUW?_[^OW_Z#_"_%Y__#[AZ6(-3 M\/+R\BY"-92DAG=AM@.GI_@[29S^^A@4$"#%TN+O7SV5Y?[[]^]Q^2^/>?(N MR[?OO_WPX>/[IN!7=#[\G4/__Y5$>_V"5:<_.XIAQN^%DF>O\?R[U.XQ9V% MO_`)?^'L3_@+?Z"_O@D>8?(5P"5_O%\*#?K4J8L*O4=:VM+S#N9Q%EVEPQ3N M2]O7_*$,\G*$[FUYF]JOLS)(!NG=EK2I\2TDR$25YN%G0H3/#AG>=?> MQWWY1":B#W_Z^(%8A'_SST489E5:%G?!:_"8P,NX").LJ'*X>"SPG%0VM1#= M2=W_U!5L[&XL[RB9PR*K\A`:65VW9U>AX%%;(335(3$\H\/T],>'K_ZUD0%4 M"!REP"^-W'_\K?YPSYI%WFWU(`\;U="/"G-HB?=AAN;@?7G:L6R39SNSEJ9Z M9&;-T>Z?.2"T1L@^1S7]:HRAEJ0G(&K;8H0B+`B(I`!'HPU"7N=C=A@(9[1K M)OVC+*QV,"V)0^E1Q[@G.$,@/88+V*-#<6H/L643%(_$H*HXW0;!_CVF_GN8 ME$7S&S(8G'XXHS[['^BOL69YA9SD.'B,D[B,87%1Y3GJXD4:W:(&H?\0SS!# M*[(V6`RVE`-17`%HU>#%S#.N*QN<3M&/5F';)A32C=5;;W8;7:,+(`^T73GH M!FD$>#"W.TN6K<6"G58@!E]]V<.T$$R=EHD\!MP<1H]']CBGL_Y:B)L7:8$] MB.(>)F3#(,C+5XT%C'8-UIU0?=O$$PJ1!HTXH/*`5`":&MR[/H;=V'>!!O7A M".!=9`GZ?)8C;_49PYY^>Y'GJ!<@_K[!`FA@97;A.-3B/C([]9!9H<%HJRJ? M9H5)K1?R\K3+3)>++(][VMJ(-(K?G<%I`G+;\WT?2O3QIRR)$"&N?JOB\O4V M*V6;@+J"UCU9I25]M+8%_OB'CY_^"FHQ@.6\6HSI=5+?53/I(=>`,UM>&=3A M"0SUQL^V;`>,'DV.4]O99IZO3#-8'PV$Y@C'E'QQMX%FFY\#/,^4A6H9 MI!2SZVRJK>"""%`1@&1`(^3%V&W2-QWWP:AC[(W;1PBO-A?9#N]N$)^2.K$7 M65$6#T]!#L^#`J_!:B]79S0?7;/U,7Y\6_3!W!K@LPUHUWE8)9!:3P"I]Q1' MSD3'M83[TZ;YFJ;+\Z#%<_?3Q42DZ$\BDS+"WA"!5-W%)=$%#5P765K&:,&3 MAITM08VEA6$]UNEO:B>[3#[($SQW:O`M%&%4Y_:!/:)G/8.QSL1F6I&?0)9O M^.@BV9-5R[P6OQ&6*N>?,<"UN)-0/1;PMPII>?4,Y2L>M8C]?0*Q]HP'="@* MZK)>30RJ;F!6R%I]X`Y&6AM08AGG0)+ZTBR2/!F81UGA'PG4^T1Z"!JQ+]1: M1.3;((U_)TL(-)Z?5T6F;F4!PW?;[/E]!./:HT0_]!U)]*M_WL!MD%RA=5+YNO@2 M%QPJ<4M9HPQ?QSYP2`E0%T'C,BKD$!Z29FU@H&S3N;J[_MYEM@MBAKY4]6X1 MJQW=TZ[?RTW_U@4<]S"O)=O=*VY&>RO$NSR+JK!KOP`^]69H4]J# ML46[+P1`4G7$"&_\[BDHX"J%G^'N$>8<3'!+V?6N&1V9?L<%`"H!?JG+N(O4 MU=1U"4(D'H?(PRGS.$A:E\Z';,<;E^'5[F9N',5!_OH0)&@Q M0(('%/.U1,;)9JY(?]XV:%WV!.#2>`5;!TOX,H$K>X.W*ZK1%1;Q=%3C-MBA M']=YD!9!B,FMG--UA.TC3,)T`+(C_V1+U:,K7[S,&?H8=9M.EC)^# M$MXE04AN$`A]!Y6``V=2H#GK29*"X%#2J6+LK)75#>.JI$>C.[?CT,>31A2YN^#QZ-=K<;*IBEQ&%0SLB3,&F2KL'M!`6O$`["2;L`9F&U"M!W"MG':ER$TM75)KE$JVN04%Z%]/DG@:8]+]_B:M\(W;96QSJ&V?OWN)G_SQKMD M6K+?WX)FM-S7RE&S4\I-?PL)3GO<&V>0TZ+<7G?+\<]Q&N^JG;+G>^6L]WU? MSW[OT[][X>=IZNH>HMS.[X-4TO,681I\T8-IMYQ]F/;T9+J^_KL?,-73U0.8 M\CJ?@:FXYRW.HJW$7:TM=Y4/)9.R/\M*;6!FW4Y2MLXYBB^^E[I/F'E9MT.< M(TNYNZ>0\P5=PMT^";[\\?1T^D838Q.'Z#P$CX^OR_09%DBBD`?J\,M:SI[" MUY<]QD7%P*&E7Y1/,45WY%A94]70K&HSL?=]R#+"]=F6":0Z?QF-?_7$T^X/V MYT'[^[C840-0JU!GH,<_@J,6Y)=$#T`5`0=-W(4P>]'4V88VB=/0:(^:`J,N MEJ$NFP]U]F*[+0^?W:AQ)V.GO?T'HDQ/1ZJ;9/=!*F5][T%N`^/P$)`S^*<" M+C=NS>QHZ8Y83G-XSZ3^/BMBG"Q\6@O6,'Q*LR3;HF7HT9APSA%>,RYB`CO< M;U]I4+N_>:7-:XL1;$'Q)!F)ZC_;CU.KM6*BO-"OG4:B65=KSSR!.T2Y$_`( MMW&:HHD0#V9UI;-J?'QP>)B^$+E+"DVM!O2U6,+$\#$4&?.\454^97EA6X>1Q#QS)^$O!:$M2BH):M$Z(7`$G7?Y_M<`ANXI0DZ_JABJ,@/4I/ M;VA<&QK5AM:SX`EB'98^`2DR-9[35/T'0(:82&/U"V(IWA=Y:=YMJ,UN#'4_ M[9L1D?L4B"$+G0\R/^$A?\08TY?W98AA[-(?84X`$3YY&T.,IJ'\$>:Y-M3K M`49I8&=\H792T[P=4OBTTQQ19)RSFO4HA#`JKI'-6!,,WR5&G!@@P3"YZ^]OSK/ZCL)`!C'9WSO MNQ]RNRH.N]S`K<2;89AKH7Q`]ORZ@Z33=$=B58^Y`:;1#0@OKCUHWG7P\WZ# M_J6&B6\R?(X6*7Z+-DLOL&^:7\`4+;[E-QKD,G:/E!3Z,Y?O(M"4![4`J"7< MIRDUM>128(G+$R5+O6'ML$B''9W3(GUJV!O6EVF8[>`AJ=8-_I+Z]J14ROI` M+[>!B.J8Q/KR=92Y%2T)0>H MH!?Y#^8QS3VA#&#(^N^&&+1'KN8"%E5&X11P2ULG#U_G/J*.=R,/[/!D\I>T M>1\YR@:W.=DC^L>[^DB1/#%_FY6+!'_Q,8$:<[Z.N(.I7\LJU@,@8DV,$1$$ M2!(<1+UR!?1[CO4(3+MMQ&;$15(_P+'&[V\HTBKPR]K=?!#HRP01JOB1'SHW;#`N. MC/+@O(5!G^8IBP!Z8VYBA&%>P>@F#A[C)"YC6+0^C?YU4>4Y&M5$TY>VN.4; M&MI6,?<<:DG0$NT-_4VF'Z83&VP?I8N(4Y-2Z/<::N]LH;\PBO9LI4\+P MI(_#$SD0[5U%,1M"NM=2AHP?]IR'RPJN,]T!44?(NL,@M4",.G(-'`'M=4=N M2IUVPV_<1FX.,BFA)NV/)CD?^!P89-/W49.G[_7H,L?YZH'N8Y%XV'80S,]Q M^=06,5]CRX138153170L-X8F_@0,-T5J%A&4VA>(?1U(?0$[<^!&A:Q9FS MB!B@Z0:MRY4TX.[N"LS?/*;^!-JT&.AW:1-9V%2>D5&?'<7(^C1@V<.;Y%!5^ M/2HENB"H*&^7X!*]V0@36A2T`"J]O6>'A+.:8(TD*@!UD*^'GFGA+#MFUY!Q M#FO9&30?%X[/U-^2(4.).H,M+AG+<$3%6@%!+*=[/B@F69[V"[I)ZMS6E)_' M^5#B!/R09\5<,6(F>8-E2C?N783=NWW+O2MK[\5Y^FD/E3=*.J4)F_@(FZT8 M-M:S-3/,Y"9H%M#29FHV>C]GM;F.4]0C.)L,21$N716;B3M(S*9E%9NNK+F$ MM=J`@R!H)+U8EPWI.#:WEVFO.0"D,DM+KZ`[D`GSJAS@Y'RA(F]=(3ZKM8/[D'+!P!SZ"CI?=M@I6>(+;%G5MDF[;;H9!S M.3IS[9`.U$<)3_R18=;X@GXM3$D&<16@[+'C&N]#PYOX&=][(I3LW#*M=1=J__!V6I>IHYZM["\^A(F512GVQ^R+'J)$P86W>1` M&N(N\C+I6,7)R]0E(WZ5J01?'V1!(_R-RW74_-:=`+(6_K&XO_K'ZN;RZO[ACW_X^.FOX.I__KA<_[M[%IDBM<^S83!UPD3]`T*9 MD$NVJ4_;VOSRZ[S0R(Q&]>0HY!55-(\/=7'D[.*^\55];R[G&US']^!,T5QY M>D?=/>KEB%'<0G=]MLCDW]("O$C&!>:%^NND]O,#^<8F0%^RR2OQPX&_#GA< MNC]&;H\7[HZ>F^-RQ:RE<_?8W7//1M^C<8;L+-VN8;Z[A(_E\?13AFZ!@'V$ MBS1G4(X*`EP2X**M(W>G?KR1]B76/D)%/0"Y%#`,T#70XF08UQN_W0[<\A'; MDY%:N,'9VK[Q`+5LSTO&9'?OKJ69&4]!#FEANBM)1-RC MWGP?TK^=QSM4%T2S1KTI^E.05+)+=]S2UEG`UYESQ[DN56_?`U+.;3C3(,5/ MP'][]^'#&8Y<`L]8!)Q]./GP@?P/%)@2##7)XP2[P3RE?0%"`;`/^]/[CA_=GWY&_ MGGW[_N/9^[./)P")[6%8QL\P\6!"$D&TSRHY/BWN?!XR?-T%<;1,+X)]C-QC MV;ZG2,+^KJ=0=V;#\)CE#1<%2YQ#FA1VNN4Y1'^2-"1.02C3W^K>IQQ!S,ZG M#GPL/FUQS(;Y4`9;>(53BN_SN("7O9B8+2YW-8QV,[S8Q=#;O7"Y):>E^"$A6GB()@1$_VJG4M8C:PWWS\H<:FMP8"QSTAV8YHD68PYI>U_C@D M3U]EE)3S3%K*UNX_K:=H:M=!=0B66N?26M*>A-OU;5*ARJNG;TQM\#P$CXLO MO7@\";B$G;$(5U;#K3):END06`.^H'%=1#B%<)K\YBBR&L7E[?KN4OT9G,;Y#N`RX*F\.%)49>O&1A8 ML'Z"8(.MR%[0#XT1S7N?[QPO0U00ZBQ%]/`SR?M;-+Z$NO9`T`ON!=K,&HGVX/"3F'[$41DXTE605. M=YNDEBFWH/`>+.\:DP54 M-%F+6F,0'Z<=QLA`.H(AY%QPG0=IL8'Y8HN:5LX5<7F[K)'HS8WF`$U90`J[ MI])P`]"`[W0/8]ZFM\8Y%?([[-.#_0@>-ELB"1\?^7K)ULA].2P5YM=3*D-=[N%#!VR@-!^F`!TH(\ M5W!?/\EPAU]DF.:0ICH5-]9I MK[G>X('D6.+)#RFG8=V(@>8>YPB`J%WN8!YG44O!+['0BU$(V1T05!;TD7LH M#VH!T(+R+UC&*6F*>H/Y@A1'N:RD_ MD3_$(E^QW\68'OIY`!N!_[LRBVY&1TZ>'U+`_4:26M6@*)'[ M4^)-%Q]V;:=J6VMDX@.VPQT96B=9A7&2CXU;=1E7Z&J596ZY9*G`2ZOW1I90 MD[;#::E M^X#+&0VP=P8OAT[W"%X'-S;?*WR&!:I;Z`:*"CIX@["G*?L>7UW`J3-HK*T' M6>'Y&&"?_Q,#8,PZ)`E"FV*^!&H-T]OI"F6.EK:W M7)'@NKMH48)Z3,Q\G*$UY],_T'P3I]MBF8:*:'EA>[Y9F9!KZA+VLW<]/;"^170[P;R:^%^!!%7VPBF/V3)YB++]UE.>D!. M19F$73)*=>]C@A0&N#1H%7?/Q^%&".XHVV'C_&UOC9!J"G0HJ8M_FVDB@Y+, MU`\A3(,\S@2'HXKR#I)%\O5FP]QI.=`4E)Z$VDV[*&EZ-O.BLMTM@H;J\&.* MTYS'FQA&PA-G[X)'HSP"H@4VKL.)0T2J(5%W!`$FO'^R!J=XP^C&-RSO4 MST]!`1?;'!*LBP_R3(2MPTO+(N9"0;WYAZ5`(P:.; MTVC&UK>8T$B._5Y"(QW@.W"P+Y*@*%8;;%`:K#7U& MR#N76]090K=;WA,6GYMJZ:'TN7F%[3\YQ=.8><&IAQ=O_&MQ>S.O)RD:>\SD MGU4I/EM53/F]4I8G^KZ.S`1#"W@PI^NJZG3JGJ@][D=PKA:W=^-/BO/NU3X-D(^)'JW@ M99S$6QS3?;799+EDJT8E8#GZ4Z(Y$]5807`H#&AI]_0S-*%?UFG,Z!>7Q^N\KQ?9;A^DKXJ4:T.J MLIR7;9"U[`M*I!9\?_/7YNE-@"L"M*;#S>]70.MR3_Z)3+^[<)H%;M[^.P$W M-Q>^C!0CF-E-,C>6EO;V*$AB_-5+BL#\%.^7^,E$6)3%^>MML!-=OC60M;Z# MH6,/$[:`9[(EI]U9_P\.PJYSC#ZNEW#+3D/4%?QU[]/%7 M@\^;#3;MSM*$GZBG1CA7390X26&`IK7B`>;/<:C::%"*V76:U%8(+Q\<1$`C MX]X1FM0=-;"W3]N]\&B)N)$O+<(3J2_M!"Z"XI,>1! M%A$'AGE!#TEB$5/TC;E*3:M=I8HG"S@%+5^?YF@JC&I%A=S[F!"[W5O<)"<_$V8,3#-S_26.,SWPW!#D?-'0(RQ+V`M MBZ*"T665Q^FVSA]9AS1=9"E^F0['9F=I$2,]ZEU#(9.'5>;@[:P!%O-?=ZHK M`G5-3291&M-VK`QT:W/[[-8$MN.W"[,4%*0)XKH)3D#A/`#1V[ZU-\:,X3/[ MZ-J^+)\@V-?]N:_RH@K08%)F(*"M(4@@XL=0TJ6@ M_L#!X]_88>(>E@%RC*+SU[;'U/[>^H@KZ:AA6).#0<345OZ8TM1"SBG:3G-G M7`&MJMR.,6.M[@PY>6-\T:K+F]%FX@Y^[';P">WA$^TNMCO<#*(R._J,X/&8 M.X1!G/\4)!5<;6K`M49"T;`CE[%\OU"N/W,[#A4'I#R^54HIUO99W-T^-#.$ MYY!LLAP4-#CF!#SCRIQ>51S0-41I['N$K'VN?0L=JG3O-6KS9`2!6S7W;W?) M6:PA:)?*.I8(:%`SF+VAYYC3(RQJ`_\$!$?+W$_YEOO)&K^UF=0AN2&-QL0; M%WBY%79'D_I+UUE.HR)%;-<4MAQ[K&D1$^E*Y9@YG,()"3>AK^X"D0?:IIC8 M??#YG76;O3AE$ZIUHY7->3;UD+!(HY^#'*T52KIZ,!H3.-(>#`H\F[3AA5_M M;:3GS3@P<%C0L:XS+F"+7FJ)@X_@Z;@PJN<6K9X[D7:=VZ%!2#GUV*#@VS0K M@WNXIYD((_F0()=QMA[@Z2]U,5L"KAD_S(QFV^\@X`/!;?2("W=?2`^1IZ_@ MQHPS.ME/&#JA4V&_YO/&HF'3^4\S[G*-G\U%MHDF\^(PF\]IUR23NUWMZ1G0SFLPY7!M[9H@_%)7BN,NS$,*HN$:MP1U).6.7@:SU7!PZ M]K!W,&L9@(6`R-V9B:+[#"/@69G;?Y1A&.M:?D!=':_,(+X=NMK\9-T?+_J/E M-'PQGO/D=S+_9E#?RAR<)E+JC7DX8EX;NS@J4D^R-V-ZON++B8K13KQ_1R9* M]7_N;Z.XWS,=V?C>G7H8G7/,=+(AC=8F?VP^?/4%YF%),C*$`` M4(DJ*7%Q_!=.ZSC?K!U!>_W+'CJHR1\E-G<-$@I[W=UZ.#UC^U.L:H%:O\ M(@EB;@J,@?58WY4UM5/FD'/.GEOQB@58Y:"NQ^46YEB#5;=*W&]D#H)N?U-S M!&XM/NG7CQ\57N=02MA_W$^HNS1&R/FMC7'ZG^AL/EI]I5`.(>:I0AW\."3` MJBJ+$HW`:%(U84%'S#T5NE;H\*$EX14I]"TY,"-3F>*4'AR`*3DB1->8=]3B M(DRRHLHA^=!J3_:Q6]/4\:;1,D7S\XZX\.O@,1&&!HZJTO);;*.L9]X+.]1& M247KZ[IRK2MIK3K!+Z16USFX)H!#]]VQJ;!@;R[X'*3!5OZ^O;BH]3&?HVT? MELY?(;Y8Z8>W8UT=C]VBP#1'Z_E:!@Q1M_#`B*=GQ!M+N$S3+(]_L@B M+.-GQ!W5(S"ZTG9'7FV;^LAH!,F%G98H.,HZAOE(^_X8[/9_O6R9XWA*,$-? M9_0?`CU[`SUQJL[QQ0K\9AU,"S+W+/"\5-.8IDZ"5Z+[2Y!'-Y*4K5-6 M;GTRF:1%N%E'3Q_);9QVM:!5[R$/#RU'ZP:D@-C`O3(]QXO)@+WF,?*9APC$/_N@Q*>,A1)@PVF?V[#IY+F+<= MN8P'BNF^R6H*SCG.=K-G2>F^;.A>_P)@!<`QM:'SQP\<-._Y;,Z4=@/;?9/! MPE#`/NQ@;1SPR.$2V770?%$4U:XVLC<3_)3A)VN3N'R]1Z;.L7@:H(1_[M:4 M+3S#4JN5,[:E",?3.BH#L#9OP-6:'-N3KRA3W"I%I?!AZ*2!G4GB#NI+ M=F0IM$BCP\LI80SYA\.+QZ+,@[!4AQ\,K]E5%,*(MI`$([1J):$(G7J%\0A- MW4X?.)N[:4X5C7,ZM'D<1&R,)9(@<&,:%EG-]Q%587D3!X]DQCYJ_"H*6](7 M=9'M0V4-)R<&%@$'F1:F7]W'&9GV$R=-A$$GC9BBUC!\2K,DV[[>Q"&>_!2! M%N+R=J<3B=Y]J!R+@J:L#\$3!A8S-KVU*44%_,Y$H8=Z>\/_ M=8Q6#O`F?H;1$O56NHW1F(!6=A#OM'\._C/#=RV*8O$EEATQ&]5B?5(PLY%Y M_81(`R(.CO*@K@#O#I,J`*D#.3JH%@^FBP']VI\Y!G>J%^@]*G@;[.!EM@MB MWFMM@VOR"<4"6PV1W(8QK@?\4M?D-YIE_6R`:'4GCSDAK/;[Y/4PY5K;WK&7#-_=LRHUN"TN?8,2Z0"C MHT^FO,(@%K&_U!5KSRQQ:5'0\J+]N-LPS@CW$Y,*0LQJ7`L_%L](JL<"_E8A MG:Z>T7_6Z'L*5U\H8?^41*@[.VXV)0$I"G!9;UQU11\P)PTZ'>`404IG6R+C M`XJ$#K0`1]ZXR=?)(1.#2H.#)@$D;28L*M MV`?(M#U90C5Q0AYL+9' MJ4&)SDZE-A_LS6)(I:Q*R^(N>,6#QB*-J)+-G!O#@JJ(_G:+&D5(^?%56I\# M1UC/02JI"M"Z2"1;`]]6=6[W1N
-\R.*`&)RJ#;4ZF8S'>GVNG`?CXJ;CU MN7N8H$$%C2PY@3C3?$F[!H3PI]76[I&7L,"+XT/QZ!HJ5S$$+W*D4)HZ"8W$^]@3NXN2C?0]2IPL(6N:1F[STP% M:395)(I3W]?"])8L$J_OT[K=1Y_&PA/L6\E>2[:[/=TA!I4.N1P^X`$3R.]-R24DEY01/[^@H`G MGCPF,=H>/Y^4T(2<#G=&/2PQ^0LL`Q8_6M(NWV,Q6!1TGF7Q=LTSWC:O5CL& M\),\T^+;.H=Y049KD2.5G`Q*F%E!+V7YP4ZLZ\+4E*@D-1+Y+7:'8!\YZB3ON/.=U.DE7Y!'/Y ME=9^**>8L;&?+[$CR>A>I&'@<__:.(6 MEP2TUR$6WTW2X4GOO21]DDS$8'W6NF>J)A@\2&!EKK4OY%-INS\6\HA?FIQR M>T/N'C[#M.+&/[%%K"\G6MJQ75__R>7R6:V>^Z5,OX/[:Q=^[]H#X&I/@E[2 M+8W^+S36NQ(9ZQ"5Z=\'Q:%LC79S&6)LR?M:X0*F4M,X(M2U]2%&)^H)(1\:'*Y7#[2&OIH*@(^6> M+9I8ZW/&"&@.YP^3><.'^4)KGO!J#C_#@KQ\4:NU3%&GHM](CX=%(@[.AX7:LP?$3=&&)DUAE^0P,J#^ M$Z6%>S*HH,,>:^O@QJ)GA`<9EI@R[T@D8=]#$NK.'THYTX33-8"A^KY`7@$9 MQE?2P8M#P*NW@\0B[B$OWC#A8'ZFC9]/M>XIW.(#&&/8JTSP9]VK@(X2^8ZW M=83^UY`E@D]+`[,E@M.CQ;HXG&TP&-F"@D#R-A?AND4V8J\#31[P>=48&W18`01(@?/5,PG8J@M:B:`(T=.P./!I$AFDDO:"&"G8H\4 M<_9(]#.,MT_H^XMGY")NX6V%`_A6&Z)BZ]:J/K>&5FB=QX8^Y:>@@C=A M6\J'533E?0OA$L9CJP.Y/+@(,:CS#*.AW`9U+Q)2.8R:61-&%]D.*T9"[M4[ M:;H5V$]/K6L9YZY<+5C/+Z=$%+1E?0@U'&S>U6\5?O,D;!5V3S`S&#(YI0=@ M<,SKL=ROD(OAJSW^$5']YR#/@T.>>@Y_!M=D^=W9(;8R[U0UZZ<^C^H\!W5% M9":@5;DDV(1F$^NRHW4OU#KIT<]HZ_1>N)VS7T^Z';O0[5AK=Z^&,[C[>.Y( M^HX9@_!'1"/==98_P/PY#L7)JO7E+8\W^G;QZ2:>K0$2!XV\NY%EK('XQG,Q MKQ5Z(XC3GK(W5!@2K3M`#&*9Q=<]FSPDJ\U%4#Q=)]F+SJ4ZN9C]MS[E5K#H M:_+(K#8`"P`BX556&9V.89[3U.X5JX?16)>[/'N.(QB=O_Z(N+!,#X'FBQ"M MA.LW7\CKA!7Z'?UCENI`<:H/N#C^GJ9E>/O\!-5-U>#Q%7R-:P=Q^@TXWJPX M?N$$'+\!CA_QY`QPMI:Z6#S\`US?K'X&U_>KSV!U=W6_6"]O?P"+B_7RI^5Z M>?7@?B28ED&<8_;)Z6-Q\RKZSZJ..B[6V3W$+1HGL!,ZL,XT[=,8:^;YG/V- ML7E:C=E&.WX&OWER^!#H!?;@/W;'J_-70(:K9 MBWZ+?PYQ&U;U,-^ZA!8X.QD=3'.H37#8I?E9?P[=VW&;6M& MQN&(P^K/X+WU9\?//?JEM>&@-(7.;L8&`<;%!)<"W.)BFKL;*%M&"P3L+Z!% MFG,W?#D'8BXAKZ]\:SN^:._'>S`SRK'#K/0U@&,U"7$.D3*7L/[_]A1:%+#4 M<:T-ZG"1J%C;/D[J8B(#&N&>4TOD/7%HQ]CY=2/\#8@:2Y$;&A`Y]_0RAB@G M;?,0?+HD(;Z2FZ*OQ=(\-PHY#\C6M4.+8"T1MY<"3:VYRR%Y)+/SWF7KB4L? MF<3!F9H]0I`YG;;PG;3F[7'":K,9BR/N`7^X5NG-4^2.'A6E-G_@- M=A23H["7Q-0`L('+J$2O2[(NPC"KT*+X+G@-'A.(PY;#,*_0X'S4VHBT>A5Z M0%Y-R[5(W-0%:&5UG'M=79O7?I%Y8`LG@K\5H#.:0YKHPBD,57QH-7&I"Q"'^K MXARGB40='&-G2;7?IB%K_Z5Q#7N8+5XJ@\.>J!0XBGFQRS;(+*3+$U[[9!OD M\8=)5>";O$G],ALX!3E]+&HO?BS*)DNUD<@\/VX&P[#Q'621>1]3U=.2'S./T/*>(!5C75+7$1'R#+A0(G/EV,`[M+=>RLW2+CT(_' M`_(TXFPR7,9%F&1%I?76UOBJG2S[1[8&UU$@ZQI::2L@!=_#X.WI@6/-GBR" M9F@85-5IO:GGY7[>5,3@[4E,QPJ+`P4Y?"B0$[W:D%0MBQV^34//)&!T)AL) MU++VJ:YA#\/E@PQYWH@DK*G%P$$.G#GEZ2"KZA>)B#EQ4>!;8=4>_28\FNOG M>9HV)AD2F@'29L9GI,R2](&,4-UB#C(Z=[3D9W*J_^Z6#@I%.!-A< MTJ+^M_BD?;X-4IK3#1&GR)(X"NBK"G>H1YL]E]6&SFM!9`6V#%&1AR]P37\4IXC#7Z5!B89U.(@4,G$1C9PJ;ZO0L1!6[ZS=L)5`%*' MXTMW$UKKGK@#X,F&-0W$YHAC(YJ]ZS*OMG=U[J[K+%_3U9?B[$A/UNX!DJ8] MHB1F6`Y007)L046]F".,.ZQSAF'>6R-@=8\F$V35$W[#%#[#)-OC.41OJ#:M MP"[`3"QCAZQ:MG[L]RAM>7A6GUJ.,9)+I_EC0OQ;2W;AA]=G?H1MH M-[/*Q_7@%5'SR"$B*"E]`IK:`*FN5:8X%/)AFVL,`)BMK_&]/V*RO*1#%R+; M55K&Y>LR1>/EKEZ9*7PP/5F[4Z2F/7U(-F)D@*T%04O2'Q?,I+\ZHZIY9YD. MJ`4,WVVSY_<1C.NQ%/W0'T+1KPZ:M!18X_Q?')C)BUM#ED)K(9@Z""*E'<)' MI^D;Q.BW^]P@6:-J%<"HBS@!`]5."`#\=S]ZO-V.O%YF&W&NGEV@ST7D&9(D MV`JZME?&:M_V]6.?@:%_![B`V][EMF6[>R4-.3=SZTC%*^3$!Z6*PKVR3KC< MUU=(:AI8>H678JBH'_SFMC:/Z)*FGAL1UV@)%R3_CA9WU^@WO(N'TM).4,'J M+,1%713@LH`4]@,9@E;G84/:Y';0T<0WZ^*C4]XA0KIZJS!RB$WW#"61OL1!,+OZA5?`BT[4.#+C:/Y0`NZ!84LH9NXT'= MRO-"X0)A,0^291K!+_\#ODJQP)1U``967P$::$%`2@)4U`<\"%J;!82TJ>=" M!'W*XSB%R3U/<7&KN)!HS>R:TN=8VFZ&'SZHJNG;"-%K]WF'C>LX@?D%^N@V MR^6#1J^D@R&CKZM@P"#%0%/.A]&"V\CL6"%IX;E`L,Z#*$ZW#Z^[QXQI?&I# MKXS5CN_KU^]R^G=0%W#;U]RV;/>RI"%G]@U(*"F)RR3/?Q:KJBS*(,7:R!T% MJ:`+KT%NBXCS-+A#XU):KF'X ME&9)MGV]J=,SB\[#Y#)VS\$4^C,1XK@XJ,N#HP"@$FYB]089LKR_78!];4AY M-"29U1"M`)!!72*TY)WC@T@=@G0.(/79,8*VO2>%;N(4+DNXX^TE*GLQMK/KO'N&!V[+, MM2AQLUJ,OY+Y26H1UW%8,E>#'XOEA;NAVQ>*H"SG3@=U@M#J^^()-3TL<(AA MGF?Y19;CJ5#S*0RS:JR//X96"EQ>O&]'Y9:B'T-Z\S2-J-Z']VI)F3@-XWT""YU[G]-4[R"9]B2MPN:.?@$M M-G0K)J1H"!*GW8)-[1Y=(W711N['A2GYPB;8GIHL;R0#@]E=\ND_];;R,NC= MFYLD18.7]]?5>;*93C?/A4MW84D'1U%] M7?M@*V)\;D-+*1;Q]LZ=C+3VX4"&"PGV&(:#!Z1OK3]:3_Z*_HW^A7YX#`I( M#/J_4$L#!!0````(`*AY#D5%Z$VZ>RH``$R_`@`5`!P`8G!T:"TR,#$T,#8S M,%]P&UL550)``-,"NU33`KM4W5X"P`!!"4.```$.0$``.U]:W/C.++E M]QNQ_\&WYG-U69;D1\?T3OA1KG6LJZ2PW=/WQL8&@R8AF=,4J>'#59Z-_>\W M04D6)2'Q("$AI;I?9JJK``@G#XC'06;BKW_[,8F/7EF61VGRVX?.+\?'Y^. M/AY]__[]EQ!:**H6?@G2R=''C_QWXBCY\]G/V1%T+,E_^_!2%--?/WWBY7\\ M9_$O:3;^=')\W/VT*/AA5O+7'WFT4OI[=U&V\^D_OMX_!B]LXG^,DKSPDV!9 MBSYN+CX5/TK%,VC7_.J_GT:^$5E*F6_CM`2_+\^+HI]Y'_UL7/RL=OY MY4<>?@`;'!W]-4MC]L!&1U4'?BW>INRW#WDTF<:\X]7?O61L]-N'YVGQ4IGY M^+1[S.O_Y28-R@E+BLLD_)P44?%VEXS2;%+U^L,1;_?WA[N5[C]'Z=0O7E[2 MF+->L4/KQD#%-RQ$Q[ M*6W)0D^_L>_S3Q#:'69I`G\,6/5[ACV5MF2#]?(Y9_\LH;W/KPVZMUG=0I\& MV=A/HG]5DRG0Q8:^;_(`%7/6IQ!X8[5:M M?(%)GL91R'_PRH_Y;N'QA3'C82-IQT(OAQF;^E%XDY7\BPG+H+A-LR>6\T_( MGMT;_XK]W8$]4"8-6]]36(6AV^Y.=B+6D37]K:WL7^RA,VQ[>[L>RY`,?V"[ M>R5[V)K^R#97(O@&H#\OK(@"WQR/7J.6^_\(9_W9EFXP&DRYC,`'2XN^8PWN MI-^V"-!J?5N(!J-K/W^YC=/O5GA8:6Y[.V0[VV#K>]T6&]JM[P0]=6.LU^%"P)6;CH-F_8@NI4J6/PVW$:K/Q<*Y+%HJ'8?V9QU;RG7=?K'?>69M+M[-PTE5*8L^"7+W$3'*TDDCR\Y[D^H"*W/H8CJ=+=0?CM(,-EZ_?>A\.`*8 M(Y9EL-&4(G6NEO-Z)4Q;51&P2)X0@YNN$ M,%\S!#?IQ(\2A*QZ$8!YZIHIH>4W"=KLMIB=+F%V!(,2EBMV![L6[-.258&Q M[)P]T^],C4=,:V\/:'V"9A4T\B(`\XP@;6LTX-0M,8BIZA.FZA(`A!S$;>R/ M$:Y6R@#0\WTD2P!"S-8I8;86P(%R-CSUV:R5!P-T]I_/ M#4!B1B$,SK;5S^P<<1/MDGQS9]@4ZRH*,`^V4<><2S((?V8/(?78(*,7P"$ M[,?_9F]2$M?*`O+N_K(H!(/02%ELN2ZS;&6ID.]XL.*`O[>/9,KQ('S2%V-N MHYAEUX!CG&;RCW*E)*"F**)I?I("*`B!E/6:I\SG5P*/;Y/G-$:H6RD#2"DJ M,DK2!"`0NBCK,//5()U,TJ3R`WA\`6OE@[+@GM9A=6ZG9Z")# MV&XCY8"1/JU?S&WYPF[=#]O&'=U:FS>P.L5I7F9,=4&GK.AU+LR_"]->/H$U MKZ"E/XV[^5[3.W%Z\C8PYNKX-X%GZ6;NE67/:<[N77\%=>=_HX^@/NV._/RY MPE?F'\>^/YW-O2PN\L7?K$_"\[_VWKWF_.&&2Q]U`7+B'S2LE@9 M2VN=RMM5O>AIMN"M^0BTZ?=U&D-'4NZS]LJ'R/SG+[GOY[CR"#-8$!LUYKF] M1V]B>\%BV1SZX7QJ@G`O!ROH9B^^I85LRZE7T3LY=[5"BCMFMB9JM^&=.+WV M,R!#O.J9`3VPCT\0SFAC<<,B`Q0KFJ*:U^VX^J*6PV$P@A,^W^U7?,QG_.LT M+_+JN'_EYWP!F*T'.M]9RY:]KM,K(6W:Q-^>#?"'=)R4!>\Z6!DEW='29AJU MXW5;^E%O&:_.1VW6D-=U>OO0G"7Q1]T`_.&LJK*@=C?JT+POUR_\7,$9^9QE M:7:=@E6#V92MI0UI-^/UW&U$=;G0W'6][ND7B:"@3F-F=9:;:-Y,`^)_;(Y MI>*OW9Y-#FDAWT@>X>)OLBM7QNDX=C+7,C)Q2 MI9`.9_ULD+_$2G3@\B!BT`%EW&"K5KW>L375=NWWO_E%=>9:!A]C$80&M;V> M4R]36Q87:+4&^'^>L$/G7!NPLNFL(<+S$X0@.O<\%=D=LK\)/STR4@[.(\*] M'C@Z\8UMEMWHU2_8,/9GFC`ZD#T2FKDF<=CRBR*S%09)8*)?I(6;>=+P M._TTJ21.Q60OJ^?UW3O%MY_PE0@)15$V'P!KZ)03O;"\UW=Z-M:G3$PUCHE0 M8&4[+XEYA)-R.M\HZ_6="H=JBG"?ADTQNL?@&ZUBF8+T96.2%1^C+527I^$(K5*A82N6J\1 MPESDRFI.V-^NK_T&.O7L[K.Y6A M#-G;Z#G"GK'&Y)Z]>M15[4"N6@/Q6E[?J;1D:554X$/XWR]Y"0&I/'5*ZWE] M$F*3BD`CVFO($"^'7>7?GM[ODE>50(U?J=.-2)]\XONV#$\ M"%467&)WX5)V+TFW;-B"=^K>M:SQC-P$*\*\L5#49G7&[F19%G#;CWG,5N7> M?9?<,.A6$,W03=*LF",=C.Z@9#*.>#J!/&?5=6CUA[O)U(^R>>K_0?'",F@K M&[-\;A%A_J"=_KYWN@Z!?J;#ZCL8A#YC^6P+"\]E6;RD692S M\-J?1H4?/Z57[,'G?X&M%9(JWJG[+"+MIW<50(1.8W'-_==8W;W`B@\18R`O9*$JJZ(HO913R M)P:)#9:_^W')6HR5U?K>Z1[(1"V&B@`M,E*,14,Z(V68I0%C87X+=N5`>5_N M>-?\>%@^QU$P&`$N\7'$N`WOU*FR9&_$F"%&1HVQU$@BLE?W/6('`;^(^*03 M^*NJZITY2[WS&+RPL.2.=U@GK]Y6_@6)9&S5GG=&PFU%BR9DDF\,FTY(H_U/ M8Q5SLRLC02/>&0G/F.:<&UTN8`:@$T]I9^`872O-)?\SIP)!0^+4[-?0D0S- M_!K"W@;.K&ERS?^,AG^-F`*!,*`$0^?IQ^8?YUT"VS+V M[J9[SW])??,OJ>6=D?#(L3UOJQ`?0H`G@E$Y9TOK>6&0G7']OS/X;T$,),[_B^)IK,),LJ8>RWM+B,^2_R-TC4T[^Z MNG=.PK<(8Q&;_36!N0TSQ5X9@")1X,=/6>3'"G\1*\QU.=;U8 MGS#_B(J7E8>8C!<)W9:]IXO0X)';#I]E*-S58\+PDWG6M8T](X"KFMKOR8WX$]OC#F*!/_0K4= MC&ZC!/K"_:32O/(=TGIG3EW=NSAU-7^^=T_I>;-2T+L@,4-J&Q=QJ]G$1,=? M9KLIP"](S(<"`E:9PKI.QSME6]F^+YQ>9F!VWV1GH]-N74HLSXHZDN9F8:]S M3.+20?EYJ2`<@I_)/!A2XYVLE8)@`!*W$!@UR!E0@,&2@XC[**(9N.O5)]&5 MA*Z5!YN0N&$0,27C5`C#D@^(>VIUPC4[QR2N""1TB/E;=OY@4H)7<<0\Z44" M/R!3''5+[1;VD2:&^!I/7`2"14'/VMD`8<6TX4[C_?6QYE MR^ZC5^Y74$F]E^.,S5YG_9*EN>Q,JJP+QB*A`&DP*AX*F@@/R=FB!GDCUT\0 ME).RNERH)P72&R&:C8%!23C8VA@R1I!;.VUYT."?6K\3C1!VG+Q\+]!F.&5+E)!-@D5#%3]636 M;UN.#^[IJCD:\C?*>`X0?HT*>Y990GV-K:%N$V`Z$H*9F1!JALZ6,X3[36,- MM[Y0BE<"\Y`0W1,7,W<3>= M#@D-T(Q=:$,/YB`AWC6C&<-C M+6>Y^P-]FHR?6#:Y8<_%4JV242RLX'5.2&AO5LYK$H2'DZB\9BF]#QH,0$*" MLWPDG\&REL'<^0?=2).36?&$A`IG@W45RL/)>SY<]+>"7.5DEK`O*`T&(:&_ MJ2@3$XT"LI6TG,*M;.UU817!ZT7!&"0$MF;LBM'8RC).@=IEBNBA'X5WR?R9 M!IF*(JX!IB$AH34C6@K*5GYP]Y-U+5#VD;^Y])GG_YGR]SENV"@*HJ+F)#!+ MM;]>0W8`;]TXF)N$#M=L#-G"CT07Z0MVA'PQ-BUIM#4$@Y"0[IH-"`P/0K"Y M4.?\!*#:*K>XFP=341/M;)P!)5B186$NY*T-"P?1[;`KGL(Z>I.5XV&6AF50 MW*;9$\OY2WS6'J5`+A5NHCR(T[S,F'$O),=76TU[YQ?6KD_>HS66_<)"W*7E MO0NG@II5TPHN4:2P?YI@>/K59UD=[\+]*ZD&GY$>'DL1\.Y/MTU#-B_R57]/_RM7*?K=+.`6EZQF:NZ?0@9CMJ_MM'INM\9Z'YH2AR'D.AH M%X]I]&BX%Z$\BFG7A^;V,:UMO:?1H^$QI$^#8&>#`W/[$);>/E1YL,;*>SVW M?IM&TZP&$DLID$AX!P@#C/BSW#K^FQJUP<1.O08TZ$05+0X6.[N. MU_A=_0MX@\:`N^ZV-KTPIV_&Z)DHLG@#T&WWZD,+@ZOWS2KL/XV>VR.W!U91 MHR'R]G#/6<(,&HN\/:?[5-3R*I&WASN:NE45KE(_"[G??504C'UEC/O]W#+\ MJ6R-6@#7Z592;'[!!*D#PY*.2^',H/?PJ$*XUV\$[.?4I;3]1-L4LUO-U_Y@ M42K]FX7!$"2BPTVI4P^`.CZ20O'7$$8YR_(TN>;O7&77C*OD\@E=5L?K]$E< MT6`D""9V-9R#29Q_E\!)DRU3V?%?XKS(9W%)+;`/.26AV;2M!&E)+'9\1RL$ MJ7$Y*ZD'YB$1&ZYDT(CX.C9+4K#C)5KR)"]8-LN@M0Z5?[V\BE6D:75H1+Z<3D&Z\@9P\H#4!)AUZVXDX.S MEM;>/HN+.T57]YF*O%354]Z=-]S\ M@3VP8?6\WLI=W*X]Y$S[8NPUU_0'@/R^JUGZ,7AA81FSP4CO!A5SPFO5'AC` MO5NZ93K%,W\+\_PT;GNG)$22%DRM4H]B_`F\^$Z=JB>HY3<)VNPV22^^!_[3 M#$[_L]-G;PV;MN47_2;TZGF=<[<9Z+3H,2$R#HR MDJ'7PXR]1FFI$+I62P$<][*'ELD%5(F@6/*;"R@7R! MW;6_P*A<^6UIV!]2'+I$25!H9%#1W;L,+1U]8(\B5\[1,6PS((7/V>7 MXXQ59L*O:_0K@Z5(A.@HJ!3SKPO/5FC=%A;CVRB!/1]_UFK1<_E2C)4'H$0\ M40QXU$!D*QB.T')\'?MY/AA5.JONDKQ>!XSC/HU-FV59#,A67)W3&;L.3;DH M;Q8&2Y#0AA14B?G%X-@*M;/K]G";EM7!6S'EKI3R.FY?2E196C3#"@`0CJE; M7C=5$XR"'7%I`$E"!3)@20:$<*3<3P(=>8FF58`VRXO\ZNV;/U%E1E+6!6.Y]R5J<"[4!(:,@OWR M&T*P0W#_JD66O4:`ZN2JJ`6P2.E`C1O4!(KR2\"": M&9R%"U$;IB_%7:I6/0]ZO4^+M`$HA$WWX4UHW^7!:NJ:@-M]&)0>.8:LUO$A MO#I.*K[HZ2!1I"7<*`BHW*=HT36^@#<$$$(3!:^C18^?OJ=Z7+T7!&CNA24+ M7*T!0KC:J:.1BBLHI?EEU8H"//$,+;35$>6[Z)G*S_76]*$>TWH MWD>+ZH&1W+]AU>9.&@>%A"KLHR?1.SREUB`L#_:@X2^D)DW,M@05PO)^J4M_ M^%GF:\@(*^4`/PG52$*.F$T!"H3%/?08>O"3L4H1?B\#X/?2(V@-`,+>?GD` M59C4;UTL2P%V$EK/&AD2QNK]1CC;E7./'2<=$LY`&Y2( MF1/T'>%NIWY`E@CT?^@16"\'1B#A)Z1+X&;?$0(IN`9MK@;WJL3+DBH`U[UD M8ZJ:*O$@].UA2IG*7^HNSTL6WI19E(QG*9EFSFS?V/?JG^2'2YT&P&SNU2`E MK=A)4Q\A,C#V,@Y-B/KO?ERR%N-BM3X8S;WH9'=8B``BHX)"MFWIX+Y.$_Z, M,?>'ZPA(57;W4SU''4"%A9`XT=9M4P-1OS%^C2I#6Z,<5D=`$Q1Q%)SJP:%L$C!?ZG6X_4@%#F5 MRHH`W:FNU9A/360(J123:9E0$Y0W";9G-/+-0U3:>R=W)"T8U)3:X! M.H1@"F%R0A2723B_$IFO*48,;]0&([AW;K)&,0(/X9B"@E;K_`.;SG,PB]"HHXJ MZX*Q]NY,90@.R6YI+()-4S[`7AW,#K.5S-;TL-D:V&D_#V)MX"+#@H*`MAS, MIMOU]1UL=]_/8")`"',4)"^I?%O]XP+0YQ\L"Z(JP8FVCL/"'U<"/5[Z"LW3S$VG]@&V4,T?GE?`H=95-\7S_\U[\C& M1)/VO!Z!&-BF@Z4Y8&04M4GOY>H-MT&%(J\MD=M^R`W[6<5S;8IJ\'F?6]N5 MK[UDIFDCZ<-M+9H$:`2$%QWS"_;MK7'3>>9MNZD/3WKN59C69*T.`!0FG??9 MMI4=\:3G5&-!+;])T&:W#^%1M5T_K'C2<[\/LOSU-K6"VX?F[0^?)H\OGO3( M/6FD0YUZ`-3QN7V&WE;$7^*/]9+FK1<%(SB51U3TB,D4H[#T.-PKRYY3VQ+Y M`U@5+/("$]D->V5Q.JV>)X21_!KQ%[;ER67T:H,52#Q?I,>E,3!+#\FUH]?. M!WL392S0>2UUM:#7<^NUUNQC%6&P]+:DQN,1E$@>7556`[@[^$:*H!P$._$54+J%?>*Y>ES&&P79S1D/+,` M7UWF$4=5D:'_5BTXW_TLO)?$Y-MK'"AQ[Z"XI4.6+>O8>J9N/\?AG(TO%1%W MR[*,]B',C\_S!^`44"R]A$PX' MN)5[JC:#VUXO@#L2":@<#WK;!G7\GJ$L+X_%;Q_^ZP9V8.\QL.@MX)9_USOI MD\C&M9U!O$,3.GZMT?%&Y-T8EWE>3F9V6_O4_Y[R%PWX4T4/8+UM[$^,.P', MDMI[)=/LE+`\[P]A//O_@AI..6F$%L`@)&6[+(TR"?5O/<#KP M'YJ%U%1['CC_ON<8"B*V=1^BY2G?Z3!+PS(H:J_@+7K] MAGDGZ58%6.[]0FVQ(_YN]4SPTS@D]4ED:=8.V/'H[Y3Y0FU MO,KQJ(^G7=^KC=+.'8_Z)-[L:_*5-D7[WPY&_'LAH;694J?O8-3'@Z_=*E]/ M+'A)TC@=O]U'`=_7*QQ0L/+>R2D)I0DSOD`YDD.A[$-T#46BP(^?LLB/%82) MR@)"$LJ(`5DX#$O>0.Y#H&X!8<'NHU<6W@$7R3B"E>8RSQD7X;_Z_TBS*L9' ML=@:M`+V(R%?M%EMC>$>@L.1!/02LM;KV88M@0E)."H9LVX\>'#T;KV;L`NL MK=27`-,L[:>ORXP;#3NK2:H`7!(J7E,^]?`A M=.ZAO@=0TS(I\J'_Q@?M91+.P2\L%[%\#AW^[5N:!.C0:-LDF):Z\J37N)N+)R/(?^Q'*. M^%V?7'G)D"?U'OI1>)<\%OX83Y7;M#TP&`FMK]67WPX\,EHLJ'].7%>3/(UA ML,*\=^7'?,P^OC#&UT5.PPLK^-6IF:NJ+4=KZ!.G9#"ZC1+H6.3'PW26DU[B MNVI2W3NYZ#L39Q;]4[FCKA:$+I-06?7-BR@S`E0_C3_I!0W55$#!*EEHYW\" M[]$+IZHG:OE-@C:[?0C>H^^#4T?'W"P,AB"A6JJ_,16&0_#Q'"ZZ6L4#P^2X#7@FL0T*.;,]X'<_!.*:*@.J]S*"H M"78BH4"VYWT#E"4W4_?DUQZA:+#F:]0&>Y'0),T&@38P2^ZBI`:"P5(OJ07V M(:%"-B9>#.APO$OM/;W4/::E=S5CN@[&EOP.1+>=1 M$MDNEE<&[V;*!Z/!='YMDKNX+KA+H(/LO3\:-P1(#>#KPKGJ97@IT.V0$#ZD M%M6Z!ZB`_"SW`-T.+;&B1H'Z'J#J_.'?`W0[3N4%U/**>X"JVP=U#_`8L,3/ MHE05G"(J#^:@)1:@7YH&C$.X$%B@^CW)IRR(1A$+U5$H6!TP"RT58),SA&0Y M(I))'R[CN/*@DH>)KI8".#1.ZW)[KY*$XB"@Q*/OPXASD*C>A9'5`LPTSM_& MW.G@.AB=?=?)EKH=6J=TY8)JBNT0I\(J%6`<=6Z@/W M7(L?AE2'04OK@9%(:$D*%K&O6HG,5EX$]_1_80F8*.:1G>$D2B)NGB)ZU8B# M5]0$0Y$0G!H-`2ULAY,&8<-&)O,\&(.$<-6(:`0-A1P'EJF=73O>RQ^W$Y0& M@]#0MIHMW^M`K*4[2`L_=LKLMS1)5U'.Q[#&9DU9%XQ%2[O28ET3EJV\!.Z_ M;AZBG5?/6LS@WB70)_@;J4.'N`J8AH20I`#(P=E*4.">]^J^9=-2LIE= M7`,,0T(':\6Z%)NMM`4$25?OT;$J7K=+0BBS2_L*N-8)""YFO"=LS&57FDM] MDR4>S$-":FO%O0(=0KZY%.=^E\<*K9W[2CDPPAY*;@(("(_F,IMS'C_[6<(] MA!?!*QJ;=*P*F(:$N&;&KAP-0O0>"FKK.*_\/`JXE!C%92$-[E#4!$.1$-3D M1.J1+X2&C($]U-/6GGG]5O+;VL&H@EX+>M`?<:!+.24.;,)HHV6)$AM)_/ MI:H"2)PGG[(83=(]<_6M-HXFZ9*02Z065?@IP#B'B1''MK>1> MJSZ8RWFTF"[[!H#,L:E8]M;^/AZ\0UI`;JOU]6F?5&@4::G\?OQ,G MS)2QVM]W>NA$+:]2^_OH.7._U'Y+FE^?5I`(^J5IP#@$)=^RYM>GI1%LSJ_PQDSQ'CI8%:#0.]G+;"TY\.)J?+9M4G\9AW9A!'5P$ MLDDA7,)Q+DCC!'K_Y[4_C0H_OBV3\#Z:1,7R`=0WKD;XB2+A3(.FO.XIC6.Z M,>N-P1[,&PZM+UY.241D--@]K6%PFR?*6L0%/V`/L_0U"EEX]?9[SL*[Y#VB M^!+FM-?9R]?5!I>-'7O,,&&37L1])SV)&[8`92L-G_U\W%9V2= MC;EV&V`\$O+PSJTO#``+?.$$=[E"Q,M[B4T9., MS!H"0Y+0I0DM3ZB5#B.DT"&8E MH8DW&0RZPTK?#JU3X)$97NV4W:W=Q8&9?Q+AVX:=#BHIG\@:L^RS6[PB-OP! M,#L)\=S*%7$C[+;R!U+0/&&^G^]F+H-_EE'&DQO[R3CB:X!JRZ^L"^8BH9K; M)%\\O#1-T3HA(:&30#NC;FV:`D.3T-.W/^9LV,E:=D2JJ^=ME/AP1MO>ZFGX M`V!V$I*]E=6S$?9M95-TL'9F:#D?XHD=3RNN_V36%Z. M7Z>3R3P=A>:<(JP+YB*AO.]V9I&8`ADY>_AJ2SN3;FW#`V8FH=AO?\39L!,2 M\VNNV3O?AU>F8%F4ANLBLV2HX97`/"2T=[/]L@H/0K>YADZ";@6Q`)F$GFU. MX:SG"%GF.6&J`0&]R(H]H&P/-=YESQ'*C!7:&66?$[<[P\=R.HTK,_CQ(DO+ MY]E?:*7.T:@.9B.AU)H1KH\,&1`[?0D&"1"NU@H_"F_*##8&LU6#N^?CQ.I4 M`]@D9%!]BE8IUL>(4+N'7L&+=R4Y9*D3P[(8F,"IG*A/$^:(L(X%H7,/Y<&9 M2]"3_X/E2D972H(AG,J`[4D5P$%XW4-!;S&-?4N3`/ZXO&])0L&9[R;*@SC- M2ZW'V=HV[74O2$B#36=]NW9`AMP>IH*8B9\Y`%F$RTRXM]9<$V5A1S:F5'7! M6"2T03ND(P-*SPC(B-E#5;`"R?5/^>"H%P,3D%#LMCD.-O$B>=E:>\LZ2/\'HUGOBV.`?%DL1W#64J3N^D\Z&#&J:=FC\3Z9O;=&[0"8$EX)>F1@CD+&,(]I`\1IJ,I/ZQGY7B8 MI6$9\`P?3[-]D]F'B240E?R`2JK4J>OUCH^M2:KBY_7TOAZS!J#;3L].AO85 M:*R&4"U]-)J[Y;]^XAU^]G-66?B_`%!+`P04````"`"H>0Y%@9:,UPL-``"C MBP``$0`<`&)P=&@M,C`Q-#`V,S`N>'-D550)``-,"NU33`KM4W5X"P`!!"4. M```$.0$``.U=;6_C-A+^7J#_0><##KT/CN/-[K;);5HXL;-K(!L'L7LM<#@4 MM$3;Q,JDEJ*2N(?[[S>D)%N61>K%N90%]&57$CG#9_B0U'#$<3[\]+SVG4?, M0\+H9:=_H@7*/+%9>=KA'RR(-CK.&`O#2_F M@5C5T*F$]NH_G9TPOH0JI_W>KY]OIPIUJMTG],M>[>C$Q/[Y^7E/E:95H["[ M1"C85EZ@<*ZJ)@6JX[JG_>Y9/Q5Q640%W^S;&&+W9,D>>TFA%#O+B46UYF!3+0$%!=?SLKHKKRY("`4(?<2B*1>*R`FLH(FY8+*.*I$A_7R0D M;K$`%!14!P+$)L!A(36JI,"64`1Q)Q#RIUH1;FQ-W*E0LE`K"B.,X'1"F# MI0:6*'4OGP0!H0N6W,(#.;XO).`9B#ORXN>'<>D*H2P<,C>2*\Z`>B,JB-B, M03-?J_8Z#H%.,M;88DA1>'A!*%%H^Z=]6"M3\>PEJ')B74Y&V8=>7L.WW^35 M1R'V)O1'=0T\AJ!-R;67H#U$RA&W%"T_7D;CJY'0\'L]'0N1K<#NZN M1\[TTV@TF[84-:7H'L%J+U98$$!7PM=^73-Y9]7)<[[;4_SWELP:9&[[.)PL M)H%T)`%0P<33U#.3^-9$XG0&_WT>W0&!DQMG^:$-O.TY<@>K*X1N'JQF=/IEF:K66F\GTE*B63UX/I)^?F=O)+.T7+F)OP M):+D=]4V.(5744@H#A/"=(5FGKZ7CB8)79^%$<=PDU7C(/`\4T4M.R7L/&!? M3A98C<0FIF3OB9F''_(\)+*.$F[[OJ3O[SD.$/&&/%K><^9%KHP)S6!K#M5B M+HPUS-R(2]T7.`:;CC(/O,3$&_@`(I[23B+0/5&+@EKNPN&+?*>SY\ MCU2H9V;JC8ZI1*63ZFQ?/#4IG`KF?I&/,0]'7R.24E;PW$S169ZBK(:__?7L M_!].K*>EI`HEDT#M/L$1_@5QCF@:]=,5FLEY6TB.D^A1;G*JJ:6G=/NY7A.A M5AL@`+:9TF/"U"5XN_/45S#3]"Y/4T:5(FE/6QT.?O*6J;*EKQH'N*O$=@\>MS1<_#4S,E!*&`G[\0* M6AZ:!6@&GJRBV,I>>*LE]R7(S02[JG!;L;J96FTP)M'<,OM2S!H"9E79;JC"/`(. M8CU5PW'MT#AZ:!P&YDJ'0CT1,_7%D:2",%]+]-G*XX7EQV9Y]%-\SA^`Z-/GM=^6D6V8,B04`,GWT])PZF*Y)2[.6\"E+`` M@5F,"X<69F/ITHKB1*Y;YBI5!A%YUTWENO)1M_^F>]8_>0Z]7>_7 M`;&SL1Z(5*X!B.*DK8K-IP*RW7=56S1F76D:5HT6"O:P+\+T27>GJI;]A@PH M$Z`"L>2ZNU/1"$A19ED5)%FY].9H+$79:I7`9`6W=\=R=)#85@7*5DA='0OA M,.FM"H:=5'S9W2EHA"*?25<%0RHC+XYN/Y]D5PE`*J2N&D`X3-A3+QN*ES*R M4&WE\CG?DY++U[E<-OOOCX91?4-G_S*EUZBI*\=@7HX*/";BLY MF(HX**EUV1$\DAZKJ@4^(F'>3,EY$4\R M6"GQ?=E&6C>,0)B(2)9^Y"P*TD8(J(^WS-+I_:T"Q+K&S?"SN/*9^R6U+LX@ MOA#I\R(+%\@/7]O$#%"]C66Q9)N8K(Q58^XUDTTSB>01#VBJ:R`C7$M5T5Z6 M&V+7](0NDF@-VZ4`-8;M.J'.T15[[#X6OZ9;6X.>VR-"'U=8O.`=!,3S>>;L=IW M,AY:@[X85M/!=@LC6>(/__CY5@>K;JC!^)71V27(7:_D:CRF0_7K)"16NP87 M+FEBLAA#3;HD\@Q&&&(5S5<7XW6`"$]^H&,B5IB#+K[$80)%IHLEPP#&0!"W M^S5.>O1&+%.`FQ=XT"(I`_8U?X`"XFU!I+/WO0.9B'C%[+1ODU%&%NS7I@AJ=SOWQ"92;\ MC!.@P!I;BF&5>BJ;?"MXZ@8G\:8&WBC3IYP>(-<.:LWR9&] M\`46(KU-N97(P_,Z"Y$>*;!9_+Z(P)>?!X!=/+GIW,OOA*@=N;=Q-M:&KGOWKQ#'>WJL.5:8X<>FNX3PM+#]"/S%]>,!RQNWAIK3."TVW,* M>V094EIRK`JLL48/36<+>#MR7MEC00Z0SJW<+G9J=;`'OPZ8[ET4X2&XE3(K M`X\6L&P+>TPQ8--M@`EUF4_!&?R2?!VYB>3I!MA'[SSH#6RL`T0WUMC9"+4A MM"H_JRJW6'YRG&+^"!ZS/:R6(M1[>S)O!7M3\/\1(`JO-NFE;9YZ.=8&1EKC MKU37OB,^7(W4&VU.45I MLO!!YK52[,%BF1DJ67D59P8[%$X[#*X)6N?E(\+_B?Q('O5AZS6CF'8T6VFED`M'RH/N`@XJX\5NI98YT97D/NU'Q^S36G[I&JB@:8WC3IEV-/ MG@T\?&4I#0,7?)20%'@4=G5'0X..Z)YX@.G[YX][&3<`7CI++%[3*JYB1L=, M%::*1L^8NX?G>^US)W6HZ_6`FA:)EE2)_7.]LAW5OJY5_(4CZSXZ'66&]E-P MB!&\1D'+$#]BGP7J!O[/OXJ,%E3KZXA]$M7ROJD-R?)N&B&'63 M-)/-G\;F,ORZA6F7C)%F8J0C9"\^*7WJ>T2\,>RXT-+JP^[-3=*-$-]7N7/6 M3.4\(*U#LQL'F3BD/6MK&<`*=EEI2R,'+./([OS8[1]FLW:V-3'&M%$[4)5( M[0*3-J\]U4W0!1U1N)*+4G:'!W+V>(&E`/7?[O7)?]985PUEK0VDO;]S4@.O MSGM@;I1DEX]@$R`V=FY<*J'4+4J$4Q0[E`=;`9L7(B/L:MD@%AT?T",ST9;8 M:XV/4`1*XO_0BW]%3)GR/U!+`0(>`Q0````(`*AY#D5..J\Y'V@``(LJ!``1 M`!@```````$```"D@0````!B<'1H+3(P,30P-C,P+GAM;%54!0`#3`KM4W5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`*AY#D4@0O4=Y08``"57```5`!@` M``````$```"D@6IH``!B<'1H+3(P,30P-C,P7V-A;"YX;6Q55`4``TP*[5-U M>`L``00E#@``!#D!``!02P$"'@,4````"`"H>0Y%NJ$AAVXG``"G>0(`%0`8 M```````!````I(&>;P``8G!T:"TR,#$T,#8S,%]D968N>&UL550%``-,"NU3 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`J'D.19A<$BK3.```-40#`!4` M&````````0```*2!6Y<``&)P=&@M,C`Q-#`V,S!?;&%B+GAM;%54!0`#3`KM M4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*AY#D5%Z$VZ>RH``$R_`@`5 M`!@```````$```"D@7W0``!B<'1H+3(P,30P-C,P7W!R92YX;6Q55`4``TP* M[5-U>`L``00E#@``!#D!``!02P$"'@,4````"`"H>0Y%@9:,UPL-``"CBP`` M$0`8```````!````I(%'^P``8G!T:"TR,#$T,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``G0@!```` ` end XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Prepaid Drug Product for Testing
6 Months Ended

Jun. 30, 2014

Prepaid Drug Product For Testing [Abstract]

Prepaid Drug Product for Testing

3.

Prepaid Drug Product for Testing

Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future R&D activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company incurred installments to its contract drug manufacturing and raw material suppliers totaling $51,364 in late 2013 pursuant to a Drug Supply Contract (See Note 9.) for the manufacture and delivery of the Company’s lead drug product for testing in a Phase I clinical trial. This amount was carried on the Balance Sheet as of December 31, 2013 at cost as Prepaid Drug Product for Testing. The Company incurred additional installment costs with the total costs incurred totaling $141,345 being carried on the Balance Sheet as of June 30, 2014 as Prepaid Drug Product for Testing (See Note 9.).

X

- Details

Name: bpth_PrepaidDrugProductForTestingAbstract

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Research And Development Disclosure [Text Block]

+ References

No definition available.

+ Details

Name: bpth_ResearchAndDevelopmentDisclosureTextBlock

Namespace Prefix: bpth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B.38R8C`W,5\W96)D7S1E86%?835A-E\V9CAA M,#4R,#8Y.30B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?0G5S:6YE#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS M93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?0G5S:6YE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E M;&%T961?4&%R='E?061D:71I;VYA;%]);F9O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E!R97!A:61?1')U9U]0#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\ M>#I0#I%>&-E;%=O7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^2G5N(#,P+`T*"0DR,#$T M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$R/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)T))3RU0051(($A/3$1)3D=3($E.0SQS<&%N/CPO2!#96YT M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)S`P,#$Q,S,X,3@\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\'0^)T)05$@\3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.38R8C`W,5\W96)D7S1E M86%?835A-E\V9CAA,#4R,#8Y.30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8CDV,F(P-S%?-V5B9%\T96%A7V$U839?-F8X83`U,C`V.3DT+U=O M'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$V.2PQ-C@I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#DL,S0Q/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(W M-"PX,#$\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'!E M;G-E(&EN8VQU9&5S('-T;V-K(&]P=&EO;B!E>'!E;G-E3L@)#(W+#`S,B!A;F0@)#$Y M+#8S,R!F;W(@=&AE('-I>"!M;VYT:"!P97)I;V1S(&5N9&EN9R`V+S,P+S(P M,30@86YD(#8O,S`O,C`Q,RP@3L@ M)#$X,BPP,SD@86YD("0Y+#DR,R!F;W(@=&AE('-I>"!M;VYT:"!P97)I;V1S M(&5N9&EN9R`V+S,P+S(P,30@86YD(#8O,S`O,C`Q,RP@2!I;7!A:7)M96YT(&-H87)G92!F;W(@=&AE('!E M3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B.38R8C`W,5\W96)D7S1E86%?835A-E\V M9CAA,#4R,#8Y.30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDV M,F(P-S%?-V5B9%\T96%A7V$U839?-F8X83`U,C`V.3DT+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO2!I;7!A:7)M96YT(&-H87)G93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.38R M8C`W,5\W96)D7S1E86%?835A-E\V9CAA,#4R,#8Y.30-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8CDV,F(P-S%?-V5B9%\T96%A7V$U839?-F8X M83`U,C`V.3DT+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XX,"PS,3(\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^)SQS<&%N/CPOF%T:6]N(&%N M9"!"=7-I;F5S'0^)SQD M:78@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P=#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`P<'@G/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!T#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!T;R!D971E2!A;F0@=&]L97)A;F-E(&]F(&5S8V%L871I;F<@9&]S97,@;V8@3"U' M2!D979E;&]P960@8GD@=&AE($-O;7!A;GD@=&\@ M;65A2!T96-H;F]L;V=Y(&1O97,@:6X@ M9F%C="!S=6-C97-S9G5L;'D@9&5L:79E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!T:&4@1D1!(&EN($UA2!T;R!P6QE/3-$9F]N="US='EL M93IN;W)M86P^,CPO2!R97%U97-T960@=&AE($9$02!T;R!A;&QO=R!H:6=H97(@9&]S:6YG M(&EN('!A=&EE;G1S+B!4:&4@4')I;F-I<&%L($EN=F5S=&EG871O2!B87)R:65R&EC M:71Y('!R;W9I9&5S(&$@2!T6QE.FYO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T65L;V=E;F]U M6UP M:&]B;&%S=&EC($QE=6ME;6EA("@F(S@R,C`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`Q,R!T:&4@4')I;F-I M<&%L($EN=F5S=&EG871O2!O9B!( M96UA=&]L;V=Y(&%N;G5A;"!M965T:6YG(&EN($1E8V5M8F5R(&]F(#(P,3,N M($AI9VAL:6=H=',@9G)O;2!T:&4@<')E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@ M6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6-L97,@96%C:"X\ M+V1I=CX@/"]T9#X@/"]T6QE/3-$)TU! M4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`Q M:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO M9&EV/B`\+W1D/B`\=&0@F4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/BT\+V1I=CX@/"]T9#X@/'1D/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E1W;R!P871I96YT M6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`Q:6XG/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@"`P<'0@,"XU M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE MF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`Q M:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO M9&EV/B`\+W1D/B`\=&0@71A6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@ M2!B969O6-L92X\+V1I=CX@/"]T9#X@/"]T"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`P+C(U M:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/BT\ M+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/D=R8BTR(&QE=F5L6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`Q:6XG/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)TU!4D=)3BU43U`Z M(#!P=#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`Q:6XG/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D M/B`\=&0@2P@82!S=6-C97-S9G5L(&1E;6]N2!W M:6QL(&%L;&]W('1H92!#;VUP86YY('1O(&)E9VEN(&5X<&%N9&EN9R!":6\M M4&%T:"8C.#(Q-SMS(&1R=6<@8V%N9&ED871E2!S:6UP;'D@87!P;'EI M;F<@=&AE(&1E;&EV97)Y('1E8VAN;VQO9WD@=&5M<&QA=&4@=&\@;75L=&EP M;&4@;F5W(&1R=6<@<')O9'5C="!T87)G971S+B!);B!T:&ES(&UA;FYE2!I=',@;&EP;W-O;6%L(&%N=&ES96YS92!D2!O9B!T:&4@9')U9R!T;R!D871E+"!I="!I M2!P;&%N&EC:71Y(&ES M(&$@;6%J;W(@861V86YT86=E(&9O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4@8V]N=&EN=65D+B!38V%L92UU<"!O9B!M86YU9F%C='5R:6YG M(&)A=&-H('-I>F4@<')E=FEO=7-L>2!P2!D2!N96%R+71E M6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T2`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`Q,RP@ M,C`Q-"X@5&AE('-H96QF(')E9VES=')A=&EO;B!S=&%T96UE;G0@=V%S(&9I M;&5D('1O(')E9VES=&5R('1H92!O9F9E2!O2`Q-2P@,C`Q M-"P@=V4@96YT97)E9"!I;G1O(&$@2!386)B>2!-86YA M9V5M96YT+"!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!A9W)E960@ M=&\@28C.#(Q-SMS(&5S=&EM871E9"!O9F9E'!E;G-E M2`D/&9O;G0@#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P M="!4:6UE3Y/;B!-87)C:"`U+"`R,#$T+"!T:&4@3D%31$%1(%-T;V-K($UA#L@1D].5#H@,3!P="!4 M:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!C;VYV97)T:6YG('9A;&ED871E9"!P2X@4W5B2!H87,@:&ER960@861D:71I;VYA;"!P97)S;VYN96P@=&\@861D(&9U MF%T:6]N+B!4:&4@0V]M<&%N>2!A M;G1I8VEP871E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4@;V9F:6-E(&ES(')E<75I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD M:78@6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6%B;&4@2!W87,@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG'!E;G-E(')E;&%T960@ M<&%R='D@9F]R($U$($%N9&5R6UE;G1S(')E;&%T960@<&%R='D@;V8@)#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG'!E;G-E M&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU43U`Z(#!P M>#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE3Y!9'9A;F-E('!A>6UE;G1S+"!I;F-L=61I;F<@;F]N'!E;G-E(&%S('1H M92!R96QA=&5D(&=O;V1S(&%R92!D96QI=F5R960@;W(@=&AE(')E;&%T960@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!T M:&4@0V]M<&%N>28C.#(Q-SMS(&QE860@9')U9R!P6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@1&ES8VQO6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4 M:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T&EM871E(&%M;W5N=',@ M;W=E9"!T;W1A;&EN9R`D/&9O;G0@28C.#(Q-SMS(&%U9&ET;W)S(&9O M6%B;&4@2!C;VYS:7-T M960@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!P86ED M(&EN(#(P,30N/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E M/&)R/CPO6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE3L@5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!724142#H@,"XR-6EN)SX@/&1I=CX\8CXU+CPO8CX\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IUF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'!E;G-E(&]F("0\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B'!E;G-E(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B2!O9B`D/&9O;G0@&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UE M;G1S(%)E;&%T960@4&%R='D@06)S=')A8W0\+W-T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE3L@5D525$E#04PM04Q)1TXZ('1O<"<^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,"XR-6EN)SX@ M/&1I=CX\8CXV+CPO8CX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&IU3PO8CX\+V1I=CX@/"]T9#X@/"]T M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE3Y!8V-R=65D(&QI8V5N2!T;W1A M;&EN9R`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG'!E M;G-E2!-1"!!;F1E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!.;W1E(%M!8G-T6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE M/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQB/C2<^(#QD:78^/&(^ M4W1O8VMH;VQD97)S)B,X,C$W.R!%<75I='D\+V(^/"]D:78^(#PO=&0^(#PO M='(^(#PO=&%B;&4^(#QD:78@#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2X@26X@075G=7-T(&]F(#(P,#2!P=7)S M=6%N="!T;R!A('-E8V]N9"!R;W5N9"!O9B!F:6YA;F-I;F6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T&-H86YG92!F M;W(@<')E+6UE2!O9B`R,#`X($)I;RU0 M871H(&ES&5C=71E9"!A9W)E96UE;G1S(&%N M9"!T:&4@9F%I2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!R M96-O6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG65A6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&5R8VES960@=VET:&EN('1W M;R!Y96%R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG&5R8VES960@=VET:&EN('1W;R!Y96%R6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T2!O9B`R,#$P+"!T:&4@0V]M<&%N>2!I2!P=7)S=6%N="!T;R!A('!R:79A=&4@<&QA8V5M96YT M(&UE;6]R86YD=6TN(%1H92!W87)R86YT&5R8VES92!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2!P=7)C:&%S92!A9W)E96UE;G0@ M9F]R('5P('1O("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B2!H87,@=&AE(')I9VAT('1O('-E;&P@2`Q,BP@,C`Q,"X@57!O;B!S:6=N:6YG('1H92!A9W)E96UE;G0L('1H M92!#;VUP86YY(')E8V5I=F5D("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B28C.#(Q-SMS(&-O M;6UO;B!S=&]C:R!A;F0@=V%R&5R8VES M92!P28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!B>2!,:6YC;VQN(%!A6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!W97)E(&ES6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!W97)E(&ES6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D]. M5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE3Y);B!/8W1O8F5R(&]F(#(P,3$L('1H92!#;VUP86YY(&ES6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!W M97)E(&ES6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS(&-O;6UO;B!S M=&]C:RX@3%!#('=A28C M.#(Q-SMS(&-O;6UO;B!S=&]C:R!A2!R96-E:79E M9"`D/&9O;G0@&-H86YG92!F;W(@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@3%!#('=A28C.#(Q-SMS(&-O;6UO;B!S M=&]C:R!A2!R96-E:79E9"`D/&9O;G0@&-H86YG92!F;W(@/&9O;G0@28C.#(Q-SMS(&-O;6UO M;B!S=&]C:RX@3%!#('=A28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A2!S;VQD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T2!I2!T:')O=6=H(%-E<'1E;6)E M2!S;VQD("0\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T2!S;VQD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B2!O9B`R,#$S+"!T:&4@0V]M<&%N>2!S;VQD M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!W97)E(&ES2!O9B`R,#$T+"!T:&4@0V]M<&%N>2!I6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!F;W(@86=G&5R8VES M86)L92!F;W(@82!P97)I;V0@;V8@9FEV92!Y96%R6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE M/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE3X\8CX\:3Y3=&]C:R!/<'1I;VYS/"]I/CPO8CX\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@ M,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!M861E(&$@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO;B!S M=&]C:R!F;W(@2X@5&5R;7,@;V8@=&AE('-T;V-K(&]P=&EO;B!G'!E;G-E28C.#(Q-SMS('-T;V-K(&]V97(@=&AE('!R96-E M9&EN9R!F:79E('EE87)S+B!4:&4@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!T;R!T=V\@;F5W($-O;7!A M;GD@96UP;&]Y965S+B!497)M65A&5R8VES92!P2!D971E2!O9B!O;F4@:'5N9')E9"!S979E;G1Y(&5I9VAT('!E M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG'!E8W1E9"!T97)M+CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2!U2!T;R!B92`D/&9O;G0@65A&5R8VES92!P M'!E;G-E28C.#(Q-SMS('-T;V-K M(&]V97(@=&AE('!R96-E9&EN9R!F:79E('EE87)S+B!4:&4@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T2!O9B`R,#$T+"!T:&4@0V]M<&%N>2!M861E(&$@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!H:7)E9"!O9F9I8V5R(&]F M('1H92!#;VUP86YY+B!497)M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!D971E2!O9B!O;F4@:'5N9')E9"!S979E;G1Y(&5I9VAT('!E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG'!E8W1E9"!T97)M+CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!U#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE3Y3=&]C:R!O<'1I;VX@97AP96YS92!F;W(@=&AE('%U87)T97(@96YD:6YG M($IU;F4@,S`L(#(P,30@=V%S("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.38R8C`W,5\W96)D7S1E86%? M835A-E\V9CAA,#4R,#8Y.30-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8CDV,F(P-S%?-V5B9%\T96%A7V$U839?-F8X83`U,C`V.3DT+U=O'0O:'1M;#L@ M8VAA'0^)SQD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2`M/"]I/CPO8CX@5&AE($-O;7!A;GD@:&%S(&YE M9V]T:6%T960@97AC;'5S:79E(&QI8V5N2!T;R!R96EM8G5R6UE;G1S(&%T=')I8G5T86)L92!T;R!T:&4@3&EC96YS92!! M9W)E96UE;G0@=&]T86QI;F<@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!A8V-R M=65D(&5X<&5N6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!F:6YA;"!D2!A<'!R;WAI;6%T96QY("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B2!I;B!T:&4@9F]U'!E;G-E9"!W:&5N(')E M8V5I=F5D+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS M1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B M.38R8C`W,5\W96)D7S1E86%?835A-E\V9CAA,#4R,#8Y.30-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8CDV,F(P-S%?-V5B9%\T96%A7V$U839? M-F8X83`U,C`V.3DT+U=O'0O:'1M;#L@8VAA'0^)SQD:78@#L@9F]N="US:7IE+6%D:G5S=#H@ M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^(#QT6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%=)1%1(.B`P+C(U:6XG/B`\9&EV/CQB/C$P+CPO8CX\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE65T(&5F9F5C M=&EV92P@=VEL;"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4@ M0V]M<&%N>28C.#(Q-SMS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!A<'!L:65D('1O($1317,N)B,Q-C`[(%1H92!A;65N9&UE;G1S(&%R92!E M9F9E8W1I=F4@9F]R(&%N;G5A;"!R97!O2!A9&]P=&EO;B!I65T(&)E M96X@:7-S=65D(&]R(&UA9&4@879A:6QA8FQE(&9O2!A9&]P="!!4U4@,C`Q M-"TQ,"!A6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78@#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N M;W)M86PG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`P M+C(U:6XG/B`\9&EV/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2<^(#QD:78^/&(^4W5B2!E;G1E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2`P.2P@,C`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`@("`\=&%B;&4@8VQA2!4'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E("T@3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G1S("T@3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S("T@3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!4 M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO3L@86YD("0T.#(L.3$R(&9O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6%B;&4@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A M:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@@8V]L6%B;&4@6TQI;F4@271E;7-=/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO6%B;&4L(&]T:&5R+"!C=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ-2PR-3`\'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO6%B;&4L('1R861E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ."PQ-3`\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@86YD($%C8W)U960@3&EA M8FEL:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T.2PS-#$\'!E;G-E("T@3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@6TQI;F4@ M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ-#DL,S0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N M/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B.38R8C`W M,5\W96)D7S1E86%?835A-E\V9CAA,#4R,#8Y.30-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8CDV,F(P-S%?-V5B9%\T96%A7V$U839?-F8X83`U M,C`V.3DT+U=O'0O:'1M;#L@8VAA2`S,2P@,C`Q,SQB M2!5;FET(%!U2!5;FET(%!U2!5;FET(%!U2!5;FET(%!U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&5R8VES92!O9B!W87)R86YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS M+"!''0^)SQS<&%N/CPO2!3:&%R92UB M87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!''0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R,BPW.3,\'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!#;VYT:6YG96YC>2!;3&EN92!)=&5M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!#;VYT:6YG96YC>2!;3&EN92!)=&5M&UL M/@T*+2TM+2TM/5].97AT4&%R=%]B.38R8C`W,5\W96)D7S1E86%?835A-E\V /9CAA,#4R,#8Y.30M+0T* ` end XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party
6 Months Ended

Jun. 30, 2014

Related Party Transactions [Abstract]

Related Party

2.

Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending June 30, 2014 and 2013, MD Anderson related party research and development expense was $3,213 and $32,067, respectively. MD Anderson related party research and development expense for the quarter ending June 30, 2014 was comprised of $3,213 in current patent maintenance fees for the License Agreement. Accounts payable related party was $3,213 comprised of current patent expenses for the License Agreement, accrued expense related party for MD Anderson was $52,050 for clinical trial hospital costs for the clinical trial and accrued license payments related party of $50,000 for past patent expenses (See Notes 4., 5. and 6.). MD Anderson related party research and development expense for the quarter ending June 30, 2013 was comprised of $22,050 for MD Anderson clinical trial hospital expense and $10,017 for current patent expenses for the Technology License. As of December 31, 2013, accrued expense related party consisted of $52,050 for MD Anderson clinical trial hospital costs and $100,000 in accrued license payments payable due to the related party for past patent expenses and for the annual license maintenance fee for the License Agreement. See Notes 5 and 6.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED BALANCE SHEETS (USD $)

Jun. 30, 2014

Dec. 31, 2013

Current assets

Cash $ 15,721,128 $ 3,551,832

Prepaid drug product for testing 141,345 51,364

Other current assets 171,563 64,117

Total current assets 16,034,036 3,667,313

Other assets

Technology licenses - related party 2,500,374 2,500,374

Less Accumulated Amortization (1,169,168) (1,088,856)

Intangible Assets, Net (Excluding Goodwill), Total 1,331,206 1,411,518

TOTAL ASSETS 17,365,242 5,078,831

Current liabilities

Accounts payable 78,915 76,109

Accounts payable - related party 3,213 0

Accrued expense 149,341 66,739

Accrued expense - related party 52,050 52,050

Accrued license payments - related party 50,000 100,000

Total current liabilities 333,519 294,898

Long term debt 0 0

TOTAL LIABILITIES 333,519 294,898

Shareholders' Equity

Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding 0

Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively 89,238 84,238

Additional paid in capital 34,113,436 20,096,991

Accumulated deficit during development stage (17,170,951) (15,397,296)

Total shareholders' equity 17,031,723 4,783,933

TOTAL LIABILITIES & SHAREHOLDERS' EQUITY $ 17,365,242 $ 5,078,831

X

- Definition

Accrued Liabilities, Related Parties, Current

+ References

No definition available.

+ Details

Name: bpth_AccruedLiabilitiesRelatedPartiesCurrent

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedLicenseAgreementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_OtherAssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_OtherInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)
6 Months Ended 86 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

CASH FLOW FROM OPERATING ACTIVITIES

Net loss $ (1,773,654) $ (1,083,246) $ (17,170,951)

Adjustments to reconcile net loss to net cash used in operating activities

Amortization 80,312 80,312 1,217,670

Technology impairment 0 0 690,000

Common stock issued for services 0 0 318,500

Stock options and warrants 209,071 29,557 3,927,304

(Increase) decrease in assets

Prepaid drug product for testing (89,981) (84,180) (141,345)

Other current assets (107,446) (3,836) (171,563)

Increase (decrease) in liabilities

Accounts payable and accrued expenses 38,621 (61,388) 333,519

Net cash used in operating activities (1,643,077) (1,122,781) (10,996,866)

CASH FLOW FROM INVESTING ACTIVITIES

Purchase of exclusive license - related party 0 0 (884,710)

Net cash used in investing activities 0 0 (884,710)

CASH FLOW FROM FINANCING ACTIVITIES

Proceeds from convertible notes 0 0 435,000

Cash repayment of convertible notes 0 0 (15,000)

Net proceeds from sale of common stock 13,812,373 2,515,961 27,182,704

Net cash from financing activities 13,812,373 2,515,961 27,602,704

NET INCREASE (DECREASE) IN CASH 12,169,296 1,393,180 15,721,128

Cash, beginning of period 3,551,832 534,046 0

Cash, end of period 15,721,128 1,927,226 15,721,128

Cash paid for

Interest 0 0 445

Income taxes 0 0 0

Non-cash financing activities

Common stock issued upon conversion of convertible notes 0 0 420,000

Placement Agent

Non-cash financing activities

Common stock issued 0 448,950 1,362,613

MD Anderson for License

Non-cash financing activities

Common stock issued 0 0 2,354,167

LPC

Non-cash financing activities

Common stock issued $ 0 $ 0 $ 210,755

X

- Details

Name: bpth_CashPaidDuringPeriodForAbstract

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The fair value of stock issued in noncash financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 19 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expense - Additional Information (Detail) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Accounts Payable and Accrued Liabilities [Line Items]

Accrued expense $ 149,341 $ 66,739

Accrued expense - related party 52,050 52,050

Clinical Trials

Accounts Payable and Accrued Liabilities [Line Items]

Accrued expense 149,341

MD Anderson Cancer Center

Accounts Payable and Accrued Liabilities [Line Items]

Accrued expense - related party 52,050

MD Anderson Cancer Center | Clinical Trials

Accounts Payable and Accrued Liabilities [Line Items]

Accrued expense - related party $ 52,050

X

- Details

Name: bpth_AccountsPayableAndAccruedLiabilitiesLineItems

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Accrued Liabilities, Related Parties, Current

+ References

No definition available.

+ Details

Name: bpth_AccruedLiabilitiesRelatedPartiesCurrent

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Additional Information (Detail) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 86 Months Ended 1 Months Ended 2 Months Ended 3 Months Ended 1 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended

Jan. 15, 2014

Jan. 31, 2014

Aug. 31, 2012

Oct. 31, 2011

Dec. 31, 2008

Apr. 30, 2008

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

May 31, 2013

Jun. 30, 2010

Warrant

Jun. 30, 2012

Private Placement memorandum

Sep. 30, 2013

Private Placement memorandum

May 31, 2013

Private Placement memorandum

Mar. 31, 2013

Private Placement memorandum

Dec. 31, 2012

Private Placement memorandum

Dec. 31, 2008

Investor Relations Services

Jun. 30, 2007

Founders

May 31, 2007

Founders

Mar. 31, 2012

Equity Unit Purchase Agreements

LPC

Dec. 31, 2011

Equity Unit Purchase Agreements

LPC

Nov. 30, 2011

Equity Unit Purchase Agreements

LPC

Jun. 30, 2011

Equity Unit Purchase Agreements

LPC

Nov. 30, 2010

Equity Unit Purchase Agreements

LPC

Oct. 31, 2010

Equity Unit Purchase Agreements

LPC

Sep. 30, 2010

Equity Unit Purchase Agreements

LPC

Jul. 31, 2010

Equity Unit Purchase Agreements

LPC

Jun. 30, 2010

Equity Unit Purchase Agreements

LPC

Jun. 30, 2010

Equity Unit Purchase Agreements

LPC

Minimum

Jun. 30, 2010

Equity Unit Purchase Agreements

LPC

Maximum

Apr. 30, 2012

Equity Unit Purchase Agreements

LPC

Scenario 1

Apr. 30, 2012

Equity Unit Purchase Agreements

LPC

Scenario 2

Apr. 30, 2012

Equity Unit Purchase Agreements

LPC

Scenario 3

Jun. 30, 2010

LPC financing agreement

LPC

Nov. 30, 2013

Investors

Dec. 31, 2012

Investors

Jun. 30, 2011

Investors

Jun. 30, 2013

Investors

May 31, 2010

Investors

Private Placement memorandum

Jan. 31, 2010

Investors

Private Placement memorandum

Dec. 31, 2009

Investors

Private Placement memorandum

Nov. 30, 2009

Investors

Private Placement memorandum

Jun. 30, 2009

Investors

Private Placement memorandum

Aug. 31, 2007

Investors

Private Placement memorandum

Apr. 30, 2011

Investors

Private Placement memorandum

Aug. 31, 2007

Investors

Additional Shares

Jan. 31, 2010

Investors

Additional Shares

Private Placement memorandum

Nov. 30, 2013

Placement Agent

Jun. 30, 2011

Placement Agent

Aug. 31, 2007

Placement Agent

Jun. 30, 2013

Placement Agent

May 31, 2010

Placement Agent

Private Placement memorandum

Jan. 31, 2010

Placement Agent

Private Placement memorandum

Jun. 30, 2009

Placement Agent

Private Placement memorandum

Nov. 30, 2007

MD Anderson Cancer Center

Apr. 30, 2008

BioPathHoldingsInc

Feb. 29, 2008

BioPathHoldingsInc

Feb. 29, 2008

Ogden Golf Co.

Shareholders Equity [Line Items]

Common stock and warrants issued, shares 571,429 6,505,994 6,505,994 166,667 172,414 83,333 164,853 135,135 135,135 125,000 375,000 571,429 89,286 96,154 185,185 12,000 3,975,000 1,333,334 530,833 78,000 360,000 66,000 200,000 80,000

Common stock issued , value $ 15,000,000 $ 6,506 $ 6,506 $ 993,750 $ 1,794,205 $ 1,000,000

Common stock issued , shares 50,000 150,000 5,980,685 598,069 3,138,889

Common stock issued merger transactions, shares 38,023,578

Common stock retained shareholders, shares 3,600,000

Common stock issued for services, value 40,000 180,000

Common stock issued, additional shares 24

Common stock issued for service, shares 18,500 18,500 100,000

Common stock and warrant issued, shares 5,000,000 780,000 2,700,000 660,000 900,000

Common stock repurchased, shares 2,500,000 780,000 2,700,000 660,000 900,000

Common stock and warrants issued, Value 15,000,000 273,000 675,000 675,000 165,000 225,000

Equity purchase agreement value 7,000,000 50,000 1,000,000

Proceeds from issuance of common stock and warrant from LPC 13,812,373 2,515,961 27,182,704 50,000 50,000 25,000 50,000 50,000 50,000 50,000 150,000 200,000 25,000 25,000 50,000

Committed shares issued 2,084 2,084 1,042 2,084 2,084 2,084 2,084 6,251 1,042 1,042 2,084 566,801

Warrants issued, shares 0 0 0 0 0 0 0 0 0

Common stock issued for exercise of warrant (in shares) 1,920,000

Common stock issued for exercise of warrant 576,000

Common stock issued for services $ 795,001 $ 0 $ 0 $ 318,500 $ 3,220,966 $ 2,000,198 $ 346,202 $ 708,600 $ 8,052,416 $ 3,300,337 $ 805,242

Common Stock, shares issued 89,237,872 89,237,872 84,237,872 489,501 11,664,665 1,496,499

Common Stock, shares outstanding 89,237,872 89,237,872 84,237,872

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 4.74 $ 1.50 $ 1.50 $ 1.50 $ 1.50 $ 1.50

X

- Definition

Common Stock Additional Shares Issued

+ References

No definition available.

+ Details

Name: bpth_CommonStockAdditionalSharesIssued

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Common Stock Repurchased Shares

+ References

No definition available.

+ Details

Name: bpth_CommonStockRepurchasedShares

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of common stock issued.

+ References

No definition available.

+ Details

Name: bpth_FairValueOfCommonStockIssued

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Issuance Of Common Stock And Warrants, Shares

+ References

No definition available.

+ Details

Name: bpth_IssuanceOfCommonStockAndWarrantsShares

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of issuance of common stock and warrants.

+ References

No definition available.

+ Details

Name: bpth_IssuanceOfCommonStockAndWarrantsValue

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Issuance Of Common Stock Shares For Service

+ References

No definition available.

+ Details

Name: bpth_IssuanceOfCommonStockSharesForService

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Issuance Of Warrants, Shares

+ References

No definition available.

+ Details

Name: bpth_IssuanceOfWarrantsShares

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: bpth_ShareholdersEquityLineItems

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock Committed to be Issued During Period, Shares, Acquisitions

+ References

No definition available.

+ Details

Name: bpth_StockCommittedToBeIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock Committed to be Issued During Period, Value, Acquisitions

+ References

No definition available.

+ Details

Name: bpth_StockCommittedToBeIssuedDuringPeriodValueAcquisitions

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock Issued During Period Shares Contingent Considerations

+ References

No definition available.

+ Details

Name: bpth_StockIssuedDuringPeriodSharesContingentConsiderations

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of stock issued during the period pursuant to a merger.

+ References

No definition available.

+ Details

Name: bpth_StockIssuedDuringPeriodSharesMerger

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued during the period as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: bpth_StockIssuedDuringPeriodSharesStockWarrantsExercised

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock Issued During Period Value Warrant Exercises

+ References

No definition available.

+ Details

Name: bpth_StockIssuedDuringPeriodValueWarrantExercises

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Stock Retained by Shareholders, Shares, Merger Transaction

+ References

No definition available.

+ Details

Name: bpth_StockRetainedByShareholdersSharesMergerTransaction

Namespace Prefix: bpth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Business
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

1.

Organization and Business

Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (“L-Grb-2” or “BP-100-1.01”), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement (the “License Agreement”). The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.

Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.

The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial are now being tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data needed to demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.

The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m². However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company requested the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors (the “Board”), advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose of 60 mg/m², which had been increased from 50 mg/m² in the revised protocol. The Company has enrolled patients in Cohort 6 for treatment at a dose of 90 mg/m², has two (2) evaluable patients and is currently treating another patient. Assuming the current patient successfully completes the treatment cycle the Company will be able to close Cohort 6.

Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (“AML”), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (“CML”) and Acute Lymphoblastic Leukemia (“ALL”), or Myelodysplastic Syndrome (“MDS”) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.

An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.

In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.

The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. Subsequently, in the fall of 2013 the Principal Investigator prepared an abstract of updated information on the results of the clinical trial through Cohort 5, which was accepted for presentation at the American Society of Hematology annual meeting in December of 2013. Highlights from the presentation prepared by Dr. Cortes for the meeting included:

Data from the Phase I clinical trial

-

Among 18 evaluable patients, nine experienced at least a 50 percent reduction in peripheral or bone marrow blasts from baseline.

-

Five patients demonstrated transient improvement and/or stable disease, three of whom received a total of five cycles each.

-

Two patients, in addition to achieving marked blast percentage declines, also experienced transient improvement in leukemia cutis lesions.

Disease Stabilization in MDS and AML

-

Two patients with MDS, a 53-year old male and a 72-year old female, both achieved disease stabilization and continued therapy for five cycles before disease progression.

-

A 54-year old HIV positive male with AML achieved stable disease and marked reduction in peripheral blasts, continuing therapy for five cycles before disease progression.

Experience in CML-Blast Phase

-

Patient with myeloid blast crisis of CML

-

Prior therapies consist of: imatinib, dastinib, nilotinib, DCC-2036, Cytarabine + Fludarabine + Dasatinib + Gemtuzumab, PHA-739358, Clofarabine + Dasatinib

-

Upon start of BP-100-1.01 patient showed a significant reduction in blasts from 81 percent to 5 percent but due to leptomeningeal disease progression discontinued therapy before full cycle.

Inhibition of Target Grb-2 Protein

-

Grb-2 levels were compared to baseline prior to treatment.

-

On day 15, BP-100-1.01 decreased Grb-2 in five of eight samples tested (average reduction 55 percent)

-

End of treatment day15, BP-100-1.01 decreased Grb-2 levels in eight out of nine patients (average reduction 45 percent).

Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology and has already identified one new candidate.

The Phase I clinical trial is typically ended when a maximum tolerated dose (“MTD”) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.

As noted previously, the Company has completed two of the three evaluable patients required to close Cohort 6. Once Cohort 6 is completed the Company and the Principal Investigator will determine whether the optimal biological dose has been reached, which would allow the Phase I trial to be ended. Since there has been no evidence of toxicity to date in the trial and none is expected even at a higher dose in a potential seventh cohort, the trade-off is ending the clinical trial sooner after Cohort 6 or waiting to complete a seventh cohort with a higher dose and potentially even better anti-leukemia benefits in the patient. Plans and evaluation of manufacturing scale-up of the drug substance batch size continued. Scale-up of manufacturing batch size previously produced divergence from desired drug substance product parameters, with some product in the fourth quarter of 2013 not being acceptable for use. The most recent manufacturing scale-up drug substance batch appears to have corrected this and a recent drug batch was released for use in the clinical trial by the manufacturer. Scale-up of manufacturing output of drug substance product and final drug product is critical to meeting the anticipated potential for high volume requirements of Bio-Path’s drug products for patients in multiple diseases. The larger size drug substance and final product batch sizes will also substantially drive down manufacturing cost per drug unit. The recent success on the part of the Company in raising capital should also improve drug supply by providing the financial resources that will enable the Company to commit to multiple drug batches beyond those required to satisfy near-term requirements.

Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.

At the end of January 2012, the Company’s Board held a strategic planning session. Among several topics was a discussion of the Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $345,000 at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (50%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $345,000, and cancel the license.

The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path became a publicly traded company as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.

On November 5, 2013, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on January 13, 2014. The shelf registration statement was filed to register the offering and sale of up to $100 million of our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

On January 15, 2014, we entered into a securities purchase agreement, as amended, with two dedicated healthcare funds (collectively, the “Sabby Investors”) that are managed by Sabby Management, pursuant to which the Company agreed to sell an aggregate of 5,000,000 shares of its common stock and warrants to purchase a total of 2,500,000 shares of its common stock to the Sabby Investors for gross proceeds of approximately $15,000,000. The net proceeds to the Company from the registered direct public offering, after deducting the placement agent’s fees and expenses, the Company’s estimated offering expenses, and excluding the proceeds from the exercise of the warrants issued in the offering, were approximately $13.8 million. We will use the net proceeds from this offering and sale of securities for working capital and general corporate purposes.

On March 5, 2014, the NASDAQ Stock Market LLC informed the Company that it had approved the listing of the Company’s common stock on the NASDAQ Capital Market. The Company’s common stock ceased trading on the OTCQX and commenced trading on the NASDAQ Capital Market on March 10, 2014 under the ticker symbol “BPTH.”

On March 11, 2014, the Board of the Company appointed Ulrich W. Mueller, Ph.D., as the Company’s Chief Operating Officer. This is the initial hiring step implanting a plan to put in place a core organization that can manage the Company’s expanding clinical trials and deliver on the Bio-Path business plan vision of rapidly converting validated protein disease targets into proprietary liposome-antisense drug candidates that enter Phase I clinical trials. In April 2014, the Company progressed further with its organization plan by hiring a director of clinical trials, controller and director of information technology. Subsequent to the close of the second quarter, 2014, the Company has hired additional personnel to add further to the core organization. The Company anticipates that by the end of the third quarter 2014 it will have added the remaining employees to complete the organization plan.

In April 2014 the Company entered in a lease for a larger office space. The new, expanded size office is required for the core organization the Company is adding.

As of June 30, 2014, Bio-Path had $15,721,128 in cash on hand.

As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Preferred Stock, par value $ 0.001 $ 0.001

Preferred Stock, shares authorized 10,000,000 10,000,000

Preferred Stock, shares issued 0 0

Preferred Stock, shares outstanding 0 0

Common Stock, par value $ 0.001 $ 0.001

Common Stock, shares authorized 200,000,000 200,000,000

Common Stock, shares issued 89,237,872 84,237,872

Common Stock, shares outstanding 89,237,872 84,237,872

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 24 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
6 Months Ended

Jun. 30, 2014

Subsequent Events [Abstract]

Subsequent Events

11.

Subsequent Events

At the end of July 2014, the Company’s lease on previous office space expired and the Company did not renew the lease. Previous to this, the Company entered into a lease for a larger office space, which it occupied as of August 2014.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
6 Months Ended

Jun. 30, 2014

Aug. 05, 2014

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Entity Registrant Name BIO-PATH HOLDINGS INC

Entity Central Index Key 0001133818

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol BPTH

Entity Common Stock, Shares Outstanding 89,237,872

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Business - Additional Information (Detail) (USD $)
0 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 86 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 12 Months Ended

Jan. 15, 2014

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2013

Nov. 05, 2013

Dec. 31, 2012

May 09, 2007

Jan. 15, 2014

Sabby Investors

Jun. 30, 2010

Warrant

Jan. 15, 2014

Warrant

Sabby Investors

Dec. 31, 2011

siRNA License

Organization and Nature of Operations [Line Items]

Percentage of Charge 50.00%

Impairment of License $ 345,000 $ 0 $ 0 $ 690,000 $ 345,000

Cash 15,721,128 1,927,226 15,721,128 3,551,832 534,046 0

Authorized capital to be raised 100,000,000

Stock issued during period, shares, new issues 5,000,000 571,429 2,500,000

Stock issued during period, value, new issues 15,000,000

Proceeds from issuance initial public offering $ 13,800,000

X

- Definition

Represents capital value registered through shelf registration statement

+ References

No definition available.

+ Details

Name: bpth_AuthorisedCapitalToBeRaised

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: bpth_OrganizationAndNatureOfOperationsLineItems

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of Change in Depreciation Amortization of Intangible Assets and Asset Impairment and Other Charges Operating

+ References

No definition available.

+ Details

Name: bpth_PercentageOfChangeInDepreciationAmortizationOfIntangibleAssetsAndAssetImpairmentAndOtherChargesOperating

Namespace Prefix: bpth_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from entity's first offering of stock to the public.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 27 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 6 Months Ended 86 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Revenue $ 0 $ 0 $ 0 $ 0 $ 0

Operating expense

Research and development 517,040 ^[1] 156,036 ^[1] 624,681 ^[1] 557,135 ^[1] 6,469,166 ^[1]

General & administrative 754,548 ^[2] 240,543 ^[2] 1,135,400 ^[2] 480,354 ^[2] 9,829,509 ^[2]

Total operating expense 1,274,801 428,646 1,785,012 1,084,556 17,502,932

Net operating loss (1,274,801) (428,646) (1,785,012) (1,084,556) (17,502,932)

Other income (expense)

Interest income 6,066 1,531 11,639 1,655 92,766

Other income 0 0 0 0 244,479

Other expense (42) (129) (281) (345) (5,264)

Total Other Income (Expense) 6,024 1,402 11,358 1,310 331,981

Net Loss (1,268,777) (427,244) (1,773,654) (1,083,246) (17,170,951)

Loss per share

Net loss per share, basic and diluted $ (0.01) $ (0.01) $ (0.02) $ (0.02) $ (0.33)

Basic and diluted weighted average number of common shares outstanding 89,237,872 66,606,105 89,237,872 64,412,577 52,592,648

Related Party

Operating expense

Research and development $ 3,213 ^[3] $ 32,067 ^[3] $ 24,931 ^[3] $ 47,067 ^[3] $ 1,204,257 ^[3]

[1] Research and development expense includes stock option expenses of $20,410 and $8,220 for the quarters ending 6/30/2014 and 6/30/2013, respectively; $27,032 and $19,633 for the six month periods ending 6/30/2014 and 6/30/2013, respectively; and $482,912 for the period from inception through 6/30/2014

[2] General & administrative expense includes stock for services, stock option and warrant expenses of $102,383 and $5,318 for the quarters ending 6/30/2014 and 6/30/2013, respectively; $182,039 and $9,923 for the six month periods ending 6/30/2014 and 6/30/2013, respectively; and $3,444,392 for the period from inception through 6/30/2014 for stock options and warrants and $318,500 in stock for services.

[3] Includes $690,000 technology impairment charge for the period from inception through 6/30/2014

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued License Payments - Related Party
6 Months Ended

Jun. 30, 2014

Accrued License Payments Related Party Abstract

Accrued License Payments - Related Party

6.

Accrued License Payments – Related Party

Accrued license payments related party totaling $50,000 and $100,000 were included in Current Liabilities as of June 30, 2014 and December 31, 2013, respectively. The amount included for June 30, 2014 represents reimbursement of past patent expenses incurred by MD Anderson prior to the Bio-Path license and the amount included for December 31, 2013 included past patent expenses and the annual maintenance fee for the License Agreement.

X

- Details

Name: bpth_AccruedLicensePaymentsRelatedPartyAbstract

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Collaborative and License Arrangement Disclosure [Text Block]

+ References

No definition available.

+ Details

Name: bpth_CollaborativeAndLicenseArrangementDisclosureTextBlock

Namespace Prefix: bpth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expense
6 Months Ended

Jun. 30, 2014

Accrued Liabilities [Abstract]

Accrued Expense

5.

Accrued Expense

As of June 30, 2014, Current Liabilities included accrued expense of $149,341 for clinical trial expense, advisory fees and management bonus accrual. Current Liabilities as of June 30, 2014 also included accrued expense related party of $52,050 for MD Anderson clinical trial hospital expense. (See Note 2.). As of December 31, 2013, Current Liabilities included accrued expense of $66,739 and accrued expense related party of $52,050.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued License Payments - Related Party - Additional Information (Detail) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Related Party Transaction [Line Items]

Accrued license payments - related party $ 50,000 $ 100,000

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 86 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Related Party Transaction [Line Items]

Accrued expense - related party $ 52,050 $ 52,050 $ 52,050 $ 52,050

Accrued license payments - related party 50,000 50,000 50,000 100,000

Accounts payable - related party 3,213 3,213 3,213 0

Research and Development 517,040 ^[1] 156,036 ^[1] 624,681 ^[1] 557,135 ^[1] 6,469,166 ^[1]

Md Anderson Cancer Center [Member]

Related Party Transaction [Line Items]

Accrued expense - related party 52,050 52,050 52,050

SIRNA patent technology license 10,017

Md Anderson Cancer Center [Member] | Clinical Trials [Member]

Related Party Transaction [Line Items]

Accrued expense - related party 52,050

Accrued license payments - related party 100,000

Research and Development 3,213 22,050

Md Anderson Cancer Center [Member] | Research and Development Expense [Member]

Related Party Transaction [Line Items]

Cash paid to MD Anderson Cancer Center for expenses $ 3,213 $ 32,067

[1] Research and development expense includes stock option expenses of $20,410 and $8,220 for the quarters ending 6/30/2014 and 6/30/2013, respectively; $27,032 and $19,633 for the six month periods ending 6/30/2014 and 6/30/2013, respectively; and $482,912 for the period from inception through 6/30/2014

X

- Definition

Accrued Liabilities, Related Parties, Current

+ References

No definition available.

+ Details

Name: bpth_AccruedLiabilitiesRelatedPartiesCurrent

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sirna patent technology license.

+ References

No definition available.

+ Details

Name: bpth_SirnaPatentTechnologyLicense

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
6 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9.

Commitments and Contingencies

Technology License – Related Party - The Company has negotiated exclusive licenses from the MD Anderson Cancer Center to develop drug delivery technology for antisense and siRNA drug products. These licenses require, among other things, the Company to reimburse MD Anderson for ongoing patent expense. Related party accrued license payments attributable to the License Agreement totaling $50,000 are included in Current Liabilities as of June 30, 2014. Related party accrued expense totaling $52,050 as of June 30, 2014 represents hospital costs for the clinical trial and are not related to the License Agreement. As of June 30, 2014, the Company estimates reimbursable past patent expenses will total approximately $75,000 for the License Agreement. The Company will be required to pay when invoiced the past patent expenses at the rate of $25,000 per quarter. In addition, the Company decided to discontinue development of its siRNA technology and subsequently canceled its siRNA license in June of 2012 (See Note 1).

Drug Supplier Project Plan – Bio-Path entered into two project plan agreements with the Company’s drug substance manufacturer and its final drug product manufacturer for the manufacture and delivery of final drug product for expected manufacture in the third quarter of 2014. The project plans required the Company to pay approximately $370,000 in various stages as the drug substance and final product are manufactured and delivered to the Company. Of this amount, $141,345 has been paid for by the Company, which was carried on the Balance Sheet as Prepaid Drug Product for Testing as of June 30, 2014. The drug product is anticipated to be delivered to the Company in the fourth quarter of 2014 and the Balance Sheet item Prepaid Drug Product for Testing totaling $141,345 will be expensed when received.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
6 Months Ended

Jun. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity

7.

Stockholders’ Equity

Issuance of Common Stock – In May and June of 2007, the Company issued 6,505,994 shares of common stock for $6,506 in cash to founders of the Company. In August of 2007, the Company issued 3,975,000 shares of common stock for $993,750 in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional 1,333,334 shares of common stock for $1,000,000 in cash to investors in the Company pursuant to a second round of financing. The Company issued 530,833 in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued 3,138,889 shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.

In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued 38,023,578 shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained 3,600,000 shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued 80,000 shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued 200,000 shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $180,000. In April of 2008, the Company recorded an additional 24 shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued 100,000 shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $40,000. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued 660,000 shares of common stock and warrants to purchase an additional 660,000 shares of common stock for $165,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 66,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.

In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $675,000 in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors 2,700,000 shares of common stock and warrants to purchase an additional 2,700,000 shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In January 2010, the Company also sold an additional 900,000 shares of common stock and warrants to purchase an additional 900,000 shares of common stock for $225,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $1.50 a share. In connection with these private placement sales of equity, the Company issued 360,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In May of 2010, the Company issued 780,000 shares of common stock and warrants to purchase an additional 780,000 shares of common stock for $273,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 78,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In June of 2010, the Company signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a 24-month period in amounts between $50,000 and $1,000,000 up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $200,000 from LPC as an initial purchase in exchange for 571,429 shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase 571,429 shares of the Company’s common stock at an exercise price of $1.50 per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC 12,000 shares of the Company’s common stock for its due diligence efforts and 566,801 shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.

In July of 2010, the Company received $150,000 from LPC in exchange for 375,000 shares of the Company’s common stock. LPC was also issued 6,251 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 375,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In September of 2010, the Company received $50,000 from LPC in exchange for 125,000 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In November of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

From November 2010 through April of 2011 the Company sold shares of common stock for $1,794,205 in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued 5,980,685 shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued 598,069 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.

In June of 2011, the Company received $50,000 from LPC in exchange for 164,853 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2011, the Company issued 1,920,000 shares of common stock for $576,000 to investors who exercised warrants from September to October 2011.

In November of 2011, the Company received $25,000 from LPC in exchange for 83,333 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In December of 2011, the Company received $50,000 from LPC in exchange for 172,414 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In March of 2012, the Company received $50,000 from LPC in exchange for 166,667 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $25,000 from LPC in exchange for 89,286 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $25,000 from LPC in exchange for 96,154 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $50,000 from LPC in exchange for 185,185 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In June of 2012, the Company sold $150,000 in shares of its common stock pursuant to a private placement, with shares to be issued, and $18,500 in shares of its common stock for services with shares to be issued.

In August of 2012, the Company issued 50,000 shares of its common stock for the $18,500 shares for services previously recognized in June 2012.

In July through September of 2012, the Company sold $795,001 in shares of its common stock pursuant to a private placement, with shares to be issued.

In October through December of 2012, the Company sold $708,600 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of December 31, 2012 the Company issued 3,300,337 shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.

In February and March of 2013, the Company sold $346,202 in shares of its common stock pursuant to a private placement, with shares to be issued.

In April and May of 2013, the Company sold $2,000,198 in shares of its common stock pursuant to a private placement, with shares to be issued, and $489,501 in shares of its common stock pursuant in a direct offering, with shares to be issued.

In June of 2013, the Company issued 11,664,665 shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued 1,496,499 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.

In August and September of 2013, the Company sold $3,220,966 in shares of its common stock pursuant to a private placement, with shares to be issued.

In November of 2013, the Company issued 8,052,416 shares of common stock to investors in connection with the private placement. In November of 2013 the Company issued 805,242 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.

In January of 2014, the Company issued a total of 5,000,000 shares of the Company’s common stock and warrants to purchase 2,500,000 shares of the Company’s common stock for aggregate gross proceeds of $15,000,000. The warrants are exercisable for a period of five years from the date of issuance. The exercise price of the warrants is $4.74 a share.

As of June 30, 2014, there were 89,237,872 shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2014.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options and Warrants
6 Months Ended

Jun. 30, 2014

Stock Options And Warrants [Abstract]

Stock Options and Warrants

8.

Stock Options and Warrants

Stock Options

In April of 2014, the Company made a stock option grant to purchase 25,000 shares of the Company’s common stock for services rendered by a director of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is one year from the date of grant for the director service stock option. The exercise price of the option is $2.38 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $57,425, which is being expensed following the date of grant based on the stock option vesting schedule.

In April of 2014, the Company made two stock option grants each to purchase 25,000 shares of the Company’s common stock to two new Company employees. Terms of the stock option grants require, among other things, that the individuals continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $2.71 a share, which was the closing price of the common stock at the date of the grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value for both of the stock options granted taken together was determined using this methodology to be $133,200, which is being expensed following the date of grant based on the stock option vesting schedule.

In May of 2014, the Company made a stock option grant to purchase 25,000 shares of the Company’s common stock to a new Company employee. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $2.40 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $58,975, which is being expensed following the date of grant based on the stock option vesting schedule.

In May of 2014, the Company made a stock option grant to purchase 125,000 shares of the Company’s common stock to a newly hired officer of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is four years from the date of grant for each employee stock option. The exercise price of the options is $2.40 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy eight percent (178%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the expected term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $294,500, which is being expensed following the date of grant based on the stock option vesting schedule.

Stock option expense for the quarter ending June 30, 2014 was $122,793. Of this amount, $20,410 related to stock options for personnel involved in R&D activities and $102,383 related to stock options for outside directors, officers and management of the Company.

Warrants -There were no warrants for services granted during the quarter ending June 30, 2014. The warrants issued in connection with the sale of units of common stock were for cash value received and as such were not grants of compensation-based warrants.

X

- Details

Name: bpth_StockOptionsAndWarrantsAbstract

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

New Accounting Pronouncements
6 Months Ended

Jun. 30, 2014

Accounting Changes and Error Corrections [Abstract]

New Accounting Pronouncements

10.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s consolidated financial statements upon adoption.

Recently, the FASB issued ASU 2014-10 to eliminate the concept of a development stage entity (DSE) from U.S. GAAP. This change rescinds certain financial reporting requirements that have historically applied to DSEs. The amendments are effective for annual reporting periods beginning after December 15, 2014 and interim periods therein. Early adoption is permitted for financial statements that have not yet been issued or made available for issuance. The Company expects to early adopt ASU 2014-10 as of December 31, 2014. The Company is currently assessing the impact on the consolidated financial statements.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 01

-Paragraph b

-Subparagraph 6

-Article 10

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable - Additional Information (Detail) (USD $)
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Accounts Payable [Line Items]

Accounts payable $ 78,915 $ 76,109

Accounts payable, trade 43,277

Accounts payable, other, current 15,250

Firm Owes Facility Expenses 3,213

Clinical Trials [Member]

Accounts Payable [Line Items]

Accounts payable, trade 18,150

Accounts payable, other, current $ 2,238

X

- Details

Name: bpth_AccountsPayableLineItems

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The firm owe facility expenses.

+ References

No definition available.

+ Details

Name: bpth_FirmOwesFacilityExpenses

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableOtherCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccountsPayableTradeCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 37 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies - Additional Information (Detail) (USD $)
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Product Liability Contingency [Line Items]

Estimates reimbursable past patent expenses $ 75,000

Patent expense per quarter 25,000

Accounts payable and accrued liabilities 50,000

Other inventory, gross 141,345 51,364

Drug Product Testing Agreement Consideration To Be Paid In Stages 370,000

Subsequent Event [Member]

Product Liability Contingency [Line Items]

Other inventory, gross 141,345

Licenses Agreement

Product Liability Contingency [Line Items]

Accrued expense - related party $ 52,050

X

- Definition

Accrued Liabilities Related Party Current

+ References

No definition available.

+ Details

Name: bpth_AccruedLiabilitiesRelatedPartyCurrent

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Patent Expense, Current

+ References

No definition available.

+ Details

Name: bpth_AccruedPatentExpenseCurrent

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Represents consideration to be paid in various stages with respect to agreement with its drug product manufacturer for testing.

+ References

No definition available.

+ Details

Name: bpth_DrugProductTestingAgreementConsiderationToBePaidInStages

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(1),(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 1, 5

-Article 9

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfReimbursableExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_OtherInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ProductLiabilityContingencyLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)
3 Months Ended 6 Months Ended 86 Months Ended 3 Months Ended 6 Months Ended 86 Months Ended

Jun. 30, 2014

Research and Development Expense [Member]

Jun. 30, 2013

Research and Development Expense [Member]

Jun. 30, 2014

Research and Development Expense [Member]

Jun. 30, 2013

Research and Development Expense [Member]

Jun. 30, 2014

Research and Development Expense [Member]

Jun. 30, 2014

General and Administrative Expense [Member]

Jun. 30, 2013

General and Administrative Expense [Member]

Jun. 30, 2014

General and Administrative Expense [Member]

Jun. 30, 2013

General and Administrative Expense [Member]

Jun. 30, 2014

General and Administrative Expense [Member]

Equity compensation $ 20,410 $ 8,220 $ 27,032 $ 19,633 $ 482,912

Stock option and warrant expense 102,383 5,318 182,039 9,923 3,444,392

Stock for services 318,500

Technology impairment charge $ 690,000

X

- Definition

Share Based Compensation, Stock Option And Warrant Expense

+ References

No definition available.

+ Details

Name: bpth_ShareBasedCompensationStockOptionAndWarrantExpense

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Stock Based Compensation Expense For Services

+ References

No definition available.

+ Details

Name: bpth_StockBasedCompensationExpenseForServices

Namespace Prefix: bpth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_OtherAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 39 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounts Payable
6 Months Ended

Jun. 30, 2014

Accounts Payable Disclosure [Abstract]

Accounts Payable

4.

Accounts Payable

As of June 30, 2014, Current Liabilities included accounts payable of $78,915 comprised primarily of approximate amounts owed totaling $43,277 to the Company’s auditors for work on the annual audit, $15,250 owed to the Company’s drug substance manufacturer, $18,150 to suppliers of services used in the clinical trial and other miscellaneous items totaling $2,238. As of June 30, 2014 accounts payable related party consisted of $3,213 for current patent expenses for the License Agreement. By the first week of August 2014, the June 30, 2014 amounts included in accounts payable and accounts payable related party had been substantially paid. As of December 31, 2013, Current Liabilities included accounts payable $76,109, which amounts were subsequently paid in 2014.

X

- Details

Name: bpth_AccountsPayableDisclosureAbstract

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Accounts Payable Disclosure [Text Block]

+ References

No definition available.

+ Details

Name: bpth_AccountsPayableDisclosureTextBlock

Namespace Prefix: bpth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 120 122 1 true 35 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.biopathholdings.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.biopathholdings.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.biopathholdings.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.biopathholdings.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.biopathholdings.com/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) false false R6.htm 106 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.biopathholdings.com/role/ConsolidatedStatementOfCashFlows CONSOLIDATED STATEMENT OF CASH FLOWS false false R7.htm 107 - Disclosure - Organization and Business Sheet http://www.biopathholdings.com/role/OrganizationAndBusiness Organization and Business false false R8.htm 108 - Disclosure - Related Party Sheet http://www.biopathholdings.com/role/RelatedParty Related Party false false R9.htm 109 - Disclosure - Prepaid Drug Product for Testing Sheet http://www.biopathholdings.com/role/PrepaidDrugProductForTesting Prepaid Drug Product for Testing false false R10.htm 110 - Disclosure - Accounts Payable Sheet http://www.biopathholdings.com/role/AccountsPayable Accounts Payable false false R11.htm 111 - Disclosure - Accrued Expense Sheet http://www.biopathholdings.com/role/AccruedExpense Accrued Expense false false R12.htm 112 - Disclosure - Accrued License Payments - Related Party Sheet http://www.biopathholdings.com/role/AccruedLicensePaymentsRelatedParty Accrued License Payments - Related Party false false R13.htm 113 - Disclosure - Stockholders' Equity Sheet http://www.biopathholdings.com/role/StockholdersEquity Stockholders' Equity false false R14.htm 114 - Disclosure - Stock Options and Warrants Sheet http://www.biopathholdings.com/role/StockOptionsAndWarrants Stock Options and Warrants false false R15.htm 115 - Disclosure - Commitments and Contingencies Sheet http://www.biopathholdings.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R16.htm 116 - Disclosure - New Accounting Pronouncements Sheet http://www.biopathholdings.com/role/NewAccountingPronouncements New Accounting Pronouncements false false R17.htm 117 - Disclosure - Subsequent Events Sheet http://www.biopathholdings.com/role/SubsequentEvents Subsequent Events false false R18.htm 118 - Disclosure - Organization and Business - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/OrganizationAndBusinessAdditionalInformationDetail Organization and Business - Additional Information (Detail) false false R19.htm 119 - Disclosure - Related Party - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/RelatedPartyAdditionalInformationDetail Related Party - Additional Information (Detail) false false R20.htm 120 - Disclosure - Prepaid Drug Product for Testing - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/PrepaidDrugProductForTestingAdditionalInformationDetail Prepaid Drug Product for Testing - Additional Information (Detail) false false R21.htm 121 - Disclosure - Accounts Payable - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AccountsPayableAdditionalInformationDetail Accounts Payable - Additional Information (Detail) false false R22.htm 122 - Disclosure - Accrued Expense - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AccruedExpenseAdditionalInformationDetail Accrued Expense - Additional Information (Detail) false false R23.htm 123 - Disclosure - Accrued License Payments - Related Party - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AccruedLicensePaymentsRelatedPartyAdditionalInformationDetail Accrued License Payments - Related Party - Additional Information (Detail) false false R24.htm 124 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) false false R25.htm 125 - Disclosure - Stock Options and Warrants - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/StockOptionsAndWarrantsAdditionalInformationDetail Stock Options and Warrants - Additional Information (Detail) false false R26.htm 126 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) false false All Reports Book All Reports Element bpth_StockCommittedToBeIssuedDuringPeriodValueAcquisitions had a mix of decimals attribute values: -6 0. Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'May 09, 2007' Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: Removing column 'May 31, 2013' Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Process Flow-Through: Removing column '1 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '6 Months Ended Jun. 30, 2014' Process Flow-Through: Removing column '6 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '86 Months Ended Jun. 30, 2014' Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS bpth-20140630.xml bpth-20140630.xsd bpth-20140630_cal.xml bpth-20140630_def.xml bpth-20140630_lab.xml bpth-20140630_pre.xml true true XML 41 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Prepaid Drug Product for Testing - Additional Information (Detail) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Inventory Disclosure [Line Items]

Prepaid drug product for testing $ 141,345 $ 51,364

X

- Details

Name: bpth_InventoryDisclosureLineItems

Namespace Prefix: bpth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_OtherInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Stock Options and Warrants - Additional Information (Detail) (USD $)	6 Months Ended			1 Months Ended
	Jun. 30, 2014	Jun. 30, 2014 Management	Jun. 30, 2014 R&D Activities	Apr. 30, 2014 Director [Member]	May 31, 2014 Employee Stock [Member]	Apr. 30, 2014 Employee Stock [Member]	May 31, 2014 Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				25,000	25,000	25,000	125,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 2.38	$ 2.40	$ 2.71	$ 2.40
Share based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value				$ 57,425	$ 58,975	$ 133,200	$ 294,500
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate				178.00%	178.00%	178.00%	178.00%
Stock option expense	$ 122,793	$ 102,383	$ 20,410

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets
Cash	$ 15,721,128	$ 3,551,832
Prepaid drug product for testing	141,345	51,364
Other current assets	171,563	64,117
Total current assets	16,034,036	3,667,313
Other assets
Technology licenses - related party	2,500,374	2,500,374
Less Accumulated Amortization	(1,169,168)	(1,088,856)
Intangible Assets, Net (Excluding Goodwill), Total	1,331,206	1,411,518
TOTAL ASSETS	17,365,242	5,078,831
Current liabilities
Accounts payable	78,915	76,109
Accounts payable - related party	3,213	0
Accrued expense	149,341	66,739
Accrued expense - related party	52,050	52,050
Accrued license payments - related party	50,000	100,000
Total current liabilities	333,519	294,898
Long term debt	0	0
TOTAL LIABILITIES	333,519	294,898
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding		0
Common Stock, $.001 par value, 200,000,000 shares authorized 89,237,872 and 84,237,872 shares issued and outstanding as of 6/30/14 and 12/31/13, respectively	89,238	84,238
Additional paid in capital	34,113,436	20,096,991
Accumulated deficit during development stage	(17,170,951)	(15,397,296)
Total shareholders' equity	17,031,723	4,783,933
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 17,365,242	$ 5,078,831

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	6 Months Ended		86 Months Ended
CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (1,773,654)	$ (1,083,246)	$ (17,170,951)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	80,312	80,312	1,217,670
Technology impairment	0	0	690,000
Common stock issued for services	0	0	318,500
Stock options and warrants	209,071	29,557	3,927,304
(Increase) decrease in assets
Prepaid drug product for testing	(89,981)	(84,180)	(141,345)
Other current assets	(107,446)	(3,836)	(171,563)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	38,621	(61,388)	333,519
Net cash used in operating activities	(1,643,077)	(1,122,781)	(10,996,866)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	0	(884,710)
Net cash used in investing activities	0	0	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	13,812,373	2,515,961	27,182,704
Net cash from financing activities	13,812,373	2,515,961	27,602,704
NET INCREASE (DECREASE) IN CASH	12,169,296	1,393,180	15,721,128
Cash, beginning of period	3,551,832	534,046	0
Cash, end of period	15,721,128	1,927,226	15,721,128
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	0	448,950	1,362,613
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 0	$ 210,755

Accrued Expense - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense	$ 149,341	$ 66,739
Accrued expense - related party	52,050	52,050
Clinical Trials
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense	149,341
MD Anderson Cancer Center
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense - related party	52,050
MD Anderson Cancer Center \| Clinical Trials
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense - related party		$ 52,050

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended					3 Months Ended	6 Months Ended		86 Months Ended			1 Months Ended		2 Months Ended			3 Months Ended	1 Months Ended																						1 Months Ended						6 Months Ended	1 Months Ended						1 Months Ended
	Jan. 15, 2014	Jan. 31, 2014	Aug. 31, 2012	Oct. 31, 2011	Dec. 31, 2008	Apr. 30, 2008	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013	May 31, 2013	Jun. 30, 2010 Warrant	Jun. 30, 2012 Private Placement memorandum	Sep. 30, 2013 Private Placement memorandum	May 31, 2013 Private Placement memorandum	Mar. 31, 2013 Private Placement memorandum	Dec. 31, 2012 Private Placement memorandum	Dec. 31, 2008 Investor Relations Services	Jun. 30, 2007 Founders	May 31, 2007 Founders	Mar. 31, 2012 Equity Unit Purchase Agreements LPC	Dec. 31, 2011 Equity Unit Purchase Agreements LPC	Nov. 30, 2011 Equity Unit Purchase Agreements LPC	Jun. 30, 2011 Equity Unit Purchase Agreements LPC	Nov. 30, 2010 Equity Unit Purchase Agreements LPC	Oct. 31, 2010 Equity Unit Purchase Agreements LPC	Sep. 30, 2010 Equity Unit Purchase Agreements LPC	Jul. 31, 2010 Equity Unit Purchase Agreements LPC	Jun. 30, 2010 Equity Unit Purchase Agreements LPC	Jun. 30, 2010 Equity Unit Purchase Agreements LPC Minimum	Jun. 30, 2010 Equity Unit Purchase Agreements LPC Maximum	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 1	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 2	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 3	Jun. 30, 2010 LPC financing agreement LPC	Nov. 30, 2013 Investors	Dec. 31, 2012 Investors	Jun. 30, 2011 Investors	Jun. 30, 2013 Investors	May 31, 2010 Investors Private Placement memorandum	Jan. 31, 2010 Investors Private Placement memorandum	Dec. 31, 2009 Investors Private Placement memorandum	Nov. 30, 2009 Investors Private Placement memorandum	Jun. 30, 2009 Investors Private Placement memorandum	Aug. 31, 2007 Investors Private Placement memorandum	Apr. 30, 2011 Investors Private Placement memorandum	Aug. 31, 2007 Investors Additional Shares	Jan. 31, 2010 Investors Additional Shares Private Placement memorandum	Nov. 30, 2013 Placement Agent	Jun. 30, 2011 Placement Agent	Aug. 31, 2007 Placement Agent	Jun. 30, 2013 Placement Agent	May 31, 2010 Placement Agent Private Placement memorandum	Jan. 31, 2010 Placement Agent Private Placement memorandum	Jun. 30, 2009 Placement Agent Private Placement memorandum	Nov. 30, 2007 MD Anderson Cancer Center	Apr. 30, 2008 BioPathHoldingsInc	Feb. 29, 2008 BioPathHoldingsInc	Feb. 29, 2008 Ogden Golf Co.
Shareholders Equity [Line Items]
Common stock and warrants issued, shares													571,429							6,505,994	6,505,994	166,667	172,414	83,333	164,853	135,135	135,135	125,000	375,000	571,429			89,286	96,154	185,185	12,000										3,975,000		1,333,334				530,833		78,000	360,000	66,000		200,000	80,000
Common stock issued , value	$ 15,000,000																			$ 6,506	$ 6,506																									$ 993,750	$ 1,794,205	$ 1,000,000
Common stock issued , shares			50,000											150,000																									5,980,685												598,069						3,138,889
Common stock issued merger transactions, shares																																																											38,023,578
Common stock retained shareholders, shares																																																												3,600,000
Common stock issued for services, value					40,000	180,000
Common stock issued, additional shares						24
Common stock issued for service, shares			18,500											18,500					100,000
Common stock and warrant issued, shares		5,000,000																																							780,000	2,700,000			660,000				900,000
Common stock repurchased, shares		2,500,000																																							780,000	2,700,000			660,000				900,000
Common stock and warrants issued, Value		15,000,000																																							273,000		675,000	675,000	165,000				225,000
Equity purchase agreement value																														7,000,000	50,000	1,000,000
Proceeds from issuance of common stock and warrant from LPC								13,812,373	2,515,961	27,182,704												50,000	50,000	25,000	50,000	50,000	50,000	50,000	150,000	200,000			25,000	25,000	50,000
Committed shares issued																						2,084	2,084	1,042	2,084	2,084	2,084	2,084	6,251				1,042	1,042	2,084	566,801
Warrants issued, shares																						0	0	0	0	0	0	0	0						0
Common stock issued for exercise of warrant (in shares)				1,920,000
Common stock issued for exercise of warrant				576,000
Common stock issued for services							$ 795,001	$ 0	$ 0	$ 318,500					$ 3,220,966	$ 2,000,198	$ 346,202	$ 708,600																			$ 8,052,416	$ 3,300,337												$ 805,242
Common Stock, shares issued								89,237,872		89,237,872	84,237,872	489,501																												11,664,665													1,496,499
Common Stock, shares outstanding								89,237,872		89,237,872	84,237,872
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.74																												$ 1.50											$ 1.50	$ 1.50			$ 1.50				$ 1.50

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	89,237,872	84,237,872
Common Stock, shares outstanding	89,237,872	84,237,872

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2014	Aug. 05, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Central Index Key	0001133818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BPTH
Entity Common Stock, Shares Outstanding		89,237,872

Organization and Business - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	6 Months Ended		12 Months Ended	86 Months Ended					0 Months Ended	1 Months Ended	0 Months Ended	12 Months Ended
	Jan. 15, 2014	Jun. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2011	Jun. 30, 2014	Dec. 31, 2013	Nov. 05, 2013	Dec. 31, 2012	May 09, 2007	Jan. 15, 2014 Sabby Investors	Jun. 30, 2010 Warrant	Jan. 15, 2014 Warrant Sabby Investors	Dec. 31, 2011 siRNA License
Organization and Nature of Operations [Line Items]
Percentage of Charge					50.00%
Impairment of License		$ 345,000	$ 0	$ 0		$ 690,000								$ 345,000
Cash			15,721,128	1,927,226		15,721,128	3,551,832		534,046	0
Authorized capital to be raised								100,000,000
Stock issued during period, shares, new issues											5,000,000	571,429	2,500,000
Stock issued during period, value, new issues	15,000,000
Proceeds from issuance initial public offering	$ 13,800,000

Accrued License Payments - Related Party - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Accrued license payments - related party	$ 50,000	$ 100,000

Accounts Payable - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Accounts Payable [Line Items]
Accounts payable	$ 78,915	$ 76,109
Accounts payable, trade	43,277
Accounts payable, other, current	15,250
Firm Owes Facility Expenses	3,213
Clinical Trials [Member]
Accounts Payable [Line Items]
Accounts payable, trade	18,150
Accounts payable, other, current	$ 2,238

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Product Liability Contingency [Line Items]
Estimates reimbursable past patent expenses	$ 75,000
Patent expense per quarter	25,000
Accounts payable and accrued liabilities	50,000
Other inventory, gross	141,345	51,364
Drug Product Testing Agreement Consideration To Be Paid In Stages	370,000
Subsequent Event [Member]
Product Liability Contingency [Line Items]
Other inventory, gross	141,345
Licenses Agreement
Product Liability Contingency [Line Items]
Accrued expense - related party	$ 52,050

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	3 Months Ended		6 Months Ended		86 Months Ended	3 Months Ended		6 Months Ended		86 Months Ended
	Jun. 30, 2014 Research and Development Expense [Member]	Jun. 30, 2013 Research and Development Expense [Member]	Jun. 30, 2014 Research and Development Expense [Member]	Jun. 30, 2013 Research and Development Expense [Member]	Jun. 30, 2014 Research and Development Expense [Member]	Jun. 30, 2014 General and Administrative Expense [Member]	Jun. 30, 2013 General and Administrative Expense [Member]	Jun. 30, 2014 General and Administrative Expense [Member]	Jun. 30, 2013 General and Administrative Expense [Member]	Jun. 30, 2014 General and Administrative Expense [Member]
Equity compensation	$ 20,410	$ 8,220	$ 27,032	$ 19,633	$ 482,912
Stock option and warrant expense						102,383	5,318	182,039	9,923	3,444,392
Stock for services										318,500
Technology impairment charge					$ 690,000

Prepaid Drug Product for Testing - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Line Items]
Prepaid drug product for testing	$ 141,345	$ 51,364